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Abstract 
Diseases of the retina affect hundreds of millions of patients worldwide, with limited 
treatment options available. ALG-1001 is an investigational drug that showed success in 
mitigating disease symptoms in animal models and improved patient vision in multiple 
clinical trials. To gain a better understanding of the drug’s mechanism of action, RNA 
sequencing (RNA-seq) and shotgun proteomics were employed to study the drug-induced 
transcriptome change in retinal tissue and cell culture models. Chapter 2 focuses on 
application of this approach in an animal model of the disease that showed the drug can 
reversely modulate hypoxia-activated angiogenesis and inflammation gene expression 
changes. Chapter 3 discusses the study of drug-induced transcriptome response in two cell 
culture models relevant to pathophysiology of the retinal diseases. Chapter 4 explores retinal 
cell transcriptome after short and long-term exposure to disease-relevant hypoxia condition 
and after hypoxia recovery. Appendix A documents our shotgun proteomics protocol and 
includes results from the application of this method in the study of drug mechanism.  
Typical RNA-seq studies use few biological replicates for differential expression analysis, 
mainly due to the high cost of generating sequencing data. As a result, not all comparisons 
have the proper statistical power, which result in false positives and false negatives that can 
lead the researcher to the wrong conclusion. Chapter 5 discusses a novel algorithm and 
software that help users perform quality control of their dataset to identify whether the 
appropriate sample size was used for differential gene discovery. The chapter covers 
demonstration of the software with four publicly available RNA-seq datasets to illustrate its 
utility. 
Bioresorbable vascular scaffolds (BVSs) are the application of biocompatible polymer in the 
treatment of coronary heart disease, one of the leading causes of death worldwide. BVSs are 
designed to replace metal stents, which stay permanently in the body after surgery and can 
lead to various complications, such as lethal thrombosis. In contrast, BVSs provide the 
necessary support and are resorbed by the body to leave behind a healthy artery after 2-3 
years. Improving on the existing BVS material, chapter 6 explores a new polymer 
nanocomposite that increases the structure’s radial strength in a thinner profile and provides 
radio-opacity to enhance surgery success.  
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Chapter 1. Introduction 
The human circulatory system is composed of a complex network of blood vessels that 
transport nutrients and oxygen to tissues and carry away metabolic waste. Disruption of this 
life-sustaining system can lead to tissue damage, disease, and even death. In many chronic 
diseases, abnormal growth of new blood vessels (called angiogenesis) sustains and 
aggravates the condition1. In other disorders, deterioration of existing vasculature can lead to 
irregular blood supply resulting in tissue necrosis2. The first three sections of this chapter 
(Chapter 1.1-1.3) discuss the vascular diseases of the retina, development of an 
investigational drug that targets these disorders and application of high-throughput methods 
to study the effect of the drug. The next section (Chapter 1.4) introduces the development 
of an analytical framework and an accompanying software that improves existing high-
throughput transcriptome data analysis. The last section (Chapter 1.5) explores 
characterization of a nanocomposite biomaterial that has the potential to advance treatment 
of coronary heart disease. 
1.1 Pathology and treatment of retinal diseases 
The human eye is composed of a diverse variety of cells that are organized in a complex 
three-dimensional architecture to enable a central sensory function: visual perception of the 
world around us3,4. In the eye, light first enters through the cornea and is focused by the lens 
onto the retina. Within the retina, photoreceptors (cones and rods) detect and convert the light 
to chemical signals, which are passed to retinal neurons and ultimately to the brain. Contrary 
2 
 
to our intuition, over most of the retina, photons first pass through several layers of neurons 
and blood vessels before reaching the photoreceptors. These additional cell layers disperse 
and absorb the light, reducing spatial resolution. In contrast, the macula is an approximately 
6mm dimeter region of the retina, where the neurons and the anterior blood vessels are mostly 
absent, thus allowing the light to more directly hit the photoreceptor cells. The macula also 
contains the highest density of cone photoreceptors, which provide us our high-resolution 
colored vision. The combination of high cell density and relatively lack of capillaries gives 
this highly metabolically-active tissue a predisposition for degeneration and disease5,6. 
In developed nations, degenerative diseases of the retina represent the leading cause of adult 
blindness7. Age-related Macular Degeneration (AMD) and Diabetic Retinopathy/Diabetic 
Macular Edema (DR/DME) are two major disorders that predominantly affect the macula. 
Based on the most recent statistics, AMD affects 11 million Americans (170 million 
worldwide), and accounts for more than half of all blindness and visual impairment in the 
industrialized countries8,9. Similarly, DR/DME affect approximately 4 million Americans 
(93 million worldwide), and is the largest cause of blindness under the age of 55 in the 
developed world10,11.  
Many factors, including both genetic predisposition and environmental stress, contribute to 
the onset of these diseases. Over time, presence of stress factors lead to development of 
chronic hypoxia and inflammation12, which contribute to develop of pathological 
angiogenesis (pathophysiology of DR/DME in Figure 1.4 and AMD in Figure 1.5)7,13,14. In 
early stages of AMD, the retina is inflamed with activated microglia cells (resident 
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macrophages of central nervous system) and show sign of degenerative blood vessel loss15. 
As AMD progresses, the retina become plagued by accumulation of extracellular debris in 
the posterior region in deposits called drusen16. Drusen formations hinder diffusion between 
the vasculature and retina, and their presence attracts inflammatory macrophages to the 
area17,18. The combination of these processes drive chronic hypoxia and inflammation in the 
AMD retina, contributing to the disease progression. In DR/DME, hyperglycemia is 
associated with damage and regression of retinal vasculature, creating a hypoxic/ischemic 
micro-environment in the tissue19,20. High blood sugar and excess lipid conditions also 
promote release of inflammatory mediators by the neural retina, leading to leukocyte 
recruitment. In both diseases, hypoxic and inflammatory conditions converge to drive 
cellular release of a variety of pro-angiogenic factors, including Vascular Endothelial Growth 
Factor (VEGF), a potent angiogenesis activator21. These signaling then lead to formation of 
immature vessels that are often poorly-developed and leak fluid, resulting in edema, bleeding 
and cell death in the retina/macula13. These degenerative conditions progressively get worse, 
causing vision impairment and eventually blindness.  
Currently, there are two main treatment options for the described retinal diseases. Before the 
introduction of anti-VEGF pathway antibodies, laser therapy was the most commonly used 
approach. One type of laser therapy burns the peripheral retinal tissue, while sparing the 
macula to reduce the metabolic demand and alleviate the hypoxia/ischemia condition20. A 
second type of laser therapy targets specific leaky blood vessels to seal the leakage and 
reduce edema/bleeding22. However, laser-based therapies generally damage the peripheral 
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vision and do not usually lead to vision improvement (they stabilize vision deterioration). 
Furthermore, neovascularization often re-emerges in many of the patients after surgery, 
making this treatment option only a short-term solution23. The current standard of care uses 
anti-VEGF antibodies (Ranibizumab, Aflibercept and Bevacizumab15,24) that specifically 
bind with VEGF and disrupt the activation of its signaling pathway to suppress retinal 
neovascularization. While significantly more successful than laser therapy, the antibody 
treatments are: a) expensive25, b) require burdensome intraocular (into the eye) injection 
every 30-60 days26, c) is ineffective in more than 25-50% of the patients27,28. Due to these 
drawbacks, an alternative and more efficacious therapy is needed to address the limitations 
of the existing standard of care. 
 
1.2 Discovery of an oligopeptide therapeutic agent – ALG-1001 
An investigational oligopeptide drug named ALG-1001 (Figure 1.1) was invented by 
Allegro Ophthalmics, LLC. and is currently undergoing clinical trial in the described retinal 
diseases. In an Phase I clinical trial, 15 subjects with very advanced forms of DME were 
recruited to receive three monthly intraocular injections, followed by three months of 
additional monitoring29. At the end of the study, no major drug-related side effects were 
observed in all fifteen patients and more than half of the subjects (8 out of 15 patients, 
including several that are refractory to existing antibody therapy) demonstrated a significant 
improve in vision (3 BCVA lines of improvement in visual acuity, Figure 1.2). Since this 
initial study, additional phase I/II trials with DR, DME and AMD patient cohorts were 
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completed and continued to demonstrate ALG-1001 is well-tolerated and improved vision 
with no drug-related side effects reported to date30–32. Based on these positive results, the 
company recently announced the plan to enter the drug into a phase III trial in DME, slated 
to start in early 201933.  
ALG-1001 was invented to structurally mimic a class of proteins that contain a common 
arginine, glycine, aspartic acid (RGD) amino acid sequence. The RGD sequence, in context 
of its flanking amino acids, has been studied extensively in the past for its natural role as the 
key recognition sequence of many important extracellular matrix proteins34. RGD containing 
peptides and their derivatives have also been investigated for potential therapeutic value in 
applications including tumor therapy, tissue engineering, and drug delivery35–37. The RGD 
motif was first isolated in 1984 by Pierschbacher and Ruoslahti as the specificity determining 
sequence in fibronectin proteins38. Later research found that the motif facilitates the normal 
binding of several important groups of extracellular matrix proteins to a class of cell receptors 
called integrins39. Today, 24 integrin heterodimers have been discovered in mammals, and 
their expression pattern on various cell types facilitate both normal and pathogenic cellular 
physiology. In particular, elevated expressions of certain integrins (e.g. αvβ3, αvβ5 and 
α5β1) are often observed on developing blood vessels during pathological angiogenesis40.  
In ocular tissues, it was previously reported that AMD patients express high level of αvβ3 
integrins while both αvβ3 and αvβ5 integrins were elevated in DR patients41. Similarly, α5β1 
elevation has been observed in neovascularization of the ocular tissue in animal models42. 
Since these integrins are selectively up-regulated in newly-formed blood vessels, it was 
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hypothesized that their expression is important for angiogenesis. Indeed, using the chick 
Chorioallantoic Membrane (CAM) model of angiogenesis, Brooks and Drake found that 
anti-integrin antibodies were able to inhibit vessel growth43,44. Around the same time, various 
research groups hypothesized that short RGD-containing peptides may also specifically bind 
with integrins and disrupt their normal involvement in angiogenesis. In a 1996 study, mouse 
subcutaneous injection of a cyclic RGD peptide was shown to reduce vessel proliferation by 
76% in the mouse retina45. In the same year, another independent study by Friedlander and 
coworkers reached the same conclusion using the same peptide and a different mouse 
model41. These results and additional confirmatory studies demonstrate that RGD-containing 
peptides can strongly inhibit angiogenesis through disruption of pro-angiogenic integrin 
function. 
In light of these early research, ALG-1001 was invented as an RGD mimic for treatment of 
neovascularization in the eye. Based on the RGD sequence, Dr. John Park (Allegro 
Ophthalmics, LLC.) replaced the carboxyl group on the aspartic acid with a sulfonate group, 
i.e. cysteic acid. In drug research, sulfonate and carboxylate groups are classical example of 
structurally distinct, yet bio-functionally equivalent molecular fragments46. In the original 
hypothesis, the placement of sulfonate group was proposed to induce a stronger interaction 
with the integrin binding pocket and thus increases the drug’s potency. Although more recent 
biochemical experiments call this hypothesis into question, concurrent studies revealed that 
ALG-1001 is a strong inhibitor of angiogenesis in animal models. 
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Using three different mouse models that mimic human retinal diseases, Dr. Peter 
Campochiaro (Johns Hopkins University) and his team demonstrated that ALG-1001 is 
effective in reducing ocular neovascularization (personal communication). In the Laser-
induced Choroidal Neovascularization (CNV) mouse model47, ALG-1001 injection reduced 
neovascularization by 43% compared to vehicle control. In another model named Oxygen-
induced Retinopathy (OIR)48, ALG-1001 was shown to reduce vessel growth by up to 54% 
five days after injection. In a third study of a mouse model that over-expresses human VEGF 
and subsequently develops retinal angiogenesis, ALG-1001 and the current standard of care, 
Ranibizumab, were tested in a combination study. In this experiment, both drugs comparably 
reduced subretinal neovascularization, but there was a further reduction when the two drugs 
were used in combination. The synergistic effect suggests ALG-1001 may act through a 
molecular pathway that differs from existing anti-VEGF treatment (as the effects appear to 
be additive). Collectively, these in vivo studies show that ALG-1001 is effective in 
modulating retinal neovascularization. 
 
1.3 ALG-1001 mechanism of action study 
Although ALG-1001 was designed to be a more potent inhibitor of integrin than RGD, recent 
studies found the drug’s binding affinity with various integrins are, in fact, weak. In one 
study at the Swenson lab (USC), Fluorescence Polarization Assay found micro-molar 
binding constants between ALG-1001 and αvβ3 (Kd=0.9uM), α5β1 (Kd>1uM) and αvβ5 
(Kd>1uM) integrins, in contrast to positive control between vitronectin and αvβ3 integrin (Kd 
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≅ 8nM) (personal communication). Another study performed at the Kornfield lab (Caltech) 
used Surface Plasmon Resonance (SPR) and reached the same conclusion (Kd ≅ 2mM for 
ALG-1001 with α5β1, while a control RGD peptide has a small Kd ≅ 12nM, unpublished). 
Altogether, these experiments suggest the binding affinity between ALG-1001 and 
recombinant integrins are weak and non-specific. However, these studies were also done 
with recombinant integrins that do not perfectly mimic the endogenous structure of 
integrins49 (e.g., the flexible and condition-dependent conformation of the extracellular 
domain of integrin heterodimers50). 
Based on these experiments, the hypothesis that ALG-1001 exerts its anti-angiogenesis effect 
through binding with pro-angiogenic integrins has not been confirmed and its precise 
mechanism of action requires further investigation. Toward the goal of uncovering the drug’s 
mechanism of action, my main thesis project aims to discover the biological pathways that 
confer the drug’s therapeutic effect. To do this, I evaluated two main methods to quantify the 
drug-induced changes: 1) in the transcriptome using RNA sequencing (RNA-seq) on 
polyadenylated messenger RNAs (mRNAs), and 2) in the proteome using mass-
spectrometry-based shotgun proteomics. The two methods naturally complement each other, 
as evidence in both the transcriptome and the proteome can reveal the drug-induced 
biological regulation. Additionally, the two approaches have their unique advantages and 
drawbacks that warrant their combined application.  
Methods measuring the proteome are powerful, as they directly study the expression level of 
cellular proteins, which perform a majority of functions in the cell51. Shotgun proteomics 
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started to become popular in the early 2000s as a high-throughput method to probe the 
proteome52. Despite its high-throughput nature, shotgun proteomics rely on mass 
spectrometry for measurement and current methods have little to no detection power for 
medium to low expressing proteins, on a practical scale53,54. On the other hand, nucleic acid-
based methods that probe the transcriptome can overcome this limitation through 
polymerase-based signal amplification55. As a result, methods such as RNA-seq have a much 
larger dynamic range of detection compared to typical shotgun proteomics and enables 
identification of changes in even the low expressing genes56. However, it has previously been 
reported that only around 40% of protein expression levels can be explained by mRNA 
dynamics while the rest are due to protein translation and degradation regulatory 
mechanisms57. Although recent studies suggest stronger correlations between the proteome 
and transcriptome (possibly due to better normalization methods and experimental 
protocols)58,59, the importance of protein expression regulation warrants observation at the 
proteome level. Faced with an unknown mechanism of action, I worked with Dr. Kai Yuet 
and Dr. Graham Hamblin in the Tirrell group (Caltech) to evaluate shotgun proteomics as an 
unbiased method to probe the effects of ALG-1001 at the level of the proteome. 
In shotgun proteomics, proteins are detected using liquid chromatography and tandem mass 
spectrometry (LC-MSMS) and analyzed to identify pattern of molecular fragments that 
match known protein sequences53,60. To detect differences in transient protein expression in 
response to a drug, it is necessary to differentiate between proteins synthesized before and 
after treatment, and between treated and control samples. To do this, Pulse Stable Isotope 
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Labeling by Amino Acids in Cell Culture (pSILAC) is used to provide relative protein ratio 
in two samples (one of each condition) by incorporating different isotopically-labelled amino 
acids (Lysine and Arginine) into newly-synthesized proteins (Figure 1.3)61. To obtain 
sufficient signal-to-noise ratio for the isotopically-labelled proteins, it is beneficial to 
suppress the large background of unlabeled proteins using a technique pioneered in the 
Tirrell lab at Caltech: Bioorthogonal Noncanonical Amino Acid Tagging (BONCAT), which 
introduces the noncanonical amino acid azidohomoalanine (AHA) in place of methionine62 
to enable covalent capture of nascent proteins. When AHA is introduced at the same time as 
the isotopically-labeled amino acids, BONCAT enables the enrichment of the isotopically-
labeled proteins63 and has been successfully applied in recent years in many biological 
models including mammalian cell lines63–65, mouse ex vivo brain tissue66 and Caenorhabditis 
elegans67. In our study, removal of background protein using BONCAT is important due to 
a relatively short drug treatment period (<48 hours) versus the average protein half-life (e.g., 
estimated to be around 100 hours in primary cells68).  
To validate our technique, we performed a preliminary BONCAT-pSILAC experiment 
comparing a RGD-containing peptide versus control peptide, which successfully identified 
several hundred differentially expressed (DE) proteins in mammalian cell culture. Many of 
the regulated proteins were found to function in cell to cell adhesion (Appendix A.2), in 
agreement with RGD disruption of integrin-mediated cellular interaction. However, when 
we applied BONCAT-pSILAC to search for proteomic changes in response to ALG-1001, 
we did not identify any DE proteins (Appendix A.3). Subsequent RNA-seq experiments 
11 
 
reveal the measurable effect of ALG-1001 in vitro is weak (Chapter 3), even though stronger 
changes in the transcriptome are readily measured in vivo in the OIR mouse model (Chapter 
2). Although it is beyond the scope of this thesis, proteomic effects of ALG-1001 that are 
below the sensitivity of BONCAT-pSILAC in vitro may be measurable in a disease model 
in vivo.  
In contrast to the limited detection power of shotgun proteomics, RNA-seq is capable of 
measuring even low-expressing genes. In our hands, BONCAT-pSILAC detected only a few 
thousand highly expressed proteins, which limit the search for DE proteins to a small subset 
of all proteins expressed. The ability to routinely detect more than ten thousand genes using 
RNA-seq sheds new light on the effect of ALG-1001 in various biological models.  
RNA-seq, a high-throughput method of probing mRNA expression, was first applied to study 
the complex eukaryote transcriptome by the Wold lab at Caltech69. Since then, RNA-seq 
rapidly became the standard technique to study cellular transcriptome, largely replacing 
previously popular methods such as microarray and SAGE70. In a typical RNA-seq 
experiment, mRNA-derived complementary DNAs (cDNAs) are sequenced concurrently to 
generate millions of reads that contain sequence information71. The reads can then be mapped 
to the reference genome/transcriptome to tally the number of reads that map onto each gene 
in the genome. The tabulation of the number of mapped reads per gene is repeated for each 
sample in the experiment and statistical methods are then applied to identify genes that are 
DE between the groups72,73. Finally, the list of DE genes, together with corresponding fold 
change and measure of statistical significance, serve as inputs for functional analysis to 
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search for regulatory pathways, gene ontology groups and transcription factors that are 
correlated with the observed expression variation.  
Adoption of RNA-seq as the de facto tool for study of the transcriptome has been rapid. Since 
its introduction in 2008, over 14,000 RNA-seq-related papers have been published (PubMed, 
late 2018), including more than 3,000 in 2017 alone. There are several reasons to RNA-seq’s 
popularity. First, the technique has a high dynamic range (tens of thousands of genes across 
four or more orders of magnitude in expression level can be detected simultaneously)56. 
Second, RNA-seq typically has high reproducibility, where it is not uncommon to see 
technical replicates with R2 > 0.99. Third, sample preparation and sequencing is increasingly 
streamlined as a rapid increase in the number of users spurred development of commercial 
products. Fourth, the method can be easily adapted to study any organism, a major advantage 
over microarrays. Finally, there exists an active bioinformatics community (such as the 
Bioconductor project74) that develops analytical tools to support computational analysis of 
RNA-seq data. As a result, biomedical application of RNA-seq has become generally 
accepted, particularly in fields such as cancer research, disease diagnostics and drug 
discovery75.  
In our research, we applied comparative RNA-seq to identify the transcriptome regulation 
modulated by hypoxia and ALG-1001 in various biological models: in vivo OIR mouse 
retinal neovascularization model (Chapter 2), in vitro human endothelial and immune cell 
culture models (Chapter 3), and retinal cells conditioned with short to long-term hypoxia 
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and hypoxia recovery (Chapter 4). We also documented our BONCAT-pSILAC protocol 
and the experimental results in Appendix A.  
 
1.4 Sample size in comparative RNA-seq experiments 
It is well established that comparative RNA-seq experiments require biological replicates for 
statistical testing76. Increasing the number of biological replicates improves both statistical 
power and accuracy of gene expression estimation72,77,78. However, RNA-seq experiments 
are expensive (currently, each sample typically cost several hundred dollars in library 
preparation and sequencing alone) and sample procurement may be challenging in certain 
experimental settings. As a result, RNA-seq studies often include as few as two or three 
biological replicates per experimental condition, which put the results of statistical test in 
question.  
Selecting the appropriate number of replicates (sample size) for each condition examined in 
a specific RNA-seq experiment is challenging, as several determining factors are generally 
not known a priori79. First, when the true inter-condition difference (effect size) is small, 
more replicates are needed for differential expression discovery. Second, when biological 
variance is high among samples of the same condition, more replicates are needed to improve 
statistical power. Although several software packages have been released in recent years to 
help researchers choose the appropriate sample size for RNA-seq studies, Poplawski and 
Binder (2017) found that all of the tools failed to accurately estimate sample size even for 
substantial changes in gene expression (fold change ≥ 1.5)80. This systematic study 
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performed simulation-based assessment on six RNA-seq sample size calculation tools that 
support sample size calculation with multiple genes in consideration. The results from the 
evaluation showed that the six tools provided widely different results that are highly 
dependent on the effect size in consideration and none of them gave satisfactory agreement 
with the “ground truth” (which is known for the simulated data set used in the study). At 
present, RNA-seq sample size selection remains challenging and additional tools are needed 
to ensure accurate differential expression discovery. 
In Chapter 5, we describe a solution to this problem with an algorithm that does not rely on 
data simulation or a priori assumed parameters. Instead, we approach the problem by 
analyzing an existing data set that a user has already acquired to evaluate the benefit they can 
expect to achieve with additional replicates. The method, called Empirical RNA-seq Sample 
Size Analysis (ERSSA), uses a subsampling technique to compute the effect of increasing 
number of replicates on the number of DE genes identified. Using the trend in the amount of 
marginal improvement as sample size increases, the analytical framework allows the user to 
evaluate the potential benefit of procuring additional biological replicates. The algorithm has 
been implemented in the statistical programming language R and is publicly available on 
Bioconductor at http://bioconductor.org/packages/ERSSA/. 
 
1.5 Application of Bioresorbable Vascular Scaffolds in coronary heart disease 
Coronary heart disease (CHD) is a leading cause of mortality in the world. In the US alone, 
CHD is associated with one in every five deaths each year2.  In CHD, vessel-occluding lipid 
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deposits build up in the coronary artery and obstructs or complete blocks blood flow to the 
heart muscle, eventually leading to angina and heart attack81. In recent decades, the main 
therapy for CHD is to insert a permanent metal stent at the site of occlusion to open and 
support the artery and to maintain blood flow82. While metal stents provide tremendous 
therapeutic value, they also have some important side effects, including a higher risk of life-
threatening late thrombosis83. With more than 1 million stents implanted each year in the US 
alone as of 2008, there is an urgent need to develop safer therapies for CHD84. 
Bioresorbable vascular scaffold (BVS), such as Abbott Vascular’s FDA-approved Absorb®, 
recently emerged as a promising alternative to metal stents85. Absorb® is composed of 
biodegradable poly L-lactide (PLLA) that supports the artery for the first few months and 
then completely degrades in 2-3 years86. A five year follow-up clinical trial involving 101 
patients showed that artery regains the ability to dilate and pulsate, with no incidence of late 
thrombosis in patients87. Despite this initial success, a larger follow-up study found an 
increase in thrombosis associated with BVS (~1.3% prevalence rate) relative to metal stents 
(~0.6%)88. Two potential explanations provided by clinicians include: 1) BVSs contains 
thicker struts compared to metal stents, and 2) under-deployment of BVSs over fear of 
scaffold fracture and inability to image the deployed diameter during surgery. These 
concerns motivate development of a BVS device that has thinner strut as well as superior 
radial strength to reduce the chance of thrombosis. 
Working with a team of collaborators in the Kornfield lab and at ENEA Portici in Italy, we 
explored the application of Tungsten Disulfide nanotubes (WSNT) as a reinforcing agent 
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that could increase the strength and x-ray scattering contrast of the BVS. My collaborators 
characterized the effects of WSNT on the processing behavior and semi-crystalline 
morphology of PLLA-WSNT nanocomposites. I characterized the biocompatibility of this 
reinforcing agent and of the nanocomposite. Our combined results are included in Chapter 
6.  
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1.6 Figures and Tables 
 
 
Figure 1.1 Molecular structure of ALG-1001 (Gly-Arg-Gly-Cys(acid)-Thr-Pro) 
ALG-1001 is structurally designed to mimic RGD-containing peptides. Aspartic acid in the 
RGD sequence is replaced by a noncanonical amino acid – cystic acid89.  
  
Gly-Arg-Gly-Cys(acid)-Thr-Pro 
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Figure 1.2 ALG-1001 Phase I clinical trial in DME 
Phase I study of 15 “end-stage” DME patients with severe vision impairment. Three monthly 
ALG-1001 intraocular injections were performed follow by three months of follow-ups. No 
other treatment arms were included in this trial. At the end of 150 day trial, 8 out of 15 
patients showed significant improvement in a visual acuity test (green dots), while 7 out of 
15 patients showed no further visual deterioration (yellow dots). Dashed lines outline the 
trend in vision change in the two responder groups. Vertical, solid green arrow indicates the 
magnitude of improvement illustrated by the Snellen chart simulation to the left and right of 
the graph. 
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Figure 1.3 BONCAT with pSILAC schematic 
Illustration describes the major steps in a BONCAT with pSILAC experiment. Adapted from 
a review publication by Yuet and Tirrell90. A. In a typical BONCAT with pSILAC 
experiment, cells in two groups (treated “experiment” and untreated “control”) are grown in 
conventional media (blue) to the desired confluency. At the onset of treatment, the 
conventional media is removed and replaced with media containing 30 times more AHA 
than methionine, and all of the lysine and arginine replaced by isotopically labelled 
counterparts. In the depicted study, the new media for the “experiment” also contains a 
peptide of interest (ALG denotes ALG-1001 in the green medium) while “control” does not. 
After the treatment period, cells are harvested and lysed, proteins combined in 1:1 ratio and 
enriched through click-reaction chemistry (unenriched protein mixture shown in box labeled 
“no enrichment”). The enriched proteins are then characterized using liquid chromatography 
tandem-mass spectrometry (LC-MSMS), giving the “triplets” of peaks associated with 
background protein (blue), newly-synthesized protein from the “experiment” (green) and 
newly-synthesized protein from the “control” (yellow). Met is methionine, Lys is lysine, Arg 
is arginine and m/z is mass to charge ratio. B. Conventional lysine and arginine (left) are 
compared with “heavy” counterparts (right) and “medium” counterparts (center), where 
asterisks indicate sites where deuterium (D) replaces hydrogen, 13C replaces 12C and/or 15N 
replaces 14N. 
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Figure 1.4 Model of diabetic retinopathy 
Diabetes-related hyperglycemia induce generation of oxidative stress, inflammation, 
advanced glycation end products (AGEs) and activation of Protein Kinase C (PKC) and 
polyol pathways. These activated factors/pathways contribute to hypoxia and 
neovascularization in the eye, leading to vision loss. NPDR is non-proliferative diabetic 
retinopathy, PDR is proliferative diabetic retinopathy. Figure obtained from 91 with sharing 
allowed under a CC-BY license. 
  
21 
 
 
Figure 1.5 Model of macular degeneration 
In AMD, both environmental and genetic factors activates inflammation and cause RPE 
damage. An accumulation of activated immune cells and dysregulated RPE cells then 
contribute to tissue hypoxia, which activates pathological angiogenesis that can eventually 
lead to blindness. Reprinted with permission from Ambati et al.92.  
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Chapter 2. In vivo mouse retinal transcriptome response to 
hypoxia and ALG-1001 treatment  
2.1 Introduction 
In the industrialized nations, retinal diseases are the main cause of clinical blindness1. In the 
United States alone, Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), 
and Diabetic Macular Edema (DME) affect nearly 15 million Americans combined2,3. In 
these diseases, pathogenic hypoxia4,5 and inflammation4–6 of the retinal tissue promotes 
varying amounts of tissue-damaging neovascularization, edema and cell death (DR/DME in 
Figure 1.4 and AMD in Figure 1.5). The current standard of care uses antibodies that target 
the Vascular Endothelial Growth Factor (VEGF), a potent pro-angiogenic cytokine7. For 
many patients, disrupting the disease-associated VEGF signaling slows disease progression 
and helps improve vision2,8. Despite their successes, current anti-VEGF treatments also have 
major limitations: 1) antibodies are expensive to manufacture with the high cost passed on 
to patients9, 2) antibody-based treatment requires monthly intraocular injections that burden 
patients and healthcare providers10, and 3) therapy is ineffective in more than 25-50% of the 
patients depending on the disease11,12.  
ALG-1001 or Risuteganib is an investigational oligopeptide drug that shows promise as an 
alternative therapy for a number of retinal diseases13. In a phase I trial of 15 late-stage DME 
patients, eight subjects experienced significant vision improvement, while the remaining 
seven did not show further vision deterioration14. Importantly, several of the patients that 
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responded to the drug are also refractory to the standard anti-VEGF treatment, suggesting 
ALG-1001 may be able to benefit patients who currently have no therapeutic option. More 
recently, several larger-scale, phase II trials in DR and wet AMD have been concluded with 
similar promising results15–17. In all of the human clinical trials conducted so far, ALG-1001 
showed an excellent safety profile, with no observation of major drug-related side effects 
(14,17–19 and personal communication). Interestingly, clinical data also suggest the visual 
benefit of ALG-1001 may last up to 90 days, which could help alleviate the need for monthly 
doctor visits20. Additionally, the oligopeptide may be a more cost-effective option as it can 
be readily produced synthetically and in more stable formulation than antibodies.  
ALG-1001 has also been studied in animal models of retinal neovascularization that 
resemble DR and wet AMD (Campochiaro lab, Johns Hopkins University (JHU), 
unpublished). Oxygen-Induced Retinopathy (OIR) mouse is one of the models tested and is 
widely-used to study neovascularization that matches the development in human DR 
patients21,22. In this model, one week old pups are moved to a hyperoxia chamber, where high 
oxygen tension regresses existing retinal vasculature and inhibits retinal vessel development 
that normally occurs in the first few weeks postnatal (Figure 2.1)23. After 5 days of hyperoxia 
conditioning, mice are returned to room air, where insufficient oxygen supply due to under-
developed vasculature leads to tissue hypoxia and rapid retinal neovascularization. This 
process lasts for approximately two weeks and eventually ends when balanced oxygen 
supply and demand are restored in the tissue. Thus, unlike conventional laboratory practice 
that places biological specimen in low oxygen environment to induce hypoxia, the OIR 
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model uses hyperoxia treatment to disrupt developing and existing vessels and induce a 
simulated hypoxia condition once the animal returns to room air.  
While often used to study pathology of retinal neovascularization, the OIR model has proven 
to be a useful model for testing anti-angiogenic therapeutics24,25. In a study of ALG-1001 in 
the OIR model, a significant 54% reduction in retinal vessel growth was observed after ALG-
1001 injection relative to vehicle alone (Campochiaro lab (JHU), personal communication). 
Furthermore, the therapeutic effect is dose-dependent, suggesting there is a specific 
modulation of retinal neovascularization by the drug.  
While both clinical trials and in vivo animal studies generated promising results, ALG-1001’s 
mechanism of action requires further investigation (Chapter 1.3). In this study, we applied 
RNA-sequencing (RNA-seq) to measure the drug-induced transcriptome changes in OIR 
retina to study the drug’s mechanism of action. RNA-seq is well suited for detecting effects 
of drug-tissue interaction, as it is both high-throughput and unbiased26. By analyzing the 
entire expressed transcriptome in the mouse model, we found ALG-1001 specifically 
suppressed angiogenic and inflammatory genes and pathways elevated by hypoxia. In 
addition, when compared to other drugs, we found ALG-1001 shares gene regulatory profile 
with drugs that block disease-related cell proliferation pathways. Intriguingly, we only 
observed the therapeutic effect in OIR mice, but not in control mice, suggesting the ALG-
1001’s effect is dependent on the disease state of the retina. 
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To support these analyses, we performed an in-depth analysis of the OIR retinal 
transcriptome change compared to non-hypoxia stimulated control. On top of the expected 
elevation of angiogenesis process, hypoxia-modulated gene, pathway, and transcription 
factor analyses collectively suggested a profound activation of inflammatory processes as 
well as a moderate suppression of neural signaling and metabolic processes. Intriguingly, 
these biological mechanisms also play important roles in retinal disease pathophysiology27, 
but are not well appreciated in the current literature on OIR model (predominantly thought 
as a model of retinal angiogenesis23,28). In agreement, our transcriptome analyses suggest 
OIR mouse may be suitable to model a broader range of retinal diseases and disease 
processes. Altogether, these findings provide novel insight into disease-relevant responses to 
hypoxia in the mammalian retina and modulation of the activated processes by ALG-1001.  
 
2.2 Materials and Methods 
Animal model and RNA-seq sample preparation 
Animal tissues were prepared by the Campochiaro group (JHU) following a well-established 
OIR protocol29–31. In brief, two litters of mouse pups and their mothers were reared in room 
air (RA) until Postnatal day 6 (P6), then in an elevated oxygen environment (75% oxygen 
tension) for 5 days (P7-P11), and later returned to RA on day P12 (referred to as “OIR mice”). 
As a control, two litters of mouse pups and their mothers were raised at RA throughout the 
study (referred to as “RA mice”). On P12, when OIR mice were returned to RA, all mice 
received intravitreal injection of 1uL vehicle in the left eye and 1uL 1% ALG-1001 injection 
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(equivalent to around 1-3mM concentration after complete vitreous diffusion) in the right 
eye. On day P17, all mice were euthanized and their retinal tissues dissected and stored in 
RNA-later (ThermoFisher) at 4°C for 2 days. The tissues were then briefly washed with 
phosphate-buffered saline and disrupted using micro-sized pestle for tissue (Kimble Chase) 
and with QIAshredder (Qiagen). Next, total RNA were extracted using RNeasy Mini Kit 
(Qiagen) and contaminating DNA removed using TURBO DNA-free kit (ThermoFisher). 
RNA quality was measured using Bioanalyzer (Agilent Genomics); all samples were found 
to have least 8.80 RNA integrity number. RNA-seq libraries were then prepared using 
NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs Inc.) and 
sequenced on the HiSeq 2500 (Illumina) to generate on average 12.5 million of single-end, 
100 base pair reads per sample. 
RNA-seq analysis 
Quality control 
FASTQ files generated by RNA-seq were submitted to FastQC for quality control32. All 
samples showed good sequencing quality (Figure S2.1) and were submitted for read 
alignment. Alignment was performed using Tophat233 to the mm10 genome and 
transcriptome references with Bowtie 2 sensitivity level set to very sensitive (alignment 
results summarized in Figure S2.2A). After read alignment, gene counts were quantified 
using HTSeq-count using the intersection-strict model34 (quantification results summarized 
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in Figure S2.2B). FastQC, tophat2 and HTSeq-count reports were visualized using multiQC 
software35. 
Principle Component Analysis (PCA) 
PCA was used to visualize the high-dimensional dataset. To eliminate null values, all counts 
in HTSeq-count-derived count table were increased by one. Transcript per Million (TPM) 
values were then calculated to correct for varying sequencing depth and gene length36. To 
reduce sensitivity to the uncertainty in TPM of low-expressing genes, PCA excluded genes 
for which the TPM averaged over all samples in the analysis was ⟨TPM⟩<5. Five genes that 
have sex-specific expression profile were also excluded (Xist, Uty, Kdm5d, Eif2s3y, and 
Ddx3y) based on inter-sex |log2-fold-change|>3.0 based on edgeR measurement. Finally, 
natural log of TPM values were used as input for PCA. Based on the PCA results, we 
observed one obvious outlier in the dataset. Further analysis of this sample’s profile suggest 
the tissue collected may be contaminated with lens cells (level of Cryaa gene that codes for 
lens crystalline protein37 is 60 times higher in this sample compared to the average of other 
samples). Both the outlier and the fellow eye samples were removed from the rest of the 
study.  
EdgeR differential expression comparison 
To identify modulated genes, it is beneficial to exclude genes that are not expressed or 
expressed at very low level (their inclusion reduces statistical power). Here, we retained 
expressed genes, defined as those with Count per Million (CPM)>1 in at least five samples 
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(the smallest number of biological replicates from the same condition and litter). CPM is 
calculated to normalize for sequencing depth36. Typically, around 14,000 genes remain after 
filtering. Next, edgeR was used to perform the differential expression comparison by 
applying the GLM model to block out expression variability from other confounding 
factors38. When analyzing for differences between OIR + Vehicle and RA + Vehicle, 
variability associated with sex and litter was blocked out. When analyzing for differential 
expression between ALG-1001 and vehicle (performed in either OIR or RA), animal-to-
animal variability was blocked out. After statistical test, genes with False Discovery Rate 
(FDR) ≤ 0.05 were considered as modulated and were further separated into positive and 
negative fold-change gene lists (summarized in Figure S2.7).  
Goseq enrichment analysis of modulated gene list 
Functional analyses of the hypoxia or ALG-1001-modulated genes were performed with the 
goseq package39, which mitigates gene length bias inherent to RNA-seq. Enrichment was 
evaluated for both Gene Ontology (GO) terms (biological processes, cellular components, 
and molecular functions)40 and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
biological pathways41. GO terms associated with genes were obtained from biomart42 while 
KEGG pathways were obtained from the KEGG REST server using the keggrest package43. 
Enrichment was performed separately for the positive and negative fold-change gene lists 
for each comparison. GO terms were considered enriched if FDR<0.05. The GO enrichment 
results were visualized using REVIGO, a visualization tool that aggregates closely-related 
GO terms, with similarity level set to small and GO term size determined using the UniPort 
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Mus musculus database44. Selected GO terms were labeled on the REVIGO plot based on our 
perception of their biological relevance. KEGG pathways were considered enriched if 
Benjamini-Hochberg adjusted p-value<0.05. In addition, “Human Diseases” KEGG 
pathways were removed to improve clarity. 
GAGE pathway enrichment 
In addition to goseq that analyzes genes with statistical significant change, GAGE45 was used 
as an alternative approach to identify modulated KEGG pathways. GAGE uses the measured 
log2-fold-change values of KEGG pathway genes to test if they are significantly different 
from log2-fold-change values associated with the background. Unlike goseq, this approach 
is capable of picking up many small but consistent shift in measured transcript level changes 
that may not be considered statistically significant by edgeR. Same as goseq, a KEGG 
pathway is considered enriched if FDR<0.05.  
ERSSA 
ERSSA was used to check whether the number of biological replicates used in the RNA-seq 
experiment is sufficient to identify a majority of modulated genes46. Since ERSSA currently 
does not support blocking, it was only applied to the OIR + Vehicle vs. RA + Vehicle 
comparison. Analysis was performed with |log2-fold-change| cutoff of 0.5 and 50 
subsamples at each replicate level. 
ISMARA 
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ISMARA47 was used to identify the transcription factors that may be responsible for the 
observed transcript level changes in response to OIR (OIR + Vehicle vs. RA + Vehicle) and 
in response to ALG-1001 (OIR + ALG-1001 vs. OIR + Vehicle). Samples involved in these 
two comparisons were submitted separately to ISMARA to obtain enrichment Z-scores. 
Analysis was focused on the top 50 most statistically significant transcription factor motifs 
as ranked by Z-score. Separately, all samples were also submitted together to obtain target 
gene activity profiles across all four conditions.  
Within the top 50 enriched motif groups, we surveyed their function using Genecard48 and 
Google searches and identified those with hypoxia and disease-relevant functions. Next, we 
identified KEGG pathways that are enriched in the top 50 TF motifs. In this analysis, we 
identified the KEGG pathways associated with the top TF motifs and compared them to the 
background, which consists of KEGG pathways associated with all TF analyzed by ISMARA. 
We tested for any KEGG Pathways that are over-represented in the top 50 motifs compared 
to the background using exact binominal test and then adjust the p-values using Benjamini 
& Hochberg approach49 with statistical cut off set at FDR<0.05. 
Cell type composition analysis 
From previously published mouse retina single cell RNA-seq (scRNA-seq) study50, we 
derived a list of genes that are highly expressed in specific retinal cell types. Briefly, among 
the previously identified 39 retinal cell clusters, we selected cluster #1, 2, 20, 24-26, 34-39 
representing 12 main retinal cell types. For amacrine and bipolar cells, multiple clusters were 
37 
 
identified in the single cell study and for this analysis, we only considered the most populated 
cluster. For each cell type, we isolated the top 20 genes previously found to be highly 
expressed in the particular cluster. From this list, any duplicates among the cell types were 
removed to generate the final cell type-specific marker gene list (Table 2.4). This gene list 
was then used for heat map gene level visualization and fold change analysis to identify likely 
cell type composition change by hypoxia. Only genes with ⟨TPM⟩>0.10 were considered for 
analysis. Cell types with >80% of markers with positive fold change are considered 
expanded, >80% of markers with negative fold change are considered depleted and not 
changed if neither. To validate these results, the cell type composition analysis was repeated 
for mouse brain cell markers obtained from Zeisel et al.51 Supplementary table 1, and mouse 
heart and immune cell markers from Skelly et al.52 figure 1D.  
Enrichr 
To identify other drugs that have similar effect on the transcriptome as ALG-1001, we 
submitted the list of 198 suppressed genes after drug treatment in OIR mice to Enrichr53 and 
compared them to the results of the LINCS L100054 and DrugMatrix datasets55. For this 
analysis, we looked for drugs that also suppressed the same genes as ALG-1001 with 
statistical significance (Enrichr adjusted p-value<0.05). For each analysis, we focused on the 
top 20 drugs with the strongest statistical evidence and identified their mechanism of action.  
Enrichment analysis of Ishikawa et al. (2015) gene set 
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List of modulated genes in DR retinal tissue compared to non-diabetic retina were obtained 
from the original study56. GO biological process enrichment was performed with 
PANTHER57 with adjusted p-value cutoff of 0.05. 
Analysis of Ishikawa et al. (2010) data set 
List of modulated genes in OIR retina compared to control retina were obtained from the 
original study58. Fold changes were calculated from the original microarray data using 
GEO2R59 for plotting and Pearson’s correlation calculations.  
Analysis of Mirabelli et al. (2017) data set 
With the Mirabelli et al. dataset60, differential analysis was performed using GEO2R between 
anti-VEGF antibody and anti-IgG antibody treated samples. Fold changes were used for 
plotting and Pearson’s correlation calculation. 
Correlation measurement with DR and AMD studies 
Hypoxia-modulated genes found in OIR + Vehicle vs. RA + Vehicle comparison were 
selected and converted to human gene symbol using biomart42. Fold changes for Ishikawa56, 
Newman61 and Whitmore62 studies were calculated from the original microarray data using 
GEO2R for plotting and Pearson’s correlation calculations.  
Data availability 
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Raw RNA-seq Fastq files from this study will be available at Gene Expression Omnibus63 
once the study has been published. All enrichment tables will be made available at 
CaltechDATA64. 
Reverse transcription and quantitative polymerase chain reaction (qPCR) 
From the statistically significant genes identified by edgeR, six genes were selected for 
separate validation with qPCR: Vegfa, Tgfbi, Col4a1 and Nrp1 (angiogenesis), Ccnb1 and 
Pdgfb (cell proliferation). SuperScript IV Reverse Transcriptase (ThermoFisher) and 
oligo(dT)20 primer (ThermoFisher) were used to convert polyadenylated mRNA to cDNA. 
qPCR was performed using iTaq Universal SYBR Green Supermix (Biorad) on LightCycler 
480 (Roche) with 45 amplification cycles. Three animals from each of the two litters for each 
condition were randomly selected to constitute 6 biological replicates per condition. To 
enhance accuracy, four technical qPCR replicates of the same cDNA were generated and the 
median value selected for further analysis. Differences were calculated using the ΔΔCt 
method versus Gapdh65. Primers used in this study were obtained from PrimerBank (Table 
2.1)66.  
 
2.3 Results 
In this study, RNA-seq was used to characterize the transcriptome in retinal tissue obtained 
from four conditions (RA and OIR mice treated with vehicle in the left eye and ALG-1001 
in the right eye). First, we visualized the quantified profile of RNA-seq samples with PCA 
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to identify outliers (removed from subsequent analysis) and to observe sample separation 
among the four conditions. Next, we focused on functional analysis of the transcriptome-
level response associated with retinal hypoxia and after ALG-1001 injection in both OIR and 
RA mice. Lastly, we applied analytical tools to identify transcription factors that likely 
influence the observed transcriptome changes.  
PCA of RNA-seq data 
PCA enables visualization of the RNA-seq dataset in a low-dimensional space to identify 
potential outliers and to give an initial impression on the strength of differences among the 
four conditions. First, we focused on the top three principal components (PC1-3All) obtained 
from analysis of all 48 samples (12 per condition), which capture a combined 63% of the 
total variance in the dataset. PC1All alone accounts for 46% of total variance and clearly 
separates the OIR and RA samples (Figure S2.3B). Interestingly, one sample is a strong 
outlier in PC2All dimension (characterized in Methods, Figure S2.3B). To remove the 
outlier’s effect on PCA, both the outlier and its fellow eye sample were removed and PCA 
repeated. The first three PCs from the revised PCA (PCANo-outlier) again capture 62% of total 
variance (Figure 2.2). In addition, PC1No-outlier continues to strongly separate the OIR and 
RA samples, capturing 49% of the total variance in the data set (Figure 2.2B). In comparison, 
PC2No-outlier captures 7% of the total variance and appears to weakly separate the different 
litters, indicating the presence of litter effect in the dataset (Figure S2.4A-B). We also looked 
for PCA separation based on gender and found no observable pattern in PC1-3No-outlier (after 
removal of five gender-specific genes as described in Methods, Figure S2.4C-D).  
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In the analysis of the four groups, none of the top 3 PCs in PCANo-outlier separated vehicle and 
ALG-1001 conditions at room air, whereas there is a weak separation along PC3No-outlier 
among vehicle and ALG-1001 samples in OIR mice (Figure 2.2C). Based on this 
observation, PCA is repeated with only OIR samples to better visualize the quantified 
variation induced by ALG-1001 treatment (Figure S2.5). Some of the main observations 
from this analysis include: a) the strongest principle component only explains 17% of the 
variance among the samples; b) of the top three principal components, PC2OIR distinguishes 
vehicle from ALG-1001 (all mice show higher value on PC2OIR for vehicle relative to ALG-
1001 treated fellow eye, Figure 2.3A). These results show ALG-1001 treatment induced a 
consistent perturbation of the transcriptome in the OIR mice. In contrast, no consistent shift 
was observed in PC1-3RA among the RA samples (PCARA in Figure S2.6, animal-specific 
analysis in Figure 2.3B).  
Hypoxia-associated changes in the transcriptome 
EdgeR was used to identify the genes that differ significantly in quantified level between 
hypoxia (OIR) and control (RA) retina, limited to vehicle samples to avoid confounding 
effect of ALG-1001. EdgeR analysis reveals 6208 genes modulated by hypoxia (satisfied 
FDR<0.05), representing more than 40% of the 14,402 expressed (⟨CPM⟩>1) genes (Figure 
2.4A). The vast majority of the genes modulated by hypoxia also show very strong statistical 
significance (FDR<<10-3, Figure 2.4B). Based on ERSSA analysis, a majority of hypoxia-
modulated genes with |log2-fold-change|>0.50 have been identified (discovery becomes 
marginal past n=9, Figure S2.8A). In addition, ERSSA simulation shows consensus among 
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subsamples (Figure S2.8B), FPR and TPR (Figure S2.8C) metrics continue to improve as 
sample size increases, indicating enhanced accuracy as more samples are included.  
For functional analysis of the genes that are modulated by hypoxia, they are separated into 
two lists (3141 “up” and 3067 “down”) to identify biological processes (GO) and pathways 
(KEGG) that are over-represented. Beyond “response to hypoxia”, GO biological process 
analysis of elevated genes disproportionally identified those that are associated with 
inflammation (“immune system process”, 326 out of  738 expressed “immune response” 
genes are elevated) and angiogenesis (“blood vessel development”, 181 out of 374 expressed 
“angiogenesis” genes are elevated) (Figure 2.5A), which are qualitatively in agreement with 
prior literature (Appendix 2.8.1). A number of functions identified are relevant to both 
angiogenesis67 and inflammation68, including “response to stimulus”, “cell proliferation”, 
and “cytokine production”. Additionally, a significant portion of hypoxia-elevated genes are 
strongly activated, including 586/3141 genes that are increased by more than one-fold 
(Figure S2.7). Intriguingly, processes related to glycolysis that were enriched in prior study 
with shorter hypoxia exposure (1d, P13) are not enriched in this analysis (5d, P17), 
suggesting resolved activation of glycolysis by P17 (Appendix 2.8.1).  
In contrast, GO biological process analysis of hypoxia-suppressed genes disproportionally 
identified processes related to neural system, such as “ion transport”, “chemical synaptic 
transmission”, and “neuron projection development” (Figure 2.5B). Compared to hypoxia-
elevated genes, the effect on the suppressed genes is more modest as only 78 genes are 
reduced by more than one-fold (Figure S2.7). Perhaps due to these small changes and the 
43 
 
longer hypoxia exposure, transcriptome studies of shorter hypoxia exposure in OIR mice did 
not find suppression of neural genes (Appendix 2.8.1).  
Beyond the hypoxia-response “HIF-1a signaling pathway”69, KEGG pathway analysis using 
goseq and the genes elevated in OIR identified cell proliferation and migration pathways that 
are involved in angiogenesis and inflammation: “PI3k-Akt signaling pathway”70,71, “focal 
adhesion”72,73, “regulation of actin cytoskeleton”71,74, and “cell cycle”75,76 (Figure 2.6, 
goseq). Additional KEGG pathways mainly associated with inflammation77 are also 
enriched, including “cytokine-cytokine receptor interaction”, “NF-Kappa B signaling 
pathway”, “JAK-STAT signaling pathway”, “complement and coagulation cascades”, and 
“leukocyte transendothelial migration”. In contrast, goseq applied to hypoxia-suppressed 
genes in OIR identified KEGG pathways that predominantly belong to two groups: 
metabolism and neural systems (Figure 2.7, goseq). Metabolism pathways suppressed by 
hypoxia include “oxidative phosphorylation” and “citrate cycle (TCA cycle)”, which are 
responsible for aerobic respiration78. In relation to neural system, a large number of related 
KEGG pathways are suppressed by hypoxia, including those that function in signaling, 
synapse, and secretory processes79.  
In addition to goseq (a statistical analysis of annotated gene set over-representation in a list 
of modulated genes), GAGE (a statistical analysis of rank order of annotated gene set among 
expressed genes ordered by fold change) was used as an alternative method of identifying 
KEGG pathways using observed transcriptome changes. When applied to analyze fold 
changes affected by hypoxia, GAGE identified fewer KEGG pathways than goseq and only 
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one (“TNF signaling”) that is not discovered by goseq (Figure 2.6 and 2.7, GAGE). 
Altogether, goseq and GAGE analysis provide statistical evidence that angiogenesis and 
inflammation-related pathway genes are elevated, while metabolism and neural system-
related pathway genes are suppressed. 
Transcriptome modulation by ALG-1001 
As evident in the PCA analysis, the effects of ALG-1001 treatment are measurable in OIR 
mice (albeit much weaker than the effects of hypoxia, a weak separation in PC3No-outlier in 
Figure 2.2C, consistent shift in PC2OIR in Figure 2.3A), but not in RA mice (No separation 
in PC1-3No-outlier in Figure 2.2B-C, no shift in PC1-3RA in Figure 2.3B). In contrast to the 
effects of hypoxia, which involved thousands of modulated genes (both “up” and “down”, 
Figure 2.4A), ALG-1001 treatment in RA (Figure 2.8A) and OIR (Figure 2.8B) mice 
affected only a few hundred genes, and essentially all with negative fold change (95% and 
94% of all ALG-1001-modulated genes in RA and OIR mice, respectively).  
Next, goseq-based functional analysis was used to study the suppressed genes (the number 
of elevated genes was too small for meaningful functional enrichment). When applied to the 
70 genes suppressed after ALG-1001 treatment in RA mice, goseq found a limited number 
of GO biological processes with weak statistical significance (Figure 2.9A). Curiously, 
vision-related processes such as “retinol metabolism”, “visual perception”, and “sensory 
perception of light stimulus” are enriched. In particular, five genes involved in retinol 
metabolism (Lrat, Rbp1, Rdh5, Rpe65, and Ttr) are suppressed after ALG-1001 treatment in 
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RA mice. Since retinol plays an important role in the detection of light by photoreceptors80, 
it is unclear whether moderate suppression of these genes may alter normal vision function.  
Analysis of 198 suppressed genes after ALG-1001 treatment in OIR mice identified many 
GO biological processes discovered with hypoxia-elevated genes (89/115 of enriched 
processes), including many related to angiogenesis81,82: “extracellular matrix organization”, 
“integrin-mediated signaling pathway”, “circulatory system development”, and “tube 
development” (Figure 2.9B). While not directly shown on the REVIGO plot, “angiogenesis” 
is also enriched, including 27 of 198 ALG-1001-suppressed genes (many of which are also 
elevated by hypoxia, including Vegfa). Additionally, cellular components (Figure S2.9A) 
and molecular functions (Figure S2.9B) analyses showed strong evidence that genes 
encoding extracellular matrix-located and structural-related proteins are suppressed after 
ALG-1001 treatment in OIR mice. In particular, many of these proteins form the extracellular 
matrix or are proteins that bind to the matrix, both of which are important for cell adhesion 
and migration during angiogenesis83. 
Goseq-based KEGG pathway enrichment supported the results from GO biological process 
analysis. In RA mice, “retinol metabolism” and two other KEGG pathways are enriched with 
ALG-1001-suppressed genes (Figure 2.10B, goseq, RA mice). However, evidence for their 
modulation are weak as indicated by the large adjusted p-values. On the other hand, four 
KEGG pathways are enriched with ALG-1001-suppressed genes in OIR mice, all of which 
are also enriched with hypoxia-elevated genes (highlighted, Figure 2.10B, goseq, OIR 
mice). Of the four, “PI3K-Akt signaling pathway”, “ECM-receptor interaction”, and “Focal 
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adhesion” are associated with various aspects of the angiogenesis and inflammation 
processes70–73. Within the last pathway – “Protein digestion and absorption”, we find ALG-
1001 suppressed a cluster of collagen genes that are involved in both protein metabolism and 
cell adhesion. Since the retinal tissue is not involved in gastrointestinal-based protein 
metabolism, enrichment of this pathway appears to be due to the diverse roles that collagens 
are involved in.  
GAGE analysis of KEGG pathway enrichment corroborated the goseq findings, improving 
the confidence of pathway identification and revealed a few additional modulated pathways 
related to ALG-1001 treatment in OIR mice (Figure 2.10¸GAGE). The four KEGG pathways 
that are identified by goseq with ALG-1001-suppressed genes in OIR mice are indeed the 
most confidently identified pathways found by GAGE (adjusted p-value<10-5, Figure 2.10B, 
GAGE, OIR mice). In addition, GAGE detected four additional KEGG pathways related to 
angiogenesis and inflammation and all eight pathways are enriched with hypoxia-elevated 
genes (highlighted in Figure 2.6, GAGE). Significantly, the overlap with hypoxia-modulated 
pathways is only observed with ALG-1001 treatment in OIR mice, but not in RA mice 
(compare Figure 2.10B, GAGE, OIR mice and Figure 2.10B, GAGE, RA mice).  
One of the main advantages of GAGE is it can detect small, but consistent shifts in the 
transcriptome among genes of a specific annotated gene set. In some cases, changes in 
quantified transcript level may be too small or noisy to be identified as statistically significant 
by software such as edgeR, but these small shifts can collectively have a meaningful 
biological effect. In this case, ALG-1001 only elevated a few genes with statistical 
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significance, which precludes goseq identification of related KEGG pathways. However, 
GAGE found two translation-related KEGG pathways that are elevated in response to ALG-
1001 in OIR mice (“Spliceosome” in Figure 2.10A, OIR mice) and in RA mice (“Ribosome” 
in Figure 2.10A, RA mice). While enrichment of the two pathways are not supported by 
goseq, these findings suggest ALG-1001 treatment elevated genes in protein synthesis 
pathways84, which are known to be disrupted in retinal degeneration85. 
Transcription factors enrichment 
Utilizing the transcriptome data, we used ISMARA to search for the transcription factors 
(TFs) that are likely involved in influencing the quantified changes in response to hypoxia 
(OIR + Vehicle vs. RA + Vehicle) and to ALG-1001 treatment in OIR mice (OIR + Vehicle 
vs. RA + Vehicle). The result is in form of TFs ranked by an enrichment Z-score that 
measures the confidence of their involvement (hypoxia response in Table 2.2 and ALG-1001 
response in Table 2.3). ISMARA shows many TFs that likely elevated target genes after 
hypoxia, including known regulators of cell proliferation (Jun, E2F, ETS, and Tead family 
members), angiogenesis (Fos), and inflammation (Stat2, Spi1, Irf family members, Nfatc3, 
and NF-κB family members) (labeled in Figure 2.11A, activity profile in Figure 2.12)48,86. 
Similarly, TFs with suppressed target genes after hypoxia include those relevant to cell 
proliferation (Hoxb7, Pml, Etv1, and Zbtb14), inflammation (Etv3), neuronal development 
(Rest), metabolism (Ppara), and hypoxia-response (Arnt) (labeled in Figure 2.11B, activity 
profile in Figure 2.13)48.  
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Consistent with earlier analyses, enrichment for TFs corresponding to the transcriptome 
change after ALG-1001 treatment in OIR mice is comparatively less significant. The 
difficulties posed by the small number of the modulated genes after drug treatment are 
particularly acute for ISMARA, which currently does not support removal of inter-animal 
variation to improve detection. As a result, none of the top 50 TFs have Z-score>1.0, which 
is generally used as the significance cutoff (Table 2.3). Nevertheless, biologically relevant 
TFs are observed in the top 50 TFs (labeled in Figure 2.14), with some evidence that indicate 
opposing effect of hypoxia and ALG-1001 (ALG-1001 reversed hypoxia-modulated activity 
level in 8/12 of biologically relevant TF motifs in Figure 2.15). Consistent with edgeR, 
majority of these TFs suppressed target gene activity, including several cell fate and cell 
proliferation-regulating regulator (Erg, Fosl2, Fos, Id4, Sox14, Jun, and Trp53), a hypoxia-
response regulator (Epas1), and two Bcl TFs (Bcl3 and Bcl6) that regulate inflammatory and 
cell-survival processes (Figure 2.15B)48. In particular, Erg, Fos, and Jun are also previously 
enriched with elevated target genes after hypoxia. At the same time, the top 50 TF groups 
also include three biologically relevant TFs with elevated target genes after ALG-1001 
treatment, including Etv1 and Etv6 (cell growth, angiogenesis, migration, and proliferation), 
and Foxo3 (apoptosis and protection against oxidative stress) (Figure 2.15A).  
qPCR 
qPCR was used to validate RNA-seq measured gene level profile for a limited number of 
genes. For this purpose, we selected six genes that are elevated by hypoxia and suppressed 
by ALG-1001, and are involved in angiogenesis (Vegfa, Tgfbi, Col4a1, and Nrp1) or cell 
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proliferation (Ccnb1 and Pdgfb) processes48. Consistent with RNA-seq (Figure 2.16A), 
qPCR measured changes showed the same pattern across all six genes (Figure 2.16B), 
demonstrating high reproducibility between the two detection methods.  
 
2.4 Discussion 
Hypoxia and the associated biological response play central roles in developmental 
processes, injury recovery and chronic diseases (as detailed in reviews87–89). In the eye, a 
pathological hypoxia condition is associated with diseases such as DR90, wet AMD91, 
retinopathy of prematurity90, and intraocular tumor92. In DR, hyperglycemia leads to 
oxidative stress and inflammation, which cause dysfunction of retinal vasculature and 
consequently, hypoxia (Figure 1.4)93,94. In AMD, the inability of the retinal pigment 
epithelium (RPE) to keep pace with the need for phagocytic maintenance of the posterior 
retina leads to development of waste deposits and inflammation, which cause failure of the 
blood-retina barrier and consequently, hypoxia (Figure 1.5)91,95,96. Subsequently, inadequate 
oxygen supply promotes abnormal retinal angiogenesis and inflammation that contribute to 
tissue damage and vision loss. 
As an unbiased source of information regarding the hypoxia response in OIR mouse retina, 
the value of RNA-seq comes through in four ways: a) it reveals new insight into the possible 
relationship between this animal model to human retinal diseases, b) points to possible 
therapeutic targets beyond the current clinically-approved therapies, c) shows evidence of 
change in subpopulations of retinal cells during the hypoxia response, and d) demonstrates 
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how the effects of a proposed therapeutic relate to the modulation of the transcriptome 
associated with hypoxia.  
The RNA-seq results give evidence that the OIR model may have broader relevance than the 
conventional view that it only simulates angiogenic conditions in DR patients: the 
transcriptome suggests that the elevation of the inflammatory response in the OIR mouse 
retina may make it a valuable model of retinal inflammation in both DR and AMD. In relation 
to angiogenic conditions, quantitative information from RNA-seq points to targets that are 
potentially more potent than anti-VEGF therapies that are currently the only clinically 
approved drugs. Applying RNA-seq to an intact tissue (here the retina) reflects two types of 
changes in the transcriptome: changes in tissue composition as result of proliferation, death 
and migration of certain types of cells each with a characteristic expression profile and 
changes in expression of certain genes by cells in the tissue. In relation to an investigational 
drug, application of RNA-seq in a four-arm study reveals that a particular compound has 
very little effect on the retina of unstressed mice and has effects that reverse many of the 
responses to hypoxia when administered to OIR mice. 
Retinal hypoxia activates angiogenesis and inflammation 
To better understand the biological processes active in the retina when insufficient oxygen is 
available, we use the OIR mouse model that exhibits aberrant retinal angiogenesis after 
suppression of retinal vasculature development by raising pups in a hyperoxia chamber 
(Figure 2.1)21,23. In the retina research community, the OIR model is widely used to study 
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retinal angiogenesis23, but considerably less attention has been placed on inflammation and 
other processes activated by hypoxia27. In this study, at height of morphological angiogenesis 
(5 days after inception of simulated hypoxia by returning pups to a normoxic atmosphere)97, 
we found significant elevation of not only angiogenesis, but also inflammatory genes in the 
OIR retina compared to control retina: GO analysis identifies “immune system process” and 
“blood vessel development” (goseq and REVIGO in Figure 2.5A), while enrichment analysis 
identifies KEGG pathways related to angiogenesis (e.g. “PI3K-Akt signaling pathway”70,71 
and “focal adhesion”72) and inflammation (e.g. “NF-Kappa B signaling pathway”77 and 
“leukocyte transendothelial migration”98) (goseq in Figure 2.6, and GAGE in Figure 2.6). 
More broadly, KEGG pathways enriched with genes elevated in OIR retina are involved in 
diverse cellular and system functions including adhesion, migration, proliferation, cell death, 
and inflammation. More importantly, many of the enriched pathways are implicated in DR 
and AMD human pathophysiology (e.g. “PI3K-AKT”99,100, “MAPK signaling” 99,100, “NF-
kappa B”101 and “JAK-STAT”102 pathways). 
Corroborating GO biological process and KEGG pathway analysis of hypoxia-elevated 
genes, TF enrichment also strongly points to transcriptome regulation of both angiogenesis 
and inflammation in the OIR retina (labeled TFs in Figure 2.11). In particular, TFs associated 
with both processes are over-represented with statistical significance in the list of top 50 
enriched TF motifs (Appendix 2.8.11). A particular strength of TF analysis is that it is 
capable of implicating TFs that are uncharacterized altogether, much less having known 
roles in the hypoxia response. TFs that are strongly enriched and not yet annotated (e.g. 
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Nhlh1 and Hsfy2) may represent candidates for future research in retinal hypoxia biology 
(Appendix 2.8.11).   
Retinal hypoxia disrupts neural retina 
Enrichment analysis of genes that are suppressed in OIR retina pointed to cellular 
metabolism and neural system processes (GO biological processes, Figure 2.5B). In relation 
to metabolism, enriched KEGG pathways include aerobic “oxidative phosphorylation” and 
“citrate cycle (TCA cycle)” (Figure 2.7), consistent with prior literature reporting a transition 
away from aerobic respiration to glycolysis in OIR mouse103 and in human AMD104 and 
DR105,106 patients. In relation to neural processes, GO biological process enrichment strongly 
identified neural system processes, including “synapse assembly”, “neurotransmitter 
transport”, and “neuron projection development” (Figure 2.5B). Similarly, genes in multiple 
neurotransmitter signaling and neuronal synapse KEGG pathways are suppressed (goseq and 
GAGE in Figure 2.7), likely due to disruption of normal neural development by hypoxia-
activated processes in OIR retina (in mouse pups, significant retinal neuron differentiation 
and synapse formation take place during the first 3 weeks postnatal107–109). Among the top 
50 TFs identified by ISMARA, only 1/3 were depressed in OIR; nevertheless, this small group 
includes the only neural and metabolism-related TF identified: Ppara (regulator of 
metabolism) and Rest (regulator of neuronal genes) (Figure 2.11B). Although the TF 
evidence is weak, it is compatible with the GO biological process and KEGG pathway 
evidence that metabolism and neural system processes are suppressed in the OIR retina.  
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OIR mouse as a model of human retinal diseases 
The human retina is supplied by two types of vasculature: blood vessels that reside within 
the retina and the choroid capillaries that lie outside of RPE and Bruch’s membrane28 (Figure 
2.23). Physiologically, neovascularization arises from different locations in wet AMD and 
DR. In wet AMD, vessels grow from the choroidal region. In DR, angiogenesis originates 
from the retinal vessels. Due to these differences, several animal models have been created 
to mimic each condition23. The mouse OIR model develops new vessels from the retinal 
blood vessels, as is the case in DR and unlike wet AMD. Therefore, most of the literature on 
the OIR mouse model asserts that it is a useful model for DR (bearing in mind the significant 
differences between the mouse model and the human retinal diseases, Appendix 2.8.12), and 
the conventional wisdom that the OIR mouse is not suitable to model AMD. The present 
RNA-seq data give us an opportunity to compare the changes in the retinal transcriptome of 
OIR mouse to those observed in human donor retina of particular eye diseases relative to 
individuals with no record of retinal disease. 
We begin by comparing the transcriptome changes in OIR to those reported in human donors 
diagnosed with DR in two prior transcriptome studies56,110. A study of human retinal vascular 
endothelial cells derived from DR patients vs. non-diabetic individuals110 reported 
enrichment of 57 GO biological processes among regulated genes – 42 (74%, p-value=0) of 
which were found in the present study of OIR retina, include “angiogenesis”, “inflammatory 
response”, “regulation of cell death”, and other related processes. Another study of human 
DR patients (DR vs. control retina)56, identified 87 elevated genes that are used to enrich 39 
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GO biological processes – 30 (77%, p-value=0) of which overlap our study, with most that 
are related to angiogenesis and inflammation. Intriguingly, we also found some evidence that 
suggest suppression of neural genes in DR retina, consistent with our observation in OIR 
mouse (Appendix 2.8.3).  
Next, we performed a quantitative analysis that compares transcriptome profile of hypoxia-
modulated genes in OIR retina to those found in DR and AMD patients. Based on prior 
literature, we expected to see a stronger correlation between mouse OIR and human DR, than 
for mouse OIR and human AMD. Indeed, hypoxia-modulated gene changes correlated more 
strongly with DR (Pearson’s r=0.3346, Figure 2.24A) than to AMD (r=0.0459-0.2606, 
depending on the stage of AMD, Figure 2.24C). We are surprised to see indications that the 
mouse OIR model captures the immune system process differences between diseased and 
control human retinas as well as angiogenesis genes: when only “immune system process” 
genes are considered, the correlation between OIR mouse and human DR is significant 
(r=0.3948) and nearly equal to the correlation of “angiogenesis” genes (r=0.4073). Indeed, 
the OIR mouse model correlates with immune system processes in AMD, particularly for 
disease states that are not associated with angiogenesis: r=0.261, 0.231 and 0.282 for immune 
system process genes in sub-clinical, dry, and GA AMD, respectively. For these three forms 
of AMD, hypoxia-modulated genes associated with cell death and neuron system processes 
also showed significant correlation with OIR mouse (Appendix 2.8.4).  
Over the past 20 years, the mouse OIR model has been widely used to study retinal 
angiogenesis, but the field has only recently started to appreciate the concurrent 
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inflammatory response to hypoxia27. In the broader research community, the co-occurrence 
of hypoxia-induced angiogenesis and activation of inflammation have been reported in a 
variety of human diseases111,112. Mechanistically, oxygen deprivation activates angiogenesis 
to increase oxygen supply82 and creates a local microenvironment that promotes 
inflammation113 and cell death114,115. Additionally, there is positive cross-talk between the 
activated angiogenesis and inflammation: early angiogenesis forms leaky vessels that 
enhance leukocyte adhesion and migration into the tissue to promote inflammation116, while 
inflammation increases oxygen demand in the tissue and activates angiogenesis117. As a 
result, dysregulation of these processes are thought to reinforce each other to create a 
persistent cytotoxic environment in chronic human diseases such as DR and AMD111. In 
relation, our comparative analysis suggest OIR mice may be relevant to a broader range of 
human retinal diseases (both DR and certain stages of AMD) and disease processes 
(angiogenesis, inflammation, neural disruption, and cell death). 
Angiogenic targets beyond VEGF 
Despite substantial clinical investigation in the past several decades, the only class of drug 
currently approved for DR118 and wet AMD119 consists of antibodies that target VEGF. 
VEGF is a potent pro-angiogenic factor that has been extensively studied in the past for its 
prominent role in activating angiogenesis120, including in the OIR mouse model21. In an 
examination of elevated angiogenesis genes in OIR retina at P17, we found one third of them 
(61 out of 181 total) are quantified to be elevated more than Vegfa (encodes pro-angiogenic 
form of VEGF, 2.27 fold increase, FDR=4.30×10-30). Functionally, these 61 genes are 
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closely related (Figure S2.10), with many involved in cell adhesion/migration (e.g. integrins, 
collagens, fibronectin, and cadherin) and cell proliferation (e.g. growth factors, tyrosine 
protein kinases and their associated proteins), both processes that are essential during 
angiogenesis (Table 2.8). Significantly, only 13 of these genes are downstream of VEGF 
signaling (Table 2.9). Since a majority (approximately 80%) of these highly-elevated 
angiogenesis genes do not appear to be part of VEGF signaling, they suggest other concurrent 
processes are important in driving angiogenesis in the hypoxic retina. Interestingly, Placental 
Growth Factor (Pgf)121 and Fibroblast Growth Factor 2 (Fgf2)122 are both potent pro-
angiogenic factors found to be elevated more than Vegfa, but have not been extensively 
tested in clinical trials of retinal diseases (none that specifically targets Pgf 123 or Fgf2124). 
Therapeutics targeting these growth factors and other highly elevated angiogenic proteins 
may lead to novel treatment of retinal diseases. 
Modulation of retinal cell composition by hypoxia 
Unlike traditional in vitro cell culture, animal tissue is comprised of multiple cell types whose 
populations are not static. In the retina, hypoxia response initiates subpopulation change 
among the retinal cells, which can influence the transcriptome measurement and contribute 
to differential expression identification. Specifically, hypoxia activates angiogenesis and 
inflammation that elevate blood vessel125,126 and immune127–130 cell populations in the retina 
through proliferation of resident cells and migration of systemic cells into the tissue. 
Additionally, hypoxic retinal cells increase production of reactive oxygen species and release 
excess glutamate that induce neuronal cell death131. Prior studies that used flow cytometry129 
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or fluorescent staining125,126,128 methods did observe changes in cell population in the OIR 
model, but these methods are low-throughput with the studies focused on a limited number 
of cell types at a time. On the other hand, while RNA-seq data contain transcriptome signal 
combined from all retinal cell types, it also allow us to analyze all of the retinal cell types at 
once.  
To investigate the representation of 12 common retinal cell types, we used lists of mutually 
orthogonal gene sets that we derived from a recent scRNA-seq study of the mouse retina50.  
Using these cell-type specific gene sets (as described in Methods), we found evidence that 
3 cell types may be expanded (Figure 2.19A), 3 cell types depleted (Figure 2.19B), and 6 
cell types with no strong evidence for change in cell population after hypoxia (Figure 2.20). 
In particular, we found vascular endothelial cells, pericytes and microglia numbers are likely 
expanded in OIR retina (supported by additional evidence using orthogonal markers from a 
brain51 study and a heart52 study, Appendix 2.8.2). Significantly, endothelial cells and 
pericytes are the main cells that form capillary vessels, while microglia are the retina-resident 
immune cells. Evidence for their expansion suggest the observed elevation of angiogenesis 
and immune genes in the OIR retina is not due to only gene expression change, but also tissue 
composition variation.   
We also identified three neuronal cell types that may have depleted population in OIR retina: 
ganglion, amacrine and bipolar cells, which represent 3 out of 4 major neuronal cell types in 
the retina132 (supported by additional evidence using orthogonal markers from a brain study, 
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Appendix 2.8.2). Consistent with these findings, prior study of OIR retina found evidence 
of neuron cell death (in layers of retina containing amacrine, bipolar, horizontal and ganglion 
cells) at P16-17133,134. However, imaging studies also found photoreceptors are susceptible 
to undergo cell death, which was not strongly detected in our transcriptome dataset (rods 
11/20 markers, cones 5/13 markers with negative fold-change in OIR mice). This 
discrepancy between imaging and transcriptome studies may be due to the significantly 
larger number of photoreceptors in the retina135, where death of a limited number of 
photoreceptors is not detectable by whole retina RNA-seq.  
Advantage of drug testing in both stressed and control animals 
Despite over 2000 clinical trials to date136, anti-VEGF therapy is the only class of drug 
approved for DR and wet AMD137, and alarmingly do not work for double digit percentage 
of patients (Chapter 1.1). Despite tremendous amount of clinical efforts, most experimental 
drugs fail in these diseases due to a lack of efficacy or presence of strong adverse events138. 
Thus, any new therapy needs to show both strong therapeutic benefit in patients while 
retaining a high safety profile. ALG-1001 is an experimental drug that matches this profile 
with demonstration of: a) vision improvement across multiple clinical trials in DME and 
AMD patient cohorts15–17 and b) no strong drug-related adverse events after more than 
several hundred human injections (Allegro Ophthalmics, LLC., personal communication). 
In this study, RNA-seq is applied to investigate ALG-1001’s safety profile in control mice 
(RA) and therapeutic effect in disease model mice (OIR). 
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Inclusion of both the unstressed group and the disease model enables us to discover a striking 
difference between effects of an active agent in the two treatment conditions. Specifically, 
we discovered ALG-1001’s pronounced anti-angiogenic and anti-inflammatory effects in the 
OIR group are absent in the RA group (compare GO biological processes enriched in RA 
group in Figure 2.9A and OIR group in Figure 2.9B). Indeed, the ALG-1001 treated eyes 
in the control animals are almost indistinguishable from their sham treated fellows (number 
of drug modulated genes in Figure 2.8A, biological processes enriched in Figure 2.9A and 
lack of separation in PCARA in Figure 2.3B). Altogether, this two-pronged experimental 
design enables quantitative identification of the (potentially therapeutic) effects of an active 
agent in a diseased tissue and the (desirable) absence of effects in unstressed tissue. Our 
findings show potential benefits of using this type of experimental design, which is 
uncommon in the research community that uses transcriptome methods to study drugs and 
diseases (small-scale survey with results summarized in Appendix 2.8.9). 
ALG-1001 modulates hypoxia-induced transcriptome changes 
After ALG-1001 treatment, transcriptome data reveal drug exposure in OIR mice suppressed 
genes that are part of hypoxia-activated angiogenesis and inflammatory-related biological 
processes (GO biological processes, Figure 2.9B) and pathways (goseq in Figure 2.10B, 
GAGE in Figure 2.10B), along with corroborating regulatory evidence (Appendix 2.8.7) 
and analysis that show a general inverse relationship between effects of hypoxia and ALG-
1001 (Appendix 2.8.13). Expanding on these observations, a protein-protein interaction 
graph of the 198 drug-suppressed genes revealed two noticeable clusters of highly-
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interacting proteins (Figure 2.25). One cluster contains growth factors (Vegfa, Fgf1 and 
Pdgfb), growth factor receptors (Met, Pgr and Fgfr2), cell cycle regulators (Ccnb1, Ccnd1, 
Cdk14 and Cdkn1a) and angiogenesis-related proteins (Nrp1, Ets1 and Esm1). The second 
cluster contains many highly related structural proteins including 8 collagen subunits, 3 
laminin subunits, and others (Bgn, Itga9, Timp3, and Zyx). In particular, collagen and 
laminin are important for cell adhesion and migration and promote angiogenesis by 
interacting with endothelial integrin receptors83. Focusing on integrins, we found only one 
integrin subunit (Itga9) is suppressed with statistical significance, but 16/19 of expressed 
integrin subunits have negative fold changes. These changes are too small for statistical 
significance, but when combined with suppression of their extracellular matrix (ECM) 
binding partners, the overall effect may explain drug’s anti-angiogenic mechanism. Indeed, 
in vitro studies of endothelial cells treated with ALG-1001 revealed suppression of cell 
migration and adhesion genes (Chapter 3), which result in measurable reduction of physical 
adhesion and migration of endothelial cells on ECM-coated surfaces (Campochiaro lab, JHU, 
described in Appendix 2.8.5). 
Moderation of hypoxia’s transcriptome effect correlates with observation of mitigated OIR 
vessel growth after ALG-1001 treatment, in a manner that is comparable to current standard 
of care – anti-VEGF antibodies. In this study, we did not test anti-VEGF antibodies (due to 
the high cost of RNA-seq and the paired eye experimental design), but we set out to explore 
the existing literature on transcriptome studies of anti-VEGF treatment for comparative 
analysis with ALG-1001. Despite an extensive search, we only found one microarray dataset 
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that tested anti-VEGF therapy in a stressed rat cornea model and, due to the modest effect of 
anti-VEGF therapy in this model (no regulated genes found), the comparative assessment is 
inconclusive (Appendix 2.8.6). Next, we broadened our analysis to large-scale transcriptome 
studies of drugs, where enrichr was used to search for drugs that primarily suppressed the 
same genes as ALG-1001.  
Despite wide adoption of high-throughput transcriptome methods, only a handful of studies 
had explored drug-induced transcriptome changes on a large number of drugs. Specifically, 
we found two datasets in which we could search for drugs that show significant similarity to 
ALG-1001: 1) the LINCS L1000 data set provides ~20,000 compounds/drugs studied in 
human cancer cell lines across around ~30,000 total experimental settings (varying dosage, 
treatment time, and cell lines)54 and 2) DrugMatrix data set contains 600 compounds tested 
in rat across around 4,000 total experimental settings (varying dosage, treatment time, and 
analyzed tissue)55. First, with the L1000 dataset, enrichr found ALG-1001 transcriptome 
profile matches 390 compounds with statistical significance, albeit with important caveats 
(Appendix 2.8.8). Within the set of 390 drugs, we are surprised that one of ALG-1001’s 
attributes is very rare: genes modulated by ALG-1001 overwhelmingly (93.8%) have 
negative fold change, but only 4 of the 390 drugs showing similarities to ALG-1001 have 
>80% of their DE genes in the negative fold-change category (none of 390 have >90% of 
DE gene as suppressed). Similarly, when this analysis is applied to the DrugMatrix dataset, 
we found ALG-1001 expression profile matches 89 drugs with statistical significance. Of the 
89 drugs with similarities to ALG-1001, none have >70% of their modulated genes as 
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suppressed (only one drug showed >60% of their modulated genes have negative fold 
change). Collectively, these observations suggest ALG-1001 is relatively unique in terms of 
its ability to mainly suppress genes.  
Next, we set out to identify any known mechanism of action among the top 20 enriched 
L1000 (Table 2.11) and DrugMatrix (Table 2.12) compounds. Through a manual search, 
we found known mechanism of action for a majority of the top 20 L1000 drugs, while the 
opposite is true with DrugMatrix compounds (Appendix 2.8.10 describes annotation of 
DrugMatrix top 20 enriched compounds). Here, we will focus on the enriched L1000 
compounds as they can help expand our understanding of ALG-1001’s mechanism of action. 
Among these 20 compounds, we are intrigued to see a majority of them (18/20) are either 
cancer drugs or cell cycle inhibitors. When specifically focused on the cancer drugs, we 
notice more than half of them (8/15, bolded in Table 2.11) are inhibitors of tyrosine kinases, 
which are a large family of proteins that facilitate signal transduction in the cell and play key 
roles in pathological cell proliferation, differentiation, migration, metabolism and cell 
death139,140. In relation to these observations, specific enrichment of tyrosine kinase inhibitors 
suggest ALG-1001 may disrupt targets in related processes, potentially explaining its 
positive effect in retinal diseases. 
 
2.5 Conclusions 
Neovascularizing diseases of the retina are the main cause of clinical blindness in the 
developed nations1. In these diseases, hypoxia is one of the main drivers of 
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neovascularization and inflammation that subsequently disrupt cell function and cause cell 
death91,93,95. Current treatments for these conditions are expensive9, burdensome10 and 
alarmingly do not work in a double digit percentage of patients11,12. ALG-1001 is an 
investigational peptide drug that is promising in treatment of blinding retinal diseases14,19, 
but its mechanism of action requires further exploration.  
In this study, RNA-seq shows simulated hypoxia in mouse OIR retina modulated thousands 
of genes: strongly elevating those related to angiogenesis and inflammation, while weakly 
suppressing others related to metabolism and neural system processes. These quantified 
changes can be explained by a combination of gene expression change in retinal cells and 
hypoxia-induced tissue composition variation, as revealed in a robust cell marker analysis. 
Additionally, quantitative comparative analyses to prior human datasets suggest the OIR 
model may be useful to model a wider range of human retinal diseases and disease processes. 
More broadly, our comparatively large transcriptome dataset can serve as a resource to the 
retinal research community as a foundation to further unravel the extremely complex 
biological processes that drive retinal diseases. 
In terms of therapeutic treatment of these diseases, RNA-seq reveal ALG-1001 co-treatment 
reversed of some of the transcriptome changes activated by hypoxia in OIR retina, 
specifically, the stimulated angiogenesis and inflammation processes. These findings support 
unpublished studies that showed ALG-1001 is effective in mitigating hypoxia-induced 
retinal neovascularization in OIR and several other mouse models (Campochiaro lab, JHU). 
Additionally, these effects are absent in control mice, where the transcriptome change is 
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minor and serves as quantitative evidence that corroborates the drug’s high safety profile in 
clinical studies14,17–19. In fact, this type of four-arm design for transcriptome study is 
uncommon in the drug research field, but should be adapted more widely to identify both 
therapeutic effect and safety profile related to a drug. 
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2.6 Figures and Tables 
 
Figure 2.1 Generation of OIR and RA groups 
Schematic showing treatments applied to all mice in the study. Mice were divided into two 
cohorts: OIR and RA (Room Air) groups. In the RA group, mice were left at room air for 
normal retinal development. In OIR group, mice were treated to 5 days of hyperoxia to 
regress retinal vessels, which then causes retinal angiogenesis that reaches peak development 
on P17. On P12, all mice are also injected intraocularly with either vehicle (Veh) or ALG-
1001 (ALG). Retinal sample were collected on P17 for whole tissue RNA-seq. Schematic 
developed with significant modification from original figure by Stahl et al.23.  
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Figure 2.2 PCA with outlier pair of samples removed 
PCANo-outlier with all samples except the outlier and its fellow eye sample. PC_# is principal 
component #. A. Percent of overall variance captured by the top 10 principal components. 
B-C. Samples in PC1 and PC2, PC1, and PC3, respectively. Percent of variance explained is 
shown in axis label. PC1No-outlier strongly separates OIR from RA samples. 
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Figure 2.3 Animal-specific change in PCA coordinate values between ALG-1001 and 
vehicle treated eyes 
PCA performed separately for OIR mice (A, PCAOIR in Figure S2.5) and RA mice (B, 
PCARA in Figure S2.6). For each paired sample from the same animal, the difference in PCA 
transformed value is calculated and plotted. In OIR mice, ALG-1001 treated samples show 
a consistent shift in PC2OIR compared to fellow vehicle treated samples. Red line indicates 
zero difference. PC_# is principal component # and analysis excluded outlier sample pair. 
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Figure 2.4 edgeR comparison that reveals hypoxia-modulated genes in retina 
EdgeR comparison of OIR + vehicle relative to RA + vehicle as control. Modulated genes 
are colored red while all others are black. Genes outside of display window are symbolized 
by triangle. A. Measured CPM and fold-change for each expressed gene. B. Measured fold-
change and FDR displayed for each expressed gene. Blue dashed line indicates FDR=0.05.  
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Figure 2.5 GO biological process enrichment with hypoxia-elevated and -suppressed 
genes  
Hypoxia-elevated (A) and -suppressed (B) genes (OIR + Vehicle vs. RA + Vehicle) are 
submitted for GO enrichment with results visualized using REVIGO. In part A, many GO 
processes enriched are related to angiogenesis and inflammation. In part B, a significant 
number of GO processes enriched are related to neural system. P-value is REVIGO-derived 
GO enrichment p-value. Selected biologically relevant processes are labeled.   
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Figure 2.6 KEGG pathways enriched with hypoxia-elevated genes 
Elevated KEGG pathways enriched with goseq using hypoxia-elevated genes (left) or GAGE 
with edgeR measured fold changes in comparison of OIR + Vehicle vs. RA + Vehicle (right). 
Many enriched pathways are related to inflammation, angiogenesis, cell proliferation and 
death. Highlighted pathways are enriched with ALG-1001-suppressed genes in OIR mice by 
goseq or GAGE. Statistically significant pathways are displayed. Benjamini Hochberg (BH) 
adjusted P-value is displayed on the x-axis.   
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Figure 2.7 KEGG pathway enriched with hypoxia-suppressed genes 
Suppressed KEGG pathways enriched with goseq using hypoxia-suppressed genes (left) or 
GAGE with edgeR measured fold changes in comparison of OIR + Vehicle vs. RA + Vehicle 
(right). Many enriched pathways are related to metabolism and neural system. No pathways 
overlap with those enriched with ALG-1001-elevated genes in OIR mice. Statistically 
significant pathways are displayed. Benjamini Hochberg (BH) adjusted P-value is displayed 
on the x-axis.   
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Figure 2.8 edgeR comparisons of ALG-1001 vs. vehicle treatment 
EdgeR comparison of RA + ALG-1001 vs. RA + vehicle (A, C) and OIR + ALG-1001 vs. 
OIR + vehicle (B, D). Modulated genes are colored red while all others are black. A-B. 
Measured CPM and fold-change for each expressed gene. C-D. Measured fold-change and 
FDR displayed for each expressed gene. Blue dashed line indicates FDR=0.05.  
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Figure 2.9 GO biological process enrichment of genes suppressed after ALG-1001 
treatment 
Suppressed genes after ALG-1001 treatment in RA mice (A) and OIR mice (B) relative to 
vehicle treated control are submitted for GO biological process enrichment with results 
visualized using REVIGO. Few processes with weak statistics are enriched with ALG-1001 
treatment in RA mice, while those related to angiogenesis and inflammation are enriched 
with ALG-1001 treatment in OIR mice. P-value is REVIGO-derived GO enrichment p-value. 
Selected biologically relevant processes are labeled.  
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Figure 2.10 KEGG pathways enriched with ALG-1001-modulated genes 
KEGG pathways significantly enriched with genes (A) elevated in the ALG-1001-treated 
eye relative to its fellow eye and (B) suppressed in ALG-1001-treated eye relative to its 
fellow eye. In each case, results for the RA mice are above those of the OIR mice. Results 
are shown for analysis with both goseq and GAGE. Benjamini Hochberg (BH) adjusted P-
value is displayed on the x-axis. 
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Figure 2.11 ISMARA enrichment for TFs associated with retinal hypoxia response 
Raw reads of OIR + Vehicle and RA + Vehicle samples were submitted to ISMARA to enrich 
for TFs that are likely involved in regulating retinal hypoxia response. Plot shows the top 50 
enriched TFs (Table 2.2) ranked by Z-score with: elevated (A) or suppressed (B) average 
target gene activity in OIR mice. Biologically relevant TFs are labeled with color by 
associated functions: cell proliferation and death (orange), angiogenesis (pink), inflammation 
(blue), neuronal development (black), metabolism (green), and hypoxia-response (gray).   
76 
 
 
Figure 2.12 Activity profile of selected TF motifs with hypoxia-elevated target genes 
OIR + Vehicle and RA + Vehicle samples were submitted to ISMARA to enrichment for TFs 
that are likely involved in retinal hypoxia transcriptome response. Activity profile (mean + 
standard deviation, values multiplied by 100) of selected TF motifs with elevated target 
activity in OIR vehicle condition are plotted.   
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Figure 2.13 Activity profile of selected TF motifs with hypoxia-suppressed genes 
OIR + Vehicle and RA + Vehicle samples were submitted to ISMARA to enrichment for TFs 
that are likely involved in retinal hypoxia transcriptome response. Activity profile (mean + 
standard deviation, values multiplied by 100) of selected TF motifs with suppressed target 
activity in OIR vehicle condition are plotted.   
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Figure 2.14 ISMARA enrichment for TFs associated with ALG-1001 treatment 
response in OIR mice 
Raw reads of OIR + ALG-1001 and OIR + Vehicle samples were submitted to ISMARA to 
enrich for TFs that are likely involved in regulating ALG-1001’s effect in OIR mice. Plot 
shows the top 50 enriched TFs (Table 2.3) ranked by Z-score with: elevated (A) or 
suppressed (B) average target gene activity in ALG-1001-treated samples. Biologically 
relevant TFs are labeled with color by associated functions: cell proliferation and death 
(orange), inflammation (blue), and hypoxia-response (gray). 
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Figure 2.15 Activity profiles of selected TF motifs with ALG-1001-modulated genes 
in OIR 
OIR + ALG-1001 and OIR + Vehicle samples were submitted to ISMARA to enrichment for 
TFs that are likely involved in regulating ALG-1001’s effect in OIR mice. Activity profile 
(mean + standard deviation, values multiplied by 100) of selected TFs with (A) elevated or 
(B) suppressed target activity in OIR + ALG-1001 condition are plotted.  
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Figure 2.16 qPCR validation of selected RNA-seq results 
Six genes shown by RNA-seq to be activated during retinal hypoxia (OIR + Vehicle vs. RA 
+ Vehicle) and suppressed by ALG-1001 (OIR + ALG-1001 vs. OIR + Vehicle) are selected 
for qPCR validation. Quantified gene levels are normalized in both plots so that average RA 
+ Vehicle level is 1. The mean and standard deviation are shown. A. RNA-seq gene level 
based on TPM values. B. qPCR gene level based on ΔΔCt-derived fold changes. RNA-seq 
and qPCR quantified gene levels are consistent across genes and conditions. 
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Figure 2.17 Compare P12.5 and P17 hypoxia-modulated genes 
Analysis limited to hypoxia-modulated genes at (A) P12.5, (B) P17, and (C) P17 modulated 
genes with |log2-fold-change|>1 in the present study. X-axis shows fold changes in P17 
mouse OIR retina compared to control (current study, vehicle comparison), Y-axis shows 
fold changes in P12.5 mouse OIR retina compared to control (Ishikawa et al.58, untreated 
comparison). Dashed blue lines indicate Y=0 and X=0 lines. Log2FC is log2-fold-change. 
Pearson’s correlation coefficients are shown in plot title. Correlation values show positive 
correlations across all gene sets tested, but significantly higher correlation when analysis is 
limited to hypoxia-modulated genes at P12.5.   
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Figure 2.18 High correlation between qPCR from Sato study and RNA-seq 
Genes in Sato study97 are selected for visualization, with RNA-seq measured fold change 
(OIR + Vehicle vs. RA + Vehicle) on X-axis and qPCR (OIR vs. RA) measured fold change 
on Y-axis. Dashed blue lines indicate Y=0 and X=0 lines. Pearson’s correlation coefficients 
are shown in plot title. All genes measured in the Sato study that are also measurable with 
RNA-seq are plotted in (A). Nrp2 appears to be an outlier and is removed in (B) with 
Pearson’s correlation re-calculated. With Nrp2 removed, a relatively high correlation is 
observed between the two datasets.   
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Figure 2.19 Retinal cell type-specific gene level change heatmap – part 1 
Normalized TPM (Norm. TPM) values of retinal cell type-specific genes are visualized in 
form of heatmap. All non-outlier samples are sorted column-wise by condition as indicated 
by color bar on top of heatmap. Norm. TPM values of each sample are summarized by box 
plot below heatmap. Cell types are categorized by >80% (A) or <20% (B) of markers with 
positive hypoxia-induced fold change (OIR + Vehicle vs. RA + Vehicle), suggesting 
evidence for specific cell type expansion or depletion after hypoxia. 
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Figure 2.20 Retinal cell type-specific gene level change heatmap – part 2 
Normalized TPM (Norm. TPM) values of retinal cell type-specific genes are visualized in 
form of heatmap. All non-outlier samples are sorted column-wise by condition as indicated 
by color bar on top of heatmap. Norm. TPM values of each sample are summarized by box 
plot below heatmap. All cell types have within 20-80% of markers with positive hypoxia-
induced fold change (OIR + Vehicle vs. RA + Vehicle), suggest lack of strong evidence for 
cell composition change by hypoxia.  
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Figure 2.21 Brain cell type-specific gene level heatmap 
Normalized TPM (Norm. TPM) values of brain cell type-specific genes are visualized in 
form of heatmap. All non-outlier samples are sorted column-wise by condition as indicated 
by color bar on top of heatmap. Norm. TPM values of each sample plotted as a heatmap and 
summarized by box plot below heatmap. Endothelial and microglia cells show transcriptome 
sign of cell number expansion after hypoxia while interneuron show sign of cell number 
depletion.  
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Figure 2.22 Heart and immune cell type-specific gene level heatmap 
Normalized TPM (Norm. TPM) values of heart and immune cell type-specific genes are 
visualized in form of heatmap. All non-outlier samples are sorted column-wise by condition 
as indicated by color bar on top of heatmap. Norm. TPM values of each sample plotted as a 
heatmap and summarized by box plot below heatmap. Endothelial, macrophage and 
pericytes cells show transcriptome signs of cell number expansion after hypoxia.   
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Figure 2.23 Blood vessels that support the retina 
The retinal tissue is composed of distinguishable cell layers and is supported by two systems 
of blood vessel: choroidal and retinal vessels. In diabetic retinopathy and related diseases, 
neovascularization originates from the retinal vessels. In wet age-related macular 
degeneration, vessel growth stems from chorodial vessel and expand into the retina through 
Bruch’s membrane and retinal pigment epithelium.  
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Figure 2.24 Hypoxia-modulated genes in OIR show positive correlation with DR and 
AMD 
Hypoxia-modulated genes in OIR + Vehicle vs. RA + Vehicle were selected for plotting with 
their log2-fold-change on the X-axis. Y-axis shows log2-fold-change derived from human 
clinical studies of DR (A, Ishikawa study56) and AMD (B, Whitmore study62 and C, Newman 
study with samples from various stages of AMD61) patients versus healthy cohorts. Pearson’s 
correlations are calculated for each plot and displayed in the title. Correlation to Whitmore 
study is low due to different tissues tested (RPE and choroid tissue in Whitmore study versus 
retina in the present study). Positive correlations are observed across all comparisons with 
the highest between OIR mice and DR patients.  
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Figure 2.25 Protein-protein interaction graph of ALG-1001-suppressed genes in OIR 
mice 
Suppressed genes in the comparison OIR + ALG-1001 vs. OIR + Vehicle were submitted to 
STRING to visualize connection between the proteins these genes encode. Closely-associated 
proteins were clustered into two observable clusters that include proteins that regulate 
angiogenesis, cell growth, motility and adhesion.   
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Gene Direction 5' to 3' Sequence 
Gapdh Forward AGGTCGGTGTGAACGGATTTG 
Gapdh Reverse TGTAGACCATGTAGTTGAGGTCA 
Vegfa Forward GCACATAGAGAGAATGAGCTTCC 
Vegfa Reverse CTCCGCTCTGAACAAGGCT 
Tgfbi Forward CAGCACGGCCCCAATGTAT 
Tgfbi Reverse GGGACCTTTTCATATCCAGGACA 
Col4a1 Forward CTGGCACAAAAGGGACGAG 
Col4a1 Reverse ACGTGGCCGAGAATTTCACC 
Ccnb1 Forward AGAGCTATCCTCATTGACTGGC 
Ccnb1 Reverse AACATGGCCGTTACACCGAC 
Pdgfb Forward TGCTGCACAGAGACTCCGTA 
Pdgfb Reverse GATGAGCTTTCCAACTCGACTC 
Nrp1 Forward GACAAATGTGGCGGGACCATA 
Nrp1 Reverse TGGATTAGCCATTCACACTTCTC 
Table 2.1 qPCR primers 
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Transcription Factor Z-score 
Activity diff. 
OIR + Vehicle –  
RA + Vehicle 
Activity diff.  
OIR + ALG-1001 – 
OIR + Vehicle 
Esrrb_Esrra 3.430265 -0.03231 -0.00108 
Hoxb7 3.320527 -0.05074 -0.00091 
Rest 3.299146 -0.04594 -0.00013 
Erg 3.294661 0.038089 -0.00408 
Stat2 3.211164 0.055767 -0.00141 
Spi1 3.082239 0.024399 -0.00136 
Irf2_Irf1_Irf8_Irf9_Irf7 3.033734 0.064852 -0.0005 
Elf1_Elf2_Etv2_Elf4 2.875717 0.022166 0.004149 
Tead1 2.379707 0.023405 -0.00212 
Tead3_Tead4 2.340649 0.034684 -0.00265 
Etv3_Erf_Fev_Elk4_Elk1_E
lk3 
2.322505 -0.02009 0.001095 
Irf5_Irf6 2.314453 0.016595 0.000054 
Ppara 2.237315 -0.0259 0.000813 
Irf3 2.143088 0.022035 0.000424 
Spic 2.130711 0.031155 0.00171 
E2f1 2.093629 0.023454 0.000368 
Rela_Rel_Nfkb1 2.019875 0.035114 -0.00309 
Nhlh1 2.013827 -0.01724 0.000541 
Hsfy2 1.929333 0.018104 -0.00114 
Etv1_Etv5_Gabpa 1.897489 -0.01673 0.004982 
Nfil3_Tef 1.893919 -0.02395 0.000293 
Runx2_Bcl11a 1.864103 0.015979 0.000558 
Zbtb14 1.86305 -0.01603 -0.00019 
Onecut1_Cux2 1.810252 -0.01471 -0.00137 
Spib 1.796229 0.022922 0.001562 
Tcf7l1 1.791399 0.020335 -0.00218 
Nkx3-2 1.739507 0.018187 -0.00146 
Vdr 1.726826 -0.01608 0.001313 
Klf4_Sp3 1.699623 0.01458 -0.00276 
Fos 1.691026 0.016206 -0.00398 
Srf 1.638139 0.023866 -0.00307 
Nfic_Nfib 1.602884 0.02684 -0.00318 
Chd1_Pml 1.592378 -0.01424 -5.6E-05 
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Nfatc3 1.554134 0.018816 0.000899 
Cebpb 1.53586 0.023171 -0.00088 
Myog_Tcf12 1.527287 -0.01169 -0.00254 
Jun 1.522605 0.014055 -0.00274 
Brca1 1.502649 -0.01066 -0.00058 
Nfe2_Bach1_Mafk 1.493496 -0.01506 -0.00204 
Arnt 1.462555 -0.01142 -0.00049 
Nr2c2 1.454343 0.020481 0.002312 
Foxf1 1.445879 -0.01458 -0.00062 
Nrf1 1.433137 -0.01262 0.006486 
Hey2 1.426067 -0.00987 -0.0005 
Hoxa4 1.421377 -0.01097 0.001539 
E2f4 1.404575 0.013226 -0.00129 
E2f2_E2f5 1.380132 0.021169 -0.00248 
Nr2e1 1.370329 -0.00996 0.00128 
Snai1_Zeb1_Snai2 1.358701 -0.01225 0.002979 
Pou2f2_Pou3f1 1.346542 0.019262 0.000696 
Table 2.2 Top 50 TF motifs enriched with hypoxia 
TF motifs are ordered by Z-score calculated by ISMARA between OIR + Vehicle and RA + 
Vehicle. “Activity diff. OIR + Vehicle – RA + Vehicle” is the average target gene activity 
difference between OIR + Vehicle and RA + Vehicle conditions. “Activity diff. OIR + ALG-
1001 – OIR + Vehicle” is the average target gene activity difference between OIR + ALG-
1001 and OIR + Vehicle conditions. Average target gene activity value was calculated by 
ISMARA and is a measure of average expression of genes that contain the TF motif47. A 
positive activity difference indicates higher average expression of target genes in the first 
condition of the comparison. Bolded TFs indicate those that are also found in the list of top 
50 TF motifs identified with ALG-1001 treatment in hypoxia condition. Selected 
biologically relevant TFs are labeled in Figure 2.11 and their activity profile in Figure 2.12 
and 2.13. 
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Transcription Factor Z-score 
Activity diff. 
OIR + Vehicle –  
RA + Vehicle 
Activity diff.  
OIR + ALG-1001 – 
OIR + Vehicle 
Fosl2_Bach2 0.866357 -0.0049 -0.00509 
Zfp263 0.819355 0.012223 -0.00343 
Epas1_Bcl3 0.811259 -0.00834 -0.00519 
Zfx_Zfp711 0.728028 -0.00205 0.004629 
Fos 0.693695 0.016206 -0.00398 
Etv1_Etv5_Gabpa 0.662583 -0.01673 0.004982 
Id4 0.620802 0.003379 -0.00362 
Zfp652 0.616116 0.011292 -0.00288 
Etv6 0.567969 -0.005 0.002375 
Bcl6 0.562167 0.000266 -0.00336 
Nr1i2 0.556931 0.005574 -0.00342 
Sox14 0.552916 0.000295 -0.00319 
Nfe2l2 0.552207 -0.00472 -0.00257 
Tcf21_Msc 0.530699 -0.00055 0.002127 
Klf1 0.512749 0.00123 -0.00515 
Nrf1 0.510102 -0.01262 0.006486 
Nr5a2 0.506052 0.000782 0.002753 
Pitx3 0.501015 0.012145 0.00327 
Hes5_Hes7 0.496144 -0.00357 0.001916 
Tfap2d 0.492704 0.007685 0.002097 
Hmx1 0.489585 0.005463 0.002019 
Elf1_Elf2_Etv2_Elf4 0.489097 0.022166 0.004149 
Rfx5 0.486523 0.011514 0.002021 
Zfp219_Zfp740 0.475588 0.000603 0.003176 
Hcfc1_Six5_Smarcc2_Zfp14
3 
0.461353 -0.00939 0.005259 
Atf3 0.457336 -0.00924 0.003532 
Jun 0.456271 0.014055 -0.00274 
Myf6 0.451113 -0.0023 -0.00301 
Zic4 0.445612 -0.00533 0.001703 
Bsx 0.444895 0.004805 -0.00175 
Tead1 0.437919 0.023405 -0.00212 
Rorc_Nr1d1 0.424381 0.001066 0.001643 
Cux1 0.42068 -0.00216 0.002518 
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Foxo3 0.420198 0.003627 0.00162 
Zbtb4 0.41824 -0.00849 0.001714 
Srf 0.416023 0.023866 -0.00307 
Taf1 0.412891 -0.01311 0.007399 
Mafb 0.411795 0.001309 0.001874 
Arntl_Tfe3_Mlx_ 
Mitf_Mlxipl_Tfec 
0.406988 0.005772 0.002271 
Erg 0.40352 0.038089 -0.00408 
Tcf7l1 0.401934 0.020335 -0.00218 
Pitx2_Otx2 0.398509 0.01238 0.003785 
Myog_Tcf12 0.398378 -0.01169 -0.00254 
Gsx1_Alx1_Mixl1_Lbx2 0.397332 -0.00475 -0.00163 
Vsx1_Uncx_Prrx2_ 
Shox2_Noto 
0.396899 -0.00391 -0.00281 
Elf5 0.392256 -0.00897 0.003303 
Gsc2_Dmbx1 0.389319 -0.00164 0.001911 
Sox6_Sox9 0.384688 0.015104 -0.0018 
Trp53 0.382392 0.010513 -0.00165 
Nfe2_Bach1_Mafk 0.381502 -0.01506 -0.00204 
Table 2.3 Top 50 TF groups identified with ALG-1001 treatment under hypoxia 
TF motifs are ordered by Z-score calculated by ISMARA between OIR + ALG-1001 and OIR 
+ Vehicle. “Activity diff. OIR + Vehicle – RA + Vehicle” is the average target gene activity 
difference between OIR + Vehicle and RA + Vehicle conditions. “Activity diff. OIR + ALG-
1001 – OIR + Vehicle” is the average target gene activity difference between OIR + ALG-
1001 and OIR + Vehicle conditions. Average target gene activity value was calculated by 
ISMARA and is a measure of average expression of genes that contain the TF motif47. A 
positive activity difference indicates higher average expression of target genes in the first 
condition of the comparison. Bolded TFs indicate those that are also found in the list of top 
50 TF motifs enriched with hypoxia exposure. Selected biologically relevant TFs are labeled 
in Figure 2.14 and their activity profile in Figure 2.15. 
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Cell type Genes 
Horizontal 
cells 
Calb1;Tpm3;Sept4;Slc4a3;Vim;Gnas;Pcsk1n;Smarca4;Snhg11; 
Ndrg1;Snap25;Cd47;Maged1;Tfap2b;Mgarp;Ndrg4;Ppp1r1a 
Retinal 
ganglion cells 
Nefl;Nefm;Stmn2;Sncg;Uchl1;Stmn3;Thy1;Slc17a6;Nrn1;Gap43; 
Cdk14;Ywhah;Tubb2a;Calm2 
Amacrine cells Ppp1r17;Tcf4;Meg3;Syt1;Ebf3;Pnmal2;Marcks;Lgr5;Celf4;Elavl3; 
Gria2;Ebf1;Basp1;Snca;Sphkap 
Rods Rho;Sag;Pdc;Gngt1;Gnat1;Prph2;Gnb1;Pde6g;Pde6b;Rcvrn;Rp1; 
Tulp1;Rom1;Cnga1;Nr2e3;Nrl;Slc24a1;Hmgn1;Rpgrip1;Rs1 
Cones Pde6h;Opn1sw;Gngt2;Opn1mw;Arr3;Gnat2;Pde6c;Kcne2;Guca1a; 
Cd59a;Ccdc136;Gnb3;Scg3 
Bipolar cells Trpm1;Pcp2;Calm1;Gng13;Isl1;Gnao1;Pcp4;Prkca;Nme1;Car8; 
Chgb;Gpr179;Vsx2;Lrtm1;Qpct;Lin7a;Ablim1;Grm6;Map4;Gm4792 
Muller glia Acsl3;Rlbp1;Slc1a3;Car2;Spc25;Car14;Mfge8;Crym;Rtn4; 
Gpr37 
Astrocytes Igf2;Aldoc;S100b;Pdgfra;Gpm6b;Id3;Cntnap2;Mlc1 
Fibroblasts Crhbp;Optc;Col18a1;Gja1;Ptgds;Fbn2;Fstl1;Fbln1;Tsc22d1;Pvrl3; 
Col23a1;Timp3 
Vascular 
endothelium 
Bsg;Flt1;Cldn5;Ptprb;Itm2a;Ramp2;Cd93;Fn1;Spock2;Ctla2a;Pltp 
Pericytes Rgs5;Mgp;Cald1;Aspn;Nid1;Itga1;Serpine2;Pdgfrb;Myl9;Itgb1; 
Higd1b 
Microglia Ctss;Hexb;C1qb;Lgmn;C1qc;C1qa;B2m;Sepp1;Cx3cr1;Ly86; 
Laptm5;Jun;Ctsb;Csf1r 
Table 2.4 Mouse retina cell type-specific marker genes  
The set of cell type-specific markers are derived from the Macosko et al. scRNA-seq 
dataset50. The selected marker genes are found to be expressed at a high level in each cell 
type and not in the other cell types included in this analysis.  
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Human 
Disease 
Comparison 
Modul
ated 
genes 
in 
OIR1 
Non-
modul
ated 
genes 
in 
OIR2 
Modulated gene in OIR with GO term3 
Immun
e system 
process 
Angiog
enesis 
Cell 
death 
Metabolic 
process 
Nervou
s system 
develop
ment 
Diabetic Retinopathy (Ishikawa) 
DR 0.3347 0.059 0.3948 0.4073 0.3484 0.3293 0.2999 
Age-related Macular Degeneration (Newman) 
Pre-AMD 0.0459 0.0108 -0.0042 0.0641 0.0631 0.0411 0.1096 
Sub-clinical 
AMD  
0.2606 0.0386 0.2613 0.1367 0.2767 0.2561 0.3292 
Dry AMD 0.199 0.052 0.2307 0.1765 0.2592 0.2189 0.2761 
GA AMD 0.216 0.0284 0.2818 0.2264 0.2627 0.2355 0.2477 
CNV AMD 0.123 0.0043 0.2179 0.0477 0.1751 0.1243 0.1638 
GA and 
CNV AMD 
0.0654 -0.0205 0.1194 -0.0415 0.0625 0.0602 0.0898 
Age-related Macular Degeneration (Whitmore) 
Dry AMD 0.0324 0.0116 0.0286 0.1102 0.0339 0.0075 0.018 
Table 2.5 Pearson’s correlation of fold changes between OIR and disease studies 
1All hypoxia-modulated genes found in OIR + Vehicle vs. RA + Vehicle comparison are 
included for calculation. 
2All non-hypoxia-modulated genes found expressed in mouse retina are included for 
calculation. 
3Pearson’s r calculated with genes included in the following GO biological processes: 
“immune system process”, “angiogenesis”, “cell death”, “metabolic process” and “nervous 
system development”. Aside from “metabolic process”, all others are enriched in goseq 
enrichment analysis. “Metabolic process” is selected as it encompasses several related 
metabolic processes that are enriched in goseq analysis. 
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Correlation to Whitmore study is low due to different tissues analyzed (RPE and choroid 
tissue in Whitmore study versus retina in Ishikawa, Newman, and the present studies). 
 
 
 
 
 
 
 
Study Method Sample 
size 
OIR 
time 
point 
Study 
of 
hypoxia 
Study 
of 
drug 
Raw 
data 
available 
Modulated 
gene list 
available 
Hoppe141 RNA-seq 6 P12 No Yes No No 
Ishikawa58 Microarray 3 P12.5 Yes No Yes Yes 
Yang142 Microarray 3 P13 Yes No No Yes 
Oubaha143 Microarray 2 P14 Yes No No No 
Sato97 qPCR,  
94 genes 
1 P12-
P21 
Yes No Yes No 
Table 2.6 Mouse OIR transcriptome studies 
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Study Method Sample size Disease Raw data 
available 
Modulated 
gene list 
available 
Ishikawa56 Microarray 3 control, 
6 DR 
DR Yes Yes 
Lam110 RNA-seq 4 control, 
8 DR 
DR No No 
Newman61 Microarray 31 control, 
37 AMD 
AMD Yes Yes 
Hunter144 Microarray 11 control, 
10 AMD 
AMD No Yes, but 
discovery 
with mixed 
samples 
Radeke6 Microarray 10 control, 
5 AMD 
AMD No Yes, but 
between 
macular and 
extramacular 
samples 
Whitmore62 Microarray 9 control, 
9 AMD 
AMD Yes No 
Table 2.7 Human retinal disease transcriptome studies 
Comparative analysis limited to Ishikawa, Lam, Newman, and Whitmore studies due to 
availability of raw data (Ishikawa, Newman, and Whitmore) and GO biological processes 
enriched using genes with statistically significant change (Lam). Hunter study is excluded 
due to both a lack of raw data and mixing of samples from different AMD stages and tissue 
specimens. Radeke study is excluded as it did not study expression difference between AMD 
and control cohorts.  
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Gene Ontology Selected 
Gene 
Frequency 
Total 
Frequency 
Percent 
of Total 
Biological process 61 20952 0.3 
Developmental process 61 5717 1.1 
Anatomical structure development 61 5271 1.2 
Multicellular organism development 61 4846 1.3 
System development 61 4354 1.4 
Anatomical structure morphogenesis 61 2409 2.5 
Anatomical structure formation involved in 
morphogenesis 
61 1050 5.8 
Circulatory system development 61 1030 5.9 
Cardiovascular system development 61 699 8.7 
Vasculature development 61 687 8.9 
Blood vessel development 61 663 9.2 
Blood vessel morphogenesis 61 568 10.7 
Angiogenesis 61 476 12.8 
Cellular process 59 16081 0.4 
Regulation of cellular process 55 11255 0.5 
Response to stimulus 52 9183 0.6 
Regulation of developmental process 45 2380 1.9 
Localization 44 5544 0.8 
Cell communication 43 6871 0.6 
Signaling 43 6807 0.6 
Cell differentiation 42 3789 1.1 
Metabolic process 41 11008 0.4 
Organic substance metabolic process 41 10448 0.4 
Nitrogen compound metabolic process 41 9491 0.4 
Signal transduction 41 6394 0.6 
Cellular metabolic process 38 9910 0.4 
Regulation of metabolic process 35 6173 0.6 
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Regulation of cellular metabolic process 35 5833 0.6 
Regulation of nitrogen compound metabolic 
process 
35 5613 0.6 
Response to stress 35 3398 1 
Locomotion 35 1544 2.3 
Regulation of vasculature development 35 310 11.3 
Regulation of angiogenesis 35 283 12.4 
Negative regulation of cellular process 34 4487 0.8 
Animal organ development 34 3217 1.1 
Cell motility 34 1337 2.5 
Cell migration 34 1210 2.8 
Positive regulation of metabolic process 32 3111 1 
Cellular component organization 30 5578 0.5 
Response to organic substance 30 2990 1 
Positive regulation of cellular metabolic process 30 2903 1 
Cell proliferation 30 1866 1.6 
Cell surface receptor signaling pathway 29 2392 1.2 
Tissue development 29 1729 1.7 
Gene expression 28 5132 0.5 
Biosynthetic process 26 5708 0.5 
Protein metabolic process 26 5511 0.5 
Regulation of cellular component movement 26 852 3.1 
Regulation of locomotion 26 841 3.1 
Regulation of cell motility 26 773 3.4 
Regulation of cell migration 26 730 3.6 
Cellular biosynthetic process 25 5533 0.5 
Regulation of gene expression 25 4226 0.6 
Regulation of signaling 25 3046 0.8 
Regulation of cell communication 25 3023 0.8 
Regulation of signal transduction 25 2743 0.9 
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Regulation of cell proliferation 25 1541 1.6 
Organic cyclic compound metabolic process 24 5679 0.4 
Cellular aromatic compound metabolic process 24 5509 0.4 
Heterocycle metabolic process 24 5460 0.4 
Nucleobase-containing compound metabolic 
process 
24 5335 0.4 
Cell adhesion 24 1208 2 
Cellular macromolecule biosynthetic process 22 4672 0.5 
RNA metabolic process 22 4331 0.5 
RNA biosynthetic process 22 3526 0.6 
Transcription, DNA-templated 22 3489 0.6 
Regulation of molecular function 22 3060 0.7 
Immune system process 22 2343 0.9 
Positive regulation of vasculature 
development 
22 175 12.6 
Positive regulation of angiogenesis 22 157 14 
Cellular protein metabolic process 21 4730 0.4 
Regulation of cell differentiation 21 1660 1.3 
Regulation of RNA metabolic process 20 3611 0.6 
Regulation of RNA biosynthetic process 20 3445 0.6 
Regulation of nucleic acid-templated 
transcription 
20 3438 0.6 
Regulation of transcription, DNA-templated 20 3421 0.6 
Regulation of protein metabolic process 20 2630 0.8 
Cellular response to organic substance 20 2175 0.9 
Epithelium development 20 1057 1.9 
Table 2.8 Top GO biological process annotations associated with the 61 
“angiogenesis” genes with larger fold change than Vegfa in OIR + Vehicle vs. RA + 
Vehicle 
GO biological processes associated with the 61 “angiogenesis” genes with larger fold change 
than Vegfa in OIR + Vehicle vs. RA + Vehicle comparison are identified and those processes 
with at least 20 genes are displayed in the table. “Selected gene frequency” represents the 
number of selected “angiogenesis” genes associated with each process. “Total frequency” 
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represents the total number of mouse genes associated with each process. “Percent of total” 
is percentage of selected gene frequency out of total frequency. Processes with percentage 
less than 1.5% are shaded gray, between 1.5% to 10% are italicized and more than 10% are 
bolded.  
 
 
 
 
 
 
KEGG Pathway Number of 
genes in 
pathway 
Subset of 61 “angiogenesis” genes with 
larger fold change than Vegfa that are 
found in pathway 
VEGF signaling pathway 58 None 
Calcium signaling 
pathway 
183 Ednra; Tbxa2r 
PI3K-Akt signaling 
pathway 
356 Fgf2; Angpt2; Epha2; Pgf; Itgb3; Syk; 
Itga5; Thbs2; Col4a1; Col4a2; Fn1 
MAPK signaling 
pathway 
294 Fgf2; Angpt2; Epha2; Pgf 
Focal adhesion 199 Pgf; Itgb3; Itga5; Thbs2; Col4a1; Col4a2; 
Fn1 
Arachidonic acid 
metabolism 
89 None 
Table 2.9 Subset of 61 “angiogenesis” genes with larger fold change than Vegfa that 
are found in pathways down-stream of KEGG “VEGF signaling pathway” 
None of the 61 angiogenesis genes with larger fold change than Vegfa in OIR + Vehicle vs. 
RA + Vehicle comparison are part of the KEGG “VEGF signaling pathway”. The number 
of selected “angiogenesis” genes that are part of the five pathways downstream of “VEGF 
signaling pathway” are limited.  
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KEGG pathway P-value Adjusted P-
value 
General 
function 
mmu04620 Toll-like receptor 
signaling pathway 
5.48E-05 0.001645 Immune 
mmu04621 NOD-like receptor 
signaling pathway 
5.48E-05 0.001645 Immune 
mmu04622 RIG-I-like receptor 
signaling pathway 
0.001454 0.016353 Immune 
mmu04623 Cytosolic DNA-sensing 
pathway 
0.001454 0.016353 Immune 
mmu04660 T cell receptor signaling 
pathway 
0.001635 0.016353 Immune 
mmu04662 B cell receptor signaling 
pathway 
0.001635 0.016353 Immune 
mmu04625 C-type lectin receptor 
signaling pathway 
0.003258 0.024432 Immune 
mmu04657 IL-17 signaling pathway 0.002905 0.024432 Immune 
mmu04010 MAPK signaling pathway 0.003874 0.025825 Proliferation, 
migration 
mmu04392 Hippo signaling pathway - 
multiple species 
0.005866 0.035198 Proliferation, 
apoptosis 
mmu04014 Ras signaling pathway 0.010398 0.045432 Proliferation, 
migration 
mmu04210 Apoptosis 0.010398 0.045432 Apoptosis 
mmu04380 Osteoclast differentiation 0.010601 0.045432 Immune 
mmu04668 TNF signaling pathway 0.009687 0.045432 Immune 
Table 2.10 KEGG pathways enriched in top 50 TF motifs involved in hypoxia 
TFs in the top 50 TF motif groups enriched with OIR + Vehicle vs. RA + Vehicle samples 
are used to test if any KEGG pathways that the TFs are associated with are observed more 
than by random chance. 14 KEGG pathways are enriched in this analysis, with eight that are 
also enriched by KEGG pathway enrichment of hypoxia-modulated genes using goseq and 
GAGE (in bold). The enriched pathways function in immune system, cell proliferation, 
migration, and death.  
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Drug Adjusted P-value Characteristics 
Selumetinib 5.38E-12 MAPK kinase inhibitor, cancer drug 
Radicicol 2.15E-10 HSP90 inhibitor, cancer drug 
Dacomitinib 2.17E-10 EGFR inhibitor, cancer drug 
NVP-AUY922 6.00E-10 HSP90 inhibitor, cancer drug 
Ruxolitinib 7.63E-10 JAK inhibitor, cancer drug 
Geldanamycin 1.06E-09 HSP90 inhibitor, cancer drug 
Sunitinib 4.84E-09 Receptor tyrosine kinase inhibitor, cancer drug 
BMS-345541 7.07E-09 Anti-inflammatory compound 
BMS-387032 8.51E-09 CDK2 inhibitor, cell cycle inhibitor 
QL-XII-47 1.22E-08 BTK inhibitor, cancer drug 
PHA-767491 1.43E-08 Cdc7/CDK9 inhibitor, cell cycle inhibitor 
NVP-TAE684 1.46E-08 NPM-ALK inhibitor, cancer drug 
Vorinostat 1.65E-08 HDAC inhibitor, cancer drug 
PD-184352 1.65E-08 MAPKK inhibitor, cancer drug 
Dovitinib 2.28E-08 FGFR3 inhibitor, cancer drug 
TWS-119 2.60E-08 WNT pathway activator 
Canertinib 2.73E-08 Tyrosine kinase inhibitor, cancer drug 
Pelitinib 2.85E-08 EGFR inhibitor, cancer drug 
PF-477736 2.85E-08 CHK1 inhibitor, cancer drug 
MK-1775 3.02E-08 Wee1 inhibitor, cell cycle inhibitor 
Table 2.11 Top 20 LINCS L1000 studied drugs that show a transcriptome profile in 
vitro that correlates with that of ALG-1001 in vivo in OIR mouse 
15/20 are cancer drugs with 8 of them being tyrosine kinase inhibitors (in bold). The 
remaining 5 drugs include three cell cycle inhibitors, an anti-inflammatory compound and a 
WNT pathway activator.  
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Drug Adjusted 
P-value 
Characteristics Lower 
choleste
rol1 
Target 
CNS2 
Anti-
inflam
matory3 
Amiodarone 0.000554 Treat heart rhythm 
problems 
   
Simvastatin 0.000923 Statin drug, reduce 
cholesterol production 
X 
  
Fluphenazine 0.001072 Anti-psychotic drug, 
block dopaminergic 
receptors 
 X 
 
Fluoxetine 0.001106 Anti-depressant, serotonin 
reuptake inhibitor 
 
X 
 
Fludrocortiso
ne Acetate 
0.00152 Glucocorticoid 
replacement 
   
Fenofibrate 0.00152 Reduce cholesterol level X 
  
Dexamethaso
ne 
0.001748 Corticosteroid, anti-
inflammatory 
  
X 
Droperidol 0.002001 Anti-dopaminergic drug 
 
X 
 
Cerivastatin 0.002077 Reduce cholesterol level X 
  
Beta-
Estradiol 
0.002077 Estrogen steroid hormone 
   
Sodium 
Nitroprusside 
0.002077 Reduce blood pressure 
   
Dexfenflura
mine 
0.0023 Increase extracellular 
serotonin 
 
X 
 
Amoxapine 0.002403 anti-depressant 
 
X 
 
Lovastatin 0.002403 Reduce cholesterol level X 
  
Carvedilol 0.002487 Reduce blood pressure 
   
Fluvastatin 0.002487 Statin drug, reduce 
cholesterol production 
X 
  
Rosiglitazone 0.002892 anti-diabetic drug, 
increase insulin response 
   
Myrtecaine 0.004 Not available 
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Buspirone 0.004 Anti-depressant drug 
 
X 
 
Indomethacin 0.004 Anti-inflammatory drug 
  
X 
Table 2.12 Top 20 DrugMatrix drugs that show a transcriptome profile in rat that 
correlates with that of ALG-1001 in OIR mouse  
Drugs that function in lower cholesterol1, that target CNS2, or have anti-inflammatory 
property3 are labeled by cross.   
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2.8 Appendix 
Appendix 2.8.1 OIR retina transcriptome at P17 compared to prior literature 
In the past, several groups have used high-throughput transcriptome methods (RNA-seq and 
microarray) to study biology of OIR retina, with limited discovery of modulated genes and 
biological processes (Table 2.6). In contrast to these earlier studies, the present study 
improved in three key aspects. First, the we measured the transcriptome at height of hypoxia-
induced angiogenesis (postnatal day P17)97, rather than at onset of hypoxia (P12141, P12.558, 
P13142, and P14143). This approach allow us to measure the full effect of retinal hypoxia and 
avoid inadvertently characterizing effects of hyperoxia, which is still measurable at P12.558 
and possibly later. Second, we included measurements of the effect of both hypoxia and a 
therapeutic agent (Hoppe et al.141 only examined effect of two drugs in OIR model, while 
Ishikawa et al.58, Yang et al.142, and Oubaha et al.143 only evaluated OIR transcriptome). 
Finally, we employed a relatively large number of replicates (n=11-12) to discern the 
transcriptome response due to retinal hypoxia (in contrast to the small number of replicates 
previously used: 3 in Ishikawa et al.58, 3 in Yang et al.142, and 2 in Oubaha et al.143). The 
large sample size allows us to detect significantly more hypoxia-regulated genes with higher 
confidence (as sample size increases, Figure S2.8A shows more genes discovered, Figure 
S2.8B-C show higher confidence in the discovery) and enables us to perform in-depth 
analyses using GO biological process, KEGG pathway and TF enrichments that are either 
not performed before58,143 or are of limited capability142 in previous studies.  
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Qualitatively, prior studies of OIR retina at P12.558 and P13142 found consistent evidence of 
elevated angiogenesis and inflammatory transcript levels. In Ishikawa et al. (moderately high 
transcriptome correlation, Figure 2.17A)58, a significant number of 53 elevated genes 
identified at P12.5 are associated with vasculogenesis and inflammation.  Similarly, at P13, 
Yang et al.142 discovered 62 elevated genes that enriched 13 GO biological processes, 
including “angiogenesis” and “immune response”. Intriguing, all of these processes are 
represented in our study except “glycolysis” and “glucose metabolic process”, which are 
known to be activated during hypoxia response145. Further analysis suggest activation of 
glycolysis may be transient and has already receded at P17: out of the six glycolysis genes 
found to be elevated at P13, only three are still elevated at P17 and with much smaller fold 
changes compared to at P13. 
Among the prior transcriptome studies of OIR retina, none of them reported a suppression 
of neural genes and only Oubaha et al.143 reported elevated levels of apoptosis and 
inflammation genes at P14, which are also observed at P17 in our dataset (“apoptosis” and 
inflammation KEGG pathways such as “NF-kB signaling”, Figure 2.6). The lack of 
evidence for activation of cell death at the early time points (P12.5, P13) and their presence 
at the later time points (P14, P17) suggest transcriptome signature of cell death may not be 
detectable until hypoxia-activated physiological responses are fully established post-P13.  
Comparative analysis also suggest VEGF-mediated blood vessel growth may be in the 
decline at P17. First, “VEGF signaling pathway” was not enriched with elevated genes at 
P17 (adjusted p-value=0.609, 15/50 pathway genes elevated). Next, we looked at a time 
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series (P12 to P21) qPCR study97 that analyzed gene levels of 94 genes (including Vegfa) 
between OIR and control retina (Pearson’s r=0.91 with exclusion of outlier Nrp2 gene, 
Figure 2.18B). In the time course study, Vegfa level gradually increased and reached peak 
level at P16 before falling 48.9% on P17, followed by further decrease on subsequent days. 
Intriguingly, Tgfb1, a blood vessel maturation146 (and possible angiogenesis inhibitor147) 
gene, was also found to be co-activated in OIR mice and reached peak level one day later on 
P17 (42.7% increase from P16) before a gradual decline. Collectively, these evidence suggest 
the molecular activation of blood vessel formation is likely already in decline at P17 with the 
tissue transitioning to post-angiogenesis vessel maturation148.  
Clearly, hypoxia-response in the OIR model is dynamic with transient elevation of 
glycolysis, angiogenesis and inflammation genes (supported by Sato et al.) and delayed signs 
of apoptosis and neural stress. While the Sato el al. study was able to capture some of these 
transcriptome dynamics by focusing on 94 genes, future studies should explore multiple time 
points in a single high-throughput study to fully capture the transient changes in the retinal 
hypoxia response. 
Appendix 2.8.2 Validation of tissue composition analysis 
To validate retinal cell marker-based tissue composition analysis (Figure 2.19, 2.20), we 
employ two well cited scRNA-seq studies of mouse brain (cortex and hippocampus)51 and 
mouse heart and immune cells52. First, we analyzed markers derived from the brain, as both 
the brain and retina are formed from the same neural tissue and presumably share similar cell 
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types149. From the brain study, we obtained markers associated with nine major brain cell 
types (3/330 or <1% overlap with retinal cell markers), which showed endothelial cell and 
microglia cell numbers are likely expanded in the OIR mice (Figure 2.21, pericyte is not 
annotated in the brain study). Additionally, >80% of interneuron (related to amacrine cells 
in the retina150) markers showed negative fold change in the OIR mice, providing additional 
evidence that selected neuronal cells are depleted in the OIR retina.  
Similarly, with the heart and immune cell markers (5/96 or 5.2% overlap with retinal cell 
markers, none are of the same cell type), we saw >80% of endothelial cell, macrophages 
(related to microglia in the retina) and pericytes markers have positive fold change in OIR 
mice (Figure 2.22). Not surprisingly, there wasn’t any cell types with a large number of 
negative fold change markers, as no neuronal cells was annotated in this data set. Altogether, 
based on mostly orthogonal gene sets derived from non-retinal tissues, these results show 
consistent evidence of vessel and immune-related cell expansion and neuronal cell depletion 
in the OIR retina.  
Appendix 2.8.3 Suppressed genes in DR retina compare to OIR retina 
In this study, we found suppressed genes in hypoxia response are over-represented with ones 
associated with neural system processes, indicative of a detectable disruption in normal 
neural function and development. Similarly, in human retinal diseases that occur much later 
in life, there are also clear signs of neural damage from hypoxia, neovascularization and 
inflammation119. Supporting these observations, we performed a GO biological process 
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enrichment of suppressed genes in human DR tissue56 and found neural system processes 
such as “ion transport” and “nervous system development” are enriched (8/36 GO biological 
processes enriched overlap with those enriched with suppressed genes in hypoxia response, 
p-value=3.00e-05). However, the DR study also has major caveat – it compared non-neural 
fibrovascular membrane tissue collected from DR patients to neural retina collected from 
normal donors. Since non-neural fibrovascular membrane presumptively contains fewer cells 
of neural origin, this could also explain the lower level of neural mRNA in the DR samples. 
Appendix 2.8.4 Correlation between OIR and human disease retina among subset of 
hypoxia-modulated genes 
We set out to find if any biological process-specific transcriptome features of hypoxia 
response in OIR mice are correlated with the human retinal diseases. In particular, we 
individually analyzed fold change correlation of genes among “immune system process”, 
“angiogenesis”, “cell death”, “metabolic process”, and “nervous system development” GO 
biological processes, all of which are enriched in GO biological process enrichment except 
“metabolic process” (included to encompass 20 other enriched metabolism-related 
processes). 
In this analysis (Table 2.5), we found when limited to “immune system process” and “cell 
death” genes, correlations generally improved across the different disease cohorts, 
demonstrating OIR mouse may be a good model for these disease processes. Next, 
correlation with “nervous system development” genes improved within the AMD cohorts, 
but slightly dropped with DR (still relatively high at r=0.2999). This observation suggest the 
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modulated neural system in OIR retina are able to capture some signatures of the neural retina 
disruption in AMD118 and DR119. With “angiogenesis” genes, correlation reaches the highest 
level in our analysis to r=0.4073 between OIR mice and DR, but dropped for most of the 
AMD cohorts, including those that develop angiogenesis. Here, the relatively high 
correlation with DR shows the OIR model is useful to model angiogenesis in these patients, 
but the low correlation to AMD cohorts, especially those that develop neovascularization, is 
surprising (perhaps due to differences in angiogenesis between the two diseases, Figure 
2.23). As a control, we also performed correlation analyses with non-statistically significant 
genes in hypoxia response, which produced near zero correlations across all disease cohorts 
and served as a validation of this analysis approach. 
Appendix 2.8.5 ALG-1001 affects endothelial cell migration and adhesion to ECM 
ALG-1001’s effect on the transcriptome of OIR retina is largely in agreement with in vitro 
HUVEC cell culture studies (Chapter 3) and is further supported by endothelial cell 
adhesion and migration studies (Campochiaro group, JHU). First, in HUVECs treated with 
ALG-1001 under hypoxia condition, a statistically significant number of angiogenesis genes 
were selectively down-regulated. Additional analysis of ALG-1001-modulated genes in vitro 
found strong evidence of selective down-regulation of genes that encode proteins that 
function in the ECM and in modulating cell adhesion. Of these, we found fibronectin, two 
collagens, two laminin, and four integrin subunit genes are down regulated after drug 
treatment.  
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Transcriptome suppression of cell adhesion and migration genes manifested in detectable 
disruption of these cellular functions in in vitro endothelial cell studies. In these experiments, 
our colleagues at the Campochiaro group found ALG-1001 specifically inhibited endothelial 
cell migration on fibronectin-coated and less strongly on vitronectin-coated surfaces 
(personal communication). Additionally, ALG-1001 treatment weakly inhibited endothelial 
adhesion to both fibronectin-coated and vitronectin-coated surfaces.  
Appendix 2.8.6 Comparison of ALG-1001 transcriptome profile to anti-VEGF treatment 
In our search, we found nearly all of the transcriptome studies of anti-VEGF drugs are 
investigation of Bevacizumab in context of cancer treatments, which are not directly 
comparable to ocular diseases due to increased complexity of cancer heterogeneity and 
pathophysiology. There is one recent study60 that tested anti-VEGF antibody and a control 
anti-IgG antibody in a rat model that develops trauma-induced angiogenesis and 
inflammation in the cornea. While analyzing the rat cornea dataset, we were surprised to see 
that after 2 days of treatment, no gene level is changed by anti-VEGF antibody compare to 
anti-IgG antibody (this observation was also reported by the original authors). Interestingly, 
the authors also noted that the effect of anti-VEGF antibody is quite modest in these models, 
where drug treatment was found to reduce neovascularization by less than 15-20%.  
Next, we compared the fold changes measured in the rat cornea study with the present study, 
limited to the genes modulated by ALG-1001 in the OIR mice. In this analysis, we found 
almost no correlation between the two datasets (Pearson’s r=-0.0324), but interestingly, 74% 
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of genes that have negative fold change after ALG-1001 treatment also have negative fold 
change after anti-VEGF treatment in rat cornea, indicating some level of consistency in the 
drug-induced transcriptome change (Figure S2.11). On the other hand, whereas ALG-1001 
mainly suppressed transcript level, there are non-statistically significant evidence that 
suggest anti-VEGF treatment appears to elevate gene level more than gene suppression (1298 
probes “up” and 1040 probes “down” with p-value<0.05 by anti-VEGF antibody, compared 
to 566 genes “up” and 1036 genes “down” with p-value<0.05 by ALG-1001 in OIR mice).  
Appendix 2.8.7 TF groups responsible for effect of ALG-1001 
ISMARA was used to predict TFs that may be involved in ALG-1001 associated 
transcriptome changes in OIR mice. In this analysis, no TF was enriched with Z-score>1.0, 
which is typically used as the statistical significance cutoff (Table 2.3). While weakly 
supported by evidence, we set out to evaluate the top 50 TF groups identified with the 
understanding that the results are not statistically sound. In the top 50 TF groups, we 
identified at least 12 TF groups with known function related to the cell proliferation, 
angiogenesis, hypoxia-response, and inflammatory processes (labeled in Figure 2.15). Out 
of the 12 identified, 9 have suppressed target gene level, consistent with edgeR that shows 
majority of drug-induced transcriptome changes are suppressed. In addition, 8/12 of these 
TF motifs are ranked very high on the enrichment list, representing more than half of the top 
15 TF groups enriched. 
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We also compared the top 50 TF motifs identified in both hypoxia and ALG-1001-modulated 
transcriptomes and find 11 TF groups that are on both lists (bold TFs in Tables 2.2 and 2.3). 
For 8 of these 11 TF groups, the direction of target gene level is reversed by ALG-1001 
treatment and will be the focus of the following discussion. Notably, the 8 TF groups include 
Fos86, Jun86 and several members of the ETS protein family151 (Erg, Etv1 and Etv5) that are 
well known regulator of cell proliferation and angiogenesis (Fos and Jun are down-stream of 
VEGF signaling152). In addition, the other TFs also play important function in various aspects 
of the hypoxia response: Tead1 (regulates cell proliferation and migration153), Tcf7l1 
(regulates cell cycle progression154), Srf (stimulates cell proliferation and differentiation155), 
and Nrf1 (regulates metabolism and cell growth156). Altogether, TF analysis provides 
additional evidence that ALG-1001 treatment in OIR mice moderated some of the hypoxia-
initiated transcriptional changes.  
Appendix 2.8.8 Limitations of the L1000 study 
There are two important caveats with the L1000 study: a) drug exposure were done in human 
cancer cell lines, and b) inference of expression in >90% of genes. First, the LINCS L1000 
transcriptome study was performed with human cancer cell lines, instead of with animal 
model or human primary cells. In our studies, there was a large gap in drug-induced 
transcriptome change between animal and cell culture studies (for example, 93.8% of ALG-
1001-modulated genes in OIR mice were suppressed, but only 48.8% in HUVEC and 53.4% 
in PBMC, Chapter 3). Thus, the results between the present in vivo study and the in vitro 
cancer cell study may not be directly comparable. A second major limitation of the LINCS 
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L1000 study is it measured the expression of 978 genes and then used their expression profile 
to infer the expression of 9196 additional genes, all of which were used to generate the list 
of compound-regulated genes. Since gene expression was not directly measured for a 
majority of the genes, analysis performed with the LINCS L1000 dataset should be 
interpreted with caution.  
Appendix 2.8.9 Literature survey shows transcriptome studies tend to use diseased model, 
but not control animals for drug research 
A small-scale survey of the recent literature on transcriptome study of ocular drug treatment 
shows our study of combined control and diseased animals is quite unconventional. Of the 
four studies that we reviewed, all of them probed the drug effect in diseased models, but not 
in control animals141,157–159. Similarly, a broader survey outside the ocular field arrived at the 
same observation160–162. While limited in scope, this survey shows current transcriptome 
studies of therapeutics tend to mainly focus on identifying the drug effect in diseased models. 
In these studies, high cost of high-throughput approaches may be one explanation for the 
lack of research in control animals. However, as sequencing cost continues to drop163, it 
becomes desirable to study the drug-induced transcriptome change not only in diseased 
model to identify therapeutic effects, but also in control animals to assess the drug’s safety 
profile164.  
Appendix 2.8.10 Comparison of ALG-1001 transcriptome profile with DrugMatrix 
compounds 
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Compared to the L1000 dataset, the DrugMatrix study is significantly smaller in scale, yet it 
measured the effect of drugs in in vivo rat animals. Among the drugs included in the 
DrugMatrix dataset, 89 compounds shared transcriptome profile with ALG-1001 with 
statistical significance. Of those, we focused on characterizing the top 20 hits (Table 2.12) 
through a manual search of their function. Unlike the L1000 study, there wasn’t an 
abundance of anti-cancer drugs in the top compounds. Instead, there are five cholesterol 
lowering drug, six central nervous system (CNS)-targeting drugs, two anti-inflammatory 
drugs and others of miscellaneous functions. Importantly, most of the enriched drugs’ 
mechanism of action remains unknown (several developed before era of molecular biology), 
reducing their utility in uncovering ALG-1001’s mechanism of action.  
Appendix 2.8.11 Enrichment of TFs involved in hypoxia response 
When ISMARA was applied to study OIR + Vehicle vs. RA + Vehicle, 104 motif groups are 
enriched with high confidence (defined as ones with Z-score>1.0, top 50 shown in Table 
2.2). To make interpretation feasible, analysis was limited to the top 50 enriched TF groups. 
Through a manual review of their biological function, we found many of them are 
involvement in cell proliferation, angiogenesis, inflammation, metabolism, hypoxia-
response and neuronal development (labeled in Figure 2.11, activity profile shown in Figure 
2.12-13). For an objective analysis, we employed the KEGG pathway database to identify 
pathways that contain one or more TFs in the top 50 enriched TF groups. Of the 156 KEGG 
pathways that contain at least one TF tested by ISMARA, we found 60 pathways contained 
at least one TF in the top 50 enriched TF groups. Next, we tested whether any of these 60 
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KEGG pathways are over-represented in the top 50 TF groups than one would expect by 
random chance and identified 14 KEGG pathways with statistical significance (Table 2.10). 
Of the 14 enriched-KEGG pathways, 8 (Table 2.10, bolded) are also enriched by goseq or 
GAGE with elevated genes in OIR mice, which serves as a validation of this line of TF 
functional analysis. Additionally, all 14 TF-enriched KEGG pathways are strikingly relevant 
to the immune system, apoptosis, and cell proliferation and migration processes, 
demonstrating the active involvement of these pathways and their associated TFs in 
regulating retinal hypoxia response. 
While many of the top TF groups are relevant to hypoxia response, it is worth noting that 
over half of them (27/50, groups not labeled in Figure 2.11 and shown in Table 2.2) are 
either not well established to regulate a putative hypoxia process or are uncharacterized 
altogether. In the top 20 TF groups alone, there are 4 groups where we did not find a 
connection with hypoxia: regulators of estrogen response (Esrra and Esrrb), iron homeostasis 
(Spic) and two mostly uncharacterized putative regulators: Nhlh1 and Hsfy2. These 
observations suggest the retinal transcriptome regulation in response to low oxygen is 
complex, with involvement of TFs of seemingly unrelated function or are uncharacterized 
altogether.  
Appendix 2.8.12 Limitations of OIR mouse model 
The extensive literature on OIR (over 15,000 publications since 1994) documents a robust 
animal model for DR23. While the OIR model has been useful in studying the development 
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of abnormal angiogenesis in the retina, it is important to bear in mind the differences between 
the mouse model and human diseases. First, in the mouse model, hypoxia and angiogenesis 
are transient events in a young animal, while the human retinal diseases are chronic and 
typically occur much later in life95. Second, in contrast to the rapidly activated and quickly 
resolved angiogenesis in the mouse OIR model23, human retinal diseases and their associated 
physiological changes develop over a long period of time and typically do not get better over 
time118,165. Furthermore, the pathophysiology of the human retinal diseases is highly complex 
and includes involvement of many contributing factors related to both environmental stress 
and genetics predisposition6,118. Thus, while the OIR model may capture hypoxia-activated 
retinal angiogenesis and other processes to a certain extent, the human diseases are driven by 
additional factors that are not part of the mouse model. As a result, it is important to view 
our findings in the context of the limited ability of the mouse OIR model to capture the 
characteristics of human retinal diseases.  
Appendix 2.8.13 Fold change of hypoxia-modulated genes after ALG-1001 treatment 
To further investigate ALG-1001’s hypoxia-modulating effect, we broadened the analysis to 
all 6208 hypoxia-modulated genes at P17 and analyzed their corresponding fold change after 
ALG-1001 treatment. Intriguingly, we found a moderate and negative correlation between 
the two comparisons (r=-0.258, Figure S2.12). In particular, of the 3139 genes elevated, over 
67% (2117/3139) have negative fold-change after ALG-1001 injection (r=-0.471). Further 
investigation of the 2117 genes using GO biological process enrichment showed many of the 
angiogenesis and inflammatory processes (Figure S2.13A) previously enriched with 
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hypoxia-elevated genes in OIR mice, are recovered (877 out of 1157, Figure S2.13C). To 
confirm ALG-1001 specifically suppressed genes associated with hypoxia-elevated 
processes, we repeated for 1000 times a randomly selection of 2117 genes from the 3139 
hypoxia-elevated genes and calculated the number of processes that are enriched with the 
selected genes and that are also previously enriched with the 3139 genes. In this analysis, we 
see the 877 common processes observed in Figure S2.13C is highly unlikely by random 
chance, as only 1/1000 selections showed a stronger overlap (across all 1000 simulations: 
mean=661, standard deviation=72 overlapping processes). Additionally, a control 
enrichment with the remaining 1022 genes (elevated in OIR mice and with positive fold 
change with ALG-1001 treatment) only identified 77 of the previous 1157 enriched 
biological processes (GO biological processes in Figure S2.13B, overlap in Figure S2.13D).  
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2.9 Appendix Figures 
 
Figure S2.1 FastQC mean sequencing quality score 
The averaged sequencing quality (Phred score, generated by FastQC32) at each base in the 
reads generated for each sample. Each green line detonates a sample and the majority of them 
overlap for the majority of the entire 100 base pair region. Phred score shows good 
sequencing quality across all samples.  
  
132 
 
 
Figure S2.2 Tophat2 and HTSeq-count statistics 
Label in bar indicates sample condition and sample ID, 12 samples per condition. A. At least 
85% of reads are mapped by Tophat2 in each of 48 samples. B. HTSeq-count uniquely 
assigned (blue bar) between 72-76% of a sample’s aligned reads to a gene.   
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Figure S2.3 PCA of all samples reveals an outlier 
PCAAll with all 48 retinal samples. A. Percent of overall variance captured by the top 10 
principal components. B-C. Samples in PC1 and PC2, PC1 and PC3, respectively. PC_# is 
principal component number and percent of variance explained is shown in axis label. PC1All 
strongly separates OIR from RA samples. One RA + ALG-1001 sample appears to be an 
outlier on PC2All. 
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Figure S2.4 PCA with outlier pair removed and color indicating litter or gender 
PCANo-outlier with all samples except the outlier and its fellow eye sample. PC_# is principal 
component number. Percent of variance explained are shown in axis label. Color-code for 
sample-litter association (A-B) or sample-gender association (C-D). (A, C) Samples in PC1 
and PC2. (B, D) Samples in PC1 and PC3. PCANo-outlier shows weak separation based on 
litter, indicating presence of litter-specific effect, which is blocked out in edgeR analysis. No 
clear separation associated with gender after exclusion of gender-specific genes (see 
Methods). 
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Figure S2.5 PCA with OIR samples 
PCAOIR with 24 OIR samples. A. Percent of overall variance captured by the top 10 principal 
components. B-C. Samples in PC1 and PC2, PC1 and PC3, respectively. PC_# is principal 
component # and percent of variance explained is shown in axis label. Symbols indicate 
condition while colors indicate animal. 
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Figure S2.6 PCA with RA samples 
PCARA with 22 RA samples excluding outlier pair (Mouse 10). A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC1 and PC2, PC1 and PC3, 
respectively. PC_# is principal component # and percent of variance explained is shown in 
axis label. Symbols indicate condition while colors indicate animal. 
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Figure S2.7 Number of modulated genes in each edgeR comparison 
The number of genes with statistically significant change (false discovery rate (FDR)<0.05) 
in each of the three edgeR comparisons are plotted as bar graph. The number of genes in each 
bar is shown above the bar. Log2FC is log2-fold-change.  
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Figure S2.8 Sample size analysis with ERSSA 
ERSSA is used to determine if sufficient sample size has been used to maximize discovery of 
genes with statistically significant change in the comparison of OIR + Vehicle vs. RA + 
Vehicle. A. Plot shows the measured number of hypoxia-modulated gene at each replicate 
number with 50 combinations per sample size and |log2-fold-change| cut off=0.5. 
Subsampling results show improved discovery of modulated genes as sample size increases 
up to the full dataset. B. Plot shows number of modulated genes found in all subsamples at 
each replicate number. As sample size increases, the consensus improves among the 
subsamples, indicating more reliable discovery. C. Plot shows individual and averaged false 
positive rate (FPR) and true positive rate (TPR) among the subsamples with full dataset 
discovery as the ground truth. TPR tend to increase, while FPR tend to decrease as sample 
size increases.   
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Figure S2.9 Cellular components and molecular functions enriched with 198 genes 
suppressed by ALG-1001 in OIR mice 
Suppressed genes after ALG-1001 treatment OIR mice relative to vehicle treated control are 
submitted for GO cellular component (A) and molecular function (B) enrichment with results 
visualized using REVIGO. P-value is REVIGO-derived GO enrichment p-value. Selected 
biologically relevant processes are labeled.  
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Figure S2.10 STRING connection map of 61 selected “angiogenesis” genes  
Selected “angiogenesis” genes have larger fold change than Vegfa in OIR mice (OIR + 
Vehicle vs. RA + Vehicle). The 61 genes are submitted to STRING to visualize connection 
between gene-coded proteins. STRING connection map shows the 61 “angiogenesis” genes 
are closely connected. 
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Figure S2.11 Fold change comparison with anti-VEGF drug in rat cornea 
Log2-fold-change of modulated genes after ALG-1001 treatment in OIR mice relative to 
vehicle treated fellow control are plotted on the X-axis. The same gene’s log2-fold-change 
after anti-VEGF drug treatment in rat cornea trauma study is plotted on the Y-axis. Dashed 
blue lines indicate Y=0 and X=0. Pearson’s correlation coefficient is indicated in the plot 
title. While little to no correlation is detected between the datasets, 74% of genes suppressed 
by ALG-1001 also have negative fold change in anti-VEGF treated animals. 
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Figure S2.12 Fold change of hypoxia-response genes after ALG-1001 treatment 
Each dot represents a gene modulated in OIR + Vehicle vs. RA + Vehicle comparison, with 
the gene’s log2-fold-change plotted on the x-axis. The same gene’s fold change after ALG-
1001 treatment in OIR mice relative to vehicle control is plotted on the y-axis. Plot window 
is limited to the (-1, 1) range on both axes. Pearson’s r value is measured as -0.258. The plot 
can be divided into four quadrants, as indicated by the blue dashed lines with 1520 genes in 
the top left, 1507 in the bottom left, 1022 in the top right, and 2117 in the bottom right 
quadrant. Note the numbers do not add up to the number of modulated genes in OIR + 
Vehicle vs. RA + Vehicle, because some genes failed to pass TPM cutoff in OIR + ALG-
1001 vs. OIR + Vehicle comparison.   
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Figure S2.13 GO biological process enrichment of elevated genes in OIR mice 
Among hypoxia-elevated genes (OIR + Vehicle vs. RA + Vehicle), 2177 genes with negative 
fold change (A) and 1022 genes with positive fold change (B) after ALG-1001 treatment 
(OIR + ALG-1001 vs. OIR + Vehicle) are submitted for GO biological process enrichment 
with results visualized using REVIGO. P-value is REVIGO-derived GO enrichment p-value. 
Selected biologically relevant processes are labeled. C-D. Overlap of enriched processes in 
(A or B, respectively) with those enriched with all 3141 hypoxia-elevated genes.  
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Chapter 3. Transcriptome response to ALG-1001 treatment in 
human endothelial and immune cell cultures 
 
3.1 Introduction 
Degenerative diseases of the retina affect millions of Americans, who suffer from vision loss 
and even blindness1–5. The current standard of care uses antibodies to disrupt the Vascular 
Endothelial Growth Factor (VEGF) pathway to suppress the disease-worsening retinal 
neovascularization5. However, the current treatment has many shortcomings, raising the need 
to develop a second line of effective therapeutic (see Chapter 1.1 and 2.1 for more detail)6,7. 
To address these unmet needs, ALG-1001 was developed by Allegro Ophthalmics, LLC. and 
is currently undergoing clinical testing with promising results8. In multiple phase I and II 
clinical trials, patients who received intraocular injections of the drug experienced favorable 
vision improvement with no drug-related adverse effect to date9,10. Despite its success in the 
clinical trials, the precise mechanism of action of ALG-1001 remains unclear.  
In this study, we employed two human primary cell culture models to study the transcriptome 
regulation driven by ALG-1001 treatment. First, human umbilical vein endothelial cells 
(HUVECs) are used as a model for vascular endothelial cells, which play a primary role 
during neovascularization through their active proliferation, migration and tube formation11. 
Retinal neovascularization has long been associated with retinal disease progression12,13 and 
previous in vivo mouse studies have showed ALG-1001 has anti-angiogenic property (see 
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Chapter 1.2 and 2.1 for more detail). Second, human peripheral blood mononuclear cells 
(PBMCs) consisting of mostly lymphocytes (T cells, B cells and NK cells) and monotypes 
are used as a model for immune cells typically found in sustaining a pro-inflammatory state 
in the retinal diseases (see Chapter 1.1 for detail)14–16.  
For each cell culture model, we treated the cells with ALG-1001 and then captured the drug-
related transcriptome response using RNA-sequencing (RNA-seq)17. In addition, we exposed 
HUVECs to 3% O2 hypoxia to induce a disease-relevant growth environment and probed the 
gene expression with and without ALG-1001 co-treatment. By analyzing the expressed 
transcriptome, we identified the genes, biological processes and pathways regulated by ALG-
1001 in both models and by hypoxia in HUVECs. Using the available expression dataset, we 
also identified transcription factors (TFs) that may be involved in the expression regulation. 
Results from these analyses suggest ALG-1001 can specifically modulate angiogenesis 
genes in endothelial cells and inflammatory genes in immune cells, bringing us closer to a 
broader understanding of the drug’s therapeutic effect in retinal diseases.  
 
3.2 Materials and Methods 
Cell culture 
Pooled HUVECs at passage 2 (P2) were purchased from American Type Culture Collection 
(ATCC) and grown to P5-P6 for experiments. Cell cultures were kept in a 37˚C humidified 
incubator with pH controlled by 5% CO2 and media exchanged every two days. The cells 
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were grown in Vascular Cell Basal Medium (ATCC) with Endothelial Cell Growth Kit-BBE 
(ATCC) and Antibiotic Antimycotic Solution (Sigma-Aldrich) added according to the 
manufacturer’s instruction. For hypoxia treatment, the culture plates were moved to a 
hypoxia chamber (Biospherix) with O2 concentration set to 3% and placed inside the cell 
culture incubator. For ALG-1001 treatment, the peptide (CPC Scientific) was dissolved in 
water at a high concentration and then added to the growth media to the final concentration 
for cell exposure. 500µM of ALG-1001 was used for RNA-seq experiments while a 
concentration series of ALG-1001 was used for other assays. Equal volume of vehicle water 
was also added to control samples. After appropriate amount of hypoxia and drug exposure, 
the cells were collected and assayed (see Figure 3.1 for more details). 
For PBMC study, freshly collected PBMCs from a human donor were purchased from Zen-
Bio. Immediately upon arrival, the cells were washed with growth media (RPMI (Thermo 
Fisher) with 5% heat-inactivated fetal bovine serum (Thermo Fisher) and Antibiotic 
Antimycotic Solution) and stained with trypan blue to confirm >90% cell viability. Cells 
were then allowed to rest in 6-well, Ultra-low attachment plates (Corning) overnight in a 
37˚C humidified incubator with pH controlled by 5% CO2. The next morning, cells were 
treated for 8 hours with 100µM of ALG-1001 (peptide was first dissolved in water to a high 
concentration and then added to the growth media to the final treatment concentration). The 
same volume of vehicle water was added to control samples. At the end of 8 hours treatment 
period, both suspended and adherent cells were collected for RNA-seq sample preparation. 
Dead and live staining 
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Dead and live staining was performed with HUVECs after treatment with a concentration 
series of ALG-1001. Cells were cultured in 12-well plates (Falcon) and followed the 
treatment regime specified in Figure 3.1. After treatment, LIVE/DEAD 
Viability/Cytotoxicity Kit (Invitrogen) was used to simultaneously capture the status of both 
dead and live cells. At start of the assay, cells were washed once with Dulbecco's Phosphate-
Buffered Saline (PBS, Thermo Fisher) before incubation for 30 minutes at 37˚C in the media-
dye mixture. At end of incubation, cells were washed with PBS and imaged on a Zeiss 
Axiovert 25CFL microscope. FIJI software package was used to merge fluorescent signals 
into one image with red indicating dead cells and green indicating live cells. Phase contrast 
images were captured on the same microscopy system with bright-field illumination. A 10x 
Lysis Buffer (Thermo Scientific Pierce) was used as the lethal control and added to the wells 
to working concentration for 15 minute incubation before staining. 
WST-1 assay 
WST-1 assay was performed with HUVECs treated with a concentration series of ALG-
1001. Cells were cultured in 96-well plates (Falcon) and followed the treatment regime 
specified in Figure 3.1. At start of the assay, WST-1 cell proliferation reagent (Roche) was 
added to the cell culture media at the recommended working concentration for four hours 
incubation at 37˚C. At end of incubation, the assay intensity was measured on a Flexstation 
3 microplate reader (440nm and 690nm). The baseline absorption from the background and 
media was subtracted to isolate the contribution of the cells. All test well measurements were 
normalized as a percentage of the mean control well value. One-way ANOVA tests were 
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performed between control and treated cells in GraphPad Prism 7.00 with the statistical 
significance threshold set at p-value < 0.05.  
RNA-seq sample preparation 
For RNA-seq studies, HUVECs were cultured on 6-well plates (Falcon) and PBMCs on 6-
well, Ultra-low attachment plates (Corning). At end of treatment, HUVECs were washed 
once with PBS without calcium and magnesium (Thermo Fisher) and collected using 
Accutase (Stemcell Technologies). For PBMC, suspended cells were first collected and then 
combined with adherent cells isolated with the same technique as in HUVECs. Total RNA 
was extracted using RNeasy Mini Kit (Qiagen) and contaminating DNA removed using 
TURBO DNA-free kit (Thermo Fisher). RNA quality was measured using Bioanalyzer 
(Agilent Genomics); all samples were found to have at least 8.40 RNA integrity number. 
RNA-seq libraries were then prepared using NEBNext Ultra RNA Library Prep Kit for 
Illumina (New England Biolabs Inc.) and sequenced on the HiSeq 2500 (Illumina) to 
generate on average 12.5 million, single-end, 100 base pair reads per sample. 
RNA-seq analysis 
Quality control 
FASTQ files generated by RNA-seq were submitted to FastQC for quality control. All 
samples showed good sequencing quality and were submitted for read alignment. Alignment 
was performed using Tophat2 to the hg38 genome and transcriptome references with Bowtie 
2 sensitivity level set to very sensitive18. After read alignment, gene counts were quantified 
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using HTSeq-count using the intersection-strict model19. FastQC, tophat2, and HTSeq-count 
reports were visualized using multiQC software (Figures 3.2-3.7)20. All samples exhibited 
good alignment property except replicate 5 of the ALG-1001+hypoxia condition in HUVEC 
batch 1 study, and as a result this sample was removed from all subsequent analysis. 
Principle Component Analysis (PCA) 
PCA was used to visualize the high-dimensional datasets. To eliminate null values, all counts 
in HTSeq-count-derived count table were increased by one. Transcript per Million (TPM) 
values were then calculated to correct for varying sequencing depth and gene length21. To 
reduce sensitivity to the uncertainty in TPM of low-expressing genes, PCA excluded genes 
for which the TPM averaged over all samples in the analysis was < 5. Finally, natural log of 
TPM values were used as input for PCA. For HUVEC dataset, PCA was first performed 
individually for each batch experiment. Based on the PCA results (Figure 3.10-3.12), several 
outliers were detected (based on separation from other biological replicates) and 
subsequently removed from further analysis: batch 1’s control replicates 3, ALG-1001 
replicates 5 and 6, batch 2’s ALG-1001 replicates 6 and hypoxia replicates 6, and batch 3’s 
ALG-1001+hypoxia replicates 6. PCA was performed again with all HUVEC samples 
excluding the outliers. For the PBMC dataset, PCA did not detect any obvious outliers 
(Figure 3.33). 
EdgeR differential expression comparison 
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In the analysis of differential expression, it is beneficial to exclude genes that are not 
expressed (they reduce statistical power for identifying differential expression). Here, we 
retained expressed genes, defined as those with Count per Million (CPM) > 1 in at least four 
HUVEC samples or six PBMC samples (the smallest number of biological replicates from 
the same condition and batch experiment). CPM is calculated to normalize for sequencing 
depth 21. Typically, around 13,000 genes remain after filtering. Next, GLM-based edgeR was 
used to perform the differential expression comparisons in the HUVEC study with batch 
variation removed from differential analysis22. Classic edgeR was used for the PBMC 
comparison. After statistical test, genes with False Discovery Rate (FDR) ≤ 0.05 were 
considered as differentially expressed (DE) and were further separated into up-regulated and 
down-regulated gene lists. 
ERSSA 
ERSSA was used to check whether the number of biological replicates used in the PBMC 
RNA-seq experiment is sufficient to identify the majority of DE genes23. Analysis was 
performed with absolute log2-fold-change cutoff at 0.5 with up to 50 subsamples generated 
at each replicate level. Since ERSSA currently does not support blocking, it was not used to 
test the HUVEC comparisons.  
DE gene heatmap of log2-fold-change values 
Heatmaps of TPM value were used to visualize the expression profile of DE genes. TPM 
values were first calculated from the unadjusted gene counts; then for each gene, TPM was 
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offset such that the minimum is zero and normalized so the maximum is one. DE genes were 
sorted row-wise from high to low edgeR-measured log2-fold-change values.  
Goseq enrichment analysis of DE gene list 
Functional analyses of the DE genes were performed with the goseq package, which 
mitigates gene length bias inherent to RNA-seq24. Enrichment was evaluated for both Gene 
Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) biological 
pathways25,26. GO terms associated with genes were obtained from biomart while KEGG 
pathways were obtained from the KEGG REST server using the keggrest package27,28. 
Enrichment was performed separately for the up- and down-regulated gene lists. GO terms 
were considered enriched if FDR < 0.05. The GO enrichment results were visualized using 
REVIGO, a visualization tool that aggregates closely-related GO terms, with similarity level 
set to small and GO term size determined using the UniPort Homo Sapiens database29. For 
the particular cluster of GO terms that includes “angiogenesis” GO annotation, the cluster is 
represented by “angiogenesis” instead of the default selected GO annotation. Selected GO 
terms were labeled on the REVIGO plot based on our perception of their biological relevance. 
KEGG pathways were considered enriched if Benjamini-Hochberg adjusted p-value < 0.05 
(p-value displayed in bar plots). In addition, “Human Diseases” KEGG pathways were 
removed to improve clarity. 
Pathview 
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Pathview enables visualization of the fold changes across all expressed genes in any 
particular KEGG biological pathway30. EdgeR measured fold changes were used as input for 
Pathview visualization of selected pathways enriched in the PBMC analysis. For genes that 
share a common node on the KEGG pathway, the averaged fold change is displayed.  
ISMARA 
ISMARA was used to identify the transcription factors (TFs) that may be responsible for the 
observed profiles of gene expression across all comparisons31. Samples involved in specific 
comparisons were submitted together to ISMARA to obtain enrichment Z-scores. Analysis 
was focused on the top 50 most active motifs with Z-score > 1.0. Separately, all HUVEC 
samples were submitted together to obtain target gene activity profiles across all four 
conditions.  
Data availability 
Raw RNA-seq Fastq files will be available at Gene Expression Omnibus once the study has 
been published32. All enrichment tables will be made available at CaltechDATA33. 
Reverse transcription and quantitative polymerase chain reaction (qPCR) 
Based on edgeR DE gene discovery, ALG-1001 regulated genes were selected for manual 
validation of expression among the HUVEC (six genes) and PBMC (three genes) samples. 
SuperScript IV Reverse Transcriptase (ThermoFisher) and oligo(dT)20 primer 
(ThermoFisher) were used to convert polyadenylated mRNA to cDNA. qPCR was 
performed using iTaq Universal SYBR Green Supermix (Biorad) on LightCycler 480 
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(Roche) with 45 amplification cycles. For HUVEC comparisons, six non-outlier replicates 
per condition from batch 1 and batch 2 (3 per batch experiment) were selected for qPCR. All 
PBMC samples were selected for qPCR. To enhance accuracy, four technical qPCR 
replicates of the same cDNA were generated and the median value selected for further 
analysis. Differences were calculated using the ΔΔCt method versus Actb34. Primers used in 
this study were obtained from PrimerBank or designed using Primer-BLAST (Table 
2.1)35,36.  
 
3.3 Results 
WST-1 metabolic assay of HUVEC 
ALG-1001 treatment in in vivo mouse models of retinal neovascularization generated strong 
anti-angiogenic effect (see Chapter 1.2 for more detail, experiment performed by 
Campochiaro lab, Johns Hopkins University, unpublished). Here, we employed HUVECs to 
model human vascular endothelial cells and exposed them to an ALG-1001 concentration 
series to investigate the drug’s anti-angiogenic property in vitro. First, cells seeded at low 
density were exposed to the drug for 2 days before measurement of cellular metabolic level 
as an indicator of cell density. During the incubation period, normal HUVEC growth media 
was supplied to promote active cell proliferation as during angiogenesis. Additionally, a 
separate set of samples were exposed to 24 hours of hypoxia to stimulate endothelial cells in 
a more disease-relevant environment (treatments described in Figure 3.1). 
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At end of the incubation period, metabolic assay shows HUVECs exhibited an ALG-1001 
dose-dependent drop in metabolic activity (Figure 3.8). At room air oxygen tension (Figure 
3.8A), a small reduction is already measurable at the lowest drug concentration tested 
(10µM) and continues to only around 30% of the control metabolic level at the highest drug 
concentration (5mM). The measurable decline is less apparent in the hypoxia treatment 
condition with only two of the highest concentrations tested (2.5 and 5.0mM) showing 
statistical significant reduction (Figure 3.8B). A higher biological variance was also 
observed with hypoxia co-treatment, which reduces our ability to accurately detect changes 
induced by ALG-1001. 
Dead and live staining of HUVEC 
To confirm the observation with metabolic assay is not due to drug-induced cell death, we 
performed dead and live staining of HUVECs at three ALG-1001 concentrations (500, 1000 
and 2500µM). At both room air oxygen tension (Figure 3.9A) and 3% O2 hypoxia (Figure 
3.9B) conditions, we observed no obvious cell death or change in cell morphology in 
HUVECs after AGL1-1001 treatment. In addition, we found a noticeable drop in cell density 
at the highest drug concentration tested in both oxygen conditions (Control vs. 2500µM in 
Figure 3.9A-B). Combined with the metabolic assay findings, ALG-1001 appears to 
suppress vascular endothelial cell proliferation without causing cell death and morphology 
change.  
PCA of HUVEC RNA-seq dataset 
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RNA-seq was used as an unbiased approach to explore the transcriptome regulation that may 
explain the metabolic assay and dead and live staining observations. For this study, four 
conditions were prepared by exposing HUVECs to vehicle or 500µM ALG-1001 in 
combination with room air oxygen tension or 24 hours of 3% O2 hypoxia. To reduce batch 
effect and improve detection of the subtle effect of the drug on HUVEC transcriptome, the 
experiment was repeated three times to generate 18 biological replicates (6 replicates per 
study) for each condition. 
Before performing differential expression analysis, PCA was first applied individually to 
each batch to visualize the RNA-seq samples in a low-dimensional space (Figure 3.10-3.12). 
In all three batch-specific PCAs, we see a clear separation between room air oxygen tension 
and hypoxia samples, suggesting the presence of a hypoxia-induced transcriptome shift. 
PCAs also show ALG-1001 treated samples appear to cluster close in space to control 
samples of the same oxygen level exposure, suggesting the drug effect is weaker than the 
effect of hypoxia. In terms of outlier detection, analysis of the top three principal components 
(PCs) revealed a total of six outliers (see Figure 3.10-3.12 legend for specific samples) that 
are excluded from all subsequent analysis. Here, the outliers were identified base on strong 
separation from other replicates of the same condition, suggesting possible sample cross-
contamination or other sample preparation issues. 
After outlier removal, all non-outlier samples were visualized using PCA (Figure 3.13). In 
this analysis, the first three PCs captured a combined 48% of total variance. One feature that 
stood out is a clear separation on PC2 between batch 1 and batch 2-3 (Figure 3.13B). 
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Incidentally, the latter two batches were prepared around the same time while batch 1 was 
sequenced roughly half a year earlier. This observable batch effect suggests batch-specific 
transcriptome expression pattern exists and should be accounted for during differential 
expression analysis. Focusing on PC1, we also noticed separation between hypoxia and room 
air oxygen tension samples on a batch-specific basis, which serves as evidence of hypoxia-
specific transcriptome regulation. On the other hand, separation between ALG-1001 treated 
samples and their respective control remains weak in all three PCs. In summary, PCA of 
HUVEC samples indicate: a) a strong batch effect exists in this dataset, b) there is an 
observable transcriptome shift by hypoxia treatment, and c) the expression regulation by 
ALG-1001 appears to be more subtle. 
Hypoxia-associated transcriptome regulation in HUVEC 
EdgeR was used to identify DE genes regulated by 24 hours of 3% O2 hypoxia exposure in 
HUVECs (Figure 3.14). Between hypoxia and control conditions, we found 5376 genes 
differentially expressed, representing around 40% of the expressed transcriptome (Figure 
3.14A). Of the 5376 DE genes, nearly all of them (5373/5376, 99%) are found to be 
moderately regulated with less than 1-fold change. This is in contrast to the large fold-
changes detected in both the OIR mouse retina (Chapter 2.3) and ARPE-19 cell culture 
(Chapter 4.3) studies. Heatmap visualization of the DE gene expression indicates consistent 
perturbation across the experimental batches and fairly uniform expression among the 
biological replicates (Figure 3.15). Unlike our other studies, ERSSA was not used to confirm 
the appropriate sample size in this comparison since blocking (used in this study to remove 
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batch effect) is not currently supported by the software. Yet, the DE results suggest the 
number of replicates used is likely sufficient given the large number of small-fold-change 
DE genes discovered. 
Next, we used goseq to identify the biological processes over-represented in the discovered 
DE genes. For this analysis, the DE genes were separated into two lists for investigation of 
up- and down-regulated biological processes (GO terms) and pathways (KEGG pathways). 
With the up-regulated genes, goseq found GO biological processes associated with known 
hypoxia-related mechanisms such as angiogenesis (e.g. “angiogenesis”, “extracellular matrix 
organization”), inflammation (e.g. “immune system process”, “cytokine production”) and 
cell growth/dead (e.g. “cell proliferation”, “cell death”) (Figure 3.16A)37. In the enriched 
“angiogenesis” GO biological process, we found 125 associated genes, consisting of 39 
positive regulator and 29 negative regulator of angiogenesis. VEGFA, which encodes for the 
potent angiogenic growth factor VEGF38, was also found to be up-regulated. With the down-
regulated genes, biological functions enriched include ones related to cell cycle (e.g. “cell 
cycle”, “DNA replication”) and metabolism (e.g. “heterocycle metabolism”, “metabolism”), 
both of which are known to be regulated by hypoxia exposure39,40.  
KEGG pathway enrichment provides additional evidence and provide several new insights. 
With up-regulated genes, both angiogenesis- and inflammation-related pathways were 
enriched (Figure 3.17A). Out of the six pathways discovered, three (“ECM-receptor 
interaction”, “Cell adhesion molecules”, and “focal adhesion”) are related to cell adhesion, 
which is actively involved in enabling vascular endothelial cell migration during 
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angiogenesis41. “Leukocyte transendothelial migration” is also enriched and is responsible 
for initiation of immune cell infiltration during inflammation37. Other enrichment results 
suggest regulation of energy-intensive translational processes in response to hypoxia: 
“ribosome” genes were found to be up-regulated while three of the four pathways enriched 
with down-regulated genes (“ribosome biogenesis in eukaryotes”, “Aminoacyl-tRNA 
biosynthesis” and “RNA transport”) are involved in various aspects of translation (Figure 
3.17A-B). Lastly, “steroid biosynthesis” and “Fanconi anemia pathway” were also enriched, 
but their adjusted p-values are very weak and their relationship with hypoxia is unclear. 
Transcriptome regulation by ALG-1001 exposure in HUVEC 
In contrast to the transcriptome regulation by hypoxia, the effect that ALG-1001 has on 
HUVEC transcriptome is relatively small. Here, we performed two comparisons to identify 
the genes regulated by the drug at both room air oxygen tension and with hypoxia co-
treatment conditions. In the two comparisons, we found 1470 (room air oxygen tension) and 
922 (hypoxia) DE genes, respectively (Figure 3.18). Heatmap visualization of the DE gene 
expression shows consistent expression pattern across the three batches with some 
heterogeneity among the biological replicates (Figure 3.19-20). ERSSA was not applied to 
these comparisons due to lack of blocking capability in existing software.  
Functional enrichment of the regulated genes generated both expected as well as surprising 
results. With the DE genes activated by ALG-1001 at room air oxygen tension, we observed 
enrichment of GO biological processes related to angiogenesis (“angiogenesis”, “circulatory 
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system development”, “extracellular matrix organization”) and inflammation 
(“inflammatory response”) (Figure 3.21A). Among the up-regulated genes, 48 are found to 
be involved with “angiogenesis” with 13 positive and 12 negative regulators. Interestingly, 
we also found 32 “angiogenesis” genes down-regulated including the positive regulator – 
VEGFA. However, GO enrichment with the down-regulated DE genes mainly identified 
several GO biological processes related to metabolism and translation (Figure 3.21B). 
Together, we found evidence of a selective up-regulation of angiogenesis and inflammation 
genes after ALG-1001 treatment at room air oxygen tension.  
In comparison, the regulation by ALG-1001 with hypoxia co-treatment shows down-
regulation of many processes activated by hypoxia (Figure 3.22B). Several noteworthy GO 
biological processes up-regulated by hypoxia and down-regulated by ALG-1001 co-
treatment include “angiogenesis”, “cell proliferation”, “cell death”, “extracellular matrix 
organization”, and “actin cytoskeleton organization”. In fact, more than 62% (135/218) of 
these enriched biological processes were previously enriched with hypoxia up-regulated DE 
genes. Complementary analysis of cellular component and molecular function GO 
annotations found strong evidence that the down-regulated genes function in the extracellular 
matrix and are involved in cell-adhesion (Figure 3.44). In addition, around 33% (303/922) 
of the ALG-1001-regulated genes in this comparison show opposite regulatory pattern 
compare to hypoxia treatment, supporting the observation that ALG-1001 moderated the 
effect of the low oxygen tension (Table 3.2, versus 21%, 196/922 that show same regulatory 
pattern). Taking one step further, we also found a weak but inverse relationship (r=-0.160) 
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between the fold change of the hypoxia-regulated genes and their fold change with ALG-
1001 co-treatment (Figure 3.23). It is worth mentioning that among the ALG-1001 down-
regulated genes, 38 are “angiogenesis” genes with 13 positive and 6 negative regulators. 
VEGFA, previously found to be up-regulated by hypoxia, was also suppressed by ALG-1001 
during hypoxia co-treatment. In summary, with the cells stimulated in a disease-relevant 
hypoxia state, ALG-1001 appears to moderate some of the hypoxia-activated transcriptome 
regulation.  
Since “angiogenesis” GO biological process was enriched in all three comparisons, we set 
out to investigate the associated DE genes in more detail (Figure 3.25). Across the three 
comparisons, we found hypoxia treatment disproportionally increased “angiogenesis” gene 
expression (125/190 or 66% of regulated “angiogenesis” genes are elevated), while ALG-
1001 without hypoxia appeared to be more moderate (48/80 or 60% of regulated 
“angiogenesis” genes are elevated) and ALG-1001 under hypoxia condition with the reverse 
trend (26/64 or 41% of regulated “angiogenesis” genes are elevated). In terms of the fold 
change, the regulatory pattern of ALG-1001-modulated “angiogenesis” genes is quite 
consistent regardless of the hypoxia co-treatment (Figure 3.25B-C). Additionally, among 
the 354 genes regulated by ALG-1001 in both comparisons, 100% of them have the same 
regulatory direction (Table 3.3). On the other hand, expression pattern of hypoxia-regulated 
“angiogenesis” genes are more heterogeneous among the three comparisons, with the highest 
consistency still between the two ALG-1001 comparisons (Figure 3.25A). These 
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observations show in contrary to the goseq results, specific fold change of ALG-1001-
regulated “angiogenesis” genes are consistent across both oxygen conditions. 
Limited KEGG pathways were enriched with ALG-1001 regulated genes (Figure 3.24). In 
both comparisons, we found the “steroid biosynthesis” pathway enriched with ALG-1001 
up-regulated genes and “aminoacyl-tRNA biosynthesis” pathway enriched with ALG-1001 
down-regulated genes. Out of the two, we found proteins in the “aminoacyl-tRNA 
biosynthesis” pathway have alternative functions in regulating angiogenesis. Specifically, 
the tRNA synthases encoded by YARS, WARS, TARS (down-regulated by ALG-1001 in 
both comparisons) have alterative functions in activating angiogenesis, immune cell 
migration, endothelial cell detachment and migration42.  
Transcription factors enriched from HUVEC RNA-seq dataset 
ISMARA was used to identify the TFs that are likely responsible for the observed gene 
expression regulation in HUVECs. For the TFs predicted to be involved in regulating 
hypoxia response, many of the top 50 enriched are relevant to the biology of hypoxia (Figure 
3.26, Table 3.4). The associated Z-scores of these TFs are relatively high, which suggests an 
abundance of evidence for their involvement in hypoxia transcriptome regulation. Notable 
TFs with elevated target expression include those involved in regulating hypoxia-related 
processes such as cell growth/death (SMAD4, SMAD1, WRNIP1, KLF4, PLAGL1, BCL3, 
and ERG), angiogenesis (GATA3), metabolism (ESRRA), and hypoxia-response (EPAS1) 
(Figure 3.27). Similarly, many of the TFs with down-regulated target genes are found to be 
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involved in regulating cell growth/death (HCFC1, TAF1, SIN3A, MYB, ATF2, and SP1), 
angiogenesis (E2F7, E2F1, E2F3, TFDP1, and ZNF384), metabolism (NRF1, AHR), 
inflammation (STAT5A), and hypoxia-response (ARNT2, CREB1) (Figure 3.28).  
Consistent with the OIR mouse dataset (Chapter 2.3), the enrichment of TFs regulated by 
ALG-1001 is less statistically significant compared to hypoxia. For both oxygen tension 
conditions, we found less than 20 TF motifs with Z-score>1.0, which is typically used as the 
statistical cutoff for ISMARA (Figure 3.29, 3.31, Table 3.5-3.6). When analysis was 
narrowed to those TFs that passed the statistical cutoff, we found many of them are in fact 
related to processes regulated by hypoxia. At room air oxygen tension, we observed 
enrichment of TFs regulating angiogenesis (GATA3, ID4), cell growth/death (SMAD4, 
WRNIP1, ERG, FOS, TAF1, and KLF8) and inflammation (CEBPB) (Figure 3.30). At 
hypoxia condition, only 12 TFs are enriched with 6 involved in angiogenesis (ZNF384), cell 
growth/death (SP1, MNT, MYC, and KLF4) and inflammation (CEBPB) (Figure 3.32). 
Intrigued by functional analysis that showed ALG-1001 is able to moderate hypoxia 
transcriptome regulation, we looked for the same pattern in the ISMARA results. 
Interestingly, we observed that out of the 18 TF motifs that are found on both the list of top 
50 enriched TFs (Table 3.6, labeled in bold), 15 of them showed a reverse target gene 
activity. In addition, many of these 15 regulators are related to hypoxia biology, including 
SMAD1, SMAD4, KLF4, PLAGL1, ZNF384, ESRRA, E2F3, and SP1.  
Transcriptome regulation by ALG-1001 exposure in PBMC 
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Immune cells’ involvement in the pathophysiology of retinal diseases has been extensively 
reported in prior literature43,44. In OIR dataset (Chapter 2.3), we found disease-related 
hypoxia stimulation activated both angiogenesis and immune gene expression, suggesting 
modulation of immune system together with neovascularization. After ALG-1001 treatment 
in the neovascularizing retina, we also discovered evidence that hypoxia-activated immune 
genes are suppressed by the drug treatment. To further investigate ALG-1001’s involvement 
in regulating immune cells, we treated human donor PBMCs with ALG-1001 and probed the 
transcriptome regulation after drug treatment. For this study, six replicates of PBMC treated 
with vehicle or ALG-1001 were sequenced with RNA-seq. PCA of the expression profile 
indicates weak separation on PC1 (accounting for 31% of total variance) between the 
treatment conditions (Figure 3.33). EdgeR comparison identified 1204 DE genes regulated 
by ALG-1001 with few by more than 1-fold (Figure 3.34A). Heatmap of the DE genes 
shows moderate amount of expression variation between biological replicates, suggesting 
some amount of inconsistency between the replicates (Figure 3.35). We also employed 
ERSSA to test the detection power of the current sample size and the results suggest not all 
DE genes have been discovered (double digit percentage increase in DE gene discovery up 
to the full sample size, Figure 3.34C-D). As a result, the following functional analysis should 
be viewed as preliminary as more genes are likely regulated by ALG-1001. 
Goseq was used to identify GO biological processes associated with up-regulated and down-
regulated genes. With up-regulated genes, we found enrichment of “lymphocyte activation”, 
“regulation of immune system process”, and “activation of immune response” processes. 
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“rRNA processing” was also strongly enriched, suggesting regulation of translational 
processes (Figure 3.36A). With down-regulated genes, we mainly found enrichment of 
immune-related processes such as “immune response”, “leukocyte activation involved in 
immune response”, “inflammatory response”, and “leukocyte migration” (Figure 3.36B).  
KEGG pathway enrichment of the DE genes are consistent with the GO biological process 
analysis. With up-regulated genes, we found enrichment of “ribosome” and “T cell receptor 
signaling” pathways (Figure 3.37A). Consistent with GO analysis, enrichment of 
“ribosome” pathway suggest modulation of translational processes by ALG-1001. On the 
other hand, enrichment of “T cell signaling pathway” is intriguing, as stimulation of the 
pathway activates T cells, leading to their proliferation, differentiation, and immune 
modulation. Visualization of the “T cell signaling pathway” gene expression shows the 
expression profile is mixed, with predominant up-regulation of genes that encode for proteins 
that initiate the signaling process and down-regulation of genes down-stream in the pathway 
(Figure 3.38). With down-regulated genes, we see enrichment of many pro-inflammatory 
pathways, including “TNF”, “C-type lectin receptor”, “IL-17”, and “Toll-like receptor” 
signaling pathways (Figure 3.37B). In particular, TNF signaling pathway is a potent pro-
inflammatory process that has reported to be activated in retinal diseases45–47.  Visualization 
of the pathway gene expression shows down-regulation of many pathway components, 
including genes that are transcriptionally regulated by the pathway (Figure 3.39).  
Using ISMARA, We found selected TFs that are likely involved in ALG-1001 treatment 
response and are biologically relevant to retinal disease pathophysiology (Figure 3.40-3.41, 
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Table 3.7). Specifically, some of the enriched transcriptional regulators are involved in 
processes such as angiogenesis (E2F7, E2F1, E2F3, and ZNF384), cell growth/death 
(FOXO3, FOSL2, PLAGL1, SMAD1, and SMAD4) and inflammation (NFKB2, IKZF1, 
IRF4, and IRF5). Among the TFs enriched, NFKB2 is particularly interesting as it is a 
member of the NF-κB family of transcription factors that, once activated, lead to expression 
of pro-inflammatory cytokines, chemokines and adhesion molecules48. NF-κB has also 
previously been found to be activated in mouse models of retinal diseases and in retinal cells 
of diabetic patients49–51. Here, we found that expression of NFKB2 target genes are down-
regulated by ALG-1001, indicating possible suppression of pro-inflammatory gene 
expression by the drug through NF-κB (Figure 3.41B). 
qPCR (HUVEC and PBMC) 
qPCR was used to validate six selected genes found to be regulated by ALG-1001 in HUVEC 
(Figure 3.42). Compared to the RNA-seq measurements, some of the qPCR gene expression 
quantification’s standard deviation are noticeably higher. In addition, a few genes found by 
RNA-seq to be up-regulated in hypoxia condition appeared to be unchanged with qPCR 
measurement. The discrepancy is likely due to the fairly small expression change observed, 
which may be within the range of qPCR technical error. Overall, a large fraction of regulatory 
patterns are consistent between the two results despite technical limitation.  
For the PBMC dataset, we aimed to validate the RNA-seq result with three immune-relevant 
genes (CCL2, CSF1, and RELB) using qPCR. For each gene, RNA-seq showed ALG-1001 
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weakly down-regulated their gene expression (Figure 3.43A), while the corresponding 
qPCR measurements largely confirm these results except for the expression pattern of RELB 
(Figure 3.43B). For this gene, the expression change is likely too small to be accurately 
detected by qPCR, as evident by the relatively large standard deviation. In short, we were 
able to observe the same expression pattern for two of the three genes tested while the 
expression change associated with the RELB appears to be too small to be accurately 
qualified by qPCR. 
 
3.4 Discussion 
Endothelial transcriptome modulation by hypoxia and ALG-1001 
Diseases of the retina affect millions of patients worldwide with few effective treatment 
options available12,13,52. With the current antibody-based standard of care ineffective in 
double digit percentage of patients, new solutions are sorely needed6,7. In recent years, the 
development of ALG-1001 as a potential therapy has produced promising clinical trial results 
as well as positive data in mouse (see Chapter 1.2 and 2.1 for more detail)10,53. Here, we 
applied RNA-seq to study the therapeutic effect of the drug in two human primary cell culture 
systems that represent cells relevant to disease pathophysiology. In particular, low passage 
HUVECs were used to study the drug’s effect on proliferating endothelial cells that play an 
essential role in disease-associated retinal neovascularization54. Freshly collected PBMCs 
were also tested to identify ALG-1001’s effect on immune cells that generally promote a 
cytotoxic inflammatory environment in diseased retinal tissue14–16. Through these 
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approaches, we found weak, but specific regulation by the drug on angiogenesis and 
inflammation.  
Using proliferating HUVECs, we set out to validate the anti-angiogenic effect observed in 
the OIR mouse model. Employing metabolic activity measurement as a proxy for cell 
density, we observed a dose-dependent suppression of endothelial cell proliferation by ALG-
1001 (Figure 3.8). In addition, fluorescent staining confirmed this effect is through inhibition 
of cell proliferation, instead of by inducing cell death as previously observed with structurally 
similar RGD peptide (Figure 3.9)55. Collectively, metabolic and imaging assays suggest 
ALG-1001 can suppress endothelial proliferation, even in a highly angiogenic cell culture 
environment where cells are induced to undergo rapid cell division. 
Next, RNA-seq was used as an unbiased approach to study HUVEC’s transcriptome 
response to disease-relevant hypoxia exposure and ALG-1001 treatment. After 24 hours of 
3% O2 low oxygen exposure, differential expression analysis found more than 5000 genes 
regulated by the treatment (Figure 3.14). However, compared to the magnitude of the 
hypoxia-induced expression change observed in OIR mouse retina (Chapter 2.3) and ARPE-
19 cells (Chapter 4.3), the fold changes are noticeably smaller in HUVECs. We suspect this 
is likely due to different cell microenvironments among the three models. In both OIR mouse 
model and ARPE-19 cell culture experiments, the retinal cells reside in a low proliferating 
state before hypoxia exposure. On the other hand, the HUVEC experiments were conducted 
in nutrient-rich growth media that promotes fast proliferation of the vascular endothelial 
cells. Thus, it is likely that HUVEC transcriptome is already in a state that sustains rapid cell 
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proliferation, leaving little room for hypoxia to induce further transcriptome change in the 
direction of promoting cell division.  
While the magnitude of expression changes is relatively small, functional analysis of the 
roughly five thousand DE genes enriched many biological processes relevant to hypoxia 
biology. In particular, GO enrichment with hypoxia up-regulated genes revealed biological 
processes related to angiogenesis, cell growth/death, inflammation and hypoxia response 
(Figure 3.16A)56,57. Similarly, down-regulated genes are over-represented with those related 
to hypoxia response such as cell cycle and metabolism (Figure 3.16B)39,40. In agreement, 
KEGG pathway enrichment found up-regulation of genes involved in cell adhesion (an 
important component of angiogenesis) and immune cell transendothelial migration (Figure 
3.17A)37,41. However, unlike biological process analysis, KEGG pathway enrichment of 
hypoxia down-regulated genes identified three pathways related to translation, but not those 
related to cell cycle and metabolism (Figure 3.17B). In relation to translation, hypoxia is 
known to suppress translation due to a state of cellular energy shortage58.  
Compared to the hypoxia-induced transcriptome change, ALG-1001’s effect on gene 
expression is relatively small. After 48 hours of ALG-1001 treatment, we found 1470 and 
922 DE genes at room air oxygen tension and hypoxia conditions, respectively (Figure 3.18). 
Of the genes regulated by ALG-1001 at room air oxygen tension, we are surprised to find 
over-representation of several GO biological processes that were previously found to be 
associated with hypoxia response (Figure 3.21). In particular, there are several that suggest 
selective up-regulation of angiogenesis genes by ALG-1001. In terms of fold change, we 
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found a positive correlation (r=0.407) among hypoxia-regulated “angiogenesis” genes 
between hypoxia-response and ALG-1001 response at room air oxygen tension (Figure 
3.25A). Taken together, these results suggest, on face value, that ALG-1001 may be 
activating angiogenesis instead of suppressing it.  
It is worth noting that there are also “angiogenesis” genes down-regulated by ALG-1001 that 
are up-regulated by hypoxia. In fact, we noticed several important angiogenesis genes that 
are up-regulated by hypoxia and suppressed by ALG-1001 at both oxygen treatment 
conditions. Four notable genes that exhibit this pattern include VEGFA and ANXA3, both 
of which are potent pro-angiogenesis proteins38,59; TGFB2, which was reported to suppress 
angiogenesis60; and TGFBI, which plays a role in cell adheison61. Additionally, both VEGFA 
and ANXA3 were also observed to be down-regulated by ALG-1001 in the OIR mouse retina 
(Chapter 2), indicating possible regulation of angiogenesis through modulation of these key 
players.  
Interestingly, the transcriptome regulation by ALG-1001 with hypoxia co-treatment tells a 
different story. Under hypoxic condition, we detected an inverse relationship between 
hypoxia-induced gene expression and after co-treatment with ALG-1001 (Pearson’s r=-
0.160, Figure 3.23), which suggest ALG-1001 moderated some of transcriptome response 
to hypoxia stimulation. Additionally, more than half of the GO biological processes enriched 
with ALG-1001-suppressed genes (e.g. “angiogenesis”, “cell death”, “cell proliferation”, and 
“extracellular matrix organization”) are enriched with hypoxia up-regulated genes (Figure 
3.22). KEGG pathway enrichment supports these findings with enrichment of “aminoacyl-
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tRNA biosynthesis” pathway among ALG-1001-suppressed genes (Figure 3.24). 
Specifically, we found three tRNA synthases (YARS, WARS, and TARS) down-regulated 
by ALG-1001 also have alternative function in modulating angiogenesis42. For instance, 
tyrosyl-tRNA synthase (YARS) can be secreted and cleaved into cytokine fragments with 
pro-angiogenic effect, while threonyl-tRNA synthase (TARS) is secreted to stimulate vessel 
migration, patterning and maturation. On the other hand, Tryptophanyl-tRNA synthase 
(WARS) appears to inhibit angiogenesis, where its cleaved form can be secreted to disrupt 
endothelial cell attachment and angiogenic signaling molecule. Since tRNA synthases 
function in both translation and angiogenesis regulation, it is unclear from gene expression 
alone whether they are actually involved in ALG-1001’s anti-angiogenic effect. Additional 
biochemistry and genetics experiments could help clarify their involvement. 
A key component of drug mechanism of action study is identification of both the drug target 
and the modulated down-stream effector proteins. With RNA-seq data, we are unable to 
directly identify either of these components, but we can use the gene expression profile to 
infer TFs that are likely involved in driving the gene regulation. For this analysis, we used 
ISMARA to identify the factors that are predicted to participate in hypoxia response and after 
ALG-1001 treatment. When applied to study hypoxia, the algorithm enriched many TFs that 
are known regulator of hypoxia-regulated processes such as cell growth/death, angiogenesis, 
metabolism, inflammation, and hypoxia-response (Figure 3.26). In terms of ALG-1001 
transcriptome modulation, limited number of TFs were enriched with statistical significance 
(Figure 3.29, 3.31). Interestingly, enriched factors include those involved in angiogenesis, 
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cell growth/death, and inflammation processes. Additionally, ALG-1001 treatment reversed 
target gene activity for several TFs that are regulated by hypoxia (e.g. SMAD family proteins, 
SP1 and KLF4), suggesting these TFs may play a role as down-stream effector of ALG-
1001. Intriguingly, these factors are also involved in regulating a wide range of biological 
activities, including cell growth, adhesion, apoptosis, development, metabolism, immune 
system and morphogenesis62–66. Although RNA-seq data does not provide concrete evidence 
that these TFs are involved in ALG-1001’s therapeutic effect, our findings warrant further 
investigation to confirm their roles in the drug’s mechanism of action. 
Immune cell gene expression modulated by ALG-1001 
In a second study, fresh human donor PBMCs were treated with low dosage of ALG-1001 
for 8 hours and then probed with RNA-seq to identify the genes regulated. Comparable to 
the HUVEC results, we found around 1200 DE genes, many with small fold changes (Figure 
3.34). Interestingly, functional analysis of the enriched genes suggest regulation of multiple 
immune processes by ALG-1001 (Figure 3.36, 3.37). Using KEGG pathway enrichment, 
we found over-representation of “TNF signaling pathway” genes in the down-regulated gene 
list (Figure 3.37B). Visualization of the changes in the pathway shows that majority of the 
pathway is weakly down-regulated by ALG-1001 (Figure 3.39). Intriguingly, we also 
enriched “T cell receptor signaling pathway” with up-regulated genes. T cell receptor 
signaling is activated after successful antigen binding and its activation suggest possible T 
cell receptor recognition of ALG-1001, leading to initiation of T cell activity (Figure 3.37A, 
3.38). In terms of ISMARA TF enrichment, we found: a) enrichment of NFKB2, a member 
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of the pro-inflammatory NF-κB protein family and b) identification of SMAD4 and SNF384, 
which were also enriched in the HUVEC experiment. In particular, ALG-1001 suppressed 
these two factor’s target gene activity in both models, indicating a common predicted 
regulatory effect.  
While these results are promising, the PBMC study was repeated only once with PBMCs 
collected from a single donor. As a result, these findings should be considered as preliminary 
as additional samples are needed for more concrete conclusions (suggested by ERSSA, 
Figure 3.34C-D). Additionally, PBMCs are composed of multiple immune cell types and 
bulk RNA-seq cannot easily discern the effect of ALG-1001 on individual cell types. More 
studies should be carried out with purified samples of specific cell types, with monocytes as 
a priority due to their known involvement in retinal diseases67.  
Limitation of in vitro cell culture 
In general, results from in vitro cell culture should be further validated in vivo. In cell culture, 
the cells are removed from their in vivo tissue microenvironment, which can alter their 
response to drug treatment68. Indeed, as in most cell culture studies, the culture environment 
employed in our studies are artificial: a) high level of oxygen tension (typical room air 
oxygen percentage of around 21% vs. around 5% in normal tissue69), b) nutrient-rich growth 
media (induce rapid cell proliferation with growth factor levels much higher than those found 
in tissue), c) cells grown in monolayer without interaction with other cell types. Additionally, 
this study have the added challenge of trying to mimic the diseased microenvironment in cell 
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culture, which is very challenging. Overall, our results from cell culture studies should be 
viewed in context of these limitations, such that any observations in vitro need to be validated 
with the appropriate animal model.  
 
3.5 Conclusions 
Retinal diseases are currently untreatable for millions of patients worldwide. ALG-1001 is 
an oligopeptide drug that is currently under clinical investigation for treatment of these 
blinding eye diseases. In this study, we used human primary cell culture models of vascular 
endothelial and immune cells to study the drug’s therapeutic effect, through analysis of the 
treatment-associated transcriptome regulation. In endothelial cells, we found ALG-1001 
modulated expression of angiogenesis genes activated by disease-relevant hypoxia exposure. 
In immune cells, we found ALG-1001 treatment down-regulated pro-inflammatory TNF 
signaling pathway, potentially through modulation of NF-κB. Altogether, our results 
provided evidence of cell type-specific regulation by ALG-1001, particularly in suppressing 
disease-worsening angiogenesis and inflammation. It is also important to view these results 
in context of the limitations of cell culture models, which always require further validation 
with animal studies.  
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3.6 Figures and Tables 
 
Figure 3.1 HUVEC treatment design 
HUVECs were exposed to vehicle (empty) or ALG-1001 (blue bar) at experiment-specific 
concentration for 48 hours and with or without 3% O2 hypoxia (red bar) for 24 hours before 
assay. This treatment scheme is applied to prepare WST-1 assay, Dead/live staining and 
RNA-seq samples.  
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Figure 3.2 FastQC mean sequencing quality score – part 1 
MultiQC plots the average sequencing quality Phred score at each base in the reads generated 
for each sample. Each line detonates a sample, with majority of them overlapping throughout 
the entire 100 base pair region. Phred score plot indicates good sequence quality across all 
samples. A. HUVEC study, batch 1 samples B. HUVEC study, batch 2 samples. 
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Figure 3.3 FastQC mean sequencing quality score – part 2 
MultiQC plots the average sequencing quality Phred score at each base in the reads generated 
for each sample. Each line detonates a sample, with majority of them overlapping throughout 
the entire 100 base pair region. Phred score plot indicates good sequence quality across all 
samples. A. HUVEC study, batch 3 samples B. PBMC study samples. 
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Figure 3.4 Tophat2 and HTSeq-count statistics – HUVEC, batch 1 samples 
A. At least 88% of reads were mapped in all samples by Tophat2. B. HTSeq-count uniquely 
assigned (blue bar) between 77-79% of a sample’s aligned reads to a gene except replicate 
5 of ALG-1001+hypoxia condition (62.5%). 
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Figure 3.5 Tophat2 and HTSeq-count statistics – HUVEC, batch 2 samples 
A. At least 91% of reads were mapped in all samples by Tophat2. B. HTSeq-count uniquely 
assigned (blue bar) between 76-79% of a sample’s aligned reads to a gene. 
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Figure 3.6 Tophat2 and HTSeq-count statistics – HUVEC, batch 3 samples 
A. At least 92% of reads were mapped in all samples by Tophat2. B. HTSeq-count uniquely 
assigned (blue bar) between 77-80% of a sample’s aligned reads to a gene. 
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Figure 3.7 Tophat2 and HTSeq-count statistics – PBMC samples 
A. Between 76-87% of reads were mapped in all samples by Tophat2. B. HTSeq-count 
uniquely assigned (blue bar) between 63-67% of a sample’s aligned reads to a gene. 
Trouble uniquely assigning reads likely due to difficulty with polymorphic antibody and T 
cell receptor genes. 
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Figure 3.8 WST-1 assay of HUVECs treated with ALG-1001 concentration series 
After 48 hours of ALG-1001 treatment at specified concentration, cellular metabolic activity 
level was measured as an indicator of cell density. At both room air oxygen tension (A) and 
24 hours of 3% O2 hypoxia exposure (B) conditions, HUVECs treated with ALG-1001 
demonstrated a dose-dependent drop in cell density at end of treatment. Experiment was 
performed once with n=6 per condition. Metabolic activity was normalized with mean 
activity of control cells as 100%. Mean and standard deviation plotted. All statistical tests 
were performed against control condition with the stars indicate the magnitude of the 
adjusted p-value (* P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001).   
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Figure 3.9 Dead and live staining of HUVECs treated with ALG-1001 concentration 
series 
After 48 hours of ALG-1001 treatment at specified concentrations, dead and live staining 
was performed to detect cell state. (left) Phase contrast micrographs and (right) merged live 
(green) and dead (red) stained images show no obvious cell death or change in cell 
morphology after drug exposure. Experiment was repeated at both room air oxygen tension 
(A) and after 24 hours of 3% O2 hypoxia (B) conditions. Lethal control shows cells that are 
dead with compromised cell membrane.  
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Figure 3.10 PCA of HUVEC, batch 1 samples 
PCA of 24 HUVEC, batch 1 samples. ALG48h is ALG-1001, Hypoxia_ALG48h is ALG-
1001+hypoxia conditions. PC_# is principal component #. A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC_1 and PC_2, PC_1 and 
PC_3, respectively. Percent of variance explained are shown in axis label. Three obvious 
outliers were detected: control replicate 3, and ALG-1001 replicate 5 and 6. 
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Figure 3.11 PCA of HUVEC, batch 2 samples 
PCA of 24 HUVEC, batch 2 samples. ALG48h is ALG-1001, Hypoxia_ALG48h is ALG-
1001+hypoxia conditions. PC_# is principal component #. A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC_1 and PC_2, PC_1 and 
PC_3, respectively. Percent of variance explained are shown in axis label. Two obvious 
outliers were detected: ALG-1001 replicate 6 and hypoxia replicate 6. 
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Figure 3.12 PCA of HUVEC, batch 3 samples 
PCA of 24 HUVEC, batch 3 samples. ALG48h is ALG-1001, Hypoxia_ALG48h is ALG-
1001+hypoxia conditions. PC_# is principal component #. A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC_1 and PC_2, PC_1 and 
PC_3, respectively. Percent of variance explained are shown in axis label. One obvious 
outlier was detected: ALG-1001+hypoxia replicate 6.  
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Figure 3.13 PCA of all non-outlier HUVEC samples 
PCA of 66 non-outlier HUVEC samples. ALG48h is ALG-1001, Hypoxia_ALG48h is ALG-
1001+hypoxia conditions. PC_# is principal component #. A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC_1 and PC_2, PC_1 and 
PC_3, respectively. Percent of variance explained are shown in axis label. Experimental 
batch is symbol-coded while condition is color-coded. 
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Figure 3.14 edgeR comparison of HUVEC control and hypoxia conditions 
A. Measured CPM and fold-change for each expressed gene. DE genes are colored red while 
all others are black. Genes outside of display window are symbolized by triangle. B. edgeR 
measured fold-change and FDR displayed for each gene. DE genes are colored red while all 
others are black. Genes outside of display window are symbolized by triangle. Blue dashed 
line indicates FDR=0.05.  
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Figure 3.15 Heatmap of 5376 DE genes found to be regulated by hypoxia in HUVEC 
Normalized (Norm.) TPM values are plotted for DE genes between HUVEC control and 
hypoxia conditions. Genes are plotted on rows and are ranked by decreasing log2-fold-
change. Samples are grouped by condition (gray-scale) and by experimental batch (color) as 
indicated by the bars shown below the heatmap.  
189 
 
 
Figure 3.16 GO enrichment of DE genes regulated by hypoxia in HUVEC 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO term. 
Selected biologically relevant GO terms were labeled.  
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Figure 3.17 KEGG pathway enrichment of DE genes regulated by hypoxia in HUVEC 
Goseq-enriched KEGG pathways with up-regulated (A) or down-regulated (B) DE genes. 
Statistically significant pathways are displayed. Benjamini Hochberg (BH) adjusted P-value 
is displayed on the x-axis.  
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Figure 3.18 DE genes regulated by ALG-1001 at room air oxygen tension and hypoxia 
conditions 
EdgeR used to identify DE genes between control and ALG-1001 conditions (A-B) and 
hypoxia and ALG-1001 + hypoxia conditions (C-D). (A, C) Measured CPM and fold-change 
for each expressed gene. DE genes are colored red while all others are black. Genes outside 
of display window are symbolized by triangle. (B, D) EdgeR measured fold-change and FDR 
displayed for each gene. DE genes are colored red while all others are black. Genes outside 
of display window are symbolized by triangle. Blue dashed line indicates FDR=0.05. 
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Figure 3.19 Heatmap of 1470 DE genes regulated by ALG-1001 at room air oxygen 
tension in HUVEC 
Normalized (Norm.) TPM values are plotted for DE genes between HUVEC control and 
ALG-1001 conditions. Genes are plotted on rows and are ranked by decreasing log2-fold-
change. Samples are grouped by condition (gray-scale) and by experimental batch (color) as 
indicated by the bars shown below the heatmap.
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Figure 3.20 Heatmap of 922 DE genes regulated by ALG-1001 with hypoxia co-
treatment in HUVEC 
Normalized (Norm.) TPM values are plotted for DE genes between HUVEC hypoxia and 
ALG-1001 + hypoxia conditions. Genes are plotted on rows and are ranked by decreasing 
log2-fold-change. Samples are grouped by condition (gray-scale) and by experimental batch 
(color) as indicated by the bars shown below the heatmap.  
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Figure 3.21 GO enrichment of DE genes regulated by ALG-1001 at room air oxygen 
tension 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO term. 
Selected biologically relevant GO terms were labeled.  
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Figure 3.22 GO enrichment of DE genes regulated by ALG-1001 with hypoxia 
stimulation 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO term. 
Selected biologically relevant GO terms were labeled. 
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Figure 3.23 ALG-1001 treatment weakly moderates hypoxia-induced transcriptome 
regulation  
Each dot represents a DE gene found to be regulated during hypoxia response. The gene’s 
log2-fold-change after hypoxia treatment is plotted on the x-axis, while the fold change with 
ALG-1001 co-treatment is plotted on the y-axis. Plot window is limited to the (-1, 1) range 
on both axes. Pearson’s r value is measured as -0.160. The plot can be divided into four 
quadrants, as indicated by the blue dashed lines, with 1710 genes in the top left, 986 in the 
bottom left, 1106 in the top right, and 1568 in the bottom right.  
 
  
197 
 
 
Figure 3.24 KEGG pathway enrichment of DE genes regulated by ALG-1001 at room 
air oxygen tension and hypoxia conditions 
Goseq-enriched KEGG pathways with up-regulated (A) or down-regulated (B) DE genes by 
ALG-1001 at room air oxygen tension and up-regulated (C) or down-regulated (D) DE genes 
by ALG-1001 with hypoxia stimulation. Statistically significant pathways are displayed. 
Benjamini Hochberg (BH) adjusted P-value is displayed on the x-axis.  
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Figure 3.25 Heatmap of DE angiogenesis genes 
Fold change of DE “angiogenesis” (GO biological process) genes are plotted as heatmap. 
Genes are plotted row-wise and comparisons column-wise. Expression profiles are clustered 
using average Euclidean distance method with results shown above the heatmap. |log2-fold-
change|>0.50 are shown as 0.50 or -0.50 to improve visualization of small changes. Log2FC 
is log2-fold-change. DE “angiogenesis” genes found in hypoxia vs. control (A), ALG-1001 
vs. control (B) and ALG-1001 + hypoxia vs. hypoxia (C) comparisons are plotted, with genes 
ranked by the log2-fold-change in each respective comparison.  
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Figure 3.26 ISMARA prediction of TFs involved during hypoxia response 
HUVEC control and hypoxia samples were submitted to ISMARA for enrichment of TFs that 
are likely involved during hypoxia-response. Top 50 enriched factors with the highest Z-
score were plotted (x-axis shows rank by Z-score). Selected biologically relevant factors with 
higher (A) or lower (B) target gene activity in hypoxia condition are labeled.   
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Figure 3.27 Activity profile of selected TF motifs with higher target activity in hypoxia 
samples 
HUVEC control and hypoxia samples were submitted to ISMARA for enrichment of TFs that 
are likely involved during hypoxia-response. Activity profile (mean + standard deviation) of 
selected TFs with higher target activity in hypoxia condition are plotted. Conditions labeled 
as follows: ALG-1001 as ALG48h, ALG-1001 + hypoxia as Hypoxia_ALG48h.   
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Figure 3.28 Activity profile of selected TF motifs with lower target activity in hypoxia 
samples 
HUVEC control and hypoxia samples were submitted to ISMARA for enrichment of TFs that 
are likely involved during hypoxia-response. Activity profile (mean + standard deviation) of 
selected TFs with lower target activity in hypoxia condition are plotted. Conditions labeled 
as follows: ALG-1001 as ALG48h, ALG-1001 + hypoxia as Hypoxia_ALG48h. 
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Figure 3.29 ISMARA prediction of TFs regulated by ALG-1001 at room air oxygen 
tension 
HUVEC control and ALG-1001 samples were submitted to ISMARA for enrichment of TFs 
that are likely involved during ALG-1001 induced transcriptome regulation. Top 50 enriched 
factors with the highest Z-score were plotted (x-axis shows rank by Z-score). Only results 
with Z-score > 1.0 (blue dashed line) are considered for further analysis. Selected 
biologically relevant factors with higher (A) or lower (B) target gene activity in drug 
treatment condition are labeled.   
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Figure 3.30 Activity profile of selected TF motifs likely involved in ALG-1001 induced 
transcriptome regulation 
HUVEC control and ALG-1001 samples were submitted to ISMARA for enrichment of TFs 
that are likely involved during ALG-1001 response. Activity profile (mean + standard 
deviation) of selected TFs with higher (A) or lower (B) target activity in ALG-1001 condition 
are plotted. Conditions labeled as follows: ALG-1001 as ALG48h, ALG-1001 + hypoxia as 
Hypoxia_ALG48h. 
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Figure 3.31 ISMARA prediction of TFs regulated by ALG-100 with hypoxia treatment 
HUVEC hypoxia and ALG-1001 + hypoxia samples were submitted to ISMARA for 
enrichment of TFs that are likely involved during ALG-1001 induced transcriptome 
regulation. Top 50 enriched factors with the highest Z-score were plotted (x-axis shows rank 
by Z-score). Only results with Z-score > 1.0 (blue dashed line) are considered for further 
analysis. Selected biologically relevant factors with higher (A) or lower (B) target gene 
activity in drug treatment condition are labeled.  
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Figure 3.32 Activity profile of selected TF motifs likely regulated by ALG-1001 with 
hypoxia treatment 
HUVEC hypoxia and ALG-1001 + hypoxia samples were submitted to ISMARA for 
enrichment of TFs that are likely involved during ALG-1001 response. Activity profile 
(mean + standard deviation) of selected TFs with higher (A) or lower (B) target activity in 
ALG-1001 + hypoxia condition are plotted. Conditions labeled as follows: ALG-1001 as 
ALG48h, ALG-1001 + hypoxia as Hypoxia_ALG48h. 
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Figure 3.33 PCA of PBMC samples 
PCA of 12 PBMC samples. ALG-1001 labeled as ALG. PC_# is principal component #. A. 
Percent of overall variance captured by the top 10 principal components. B-C. Samples in 
PC_1 and PC_2, PC_1 and PC_3, respectively. Percent of variance explained is shown in 
axis label. 
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Figure 3.34 edgeR comparison of ALG-1001 treatment in PBMC 
EdgeR comparison of control and ALG-1001 conditions. A. Measured CPM and fold-change 
for each expressed gene. DE genes are colored red while all others are black. B. edgeR 
measured fold-change and FDR displayed for each gene. DE genes are colored red while all 
others are black. Blue dashed line indicates FDR=0.05. C-D. ERSSA-generated number of 
DE gene plot (C) and marginal change plot (D) with 50 combinations per replicate level and 
log2-fold-change cut off = 0.5.  
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Figure 3.35 Heatmap of 1204 DE genes with ALG-1001 treatment in PBMC 
Normalized (Norm.) TPM values are plotted for DE genes between control and ALG-1001 
treatment conditions. Genes are plotted on rows and are ranked by decreasing log2-fold-
change.   
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Figure 3.36 GO enrichment of DE genes with ALG-1001 treatment in PBMC 
Up- (A) and down-regulated (B) DE genes were submitted for GO enrichment with results 
visualized using REVIGO. P-value is REVIGO-derived GO enrichment p-value. Size is the 
number of human proteins associated with each GO term. Selected biologically relevant GO 
terms were labeled.  
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Figure 3.37 KEGG pathway enrichment of DE genes with ALG-1001 treatment in 
PBMC 
KEGG pathways enriched with up- (A) or down-regulated (B) DE genes using goseq. 
Statistically significant pathways are displayed. Benjamini Hochberg (BH) adjusted P-value 
is displayed on the x-axis.  
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Figure 3.38 Pathview visualization of the T cell receptor signaling pathway 
ALG-1001 treatment induced pathway expression changes in PBMC are plotted. White 
colored nodes indicate genes that are not found to be expressed in the dataset. 
 
 
  
212 
 
 
Figure 3.39 Pathview visualization of the TNF signaling pathway 
ALG-1001 treatment induced pathway expression changes in PBMC are plotted. White 
colored nodes indicate genes that are not found to be expressed in the dataset. 
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Figure 3.40 ISMARA TF enrichment with PBMC samples 
PBMC samples were submitted to ISMARA for enrichment of TFs that are likely involved in 
transcriptome regulatory response to ALG-1001 treatment. Top 50 enriched factors with the 
highest Z-score were plotted (x-axis shows rank by Z-score). Only results with Z-score > 1.0 
(blue dashed line) are considered for further analysis. Selected biologically relevant factors 
with higher (A) or lower (B) target gene activity in drug treatment condition are labeled.  
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Figure 3.41 Activity profile of selected TF motifs predicted to be regulated by ALG-
1001 in PBMC samples 
PBMC samples were submitted to ISMARA for enrichment of TFs that are likely involved in 
the transcriptome regulatory response to ALG-1001 treatment. Activity profile (mean + 
standard deviation) of selected TFs with higher (A) or lower (B) target gene activity in ALG-
1001 condition are plotted.  
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Figure 3.42 qPCR validation of selected HUVEC RNA-seq results 
Six genes shown to be regulated by ALG-1001 were selected for qPCR validation. 
Expression values were normalized in both plots so that average Control expression is 1. The 
mean and standard deviation are shown. Conditions are labeled as follows: ALG-1001 as 
ALG, ALG-1001 + hypoxia as Hypoxia_ALG. A. RNA-seq expression are based on TPM 
values. B. qPCR expression are based on ΔΔCt-derived fold changes.  
 
  
216 
 
 
Figure 3.43 qPCR validation of selected PBMC RNA-seq results 
Three genes shown to be regulated by ALG-1001 were selected for qPCR validation. 
Expression values were normalized in both plots so that average Control expression is 1. The 
mean and standard deviation are shown. ALG-1001 condition is labeled as ALG. A. RNA-
seq expression are based on TPM values. B. qPCR expression are based on ΔΔCt-derived 
fold changes.  
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Figure 3.44 GO cellular component and molecular function enrichment of ALG 
down-regulated genes in HUVEC under hypoxia 
ALG-1001 down-regulated DE genes in HUVEC with hypoxia co-streatment were 
submitted for cellular component (A) and molecular function (B) GO enrichment with results 
visualized using REVIGO. P-value is REVIGO-derived GO enrichment p-value. Size is the 
number of mouse proteins associated with each GO term. Selected biologically relevant GO 
terms are labeled.  
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Gene Direction 5' to 3' Sequence 
VEGFA Forward AGGGCAGAATCATCACGAAGT 
VEGFA Reverse AGGGTCTCGATTGGATGGCA 
FSTL3 Forward ACATTGACACCGCCTGGTC 
FSTL3 Reverse GTCGCACGAATCTTTGCAG 
TGFBI Forward CACTCTCAAACCTTTACGAGACC 
TGFBI Reverse CGTTGCTAGGGGCGAAGATG 
TGFB2 Forward CAGCACACTCGATATGGACCA 
TGFB2 Reverse CCTCGGGCTCAGGATAGTCT 
YARS Forward ACCTCCACGCATACCTGGATA 
YARS Reverse TTGCTGAGCTGGTAATCAGTG 
TARS Forward GGAGAAGCCGATTGGTGCT 
TARS Reverse TCAACTCAGCTCGACCTCCAT 
ACTB Forward CATGTACGTTGCTATCCAGGC 
ACTB Reverse CTCCTTAATGTCACGCACGAT 
CCL2 Forward CAGCCAGATGCAATCAATGCC 
CCL2 Reverse TGGAATCCTGAACCCACTTCT 
CSF1 Forward TCCAGTTGCTGGAGAAGGTC 
CSF1 Reverse ACATCTTGGCTGGAGCATTC 
RELB Forward AGCTACGGCGTGGACAAG 
RELB Reverse TGGGGGTCAGAGCTGTTC 
Table 3.1 qPCR primers 
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Hypoxia vs. Control 
Up Down Total 
ALG-1001 + 
Hypoxia vs. 
Hypoxia 
Up 125 139 472 
Down 164 71 450 
Total 2674 2702 
 
Table 3.2 Two-way contingency table of hypoxia and ALG-1001 with hypoxia 
treatment regulated DE genes 
A larger portion (61%) of commonly regulated genes are in the reverse direction across the 
two comparisons.  
 
 
 
 
ALG-1001 vs. Control 
Up Down Total 
ALG-1001 + 
Hypoxia vs. 
Hypoxia 
Up 203 0 472 
Down 0 151 450 
Total 816 654 
 
Table 3.3 Two-way contingency table of ALG-1001 regulated DE genes 
All of the commonly regulated genes are in the same direction across the two ALG-1001 
comparisons.   
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Trans. Factor Z-score Activity.diff_
Hypoxia-
Control 
Activity.diff_
ALG48h-
Control 
Activity.diff_
Hypoxia_AL
G-Hypoxia 
SIX5_SMARCC2_HCF
C1 
3.984283 -0.00416 0.00095 0.000501 
TAF1 3.799678 -0.00642 -0.00235 -0.00037 
E2F7_E2F1 3.695472 -0.0064 -0.00136 9.50E-05 
NRF1 3.647543 -0.005 0.00031 5.00E-04 
ELK4_ETV5_ELK1_EL
K3_ELF4 
3.202669 -0.00497 -0.002 0.000284 
TFDP1 3.181176 -0.0051 -0.00095 0.000183 
SMAD4 3.043193 0.005763 0.002883 -0.00094 
HIC2 3.010955 0.006124 0.000152 -0.00096 
WRNIP1 2.937209 0.002543 0.001362 -0.00024 
NFIX_NFIB 2.920625 0.005313 0.001506 -0.00077 
PATZ1_KLF4 2.862023 0.004281 0.001677 -0.00124 
HOXB6_PRRX2 2.860698 -0.00449 -0.00197 -0.0007 
ZBTB33_CHD2 2.68979 -0.00538 -0.0024 0.00074 
EBF1 2.63914 0.004784 0.000684 -0.00124 
SIN3A_CHD1 2.521402 -0.00536 -0.00229 0.000184 
TAL1 2.465716 0.002684 0.00262 0.000746 
GATA3 2.463018 0.002618 0.001966 -5.00E-06 
TBP 2.416656 0.004614 0.001385 0.000431 
PLAGL1 2.402684 0.005463 0.001948 -0.00086 
POU3F2 2.401511 -0.00412 -0.00151 0.001395 
ZBTB14 2.333934 -0.00358 -0.00157 0.000131 
STAT5A 2.302745 -0.00381 -0.00241 8.70E-05 
RUNX1_RUNX2 2.299625 0.003737 0.000961 -0.00043 
POU2F2_POU3F1 2.272958 0.004328 0.001928 -6.70E-05 
MYB 2.272434 -0.00373 -0.00117 -0.00018 
IKZF1 2.261967 0.003544 0.001164 4.90E-05 
AHR_ARNT2 2.255568 -0.0031 -0.00024 2.90E-05 
POU5F1_POU2F3 2.210019 0.00378 0.001746 -0.00056 
ZNF384 2.190534 -0.00343 -0.00134 0.001379 
TFAP2C 2.107671 0.003238 -0.00094 -0.00078 
ESRRA_ESR2 2.077387 0.004888 0.000632 -0.00102 
MEIS2 2.047777 -0.00362 -0.00086 0.000553 
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ZFX 2.047151 -0.00289 -0.00121 -0.00048 
E2F3 2.030033 -0.00359 -3.10E-05 0.000927 
ATF2_ATF1_ATF3 2.030014 -0.0029 -0.00145 0.000442 
EPAS1_BCL3 2.006106 0.003194 0.001539 -0.00039 
CREB1 1.963439 -0.00377 0.000645 2.70E-05 
SMAD1 1.92378 0.00205 0.00064 -0.00076 
CXXC1 1.903042 -0.00357 -0.00186 0.000306 
SP1 1.898054 -0.00206 0.000159 0.001339 
ERG 1.880574 0.002637 0.00184 0.000737 
WT1_MTF1_ZBTB7B 1.800999 0.001699 0.000619 -0.00021 
ZNF143 1.67804 -0.0028 -0.00125 -0.00041 
MECP2 1.673895 -0.00186 0.000171 -0.00072 
DLX4_HOXD8 1.667185 -0.00281 -0.00048 0.000587 
FOXD1_FOXO1_FOXO
6_FOXG1_FOXP1 
1.665125 0.002779 0.00085 -0.00037 
GMEB2 1.659293 -0.00287 -0.00115 7.20E-05 
TLX1_NFIC 1.645351 0.003109 0.000426 -7.30E-05 
BARHL1 1.639518 -0.00295 -0.00063 0.001171 
ZNF711_TFAP2A_TFA
P2D 
1.625267 -0.00151 -9.20E-05 4.30E-05 
Table 3.4 Top 50 TF motifs enriched with hypoxia treatment in HUVEC 
TFs are ordered by Z-score. Activity.diff_Hypoxia-Control is the average target gene activity 
difference between hypoxia and control conditions. Activity.diff_ALG48h-Control is the 
average target gene activity difference between ALG-1001 and control conditions. 
Activity.diff_Hypoxia_ALG-Hypoxia is the average target gene activity difference between 
ALG-1001 + hypoxia and hypoxia conditions. Bolded TFs indicate ones that are also found 
on the list of top 50 TFs enriched with ALG-1001 and hypoxia co-treatment. 
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Trans. Factor Z-score Activity.diff_
Hypoxia-
Control 
Activity.diff_
ALG48h-
Control 
Activity.diff_
Hypoxia_AL
G-Hypoxia 
TAL1 2.330915 0.002684 0.00262 0.000746 
GATA3 1.581428 0.002618 0.001966 -5.00E-06 
KLF16_SP2 1.53227 -0.00017 0.001613 0.000985 
TAF1 1.465342 -0.00642 -0.00235 -0.00037 
ID4_TCF4_SNAI2 1.449888 0.001203 0.00179 0.000794 
STAT5A 1.4191 -0.00381 -0.00241 8.70E-05 
SMAD4 1.410515 0.005763 0.002883 -0.00094 
WRNIP1 1.406317 0.002543 0.001362 -0.00024 
MYF6 1.30968 0.001564 0.002249 0.00125 
ERG 1.273625 0.002637 0.00184 0.000737 
HOXB6_PRRX2 1.21669 -0.00449 -0.00197 -0.0007 
ATF4 1.154007 -0.00086 -0.00243 -0.00187 
CEBPB 1.148956 -0.00129 -0.00237 -0.00165 
YBX1_FOS_NFYC_NF
YA_NFYB_CEBPZ 
1.095402 0.000732 0.001037 0.00047 
ZBTB33_CHD2 1.026279 -0.00538 -0.0024 0.00074 
HOMEZ 1.00642 -0.00164 -0.00191 0.000347 
KLF8 1.00128 0.001451 -0.00123 0.000344 
POU5F1_POU2F3 0.994232 0.00378 0.001746 -0.00056 
ZBTB14 0.991485 -0.00358 -0.00157 0.000131 
POU2F2_POU3F1 0.989412 0.004328 0.001928 -6.70E-05 
ATF2_ATF1_ATF3 0.988414 -0.0029 -0.00145 0.000442 
RXRG 0.978004 0.00036 0.001877 -0.0003 
SIX5_SMARCC2_HCF
C1 
0.976472 -0.00416 0.00095 0.000501 
RHOXF1 0.965833 0.002598 0.001662 0.000477 
SIN3A_CHD1 0.962837 -0.00536 -0.00229 0.000184 
NFKB2 0.93887 0.002021 0.001801 0.000374 
EPAS1_BCL3 0.9382 0.003194 0.001539 -0.00039 
MLXIPL 0.934386 -0.00055 -0.00131 -0.00039 
NR5A2 0.928886 0.000331 0.001681 0.000279 
TCF3_MYOG 0.925927 0.001869 0.001701 0.000297 
BARX1 0.919222 0.000486 0.001714 -2.50E-05 
CPEB1 0.895738 0.001256 0.001702 2.90E-05 
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E2F7_E2F1 0.893876 -0.0064 -0.00136 9.50E-05 
NR1I2 0.888603 0.000676 0.001762 0.000138 
ZNF384 0.875025 -0.00343 -0.00134 0.001379 
ELK4_ETV5_ELK1_E
LK3_ELF4 
0.871213 -0.00497 -0.002 0.000284 
MXI1_MYC_MYCN 0.861105 -0.00028 0.001389 -0.0015 
CREB3L2 0.852152 -0.00051 -0.00172 0.000144 
PATZ1_KLF4 0.850309 0.004281 0.001677 -0.00124 
SPIC 0.845122 5.60E-05 0.001521 0.000256 
ZFX 0.845066 -0.00289 -0.00121 -0.00048 
CDC5L 0.840737 0.000397 0.00161 0.001088 
NFIX_NFIB 0.834121 0.005313 0.001506 -0.00077 
ELF3_EHF 0.821372 -0.00031 -0.00141 -0.00067 
HIC1 0.820189 -0.00042 0.001289 0.000245 
ETV4_ETS2 0.787745 0.000559 0.001413 0.000763 
ESRRB_ESRRG 0.786311 -0.00063 0.001471 0.00035 
ZNF524 0.775437 0.001632 0.00137 -0.00061 
CXXC1 0.768383 -0.00357 -0.00186 0.000306 
IRF2_STAT2_IRF8_IR
F1 
0.759538 0.000673 -0.00153 0.000411 
Table 3.5 Top 50 TF motifs enriched with ALG-1001 treatment under room air 
oxygen tension in HUVEC 
TFs are ordered by Z-score. Activity.diff_Hypoxia-Control is the average target gene activity 
difference between hypoxia and control conditions. Activity.diff_ALG48h-Control is the 
average target gene activity difference between ALG-1001 and control conditions. 
Activity.diff_Hypoxia_ALG-Hypoxia is the average target gene activity difference between 
ALG-1001 + hypoxia and hypoxia conditions.  
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Trans. Factor Z-score Activity.diff_
Hypoxia-
Control 
Activity.diff_
ALG48h-
Control 
Activity.diff_
Hypoxia_AL
G-Hypoxia 
SOX3_SOX2 1.362482 -5.00E-06 0.000532 0.001711 
MNT_HEY1_HEY2 1.243884 -0.00174 -0.00043 -0.00156 
ATF4 1.235011 -0.00086 -0.00243 -0.00187 
ZNF384 1.220908 -0.00343 -0.00134 0.001379 
POU3F2 1.169375 -0.00412 -0.00151 0.001395 
SP1 1.119032 -0.00206 0.000159 0.001339 
CEBPB 1.105643 -0.00129 -0.00237 -0.00165 
MXI1_MYC_MYC
N 
1.047564 -0.00028 0.001389 -0.0015 
PAX5 1.046509 0.000803 -0.00015 -0.00095 
PATZ1_KLF4 1.03941 0.004281 0.001677 -0.00124 
KLF16_SP2 1.034759 -0.00017 0.001613 0.000985 
EBF1 1.002073 0.004784 0.000684 -0.00124 
OLIG3_NEUROD2
_NEUROG2 
0.954093 -0.00118 0.000622 0.001352 
HMX3 0.942457 -0.00147 -0.00028 0.001316 
MYF6 0.939048 0.001564 0.002249 0.00125 
MYBL2 0.93492 -0.0024 -0.00011 0.00131 
IRX3 0.904105 -0.00114 -0.00011 0.001283 
BARHL1 0.894953 -0.00295 -0.00063 0.001171 
FOSL2_SMARCC1 0.874464 0.001586 1.70E-05 -0.00123 
ETV1_ERF_FEV_E
LF1 
0.84078 -9.00E-04 -9.70E-05 -0.00098 
MAZ_ZNF281_GT
F2F1 
0.822072 0.000742 -0.00072 0.000972 
HIVEP1 0.787989 0.002172 0.001181 -0.00114 
RAD21_SMC3 0.783436 0.00022 -0.00048 -0.00107 
HIC2 0.7788 0.006124 0.000152 -0.00096 
TAL1 0.772233 0.002684 0.00262 0.000746 
FOXK1_FOXP2_F
OXB1_FOXP3 
0.766034 0.000221 0.000118 0.001037 
CDC5L 0.7587 0.000397 0.00161 0.001088 
FOXL1 0.757831 -0.00054 -0.00029 0.001006 
MECP2 0.756401 -0.00186 0.000171 -0.00072 
SMAD1 0.752081 0.00205 0.00064 -0.00076 
225 
 
ELF2_GABPA_ELF
5 
0.740125 -0.00167 -0.00098 -0.0007 
PLAGL1 0.739074 0.005463 0.001948 -0.00086 
ID4_TCF4_SNAI2 0.736997 0.001203 0.00179 0.000794 
BPTF 0.724676 -0.00089 -0.00064 0.000837 
E2F3 0.703794 -0.00359 -3.10E-05 0.000927 
SMAD4 0.699577 0.005763 0.002883 -0.00094 
FOXD3_FOXI1_FO
XF1 
0.689003 2.30E-05 0.000115 0.000951 
TFAP2C 0.685647 0.003238 -0.00094 -0.00078 
GLI3 0.66094 0.001357 -0.0007 -0.00086 
SCRT1_SCRT2 0.651946 -0.00016 0.000298 0.000964 
FOXO4 0.646831 -0.00048 -0.00081 0.000951 
ERG 0.643106 0.002637 0.00184 0.000737 
RCOR1_MTA3 0.636119 -0.0006 8.10E-05 0.000344 
LEF1 0.614704 -0.00037 -0.00106 0.000864 
MBD2 0.593068 -0.00141 -0.00014 0.000855 
FOXC1 0.592749 -0.00024 -1.60E-05 0.000875 
ZSCAN4 0.591362 -5.40E-05 -0.00023 0.000887 
ZBTB33_CHD2 0.590825 -0.00538 -0.0024 0.00074 
NFIX_NFIB 0.589195 0.005313 0.001506 -0.00077 
ESRRA_ESR2 0.581249 0.004888 0.000632 -0.00102 
Table 3.6 Top 50 TF motifs enriched with ALG-1001 treatment with hypoxia co-
exposure in HUVEC 
TFs are ordered by Z-score. Activity.diff_Hypoxia-Control is the average target gene activity 
difference between hypoxia and control conditions. Activity.diff_ALG48h-Control is the 
average target gene activity difference between ALG-1001 and control conditions. 
Activity.diff_Hypoxia_ALG-Hypoxia is the average target gene activity difference between 
ALG-1001 + hypoxia and hypoxia conditions. Bolded TFs indicate ones that are also found 
in the list of top 50 TFs with hypoxia treatment. 
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Trans. Factor Z-score Activity.diff_ALG-
Control 
BARHL1 2.510727 0.010332 
E2F7_E2F1 2.223354 0.011538 
E2F3 2.163938 0.009745 
FOSL2_SMARCC1 1.897279 -0.01027 
PLAGL1 1.619265 -0.00773 
ZNF384 1.368142 0.006736 
MIXL1_GSX1_BSX_MEOX2_LHX4 1.222901 0.006275 
SMAD4 1.194822 -0.00684 
NFKB2 1.188247 -0.00785 
ZNF524 1.176369 -0.00768 
TFAP2C 1.15979 -0.00529 
CXXC1 1.158057 0.005567 
PPARG 1.144605 -0.00572 
FOXO3_FOXD2 1.125123 0.005529 
ESRRA_ESR2 1.107849 -0.00636 
IKZF1 1.100988 -0.00641 
POU3F2 1.099071 0.007951 
HOMEZ 1.092696 0.00778 
SMAD1 1.038231 -0.00488 
ZBTB33_CHD2 1.029819 0.00906 
ZNF740_ZNF219 1.029537 0.006702 
BPTF 1.02537 0.005366 
SP100 1.020871 0.004835 
PITX1 1.012363 -0.00747 
IRF6_IRF4_IRF5 1.00791 0.007163 
SIX5_SMARCC2_HCFC1 0.993107 0.005058 
SREBF1_TFE3 0.992486 -0.00618 
TAF1 0.989275 0.010782 
EBF1 0.98762 -0.00773 
ELK4_ETV5_ELK1_ELK3_ELF4 0.968993 0.006617 
FOXD1_FOXO1_FOXO6_FOXG1_FOXP1 0.963061 0.005478 
ZNF263 0.959227 -0.00573 
MAFB 0.945579 0.005795 
GCM2 0.929757 -0.00527 
RFX7_RFX4_RFX1 0.91573 -0.00463 
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RUNX3_BCL11A 0.915547 0.005313 
TCF7L1 0.890568 0.004693 
NR3C1 0.889856 0.00371 
ATF7 0.870925 0.00514 
ZNF711_TFAP2A_TFAP2D 0.866604 0.003493 
HOXC9 0.859728 0.004473 
PATZ1_KLF4 0.854418 -0.00217 
KLF15 0.848141 0.004259 
HSFY2 0.84565 0.006691 
PITX3 0.837512 0.004288 
SPDEF 0.835104 0.004976 
LEF1 0.830758 0.004643 
MAFK 0.82314 0.006295 
IRF9 0.802357 0.008305 
HOXC12_HOXD12 0.794469 0.004031 
Table 3.7 Top 50 TF motifs enriched with ALG-1001 treatment in PBMC 
TFs are ordered by Z-score. Activity.diff_ALG-Control is the average target gene activity 
difference between ALG-1001 and control conditions. 
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Chapter 4. Hypoxia-induced biological regulation in ARPE-19 
cells 
4.1 Introduction 
The human eye is a sophisticated organ, meticulously organized to enable the visual 
perception of our surrounding world. Light enters at front of the eye and is detected by the 
retina, a relatively thin layer tissue consists of mostly retinal photoreceptors and neurons. 
During this process, the photon signals are converted to electrical impulses that are then 
transmitted to brain, where they are interpreted1. This process is highly energy demanding, 
which renders the retina one of the most metabolically active tissue in the body2. To sustain 
the high metabolic need, nutrients are delivered to the photoreceptors through a network of 
capillaries called choroid. Between the choroid and photoreceptors, there is a monolayer of 
pigmented and supportive cells called the retinal pigment epithelium (RPE)3. Despite being 
only one cell layer thick, the RPE plays several important functions, including light energy 
absorption, nutrient and waste transportation, retinal metabolic conversion, growth factor 
secretion, and more3,4. These processes are important for both sustaining the visual system 
and maintaining tissue homeostasis, while any disruption can lead to retinal degeneration, 
reduced visual perception and in severe cases, blindness. 
Age-related macular degeneration (AMD) and diabetic macular retinopathy (DR) are two 
commonly occurring retinal diseases, where RPE plays a role in the pathophysiology. In 
AMD, genetic predisposition combined with environmental stress factors cause RPE damage 
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during the early phase of the disease, which then contribute to the production of pro-
angiogenic factors that drive pathological neovascularization4–6. Similarly, in diabetic 
patients with DR, glucose dysregulation is correlated with RPE cell apoptosis and 
neovascularization7–10. The full pathophysiology of these retinal diseases are complex and 
remain to be explored, but retinal hypoxia is one of the conditions that commonly occur 
during the early stages of retinal diseases. While the cause of the hypoxia varies, the down-
stream responses include activation of inflammation, oxidative stress, angiogenesis, and 
metabolic regulation11–13. Under normal physiological condition, the hypoxia-activated 
activities help the tissue return to homeostasis. However, under prolonged stress exposure, 
as typical of retinal diseases, the hypoxia-activated responses can become chronic and 
eventually cause irreversible damage to the tissue13,14. Thus, it has become increasingly clear 
that persistent retinal hypoxia and its activated processes contribute to dysregulation of RPE 
cells and disruption of their normal function in maintaining retinal homeostasis.  
Current research in hypoxia-activated RPE response is limited, but largely consistent with 
our general understanding of hypoxia regulation. In an in vivo mouse model study, activated 
hypoxia was shown to commit the RPE to switch from using oxidative phosphorylation to 
glycolysis for energy production. This metabolic adaptation induced the RPE to hoard 
glucose and reduce glucose delivery to the photoreceptors, thus causing retinal 
degeneration15. In other studies with in vitro ARPE-19 cells, a cell line derived from human 
RPE tissue, the putative hypoxia response protein HIF-1α was found to be stabilized after 
hypoxia exposure and contributed to elevated secretion of the potent pro-angiogenic factor – 
234 
 
vascular endothelial growth factor (VEGF)16–18. Recently, the high-throughput RNA-
sequencing (RNA-seq) technique was used by Jiang and coworkers to study the 
transcriptome regulation during acute hypoxia exposure (1-4 hours) in ARPE-19 cells19. In 
that study, the authors found acute hypoxia induced detectable up-regulation of apoptosis, 
metabolism, ribosome, and translation machinery genes and down-regulation of cell cycle 
genes. To the best of our knowledge, the Jiang study presents the first application of RNA-
seq to study the hypoxia-activated expression change in RPE cells, but the short hypoxia 
exposure used in the Jiang study cannot capture the transcriptome change associated with 
chronic hypoxia found in the retinal diseases. 
In this study, we explored the transcriptome regulation after varying length of low-oxygen 
exposure by conditioning ARPE-19 cells with short- (8 hours), intermediate- (2 days), and 
long-term (2 weeks) hypoxia (3% O2) followed by RNA-seq to identify the differentially 
expressed genes compared to untreated (maintained at room oxygen tension) control. We are 
interested in exploring the overall transcriptome change at each time point, as well as 
similarities and differences in gene expression after varying length of hypoxia exposure. 
Additionally, a separate set of samples were prepared with exposure to two weeks of hypoxia 
followed by two weeks of room air oxygen tension. Here, we asked the question whether the 
cells can recover from long-term hypoxia stimulation, and if so, what is the extent of the 
recovery. For each condition, we also performed dead and live staining and ROS 
measurement to identify the treatments’ effect on visible cell death and measurable ROS 
level. Altogether, our study provides a quantitative view of the transcriptome regulation and 
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the accompanying physiological changes after different length of hypoxia exposure and 
recovery in RPE cells.  
 
4.2 Materials and Methods 
Cell culture 
ARPE-19 cells at passage 19 (P19) were purchased from the American Type Culture 
Collection and grown to P22-24 for all experiments. Cell cultures were kept in a 37˚C 
humidified incubator with pH controlled by 5% CO2 and media exchanged twice per week. 
Initially, DMEM/F12 (Thermo Fisher) supplemented with 10% fetal bovine serum (FBS, 
Thermo Fisher) and Antibiotic Antimycotic Solution (Sigma-Aldrich) was used to culture 
the cells. Once cells reach confluency in the assay plate, the FBS concentration was reduced 
to 2% for the remainder of the experiments. After the switch to low serum, the cells were 
cultured for six more weeks with plates moved to and from a hypoxia chamber (Biospherix) 
with O2 concentration set to 3% and placed inside the cell culture incubator. All cells were 
collected or assayed at the end of the six weeks culture period after reaching the appropriate 
period of hypoxia and room air oxygen tension conditioning (see Figure 4.1 for more 
details).  
ROS assay 
For ROS assay, ARPE-19 cells were cultured on 96-well plates (Falcon). To start the assay, 
cells were washed once with Phosphate-Buffered Saline (PBS, Thermo Fisher) and then 
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incubated with 2µM H2DCFDA (Thermo Fisher) in cell culture media for 30 minutes at 
37˚C. Next the media-dye mixture was replaced with PBS and ROS-correlated fluorescent 
signal detected on a microplate reader with excitation at 482nm and emission at 520nm. 
Experiment was repeated once with n=12 per condition. Differences between hypoxia-
treated conditions and control were tested using one-way ANOVA with Dunnett multiple 
testing correction. Statistical analysis was performed in GraphPad Prism 7.00. 
Dead and live staining 
For dead and live staining, ARPE-19 cells were cultured on 24-well plates (Falcon). The 
LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) was used to simultaneously capture the 
status of both dead and live cells. At the start of the assay, cells were washed once with PBS 
before incubation for 30 minutes at 37˚C in the media-dye mixture. At the end of incubation, 
cells were washed with PBS and imaged on a Zeiss Axiovert 25CFL microscope. FIJI 
software package was used to merge fluorescent signals into one image with red indicating 
dead cells and green indicating live cells. Phase contrast images were captured on the same 
microscopy system with bright-field illumination. A 10x Lysis Buffer (Thermo Scientific 
Pierce) was used as the lethal control and was added to the wells to working concentration 
for 15 minute incubation before staining.  
RNA-seq sample preparation 
For RNA-seq study, ARPE-19 cells were cultured on laminin-coated Transwell filter inserts 
(Corning) in six-well tissue culture plates (Falcon) as previously described20. At end of cell 
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culture, cells were washed once with PBS without calcium and magnesium (Thermo Fisher) 
and collected using Accutase (Stemcell Technologies). Total RNA was extracted using 
RNeasy Mini Kit (Qiagen) and contaminating DNA removed using TURBO DNA-free kit 
(Thermo Fisher). RNA quality was measured using Bioanalyzer (Agilent Genomics); all 
samples were found to have a passing quality score of at least 7.20 RNA integrity number. 
RNA-seq libraries were then prepared using NEBNext Ultra RNA Library Prep Kit for 
Illumina (New England Biolabs Inc.) and sequenced on the HiSeq 2500 (Illumina) to 
generate on average 12.5 million, single-end, 100 base pair reads per sample. 
RNA-seq analysis 
Quality control 
FASTQ files generated by RNA-seq were submitted to FastQC for quality control. All 
samples showed good sequencing quality and were submitted for read alignment. Alignment 
was performed using Tophat2 to the hg38 genome and transcriptome references with Bowtie 
2 sensitivity level set to very sensitive21. After read alignment, gene counts were quantified 
using HTSeq-count using the intersection-strict model22. FastQC, tophat2 and HTSeq-count 
reports were visualized using multiQC software (Figure 4.2-4.4)23. 
Principle Component Analysis (PCA) 
PCA was used to visualize the high-dimensional dataset. To eliminate null values, all counts 
in HTSeq-count-derived count table were increased by one. Transcript per Million (TPM) 
values were then calculated to correct for varying sequencing depth and gene length24. To 
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reduce sensitivity to the uncertainty in TPM of low-expressing genes, PCA excluded genes 
for which the TPM averaged over all samples in the analysis was < 5. Finally, natural log of 
TPM values was used as input for PCA. From this analysis, no obvious outlier sample was 
detected. 
EdgeR differential expression comparison 
In the analysis of differential expression, it is beneficial to exclude genes that are not 
expressed (they reduce statistical power for identifying differential expression). Here, we 
retained expressed genes, defined as those with Count per Million (CPM) > 1 in at least five 
samples (the number of biological replicates per condition). CPM is calculated to normalize 
for sequencing depth 24. Around 13,000 genes remain after filtering. Next, the classical 
approach of edgeR was used to perform all of the differential expression comparisons25. After 
statistical test, genes with False Discovery Rate (FDR) ≤ 0.05 were considered as 
differentially expressed (DE) and further separated into up-regulated and down-regulated 
gene lists.  
Goseq enrichment analysis of DE gene list 
Functional analyses of the DE genes were performed with the goseq package, which 
mitigates gene length bias inherent to RNA-seq26. Enrichment was performed with both Gene 
Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) biological 
pathways27,28. GO terms associated with genes were obtained from biomart while KEGG 
pathways were obtained from the KEGG REST server using the keggrest package29,30. For 
239 
 
each comparison, enrichment was performed separately for the up- and down-regulated gene 
lists. GO terms were considered enriched with FDR < 0.05 and visualized using REVIGO, a 
visualization tool that aggregates closely-related GO terms, with similarity level set to small 
and GO term size determined using the UniPort Homo Sapiens database31. Selected GO 
terms were labeled on the REVIGO plot base on our perception of their biological relevance. 
KEGG pathways were considered enriched with Benjamini-Hochberg adjusted p-value < 
0.05 (p-values are displayed in bar plots). In addition, “Human Diseases” KEGG pathways 
were removed to improve clarity. 
ERSSA 
ERSSA was used to check whether the number of biological replicates used in the RNA-seq 
experiment is sufficient to identify the majority of DE genes32. Analysis was performed with 
absolute log2-fold-change cutoffs set to 0.5 and 50 subsamples at each replicate level. 
DE gene heatmap of log2-fold-change values 
Heatmaps of TPM value were used to visualize the expression profile of DE genes. TPM 
values were first calculated from the unadjusted gene counts; then for each gene, TPM was 
offset such that the minimum is zero and normalized so the maximum is one. DE genes were 
clustered using k-mean method with k=6 selected based on clustering performance across 
experimental conditions as well as the marginal improvement in sum squared error (Figure 
4.26A). For each cluster, associated genes were used for functional analysis using goseq as 
previously described.  
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ISMARA 
ISMARA was used to identify the transcription factors that may be responsible for the 
observed profiles of gene expression changes in this study33. All samples were submitted to 
ISMARA with analysis focused on the top 50 most active motifs as ranked by the enrichment 
Z-score. For the HIC2 protein, STRING was used to visualize the protein associations 
between the transcription factor targets34. Default settings were used for STRING network 
generation.  
Data availability 
Raw RNA-seq Fastq files will be available at Gene Expression Omnibus once the study has 
been published35. All enrichment tables will be made available at CaltechDATA36. 
Reverse transcription and quantitative polymerase chain reaction (qPCR) 
From the DE genes identified by edgeR, six genes were selected for separate validation with 
qPCR: HIF1A (hypoxia response), LDHA (sustains glycolysis), DLD (oxidative 
phosphorylation), SOD2 (clears ROS), MMP2 and VEGFA (angiogenesis). SuperScript IV 
Reverse Transcriptase (ThermoFisher) and oligo(dT)20 primer (ThermoFisher) were used to 
convert polyadenylated mRNA to cDNA. qPCR was performed using iTaq Universal SYBR 
Green Supermix (Biorad) on LightCycler 480 (Roche) with 45 amplification cycles. All 
samples were selected for analysis. To enhance accuracy, four technical qPCR replicates of 
the same cDNA were generated and the median value selected for fold change calculation. 
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Differences were calculated using the ΔΔCt method versus TUBB37. Primers used in this 
study were obtained from PrimerBank (Table 4.1)38.  
 
4.3 Results 
ROS assay 
Hypoxia is a major physiological stimulus that activates many intracellular processes 
including elevation of ROS production39. Using a non-fluorescent dye that becomes highly 
fluorescent after intracellular oxidation, we measured the ROS level in ARPE-19 cells 
exposed to different length of hypoxia exposure (Figure 4.1). Compared to control, ROS 
level appears unchanged after 8 hours of acute hypoxia, but is weakly elevated after 2 days 
and 2 weeks of prolonged hypoxia conditioning (Figure 4.5). Intriguingly, cells that were 
allowed to recovery after 2 weeks of hypoxia did not show increased ROS level compared 
to control. 
Dead and live staining 
A dual color dye system was used to stain for dead (loss of plasma membrane integrity) and 
live (active intracellular esterase activity) ARPE-19 cells after hypoxia treatment. 
Micrograph results show that in all hypoxia conditions, the cell monolayer was maintained 
and no elevated density of dead cells was observed (Figure 4.6). While it is hard to 
distinguish individual cells, the overall cell morphology also appeared to be unchanged after 
treatment. 
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PCA 
For each experimental condition, five samples were generated for RNA-seq to probe the 
transcriptome regulation modulated by each treatment relative to control. PCA was first used 
to visualize the RNA-seq samples in a low-dimensional space to identify potential outliers 
and to visualize the separation between conditions. Based on the analysis of the top three 
principal components (PC1-3 captured a combined 75% of total variance), no obvious 
outliers were detected (Figure. 4.7). The PC1 alone accounted for 47% of total variance in 
the dataset and clearly separated hypoxia samples from control and hypoxia recovery 
samples. On PC2, samples that experienced 2 weeks of hypoxia with and without recovery 
were moderately separated from the other samples. Intriguingly, there appeared to be a 
trajectory among the hypoxia samples on PC2: 8 hours-treated samples on one end, 2 days-
treated samples in the middle and 2 weeks-treated samples on the other end. In addition, 
hypoxia recovery samples appeared to cluster close to control samples on PC1 and between 
control and 2 weeks-treated samples on PC2. Without looking at the DE genes, PCA 
evidence suggest that: 1) there is a detectable transcriptome change after hypoxia exposure, 
2) hypoxia’s effect on the transcriptome varies based on treatment length, and 3) gene 
expression partially recovered after long-term hypoxia treatment, but the recovery was not 
complete.  
Transcriptome regulation during hypoxia exposure 
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EdgeR was used to identify DE genes between control and each of the hypoxia-treated 
cohorts without recovery (8 hours, 2 days and 2 weeks). Surprisingly, around 6300-6600 DE 
genes (representing roughly half of the detectable expressed genes) were discovered in each 
of the comparisons, representing a major shift in the transcriptome after hypoxia treatment 
(Figure 4.8). This transcriptome shift appeared to occur relatively quickly as it was already 
detectable after 8 hours of hypoxia exposure. To confirm enough biological replicates were 
included in the comparisons, we used ERSSA to simulate DE discovery at different sample 
sizes. The simulation showed small marginal improvements past four biological replicates in 
all three comparisons, suggesting five replicates was sufficient to identify a majority of DE 
genes with |log2-fold-change|>0.5 (Figure 4.9-4.11).  
With the DE genes, functional analysis was performed to understand the biological processes 
that are regulated during hypoxia. At all three time points, we see putative hypoxia-response 
biological processes were enriched with up-regulated DE genes: “blood vessel 
development”, “immune system process”, “response to hypoxia”, “cell proliferation”, “cell 
death”, and others (Figure 4.12A, 4.14A, 4.16A). Some of the angiogenesis-related 
processes enriched include “actin cytoskeleton organization”, “extracellular matrix 
organization”, “locomotion”, and “anatomical structure morphogenesis”. These findings are 
consistent with previous studies that found RPE under hypoxia stress will respond by 
promoting angiogenesis13,16,40. Enrichment with the down-regulated DE genes generally 
identified processes involved in metabolism: “oxidative-reduction process”, “small molecule 
metabolism”, “electron transport chain”, “cellular respiration”, and others (Figure 4.12B, 
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4.14B, 4.16B). Down-regulation of genes related to mitochondria-based metabolism is 
consistent with hypoxia-induced shut down of aerobic respiration2,40.  
To identify variation in enriched GO biological processes among each of the three hypoxia 
comparisons, each comparisons’ top 100 processes (referred to as “top processes”) with the 
strongest statistical evidence were selected and compared (Figure 4.19). This analysis 
showed there are more than 70 common top processes enriched with up-regulated genes in 
the three hypoxia comparisons (Figure 4.19A). On the other hand, the top processes enriched 
with the down-regulated genes showed less similarity with only 40 found in all three 
comparisons and 26 others that are shared between the two latter time points (2 days and 2 
weeks-treated hypoxia). More importantly, more than 51 (8 hours), 25 (2 days), and 34 (2 
weeks) top processes were found in only one of the hypoxia comparisons. A closer look at 
the 51 unique top processes at 8 hours revealed many that are involved in transcription and 
translation, such as “RNA processing”, “mRNA processing”, “ribosome biogenesis”, and 
“translation” (Figure 4.19B). On the other hand, the unique top processes enriched at the 
latter two times points appeared to be more diverse (Figure 4.20).  
Beyond GO analysis, DE genes were used to identify over-represented KEGG pathways. 
Across the pathways enriched, many are related to either inflammation (“cytokine-cytokine 
receptor interaction”, “leukocyte transendothelial migration”, “chemokine signaling 
pathway”, etc.) or angiogenesis (“MAPK signaling pathway”, “VEGF signaling pathway”, 
“PI3k-Akt signaling pathway”, “regulation of actin cytoskeleton”, and others). Additionally, 
eight KEGG pathways were consistently found to be enriched (highlighted in Figure 4.13A, 
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4.15A, 4.17), including “ribosome”, “ECM-receptor interaction”, “Cell adhesion molecules 
(CAMs)”, “HIF-1 signaling pathway”, “Focal adhesion”, and “complement coagulation 
cascades”, “Hematopoietic cell lineage”, and “axon guidance”.  
Pathway enrichment with the down-regulated genes found a combination of “genetic 
information processing” and “metabolism” pathways after 8 hours of hypoxia treatment 
(Figure 4.13B). In particular, “oxidative phosphorylation” is enriched along with those 
related to transcription (“Spliceosome” and “RNA transport”) and translation (“Ribosome 
biogenesis in eukaryotes” and “Proteasome”). As hypoxia prolong to two days and two 
weeks, we see significantly more enrichment of a variety of metabolic pathways (Figure 
4.15B, 4.18), ranging from “pyruvate metabolism” to “fatty acid degradation” and “carbon 
metabolism”. Among the three time points, four pathways are consistently enriched: 
“oxidative phosphorylation”, “metabolic pathways”, “thermogenesis”, and “proteasome”.  
Transcriptome variation after hypoxia recovery 
In agreement with PCA, the differential expression discovery with hypoxia recovery samples 
is smaller in scale compare to the other hypoxia treatment cohorts (Figure 4.21). Unlike the 
other groups, the number of DE genes discovered is reduced roughly by half to around three 
thousand genes (Figure 4.21A). In addition, their fold changes were much closer to zero, 
with no DE genes of |log2-fold-change|>2. These observations suggest the transcriptome of 
hypoxia recovery samples is much closer to control condition, a sharp contrast from other 
hypoxia groups. Additionally, ERSSA showed this comparison would benefit from additional 
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samples, as many of the genes with small change may need additional replicates to be 
identified with statistical significance (Figure 4.21D).  
GO biological process and KEGG pathway enrichment found processes and pathways 
previously enriched in hypoxia treatment groups. Some of the GO biological processes 
enriched with up-regulated genes include those involved in angiogenesis (“anatomical 
structure morphogenesis”, “extracellular matrix organization”, “actin cytoskeleton 
organization”), inflammation (“immune system process”), “response to hypoxia”, “cell 
proliferation”, and “cell death” (Figure 4.22A). On the other hand, enrichment with down-
regulated genes revealed those involved in metabolism, including “oxidative-reduction 
process”, “carboxylic acid catabolism”, and others (Figure 4.22B). Consistent with the GO 
analysis, KEGG pathway enrichment discovered many pathways previously enriched among 
all of the three hypoxia treatment groups: 6/8 pathways consistently enriched with up-
regulated genes and “metabolic pathways” with down-regulated genes (Figure 4.23-4.24). 
Next, limited to the genes regulated after 2 weeks of hypoxia exposure, we are interested in 
observing their expression profile after recovery. Intriguingly, we found a majority of these 
genes have closer to control expression level after recovery (Figure 4.25, fold changes after 
recovery are closer to zero). However, the Pearson’s r correlation is 0.7177, suggesting there 
is still strong correlation to hypoxia response despite two weeks of recovery at control 
oxygen tension.  
Hypoxia-induced transcriptome response across time series 
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To further understand gene expression variation among the treatment cohorts, we selected 
DE genes across all comparisons and used k-mean clustering to form six groups of genes 
with different expression profile (Figure 4.26B). Cluster 1 to 3 appear to contain genes that 
are up-regulated after hypoxia exposure: cluster 1 show highest expression after 2 days of 
hypoxia, cluster 2 after 2 weeks of hypoxia, and cluster 3 after 8 hours of hypoxia (Figure 
4.27, 4.28A). Genes in cluster 4 to 6 are generally down-regulated after hypoxia exposure, 
with cluster 4 showing lowest expression after 2 weeks, cluster 5 consistently across all three 
hypoxia time points, and cluster 6 after 8 hours of hypoxia (Figure 4.28B, 4.29).  
For the genes identified in each cluster, GO biological process and KEGG pathway 
enrichment were performed to identify associated functions. Out of the three clusters with 
up-regulated DE genes, only cluster 2 generated enrichment results (Figure 4.27, 4.28A), 
which included many of the same biological processes enriched after all three hypoxia 
treatments. A closer look at several of these enriched GO biological processes shows genes 
associated are consistently up-regulated after 8 hours and 2 days hypoxia and eventually 
reach peak measured expression after 2 weeks (Figure 4.30).  
Enrichment analysis of the three clusters containing down-regulated genes are consistent 
with earlier functional analysis. In cluster 6, which showed the sharpest down-regulation 
after 8 hours of hypoxia, mainly transcription and translation processes are enriched (Figure 
4.29B). Similarly, enrichment of cluster 4 genes, which showed the lowest expression after 
2 weeks of hypoxia, identified a diverse array of metabolic pathways that were previously 
enriched with down-regulated genes after 2 weeks of hypoxia (compare Figure 4.28B with 
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Figure 4.18). Lastly, cluster 5 contains genes sharply down-regulated at all three hypoxia 
time points (Figure 4.29A), which were used to enrich many pathways related to aerobic 
respiration (e.g. “oxidative phosphorylation” and “citrate cycle”).  
Transcription factor (TF) enrichment 
ISMARA was applied to identify TFs that are likely involved during hypoxia regulation. In 
the top 50 TF groups enriched as ranked by Z-score, we found many of them are well known 
regulator of biological processes important during hypoxia response (Figure 4.31 and Table 
4.2). Some of the target genes of the enriched biologically-relevant TFs have higher 
expression during hypoxia (Figure 4.31A) while others have lower expression (Figure 
4.31B).  Noteworthy TFs with higher target gene expression include known regulators of 
hypoxia response (HIF1A, ARNT, ARNT2, EPAS1), cell proliferation/apoptosis (KLF4, 
SRF, FOSL1, FOSL2, ATF4), inflammation (BCL3, CEBPB, CEBPD), and angiogenesis 
(ZBTB7B) (Figure 4.32)41. Interestingly, we see a variety of patterns in the target gene 
activity with some (e.g. HIF1A and ERG) that are highly activated during initial hypoxia 
followed by a gradual decline and others that do not become involved until after at least 2 
days of hypoxia (e.g. CEBPB and ATF4). Similarly, TFs with lower target expression are 
enriched and function in hypoxia-regulated biological processes such as cell 
proliferation/apoptosis (MYC, MXI1, MYCN, FOS, CEBPZ, HCFC1, TAF1, ATF1/2/3), 
metabolism (NRF1), oxidative stress response (NFE2L2), and hypoxia response (CREB1) 
(Figure 4.33)41. As before, a diverse array of target expression profile were detected, 
including those that initially have the lowest target gene activity that gradually recovered 
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(e.g. MYC, MXI1, MYCN, CREB1, TAF1) and others have target genes more consistently 
down-regulated throughout hypoxia exposure (e.g. NRF1, FOS, CEBPZ).  
We also observed many members of the ETS transcription factor family were enriched, 
including ERG with up-regulated targets and ETV1, ERF, FEV, ELF1, ELF2, GABPA, and 
ELF5 with down-regulated targets (Figure 4.32-33). ETS family is a large family of proteins 
known to be active in regulating a wide variety of functions including cell migration, cell 
proliferation, angiogenesis, inflammation, and apoptosis42. Indeed, several ETS family 
members were also previously found to be involved in transcriptome regulation during 
hypoxia exposure43,44. 
Since ISMARA is an unbiased approach to identify TFs that may be involved during hypoxia, 
it can also be used to discover TFs with unknown regulatory functions. In this dataset, we 
found one particular TF – HIC2 that was ranked very high on the enrichment result (number 
12, Z=2.752), but have only been studied in a few studies unrelated to hypoxia45–47. Activity 
profile of HIC2 shows its target genes are consistently up-regulated by hypoxia across all 
three treatment groups (Figure 4.34A). Intriguingly, ISMARA predict HIC2 regulated several 
genes important for angiogenesis (VEGFA, MMP2, ADM, TGFA, and collagen proteins) 
and metabolism (LDHA, PKM and GPI) (Figure 4.34B)41. Furthermore, HIC2 was also 
enriched with ISMARA analysis of HUVECs after exposure to hypoxia (number 8, Z=3.011, 
Chapter 3). 
qPCR 
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qPCR was used to validate RNA-seq measured expression profile. For this purpose, six genes 
important in hypoxia-response were selected: HIF1A (hypoxia response), LDHA (sustains 
glycolysis), DLD (oxidative phosphorylation), SOD2 (clears ROS), MMP2 (angiogenesis), 
and VEGFA (angiogenesis). RNA-seq detected hypoxia-response varies between the six 
genes: HIF1A was slightly down-regulated, LDHA, MMP2, and VEGFA were significantly 
up-regulated, while DLD and SOD2 were down-regulated. For all six genes tested, qPCR 
measured expression profiles (Figure 4.35B) are highly consistent with those identified by 
RNA-seq (Figure 4.35A), demonstrating the accuracy of RNA-seq quantification.  
 
4.4 Discussion 
In this study, we employed RNA-seq to probe the cellular transcriptomic response after short 
(8 hours) to long-term (2 weeks) hypoxia in ARPE-19 cells. Based on this dataset, we found 
many putative hypoxia response pathways are modulated with the regulation both rapid and 
dynamic. After 8 hours of hypoxia treatment, we already detected differential expression of 
slightly less than half of the expressed genes. In particular, it is surprising to see many genes 
up-regulated more than several folds (~10% of up-regulated gene with more than 1 fold 
change) after such short amount of hypoxia exposure (Figure 4.8A). Next, as hypoxia 
exposure lengthens to two days and two weeks, we are surprised to see that the number of 
regulated genes detected stayed roughly the same at around half of the expressed 
transcriptome (Figure 4.8C, E). However, further analysis of these genes suggest the identity 
of regulated genes can differ among the three time points tested.  
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First, focusing on genes up-regulated by hypoxia, many biological processes are consistently 
enriched regardless of the hypoxia treatment time (Figure 4.12A, 4.13A, 4.14A, 4.15A, 
4.16A, 4.17). This is supported by supplementary analysis of the top 100 enriched GO 
biological processes found in analysis of each hypoxia group, where 70 out of the 100 top 
processes are found in all three hypoxia cohorts (Figure 4.19A). Time series analysis 
provides another dimension to this observation. By following four processes that are enriched 
in each of the three hypoxia groups, we found their associated DE gene expression pattern is 
in fact dynamic (Figure 4.30). Thus, although many biological processes are consistently 
activated by hypoxia regardless of exposure time, the expression level of the associated genes 
is dependent on amount of low-oxygen exposure. 
Focusing on the specific biological processes up-regulated, we found they are predominantly 
involved in angiogenesis, immune activation and hypoxia response at all three time points. 
Angiogenesis and inflammation, in particular, are two well-known physiological responses 
to low tissue oxygen supply: angiogenesis grows new vessels to improve oxygen supply, 
while inflammation cleans up damaged cells and cell debris generated by the hypoxic 
stress48–50. Both conditions are also extensively reported to be active in retinal diseases and 
are associated with disease progression5,13,51,52. In fact, studies have previously shown that 
RPE cells may be the main source of the potent angiogenic factor, VEGF, in the diseased 
retina3. Collectively, these findings suggest hypoxic stress can induce RPE cells to activate 
disease-relevant physiological processes, which can contribute to disease development. 
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Next, focusing on down-regulated genes, we found GO biological process and KEGG 
pathway analyses both suggest transcription and translation-related genes are 
disproportionally down-regulated after eight hours of hypoxia (Figure 4.12B, 4.13B, 4.19B). 
As some of the most energy intensive processes, mRNA synthesis and protein translation are 
known to be rapidly suppressed during hypoxia response at a time when energy supply is 
disrupted53,54. Yet, as hypoxia continues, the biological processes that are most highly 
enriched are replaced with ones that are involved in metabolism, particularly ones involved 
in aerobic respiration, i.e. TCA cycle and oxidative phosphorylation (Figure 4.14B, 4.15B, 
4.16B, 4.18). This is consistent with our current understanding of hypoxia, where a lack of 
oxygen supply induces cells to primarily use oxygen-independent glycolysis for energy 
production. DE gene expression clustering analysis provided additional evidence to support 
these finding. In the three clusters that contained down-regulated genes after hypoxia 
exposure, cluster 6 showed the lowest expression after 8 hours of hypoxia treatment and was 
highly enriched with genes involved with transcription and translation (Figure 4.29B). 
Similarly, cluster 4 and 5 both mainly enriched metabolic related processes with genes down-
regulated the most after 2 weeks hypoxia (Figure 4.28B) or consistently down-regulated 
across all hypoxia treatments (Figure 4.29A). 
In relation to the Jiang et al. study that used RNA-seq to measure ARPE-19 transcriptomic 
response after acute hypoxia exposure (4 hours and less)19, our results show major 
similarities as well as differences. First, both datasets found acute hypoxia induced regulation 
of transcription and translation processes. However, the enrichment results differ from there 
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as the Jiang study also found activation of apoptosis and suppression of cell cycle genes. 
Among these two processes, we found very weak enrichment of “cell death” and no 
functional analysis results that suggest cell cycle down-regulation. We suspect this 
discrepancy might be due to a relatively mild 3% O2 hypoxia treatment used in our study 
compare to the 1% O2 used in the Jiang study. Consistent with the lack of apoptosis-related 
biological enrichment, dead and live staining as well as ROS assay did not reveal any 
systematic loss of cell density or significantly elevation of ROS level after 3% O2 hypoxia 
exposure (Figure 4.5-6). In a second major difference, the Jiang study did not detect the 
activation of angiogenesis and inflammatory processes and suppression of metabolic genes. 
We suspect this might be due to a lack of statistical power in the original study (2 replicates 
per condition), where only 332 DE genes were identified (versus ~6000 in each of our 
hypoxia cohorts). As a result, the limited replicates employed likely failed to capture many 
of the real changes between the conditions.  
In our dataset, we also found genes normally associated with “axon guidance” KEGG 
pathway are up-regulated by hypoxia in ARPE-19 cells. This observation is confounding as 
a literature search failed to find a connection between RPE cells and axon guidance, which 
is a key process in the formation of a neuronal network. Intriguingly, a yet unpublished study 
also found highly statistical significant enrichment of axon guidance pathway, but in the 
context of RPE cells stimulated to undergo EMT55. In that study, 40 axon guidance-related 
genes were found to be regulated after EMT induction and out of those, 37 are also regulated 
by hypoxia in at least one of the hypoxia time points in our study. These results suggest genes 
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normally involved in axon guidance may also be involved in EMT and that regulation of 
these same genes by hypoxia indicate possible induction of EMT in ARPE-19 cells. Since 
RPE cells that undergo EMT have been reported in a variety of retinal diseases including 
AMD56, our transcriptome findings suggest hypoxia may be one of the contributing factors 
to the transition. Based on these observations, further investigation in the connection between 
hypoxia and EMT is warranted, particularly in the context of the possible role EMT may 
play in retinal disease pathophysiology. 
In comparison to our other studies of hypoxia-induced transcriptome response in OIR mice 
(Chapter 2) and human endothelial cells (Chapter 3), many of the same biological 
processes were found to be enriched in ARPE-19 cells. In all three studies, we found 
inflammation, angiogenesis, and hypoxia-response processes were enriched with up-
regulated genes, which suggest activation of these processes is likely to be more universal. 
On the other hand, enrichment of down-regulated genes produced different results, where the 
mice study (Chapter 2) mainly found down-regulation of neuronal and metabolic processes, 
while the endothelial study (Chapter 3) found down-regulation of both cell cycle and 
metabolism. Additionally, since both previous studies involved hypoxia exposure longer 
than 8 hours (5 days in OIR mice and 1 day in endothelial cells), down-regulation of 
transcription and translation-related genes were not strongly detected.  
In this study, we also conditioned ARPE-19 cells to two weeks of hypoxia followed by two 
weeks of recovery at room air oxygen tension. These hypoxia recovery samples showed 
expression profile that is fairly close to control samples while retaining some signature of the 
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hypoxia-induced transcriptome modulation. First, PCA shows hypoxia recovery samples 
clustered closely with control samples on the major PC that separates the control and hypoxia 
samples (Figure 4.7A). Additionally, PC2 shows recovery samples are situated between 
control and 2 weeks hypoxia-treated samples, which suggest recovery samples likely have 
an expression profile between these two conditions. Similarly, DE gene heatmap shows gene 
expression of hypoxia recovery samples largely resided between control and week 2 hypoxia 
treated levels (Figure 4.26). Compared to the other three time points, comparison of hypoxia 
recovery samples to control also identified around half as many DE genes, many of which 
have relatively small fold change and none with |log2-fold-change|>2 (Figure 4.21A). 
Functional analysis of these DE genes revealed many of the same biological processes 
previously enriched with the other hypoxia treatment conditions, suggesting some of the 
hypoxia modulated signature is retained despite the long recovery period (Figure 4.22-4.24). 
In short, these results demonstrate ARPE-19 gene expression is adaptable to oxygen level, 
but some signature of hypoxia remains even after recovery.  
Transcription factor enrichment largely supports results of functional analysis based on DE 
genes (Figure 4.31). Focusing on the top 50 enrichment TFs, we recovered many that are 
known to regulate the biological processes enriched with the hypoxia-regulated genes. In 
addition, we also enriched a mostly uncharacterized transcription factor – HIC2, with strong 
statistical significance. Based on ISMARA calculation, expression of predicted HIC2 target 
genes were consistently up-regulated at all three hypoxia time points (Figure 4.34) and some 
of the possible targets include angiogenesis- and metabolic-related genes. At the time we 
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performed this analysis, less than five HIC2-associated papers have been published and none 
of them in context of hypoxia activation. Based on these observations, it may be interesting 
to further explore HIC2 in context of hypoxia response and identify the genes modulated by 
the transcription factor.  
 
4.5 Conclusions 
In the present study, we exposed human RPE cells to three different length (8 hours, 2 days, 
and 2 weeks) of 3% O2 hypoxia treatment and probed the hypoxia-induced transcriptome 
regulation using RNA-seq. Our results suggest the hypoxia-induced transcriptome regulation 
is both rapid and dynamic with many processes involved, such as activation of angiogenesis 
and inflammation genes as well as suppression of metabolic genes. Another set of samples 
prepared with 2 weeks of hypoxia exposure followed by room air oxygen tension recovery 
showed their transcriptome was in a state between the control and long-term hypoxia treated 
cells, suggesting at least a portion of the transcriptome response to hypoxia is reversible. We 
also discovered a poorly studied transcriptome factor that may be involved in hypoxia 
regulation and found evidence that suggest hypoxia exposure may have activated EMT in 
RPE cells, both of which are interesting areas for future research.  
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4.6 Figures and Tables 
 
 
Figure 4.1 APRE-19 hypoxia treatment design 
ARPE-19 cells were exposed to 3% O2 (red bar) or room air oxygen tension (empty) for the 
specified amount of time before assay at the end of six weeks of confluent cell culture. After 
reaching confluency (week 0), cells were cultured for two weeks without any hypoxia 
treatment to induce differentiation into RPE morphology.  
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Figure 4.2 FastQC mean sequencing quality score 
MultiQC plots the average sequencing quality Phred score at each base in the reads generated 
for each sample. Each line detonates a sample with majority of them overlapping throughout 
the entire 100 base pair region. Green Phred score indicates good sequence quality while red 
indicates poor quality.  
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Figure 4.3 Tophat2 statistics 
At least 89% of reads were mapped in all 25 samples by Tophat2. 
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Figure 4.4 HTSeq-count statistics 
HTSeq-count uniquely assigned (blue bar) between 70-77% of a sample’s aligned reads to a 
gene. 
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Figure 4.5 ROS level measured after hypoxia treatment 
After exposure to varying length of hypoxia treatment, ARPE-19 cells were assayed to 
measure ROS level using a dye that becomes highly fluorescent after intracellular oxidation. 
The results suggest there is a weakly elevated ROS level after 2 days and 2 weeks of hypoxia 
treatment, but no change after 8 hours of hypoxia and after recovery from hypoxia. ROS 
level were normalized to average measurement in control samples. Mean and standard 
deviation (n=12) plotted. All statistical tests were performed against control samples with 
the stars indicating the magnitude of the adjusted p-value (* P≤0.05, ** P≤0.01). 
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Figure 4.6 Dead and live staining of ARPE-19 after hypoxia treatment 
After exposure to varying length of hypoxia treatment (A. no hypoxia, B. 2 weeks hypoxia 
and 2 weeks recovery, D. 8 hours hypoxia, E. 2 days hypoxia, F. 2 weeks hypoxia), ARPE19 
cells were assayed to stain for dead (red) and live (green) cells as shown in bottom image of 
each subsection. Corresponding phase contrast micrographs are shown in the top image of 
each subsection. No elevated cell death is observed after hypoxia treatment. Detergent-
treated lethal control is shown in C.   
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Figure 4.7 PCA of all samples 
PCA performed with all 25 ARPE-19 samples. 2wHypo2wNorm is 2 weeks hypoxia 
followed by recovery, 8hHypo is 8 hours hypoxia, 2dHypo is 2 days hypoxia, and 2wHypo 
is 2 weeks hypoxia samples. PC # is principal component #. A. Percent of overall variance 
captured by the top 10 principal components. B-C. Samples in PC 1 and PC 2, PC 1 and PC 
3, respectively. Percent of variance explained is shown in axis label.  
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Figure 4.8 edgeR comparisons of hypoxia time points and control 
EdgeR comparisons between control and 8 hours hypoxia (A, B), 2 days hypoxia (C, D) and 
2 weeks hypoxia (E, F). A., C., E. Measured CPM and fold-change for each expressed gene. 
DE genes are colored red while all others are black. Genes outside of display window are 
symbolized by triangle. B., D., F. edgeR measured fold-change and FDR displayed for each 
gene. DE genes are colored red while all others are black. Genes outside of display window 
are symbolized by triangle. Blue dashed line indicates FDR=0.05.  
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Figure 4.9 ERSSA result of the DE comparison between 8 hours hypoxia and control 
ERSSA-generated number of DE gene plot (A) and marginal change plot (B) with 50 
combinations per replicate level and log2-fold-change cut off = 0.5. Median used to measure 
the percentage change in the marginal change plot.  
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Figure 4.10 ERSSA result of the DE comparison between 2 days hypoxia and control 
ERSSA-generated number of DE gene plot (A) and marginal change plot (B) with 50 
combinations per replicate level and log2-fold-change cut off = 0.5. Median used to measure 
the percentage change in the marginal change plot.  
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Figure 4.11 ERSSA result of the DE comparison between 2 weeks hypoxia and control 
ERSSA-generated number of DE gene plot (A) and marginal change plot (B) with 50 
combinations per replicate level and log2-fold-change cut off = 0.5. Median used to measure 
the percentage change in the marginal change plot.  
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Figure 4.12 GO biological process enrichment with DE genes in comparison between 
control and 8 hours hypoxia 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO 
biological process. Selected biologically relevant GO biological process were labeled.   
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Figure 4.13 KEGG pathway enrichment with DE genes in comparison between 
control and 8 hours hypoxia 
KEGG pathways enriched with goseq using up-regulated (A) and down-regulated (B) DE 
genes. Statistically significant pathways are displayed. Benjamini Hochberg (BH) adjusted 
P-value is displayed on the x-axis. Pathways enriched at all hypoxia time points are 
highlighted in yellow.  
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Figure 4.14 GO biological process enrichment with DE genes in comparison between 
control and 2 days hypoxia 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO 
biological process. Selected biologically relevant GO biological process were labeled.   
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Figure 4.15 KEGG pathway enrichment with DE genes in comparison between 
control and 2 days hypoxia 
KEGG pathways enriched with goseq using up-regulated (A) and down-regulated (B) DE 
genes. Statistically significant pathways are displayed. Benjamini Hochberg (BH) adjusted 
P-value is displayed on the x-axis. Pathways enriched at all hypoxia time points are 
highlighted in yellow.  
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Figure 4.16 GO biological process enrichment with DE genes in comparison between 
control and 2 weeks hypoxia 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO 
biological process. Selected biologically relevant GO biological process were labeled.   
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Figure 4.17 KEGG pathway enrichment with up-regulated DE genes in comparison 
between control and 2 weeks hypoxia 
KEGG pathways enriched with goseq using up-regulated DE genes. Statistically significant 
pathways are displayed. Benjamini Hochberg (BH) adjusted P-value is displayed on the x-
axis. Pathways enriched at all hypoxia time points are highlighted in yellow.  
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Figure 4.18 KEGG pathway enrichment with down-regulated DE genes in 
comparison between control and 2 weeks hypoxia 
KEGG pathways enriched with goseq using down-regulated DE genes. Statistically 
significant pathways are displayed. Benjamini Hochberg (BH) adjusted P-value is displayed 
on the x-axis. Pathways enriched at all hypoxia time points are highlighted in yellow. 
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Figure 4.19 Top 100 enriched GO biological processes compared between three 
comparisons – part 1 
Top 100 enriched GO biological processes from each GO enrichment were compared. A. 
Plot shows the overlap between the top 100 lists. Bars indicate the number of overlap among 
the 6 lists of GO annotations. Dot with connected line indicate inclusion in the GO list. GO 
lists are named with syntax: Hypoxia_TimePoint_v_Control_Direction with TimePoint of 
2w as 2 weeks, 2d as 2 days, and 8h as 8 hours. Direction is either up- or down-regulation. 
B. REVIGO visualization of 51 unique GO biological process in the top 100 enriched with 8 
hours hypoxia down-regulated genes. Selected biologically relevant processes were labeled.   
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Figure 4.20 Top 100 enriched GO biological processes compared between three 
comparisons – part 2 
A. REVIGO visualization of 25 unique processes in the top 100 enriched with 2 days hypoxia 
down-regulated genes. Selected biologically relevant processes were labeled. B. REVIGO 
visualization of 34 unique processes in the top 100 enriched with 2 weeks hypoxia down-
regulated genes. Selected biologically relevant processes were labeled.  
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Figure 4.21 edgeR and ERSSA results of DE comparison between hypoxia recovery 
and control 
A. edgeR-measured CPM and fold-change for each expressed gene. DE genes are colored 
red while all others are black. Genes outside of display window are symbolized by triangle.  
B. edgeR-measured fold-change and FDR displayed for each gene. DE genes are colored red 
while all others are black. Genes outside of display window are symbolized by triangle. Blue 
dash line indicates FDR=0.05. C-D. ERSSA-generated number of DE gene plot (C) and 
marginal change plot (D) with 50 combinations per replicate level and log2-fold-change cut 
off = 0.5. Median used to measure the percentage change in the marginal change plot.  
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Figure 4.22 GO biological process enrichment with DE genes in comparison between 
control and hypoxia recovery 
Up- (A) and down-regulated (B) DE genes were submitted for GO biological process 
enrichment with results visualized using REVIGO. P-value is REVIGO-derived GO 
enrichment p-value. Size is the number of human proteins associated with each GO 
biological process. Selected biologically relevant processes were labeled.  
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Figure 4.23 KEGG pathway enrichment with up-regulated DE genes in comparison 
between control and hypoxia recovery 
KEGG pathways enriched with goseq using up-regulated DE genes. Statistically significant 
pathways are displayed. Benjamini Hochberg (BH) adjusted P-value is displayed on the x-
axis. Pathways also enriched at all hypoxia time points without recovery are highlighted in 
green. 
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Figure 4.24 KEGG pathway enrichment with down-regulated DE genes in 
comparison between control and hypoxia recovery 
KEGG pathways enriched with goseq using down-regulated DE genes. Statistically 
significant pathways are displayed. Benjamini Hochberg (BH) adjusted P-value is displayed 
on the x-axis. Pathways also enriched at all hypoxia time points without recovery are 
highlighted in green. 
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Figure 4.25 Fold change of 2 weeks hypoxia-regulated DE gene after hypoxia recovery 
Each dot represent a DE gene found to be regulated after 2 weeks hypoxia treatment. The 
gene’s log2-fold-change after 2 weeks hypoxia treatment is plotted on the x-axis, while the 
fold change after hypoxia recovery is plotted on the y-axis. The plot window is limited to the 
(-2, -2) range on both axes. Pearson’s r value is measured as 0.7177. It is worth noting that a 
majority of genes sits below y=x line (dash dark blue line) in positive x-axis regime and 
above y=x line in negative x-axis regime, suggesting hypoxia recovery moderated hypoxia-
induced transcriptome regulation. 
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Figure 4.26 Expression profile of all DE genes clustered by k-mean method 
A. Sum squared error of k-mean clustering with up to k=10 clusters. k=6 selected for further 
cluster-specific analysis. B. Gene-wise normalized (Norm.) TPM plotted as a heatmap with 
genes on rows and samples organized by conditions (color-coded on top of heatmap) on 
columns. Genes sorted by k-mean clustering result (k=6). Cluster association indicated by 
color and number on the left of heatmap. 
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Figure 4.27 Cluster-specific expression profile and enrichment 
For cluster 1 (A) or cluster 2 (B), every gene’s condition-averaged expression profile is 
plotted in black and the average across genes plotted as a thick colored line. Cluster 
associated genes are used for GO biological process enrichment with results visualized with 
REVIGO. Statistically significant pathways enriched are also displayed.   
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Figure 4.28 Cluster-specific expression profile and enrichment 
For cluster 3 (A) or cluster 4 (B), every gene’s condition-averaged expression profile is 
plotted in black and the average across genes plotted as a thick colored line. Cluster 
associated genes are used for GO biological process enrichment with results visualized with 
REVIGO. Statistically significant pathways enriched are also displayed.  
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Figure 4.29 Cluster-specific expression profile and enrichment 
For cluster 5 (A) or cluster 6 (B), every gene’s condition-averaged expression profile is 
plotted in black and the average across genes plotted as a thick colored line. Cluster 
associated genes are used for GO biological process enrichment with results visualized with 
REVIGO. Statistically significant pathways enriched are also displayed.  
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Figure 4.30 Expression profile across selected GO 
All DE genes in cluster 1, 2 and 3 that belong to one of the four GO biological processes 
selected were used to plot individual gene expression profile in gray lines and average 
expression in thick solid black line. For all four GO biological processes, the average selected 
genes’ expression is elevated after 8 hours and 2 days hypoxia and reached peak expression 
after 2 weeks hypoxia. 8hHypo is 8 hours hypoxia, 2dHypo is 2 days hypoxia, 2wHypo is 2 
weeks hypoxia, and 2wHypo2wNorm is hypoxia recovery conditions. 
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Figure 4.31 ISMARA TF enrichment 
All samples were submitted to ISMARA for enrichment of TFs that are involved in ARPE-
19 hypoxia response. Top 50 enriched factors as ranked by Z-score are plotted (x-axis shows 
rank by Z-score). Selected biological relevant factors with higher (A) or lower (B) target 
gene activity in hypoxia response are labeled.  
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Figure 4.32 Activity profiles of selected TF motifs with higher target gene activity 
during hypoxia 
Activity profile (mean + standard deviation) of selected TFs with higher target gene activity 
are plotted. Hypo_8h is 8 hours hypoxia, Hypo_2d is 2 days hypoxia, Hypo_2w is 2 weeks 
hypoxia, and Hypo_2w_Norm_2w is hypoxia recovery conditions.   
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Figure 4.33 Activity profiles of selected TF motifs with lower target gene activity 
during hypoxia 
Activity profile (mean + standard deviation) of selected TFs with lower target gene activity 
are plotted. Hypo_8h is 8 hours hypoxia, Hypo_2d is 2 days hypoxia, Hypo_2w is 2 weeks 
hypoxia, and Hypo_2w_Norm_2w is hypoxia recovery conditions.  
  
290 
 
 
Figure 4.34 ISMARA found predicted HIC2 targets are regulated during hypoxia 
A. Activity profile (mean + standard deviation) of HIC2 target genes. Hypo_8h is 8 hours 
hypoxia, Hypo_2d is 2 days hypoxia, Hypo_2w is 2 weeks hypoxia and 
Hypo_2w_Norm_2w is hypoxia recovery conditions. B. STRING representation of the 
predicted HIC2 targets that ISMARA found to be regulated in this dataset. Proteins with 
related interactions are connected by edges.  
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Figure 4.35 qPCR validation of selected RNA-seq results 
Six genes shown by RNA-seq to be regulated during hypoxia were selected for qPCR 
validation. Expression values were normalized in both plots so that the average expression 
in control condition is 1. The mean and standard deviation are shown. Hypoxia_8h is 8 hours 
hypoxia, hypoxia_2d is 2 days hypoxia, hypoxia_2w is 2 weeks hypoxia, and 
hypoxia_2w_normoxia_2w is hypoxia recovery conditions. A. RNA-seq expression based 
on TPM values. B. qPCR expression based on ΔΔCt-derived fold changes. 
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Gene Direction 5' to 3' Sequence 
HIF1A Forward GAACGTCGAAAAGAAAAGTCTCG 
HIF1A Reverse CCTTATCAAGATGCGAACTCACA 
LDHA Forward ATGGCAACTCTAAAGGATCAGC 
LDHA Reverse CCAACCCCAACAACTGTAATCT 
DLD Forward CTCATGGCCTACAGGGACTTT 
DLD Reverse GCATGTTCCACCAAGTGTTTCAT 
MMP2 Forward TACAGGATCATTGGCTACACACC 
MMP2 Reverse GGTCACATCGCTCCAGACT 
SOD2 Forward TTTCAATAAGGAACGGGGACAC 
SOD2 Reverse GTGCTCCCACACATCAATCC 
VEGFA Forward AGGGCAGAATCATCACGAAGT 
VEGFA Reverse AGGGTCTCGATTGGATGGCA 
TUBB Forward TGGACTCTGTTCGCTCAGGT 
TUBB Reverse TGCCTCCTTCCGTACCACAT 
Table 4.1 qPCR primers 
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Trans. Factor Z-score 
Activity.
diff 
Hypoxia
_8h-
Control 
Activity.
diff 
Hypoxia
_2d-
Control 
Activity.
diff 
Hypoxia
_2w-
Control 
Activity.
diff 
Hypoxia
_2w_nor
moxia_2
w-
Control 
MXI1_MYC_MYCN 5.985751 -0.04156 -0.02475 -0.01506 -0.00251 
NRF1 4.709144 -0.01371 -0.01576 -0.01061 0.003826 
HIF1A 4.702637 0.037304 0.031275 0.02326 0.004819 
ARNT 3.969943 0.026974 0.026438 0.026203 0.00866 
YBX1_FOS_NFYC_NFY
A_NFYB_CEBPZ 
3.583263 -0.0186 -0.01836 -0.01918 -0.00067 
SIX5_SMARCC2_HCFC1 3.433916 -0.00965 -0.01465 -0.01192 -0.00198 
PATZ1_KLF4 3.377575 0.005596 0.009211 0.009242 0.002927 
EPAS1_BCL3 3.002331 0.026016 0.007556 0.006703 0.002857 
ELF2_GABPA_ELF5 2.954512 -0.01664 -0.01427 -0.00911 -0.003 
ZNF711_TFAP2A_TFAP2
D 
2.868172 -0.01185 -0.00687 -0.00262 -0.00193 
PITX3 2.862096 -0.01573 -0.01699 -0.01735 -0.00546 
HIC2 2.751785 0.015762 0.017797 0.015536 0.008411 
WT1_MTF1_ZBTB7B 2.688741 0.013391 0.009849 0.008728 0.002619 
AHR_ARNT2 2.687516 0.01195 0.011722 0.009293 -0.00062 
BACH1_NFE2_NFE2L2 2.682164 -0.01493 -0.02065 -0.022 -0.00786 
ESRRB_ESRRG 2.587262 -0.01033 -0.01781 -0.01954 -0.00744 
CREB1 2.584654 -0.01806 -0.0142 -0.00827 0.000501 
TAF1 2.576257 -0.02713 -0.02198 -0.01851 -0.00941 
MECP2 2.561408 -0.00492 -0.00517 -0.00465 0.000575 
SRF 2.516779 0.00486 -0.00354 0.02003 0.012833 
MAZ_ZNF281_GTF2F1 2.50939 0.009488 0.011252 0.008038 0.000994 
WRNIP1 2.468187 0.008925 0.005619 0.004495 0.000455 
GTF2I 2.441592 0.012833 0.008224 0.007822 -0.00223 
FOSL2_SMARCC1 2.405661 0.015183 0.016825 0.021105 0.007225 
CEBPB 2.387667 0.000121 -8.50E-
05 
0.017481 -0.00211 
ZFX 2.385102 -0.01729 -0.01044 -0.00985 -0.00739 
FOSL1 2.366784 0.014858 0.014785 0.012922 0.001207 
ERG 2.30491 0.013408 0.009604 0.005387 -0.00036 
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ATF4 2.302819 -0.0022 0.001443 0.018105 0.000298 
ATF2_ATF1_ATF3 2.281693 -0.0125 -0.01138 -0.00888 -0.00064 
HOXB2_UNCX_HOXD3 2.233088 -0.00791 -0.01757 -0.0108 -0.00452 
ZNF143 2.229308 -0.01519 -0.0033 -0.00225 0.0039 
MEIS2 2.147955 -0.00316 -0.00834 -0.01007 -0.00115 
EBF1 2.10306 0.012099 0.012974 0.012471 0.000648 
ZBTB14 2.088882 0.011221 0.004773 0.004971 -0.0014 
PPARA 1.999801 -0.01269 -0.0133 -0.01742 -0.00929 
HSF4 1.978446 -0.01271 -0.01112 -0.01423 -0.00162 
NR5A2 1.959715 -0.01511 -0.01196 -0.01396 -0.00408 
MYF6 1.952703 0.015941 0.013566 0.015877 0.009493 
SOX4 1.946565 0.01024 0.011339 0.014389 0.000526 
ETV1_ERF_FEV_ELF1 1.93076 -0.00905 -0.01416 -0.00812 0.005953 
CTCF_CTCFL 1.920265 0.011528 0.011027 0.01426 0.004409 
POU5F1_POU2F3 1.909801 0.012421 0.006181 -0.00168 0.001858 
TFAP2C 1.895419 0.00527 0.006948 0.008185 -0.00154 
MESP1 1.85942 0.009111 0.01138 0.010689 0.00149 
MIXL1_GSX1_BSX_ME
OX2_LHX4 
1.811681 -0.00953 -0.01093 -0.01296 -0.00372 
NFIA 1.811268 0.016127 0.005478 -0.00114 -0.00094 
CEBPE_CEBPD 1.794327 0.009854 0.016299 0.00577 0.001329 
NR1I2 1.786169 0.012905 0.010234 0.004668 0.000229 
RFX7_RFX4_RFX1 1.7746 0.012971 0.000765 0.004503 2.90E-05 
Table 4.2 Top 50 TF groups enriched 
TFs are ordered by Z-score. Last four columns contain average target gene activity difference 
between control and each of Hypoxia_8h (8 hours hypoxia), Hypoxia_2d (2 days hypoxia), 
Hypoxia_2w (2 weeks hypoxia), and Hypoxia_2w_normoxia_2w (hypoxia recovery) 
conditions.   
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Chapter 5. ERSSA, a subsampling-based RNA-seq sample size 
analysis method 
5.1 Introduction 
For comparative RNA-seq experiments, selecting the appropriate sample size is an important 
optimization step1. Comparisons with limited biological replicates tend to be under-powered 
with inferior differential expression (DE) discovery. On the other hand, the improvement in 
DE identification becomes marginally small as more replicates are added, while cost 
increases linearly2. In the past few years, several algorithms have been proposed to identify 
the appropriate sample size for RNA-seq experiments3. As summarized in Chapter 1.4, a 
recent survey article set out to systematically evaluate these algorithms and found all of them 
are ineffective in estimating the correct sample size when the inter-condition differences 
(effect size) are modest4. Here, we present a new method called Empirical RNA-seq Sample 
Size Analysis (ERSSA5) that tackles this challenge from a different angle: instead of 
attempting to predict the appropriate sample size using a priori assumptions prior to 
acquiring data, ERSSA evaluates existing RNA-seq data to estimate the marginal return in 
DE gene discovery as sample size increases. The results then allow the user to assess whether 
the number of replicates already acquired is sufficient for their study.  
To demonstrate ERSSA’s utility, we applied the analytical approach to several publicly 
available RNA-seq datasets that span four types of experimental systems: mouse tissue, 
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human tissue, human population, and in vitro cell culture. We will cover comparisons where 
ERSSA shows sufficient replicates have been included and examples where additional 
samples could be beneficial. More broadly, the results from this study depict the importance 
of post-data acquisition sample size validation, a practice largely ignored in the RNA-seq 
research community. By incorporating ERSSA (and the accompany software, ERSSA) into 
existing research projects, users can benefit from both a better understanding of their 
experimental dataset and avoid biological interpretation based on insufficiently powered 
experiments.  
 
5.2 Materials and Methods 
Software development and data acquisition 
The ERSSA algorithm is implemented in the statistical programming language R and the 
software package (also named ERSSA) is available on Bioconductor for download5. ERSSA 
currently supports differential expression testing with edgeR6 and DESeq27, but additional 
tools can be incorporated through manual modification of the code8. 
To demonstrate ERSSA’s utility, we applied the technique to four biomedically-relevant 
datasets that represent a diverse set of RNA-seq experiments:  
1) GTEx: a dataset containing human heart and muscle tissues9. 
2) Bottomly: brain tissues from two mouse strains often used in neuroscience research10. 
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3) Montgomery-Pickrell (MP): lymphoblastoid cell lines derived from Europeans and 
Nigerians11,12. 
4) Fossum: cell lines treated with transcription factor knockdown or control siRNA13. 
The four publicly available datasets were downloaded from the recount and recount2 
projects, which are systematic efforts to generated gene expression count table from 
thousands of RNA-seq studies14,15. Bottomly and MP datasets were obtained from the 
original recount project. GTEx and Fossum datasets were downloaded from the recount2 
project. Recount2 count files were scaled using the recount software package as 
recommended by the authors before usage in ERSSA16. All analyses were performed in R 
with random seed set to 1. For GTEx and MP, the entire datasets are too large for the purpose 
of ERSSA evaluation. For these two datasets, 25 replicates of each condition were randomly 
selected for analysis. Furthermore, the GTEx dataset is broken down into three datasets 
containing 5, 10, and 25 replicates per condition for testing purposes. Table 5.1 (GTEX), 5.2 
(GTEX), 5.4 (Bottomly), 5.6 (MP), and 5.8 (Fossum) display the original ID of the samples 
used in this study. 
Algorithm 
Before running ERSSA, two inputs need to be prepared ahead of time:  
1) A RNA-seq count table containing samples from two conditions; 
2) A table that specifies the sample-condition relationship.  
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Examples of the input tables are included in the ERSSA vignette section 3.28. Once the inputs 
are ready, the ERSSA algorithm runs through four sequential steps: 1) filter count table to 
remove non-expressed genes, 2) generate unique subsamples (combinations of samples from 
both conditions) at each replicate level, 3) perform DE analysis of the subsamples using well-
established DE software, and 4) generate plots to visualize and interpret the results. Here, we 
will briefly describe each step; full descriptions are available in the ERSSA software 
documentation5. 
Filter count table 
Removal of non-expressed genes before differential expression comparison is a widely 
accepted practice that is recommended to maximize discovery17. ERSSA uses a simple gene-
wise average Count per Million (CPM) value to identify non-expressed genes: 
 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑃𝑀𝑔 = (∑
𝑐𝑜𝑢𝑛𝑡𝑔𝑖 ∗ 10
6
 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡𝑖
𝑀
𝑖 ) 𝑀⁄  ,  
where g denotes a specific gene, i denotes a specific sample, and M is the total number of 
samples. At default, genes with average CPM<1 are removed from further analysis. 
Additionally, the user can elect to supply their own pre-filtered count table generated from 
other filtering methods. The filtered count table is then passed to the differential testing step 
(DE analysis, below). 
Generate subsample combinations 
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One of the core features of ERSSA is to use subsamples selected at each replicate level to 
observe the trend in DE gene discovery as a function of sample size. Using the sample-
condition relationship table, the algorithm first identifies the smaller of the two numbers of 
replicates (N) available among the two conditions. Next the algorithm performs a pre-
determined number of subsampling, where possible, at each step-wise replicate levels (n= 2, 
3, 4, ..., N-1). For large N, the number of unique subsamples at some replicate levels n 
becomes very large and it is not necessary to evaluate all combinations. Typically, Ns=30-50 
subsamples at each replicate level are sufficient to observe the pattern in DE gene discovery 
as a function of sample size. When the total number of unique sample combinations is less 
than Ns (for example: N=3 and n=2 produces 9 unique subsamples), then all unique 
subsamples are selected. When the number of possible combinations exceeds Ns, the 
algorithm generates Ns unique and random subsamples. At default, ERSSA generates Ns=30 
subsamples at each n; the user can change the value Ns, which affects run time linearly. The 
generated subsample combinations together with the filtered count table are then passed to 
DE software for statistical testing. 
DE analysis 
Using the previously generated filtered count table and subsample combinations, ERSSA 
makes a call to a DE software for statistical testing. Currently, ERSSA supports edgeR and 
DESeq2, two of the most widely used DE software packages, for differential discovery18. At 
default, edgeR is used as it is slightly faster in runtime compare to DESeq2. After statistical 
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testing, DE genes are defined by two cutoff statistics: multiple-test corrected p-value 
(adjusted p-value in DESeq2 and False Discovery Rate (FDR) in edgeR)<0.05 and  
|log2-fold-change|>1. Unless otherwise specified, genes that match both criteria are 
considered to be DE in the scope of ERSSA calculations. At the end of the test, the identity 
of the DE genes are retained and subsequently used for quantification and visualization. 
Plot DE results 
Using the test outputs, ERSSA generates four summary plots to help the user interpret the 
results. Further detail regarding the four summary plots and their utility can be found in the 
Results section (Chapter 5.3) below. The first plot displays the number of DE genes 
identified as a function of the number of replicates (n) employed. The second plot shows the 
percent change in average number of DE genes identified as n increases. The third plot 
displays the number of DE genes that are identified in all of the subsamples at each replicate 
level, revealing the increase in the consistency of DE gene discovery as n increases. Based 
on the statistics from this plot, the percentage of consistently discovered DE genes found in 
all subsamples can be calculated. The last plot must be viewed with care. Since the ground 
truth is not known in RNA-seq studies, the DE discovery at the full replicate level is used as 
the “pseudo ground truth” for calculating a True Positive Rate (TPR) and False Positive Rate 
(FPR) of DE discovery for each subsample, color coded for corresponding sample size n. 
The average rates (TPR and FPR) at each replicate level are also displayed. It is important to 
consider that when the discovery with the full dataset is not reliable, interpretation of this 
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plot is inappropriate. Only when ERSSA shows the full dataset is able to detect a majority of 
DE genes consistently (through interpretation of first three plots) is this analysis useful. 
All four plots are created using the ggplot2 R package with the plot objects and the plotted 
data saved19. From there, further modifications can be applied to adapt to various display 
preferences. Lastly, the raw data generated during the calculations are also available to the 
user for additional analysis outside the scope of ERSSA. 
 
5.3 Results 
GTEx – human muscle and heart tissue dataset 
The original dataset from GTEx contains hundreds of human tissue samples, including ones 
from muscle and heart. For the purpose of ERSSA evaluation, 25 muscle and heart samples 
were randomly selected for inclusion (Tables 5.1, 5.2). To illustrate how ERSSA enables 
discrimination of statistical power as a function of the number of replicates, we analyzed 
three cases: N=5, N=10, and N=25. A single random selection of 5 replicates taken from the 
25 total illustrates what would be observed if N=5. Likewise, a single random selection of 10 
from the 25 total illustrates what would be observed with N=10. This example shows how a 
user can evaluate a small number of replicates and see the likelihood that significant gains 
could be achieved by increasing the number of replicates (results for N=5 indicate that 
additional replicates could bring significant improvements, which is confirmed by the 
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analysis for N=10). This example also shows how a user can evaluate an intermediate number 
of replicates and accurately infer that further replicates are unlikely to reveal additional DE 
genes (results for N=10 suggest that the improvement with increasing N has saturated, which 
is confirmed by the analysis for N=25). 
For most studies, the average number of identified DE genes generally increases as sample 
size increases. In our literature search, we observed that most RNA-seq studies use N≤5 
replicates. While this might be sufficient in well controlled studies testing large transcriptome 
changes, others could see significant improvement in detection with more replicates. 
Therefore, we chose a mock experiment with only 5 replicates as an example. In this analysis, 
the test result with all 5 replicates is taken as the “pseudo ground truth” and the improvement 
with increasing n is computed for subsamples of n=2, 3, and 4. The increase in the mean 
number of DE genes and the decrease in the variability among the different subsamples is 
strong over this range of n (Figure 5.1A, note the increase in the mean (red line) and the 
median, as well as the decrease in the difference from the 1st to 3rd quartiles as n increases 
from 2 to 4). The potential for significant further increase in the number of DE genes 
discovered is indicated by the percent increase in the DE gene discovery for n=5 relative to 
n=4 (Figure 5.1B suggests improvements in the order of 5-10% could be achieved with 
additional replicates). Furthermore, ERSSA shows that there is potentially a significant 
increase in the fraction of genes that can be reliably discovered with more replicates (Figure 
5.2A) as only 40% of the DE genes at n=4 is found in all subsample results (Table 5.3). 
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Finally, the graph of TPR and FPR must be regarded with caution in the view of the previous 
three ERSSA outputs: the “pseudo ground truth” using N=5 is not a good approximation for 
the ground truth (Figure 5.2B). 
Based on the ERSSA results for N=5, a user might choose to acquire 5 additional replicates 
to improve discovery. As anticipated based on Figure 5.1, the N=10 dataset identified around 
6200 DE genes (Figure 5.3A), a significant increase relative to around 5500 for N=5. Indeed, 
5 additional replicates provided a DE gene discovery increase in the low double digits 
percentage range, which is consistent with the prediction base on the N=5 analysis. With 
N=10, ERSSA also suggests that the number of DE genes identified hardly changed with 
increase of n from 8 to 9 and 10 (Figure 5.3A and B). This observable “plateau” at the large 
n regime suggests that a majority of DE genes have already been discovered with the 
available biological replicates. At this regime, the additional benefit of increasing replicates 
is the confidence that regardless of the particular set of samples obtained for the experiment, 
each one will find DE genes that would be identified in any other subsamples (Figure 5.4A, 
Table 5.3).  
Based on the evidence that the “pseudo ground truth” represented by the DE genes 
discovered using N=10 is a good approximation, the fourth output of ERSSA has greater value 
in this case than it did for N=5. The graph of TPR and FPR indicates that the FPR only begins 
to decrease when n > 4 and that it decreases from around 5% at n=6 to around 2% for n=9 
(Figure 5.4B). Additionally, the TPR continuously progress from n=8 to 9 to 10, suggesting 
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that the actual ground truth might reveal that TPR for N=10 is less than 100%. Lastly, it is 
again worth noting that this particular sampling of N=10 replicates is not a perfect 
representation of the ground truth; the data point for the full data set is placed at TPR=1, 
FPR=0 simply because it is used as the “pseudo ground truth.” 
When we proceed to N=25 replicates, the expectations based on application of ERSSA at 
N=10 are borne out. The mean number of genes discovered hardly changed for n>10 (Figure 
5.5A and B). The benefit of the increase in the number of replicates is that approximately 
5300 DE genes are reliably found by any subsamples at n=24 (Figure 5.6A), corresponding 
to a high of 83% of all DE genes discovered (Table 5.3). The TPR increases a few percent 
as n increases from 21 to 24 and the FPR is consistently less than 2% for n>21 (Figure 5.6B), 
suggesting that the marginal return on acquiring additional replicates has become 
increasingly small. 
As demonstrated with the GTEx example dataset, ERSSA helps the user deal with the fact 
that while the true list of DE genes is typically never known, the existing replicates at hand 
can be used to predict the amount of improvement to be gained by acquiring additional 
replicates. For N=5, ERSSA reveals that the discovery is most likely incomplete (Figure 5.1 
and 5.2A), in which the TPR and FPR calculated are not useful (Figure 5.2B). ERSSA 
analysis of N=5 replicates correctly anticipated that an additional 5 replicates could bring a 
substantial improvement (compare Figure 5.1A and 5.2A, to Figure 5.3A and 5.4A). We 
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also noticed that a large number of replicates is required to obtain a good approximation of 
the true list of DE genes (average TPR>95% for N=25, Figure 5.6B). 
Bottomly – mouse tissue dataset 
The Bottomly dataset contains brain samples from two mouse strains that are commonly 
used in neuroscience research (Table 5.4). When all 10 replicates available were tested with 
ERSSA, it appears that there are relatively few DE genes between the two strains (Figure 
5.7A). Consistent with previous observation with the GTEx dataset, there is a clear pattern 
of improved DE gene discovery as additional replicates are used (Figure 5.7B). Some 
subsamples at the low n regime did found significantly more DE genes that pass the FDR 
cutoff. However, these results are outliers with many false positive discoveries as indicated 
by the relatively low number of DE gene discovery with n=10. After inclusion of six 
replicates, the improvement is primarily in the fidelity of the DE gene identification, rather 
than the number of DE genes identified (compare the increase in bars and mean DE gene 
curve for n>6 in Figure 5.8A). Based on the fraction of consistently identified DE genes (the 
consensus DE genes represent 42% of the putative DE genes identified in at least one of the 
subsamples at n=9, Figure 5.8A, Table 5.5), the discovery with the full dataset is likely an 
imperfect approximation for the true DE gene list. This must be kept in mind when viewing 
the fourth output of ERSSA, where the full dataset is used as the “pseudo ground truth”.  In 
this dataset, TPR calculation shows a strong improvement from n=6 to 9 in Figure 5.8B, 
suggesting that there is much to be gained by increasing the number of replicates.  
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MP – human population dataset 
The MP dataset is collected as part of the International HapMap Project and contains 
lymphoblastoid cell lines derived from European and Nigerian individuals. The entire dataset 
contains more than 60 replicates per group. To illustrate the use of ERSSA, 25 replicates from 
each population were randomly selected for testing (Table 5.6). Compared to the GTEx and 
Bottomly datasets, ERSSA shows that DE gene discovery in the MP dataset requires a much 
greater number of replicates (compare Figure 5.9 to Figures 5.5 and 5.7). As n increases, 
the mean number of putative DE genes gradually increases and reaches plateau at around 
n=18 with approximately 1000 putative DE genes on average. However, fewer than 400 of 
those identified at n=18 are consistently found in all subsamples that were analyzed (Figure 
5.10A). Indeed, consensus among the subsamples remains quite low across all sample sizes 
tested (even at n=24, there are only 720 consensus DE genes, representing 53% of the 
putative DE genes identified in at least one of the subsamples, Table 5.7). Similarly, the 
average TPR is quite low in the low replicate regime and gradually improves to at least 0.75 
as n increases to 14 and higher (Figure 5.10B). However, even at the high replicate regime 
(n=20 to 24), the TPR continues to increase significantly with additional replicates. Thus, 
ERSSA shows that while the total number of DE genes detectable has plateaued, a more 
accurate DE discovery could be obtained by increasing the number of replicates.  
Fossum – cell line dataset 
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The Fossum dataset originated from an effort to identify the transcriptome change after EHF 
transcription factor perturbation. In this dataset, EHF expression was knocked down using 
siRNA and a separate cohort of samples were treated with negative control siRNA. In both 
conditions, five cell culture replicates are available for ERSSA (Table 5.8). This example 
illustrates an experiment for which the default setting of the fold-change threshold (|log2-
fold-change|>1) is too stringent. Using the default settings, only a few DE genes are detected 
at all available replicate levels (Figure 5.11), which suggests that treatment-induced 
transcriptome changes are mild and might be better explored by relaxing the fold change 
cutoff to 0.5. Analysis with the relaxed parameter allows a larger number of putative DE 
genes to be identified and the results show a substantial increase in the number of DE gene 
discovery as sample size increases, suggesting the plateau has not been reached (Figure 
5.12). Robustness among the subsamples also remains low with consensus DE genes at n=4 
representing only 18% of putative DE genes found in at least one of the subsamples (Figure 
5.13A, Table 5.9). Based on these observations, the fourth plot of ERSSA is of limited use 
as the “pseudo ground truth” with N=5 is likely a poor representation of the real ground truth. 
Indeed, the primary message from Figure 5.13B is that increasing the number of replicates 
brings a dramatic increase in calculated TPR, providing strong motivation to acquire 
additional replicates. 
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5.4 Discussion 
In recent years, many algorithms have been proposed to guide the selection of the appropriate 
sample size for RNA-seq experiments4. These algorithms typically use pilot or publicly 
available RNA-seq data to estimate parameters and rely on a priori assumptions about the 
effect size to estimate the sample size. Some well cited packages that use this approach 
include Scotty (2013)20, RNASeqPowerCalculator (2014)21, ssizeRNA (2016)22, and 
powsimR (2017)23. Typically, these algorithms are applied prior to RNA-seq experiments to 
estimate the sample size needed to gain sufficient statistical power. However, a recent paper 
showed that these approaches actually perform poorly when the effect size is modest4, as is 
the case for a large fraction of RNA-seq experiments. To the best of our knowledge, there 
are no methods available that are specifically designed to validate sample size post-RNA-
seq sample acquisition. 
The ERSSA algorithm and the accompanying ERSSA package address these needs. In 
ERSSA, a subsampling approach is used with existing DE analysis software to determine 
whether the appropriate sample size has been reached. Here, we applied the analytical 
approach to several publicly available datasets and found favorable utility across different 
experimental settings. In three datasets (GTEx, Bottomly and MP), ERSSA shows sufficient 
biological replicates have been included for DE gene discovery (Figure 5.5, 5.7, and 5.9). 
Furthermore, we performed the GTEx analysis at three maximum sample sizes and verified 
that ERSSA forecast correctly from N=5 that a substantial increase in the number of putative 
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DE genes could be achieved by obtaining additional replicates and from N=10 that a 
significant increase in the number of consensus DE genes could be obtained with additional 
replicates (Figure 5.1-5.6). In one study (Fossum), the results suggest additional samples 
could improve the number of DE gene discovery (Figures 5.11 to 5.13). Although obtaining 
additional replicates may not always be feasible or economical, ERSSA enables the user to 
appreciate the limitations of their dataset. 
In addition to estimating the quantity of putative DE genes at a certain replicate size, 
ERSSA’s subsampling approach also enables analysis of the fidelity of DE gene discovery. 
Using the number of consensus DE genes across all subsamples as a metric, we found that 
the four studies typically have low consistency at the low replicate regime and a continuous 
improvement as sample size increases (Figure 5.6A, 5.8A, 5.10A, 5.13A). The lack of 
consistency with small n is likely due to a combinations of limited DE gene discovery and 
higher variability. On the other hand, it is interesting to note that even at the high replicate 
regime, we did not observe a plateau in the consensus/putative ratio of DE genes (Table 5.3, 
5.5, 5.7, 5.9). Instead, we consistently observed a continuous increase in the percentage of 
consensus DE genes calculated from the subsample analyses. 
TPR and FPR are other metrics of evaluating the variability in the DE gene discovery. In 
figures plotting the two rates, we found that the four studies behaved very differently in terms 
of their TPR/FPR profile. In three studies (Bottomly, MP and Fossum), the average FPRs are 
across the board quite low, typically in the range of 0.01 to 0.04 (Figure 5.8B, 5.10B, 5.13B). 
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In the GTEx study, average FPRs are consistently higher in all three analyses, but still 
reasonable within a 0.05 to 0.10 range (Figure 5.2B, 5.4B, 5.6B). Additionally, we found 
that while TPR tend to increase consistently as a function of sample size, FPR can initially 
increase and then decrease (Figure 5.4B, 5.6B, 5.10B). This interesting FPR pattern is 
clearly observable in both GTEx and MP datasets, suggesting that while initial sample size 
addition improves discovery, it can also increase the number of false positives. Another 
interesting observation is that while TPR improvement appears monotonic, its marginal 
increment becomes smaller as sample size becomes larger. This is especially noticeable in 
the three larger datasets with N>5, particularly in the N=25 GTEx dataset (Figure 5.6B). 
Lastly, we would like to again emphasize that the rates are calculated by setting the list of 
DE genes discovered with the full available dataset as the ground truth. In the datasets where 
discovery is under-powered, the calculated rates are unreliable and no conclusions should be 
drawn.  
While the ERSSA algorithm does not use any a priori assumptions about the dataset, there 
are several runtime specifications that need to be considered. First, the number of subsamples 
to run per replicate level is an important ERSSA parameter. For the majority of datasets, we 
found 30 subsamples are sufficient to provide a good estimate of the discovery. On the other 
hand, some datasets are prone to outliers, where additional subsamples could reduce the 
sensitivity to any particular result (e.g. 50 subsamples used in MP dataset). Two additional 
runtime specifications that can be adjusted are the statistical test and fold change cutoffs used 
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for DE consideration. In particular, depending on the effect side, the fold change cutoff can 
be either tightened or relaxed to fit the comparison. We saw an example of this in the Fossum 
dataset where the transcriptome change after treatment is quite mild, so the fold change cutoff 
is relaxed to increase DE gene discovery (Figure 5.11, 5.12).  
While using ERSSA, we also found it useful to run the algorithm multiple times with different 
random seeds. Since ERSSA uses a random process to generate the subsamples, running the 
algorithm multiple times causes it to generate different groups of subsamples. When the 
conclusions are consistent across multiple simulations, the user can gain confidence that the 
results are independent of the specific choice of subsamples. Lastly, depending on the size 
of the dataset, hundreds to thousands of DE comparisons may need to be run (e.g. N=25 with 
default 30 subsamples require a total of 691 statistical tests). To reduce run time, the user is 
highly encouraged to turn on parallel processing in ERSSA, which is managed by the 
BiocParallel package24.  
 
5.5 Conclusions 
For any comparative RNA-seq experiment, selecting the appropriate sample size is an 
important and challenging design decision. ERSSA is a novel algorithm that enables users to 
determine whether an existing RNA-seq dataset has sufficient number of biological 
replicates. In this study, we applied an implementation of the algorithm in R to four publicly 
available RNA-seq datasets to demonstrate the utility of this approach. With these studies, 
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ERSSA shows good performance with a diverse set of experimental conditions including 
different sample size, sample type, and effect size. Results from our study further 
demonstrate that post-RNA-seq sample size analysis is an important quality control step. The 
ERSSA software can be broadly applied to any simple comparative RNA-seq studies 
(meaningfully with N>3) and is available for download at the Bioconductor website.  
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5.6 Figures and Tables 
 
Figure 5.1 ERSSA with 5 replicate GTEx dataset – part 1 
Plots generated by running ERSSA with 5 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1). Up to 30 subsamples at each replicate level. A. Dots represent the number of DE 
genes discovered in each subsample. Boxplot summarizes the results. Red and blue lines 
represent the average and full discovery, respectively. B. Percent change in average DE gene 
discovery as sample size increases. 
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Figure 5.2 ERSSA with 5 replicate GTEx dataset – part 2 
Plots generated by running ERSSA with 5 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1). Up to 30 subsamples at each replicate level. A. Bar plot of the number of DE 
genes found in all subsamples at each replicate level. Red and blue lines represent the average 
and full discovery, respectively. B. Dots indicate FPR and TPR of each subsample. 
Diamonds represent the average rates at each replicate level. DE discovery with the full 
dataset is set as the ground truth for the calculations. 
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Figure 5.3 ERSSA with 10 replicate GTEx dataset – part 1 
Plots generated by running ERSSA with 10 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1). Up to 30 subsamples at each replicate level. A. Dots represent the number of DE 
genes discovered in each subsample. Boxplot summarizes the results. Red and blue lines 
represent the average and full discovery, respectively. B. Percent change in average DE gene 
discovery as sample size increases.  
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Figure 5.4 ERSSA with 10 replicate GTEx dataset – part 2 
Plots generated by running ERSSA with 10 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1). Up to 30 subsamples at each replicate level. A. Bar plot of the number of DE 
genes found in all subsamples at each replicate level. Red and blue lines represent the average 
and full discovery, respectively. B. Dots indicate FPR and TPR of each subsample. 
Diamonds represent the average rates at each replicate level. DE discovery with the full 
dataset is set as the ground truth for the calculations. 
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Figure 5.5 ERSSA with 25 replicate GTEx dataset – part 1 
Plots generated by running ERSSA with 25 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1).  Up to 30 subsamples at each replicate level. A. Dots represent the number of 
DE genes discovered in each subsample. Boxplot summarizes the results. Red and blue lines 
represent the average and full discovery, respectively. B. Percent change in average DE gene 
discovery as sample size increases.  
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Figure 5.6 ERSSA with 25 replicate GTEx dataset – part 2 
Plots generated by running ERSSA with 25 replicate GTEx dataset comparing human muscle 
and heart tissues. Default settings used for DE definition (FDR<0.05 and |log2-fold-
change|>1). Up to 30 subsamples at each replicate level. A. Bar plot of the number of DE 
genes found in all subsamples at each replicate level. Red and blue lines represent the average 
and full discovery, respectively. B. Dots indicate FPR and TPR of each subsample. 
Diamonds represent the average rates at each replicate level. DE discovery with the full 
dataset is set as the ground truth for the calculations. 
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Figure 5.7 ERSSA with Bottomly dataset – part 1 
Plots generated by running ERSSA with Bottomly dataset comparing brain tissues from two 
mouse strains. Default settings used for DE definition (FDR<0.05 and |log2-fold-change|>1). 
Up to 30 subsamples at each replicate level. A. Dots represent the number of DE genes 
discovered in each subsample. Boxplot summarizes the results. Red and blue lines represent 
the average and full discovery, respectively. B. Percent change in average DE gene discovery 
as sample size increases.  
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Figure 5.8 ERSSA with Bottomly dataset – part 2 
Plots generated by running ERSSA with Bottomly dataset comparing brain tissues from two 
mouse strains. Default settings used for DE definition (FDR<0.05 and |log2-fold-change|>1). 
Up to 30 subsamples at each replicate level. A. Bar plot of the number of DE genes found in 
all subsamples at each replicate level. Red and blue lines represent the average and full 
discovery, respectively. B. Dots indicate FPR and TPR of each subsample. Diamonds 
represent the average rates at each replicate level. DE discovery with the full dataset is set as 
the ground truth for the calculations.  
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Figure 5.9 ERSSA with MP dataset – part 1 
Plots generated by running ERSSA with 25 replicate MP dataset comparing lymphoblastoid 
cell lines derived from Europeans and Nigerian individuals. Default settings used for DE 
definition (FDR<0.05 and |log2-fold-change|>1). Up to 50 subsamples at each replicate level. 
A. Dots represent the number of DE genes discovered in each subsample. Boxplot 
summarizes the results. Red and blue lines represent the average and full discovery, 
respectively. B. Percent change in average DE gene discovery as sample size increases.  
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Figure 5.10 ERSSA with MP dataset – part 2 
Plots generated by running ERSSA with 25 replicate MP dataset comparing lymphoblastoid 
cell lines derived from Europeans and Nigerian individuals. Default settings used for DE 
definition (FDR<0.05 and |log2-fold-change|>1). Up to 50 subsamples at each replicate level. 
A. Bar plot of the number of DE genes found in all subsamples at each replicate level. Red 
and blue lines represent the average and full discovery, respectively. B. Dots indicate FPR 
and TPR of each subsample. Diamonds represent the average rates at each replicate level. 
DE discovery with the full dataset is set as the ground truth for the calculations. 
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Figure 5.11 ERSSA with Fossum dataset using absolute log2-fold-change cutoff of 1.0 
Plot generated by running ERSSA with Fossum dataset comparing cell line treated with 
transcription factor knockdown or control siRNA. Default settings used for DE definition 
(FDR<0.05 and |log2-fold-change|>1). Up to 30 subsamples at each replicate level. Very few 
DE genes are discovered with the full dataset using the above cutoffs. Dots represent the 
number of DE genes discovered in each subsample. Boxplot summarizes the results. Red and 
blue lines represent the average and full discovery, respectively. 
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Figure 5.12 ERSSA with Fossum dataset – part 1 
Plot generated by running ERSSA with Fossum dataset comparing cell line treated with 
transcription factor knockdown or control siRNA. DE gene defined to have FDR<0.05 and 
|log2-fold-change|>0.5. Up to 30 subsamples at each replicate level. A. Dots represent the 
number of DE genes discovered in each subsample. Boxplot summarizes the results. Red and 
blue lines represent the average and full discovery, respectively. B. Percent change in average 
DE gene discovery as sample size increases.  
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Figure 5.13 ERSSA with Fossum dataset – part 2 
Plot generated by running ERSSA with Fossum dataset comparing cell line treated with 
transcription factor knockdown or control siRNA. DE gene defined to have FDR<0.05 and 
|log2-fold-change|>0.5. Up to 30 subsamples at each replicate level. A. Bar plot of the 
number of DE genes found in all subsamples at each replicate level. Red and blue lines 
represent the average and full discovery, respectively. B. Dots indicate FPR and TPR of each 
subsample. Diamonds represent the average rates at each replicate level. DE discovery with 
the full dataset is set as the ground truth for the calculations.  
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Sample ID Condition N=25 N=10 N=5 
SRR598148 heart x x x 
SRR598509 heart x x x 
SRR598589 heart x x x 
SRR599025 heart x x x 
SRR599086 heart x x x 
SRR599249 heart x x 
 
SRR599380 heart x x 
 
SRR600474 heart x x 
 
SRR600829 heart x x 
 
SRR600852 heart x x 
 
SRR600924 heart x 
  
SRR601239 heart x 
  
SRR601613 heart x 
  
SRR601645 heart x 
  
SRR601868 heart x 
  
SRR601986 heart x 
  
SRR602106 heart x 
  
SRR602437 heart x 
  
SRR602461 heart x 
  
SRR603449 heart x 
  
SRR603918 heart x 
  
SRR603968 heart x 
  
SRR604122 heart x 
  
SRR604174 heart x 
  
SRR604206 heart x 
  
Table 5.1 GTEx heart samples tested with ERSSA 
25 GTEx human heart samples included in the analysis. A portion of the samples were used 
to simulate experiments with 5 and 10 replicates. Samples with a cross indicates inclusion in 
the respective analysis (example, sample SRR598148 is included in all three analyses while 
sample SRR600924 is only used in the N=25 analysis). 
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Sample ID Condition N=25 N=10 N=5 
SRR598044 muscle x x x 
SRR598452 muscle x x x 
SRR600656 muscle x x x 
SRR600981 muscle x x x 
SRR601387 muscle x x x 
SRR601671 muscle x x 
 
SRR601695 muscle x x 
 
SRR601815 muscle x x 
 
SRR602010 muscle x x 
 
SRR603116 muscle x x 
 
SRR603164 muscle x 
  
SRR603236 muscle x 
  
SRR605101 muscle x 
  
SRR606974 muscle x 
  
SRR607067 muscle x 
  
SRR607117 muscle x 
  
SRR608264 muscle x 
  
SRR612215 muscle x 
  
SRR612227 muscle x 
  
SRR612395 muscle x 
  
SRR612539 muscle x 
  
SRR612635 muscle x 
  
SRR612683 muscle x 
  
SRR612695 muscle x 
  
SRR612767 muscle x 
  
Table 5.2 GTEx muscle samples tested with ERSSA 
25 GTEx human muscle samples included in the analysis. A portion of the samples were 
used to simulate experiments with 5 and 10 replicates. Samples with a cross indicates 
inclusion in the respective analysis (example, sample SRR598044 is included in all three 
analysis while sample SRR603164 is only used in the N=25 analysis). 
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Number 
of 
Replicates
a 
N=5, 
Union of 
all DE 
genesb 
N=5, 
Consensu
s DE 
genes 
[%]c 
N=10, 
Union of 
all DE 
genesb 
N=10, 
Consensu
s DE 
genes 
[%]c 
N=25, 
Union of 
all DE 
genesb 
N=25, 
Consensu
s DE 
genes 
[%]c 
n = 2 9102 6.62 10545 7.49 10315 5.69 
n = 3 8789 18.02 10924 13.33 11370 11.29 
n = 4 8108 39.38 10630 23.10 10984 17.52 
n = 5 
  
9751 31.51 10873 21.55 
n = 6 
  
9343 38.06 10234 24.34 
n = 7 
  
8750 46.23 10130 27.90 
n = 8 
  
8119 54.83 9369 34.70 
n = 9 
  
7516 66.14 9002 36.65 
n = 10 
    
9018 39.10 
n = 11 
    
8765 41.19 
n = 12 
    
8573 42.47 
n = 13 
    
8178 46.06 
n = 14 
    
8165 48.57 
n = 15 
    
7855 52.30 
n = 16 
    
7790 53.44 
n = 17 
    
7636 57.36 
n = 18 
    
7499 60.27 
n = 19 
    
7259 62.83 
n = 20 
    
7103 67.18 
n = 21 
    
7000 69.53 
n = 22 
    
6829 73.79 
n = 23 
    
6613 78.92 
n = 24 
    
6440 82.87 
Table 5.3 Effect of the number of replicates on the fidelity of DE gene identification: 
GTEx human muscle and human heart dataset 
Analysis repeated for all three GTEx sample size (N=5, 10 and 25). aA random selection of 
up to 30 unique subsamples were analyzed at each replicate level. bThe number of putative 
DE genes that were found in at least one of the subsample analyses. cThe fraction of those 
genes that were identified in every one of the subsample analyses.   
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Sample ID Condition 
SRX033480 C57BL/6J  
SRX033488 C57BL/6J  
SRX033481 C57BL/6J  
SRX033489 C57BL/6J  
SRX033482 C57BL/6J  
SRX033490 C57BL/6J  
SRX033483 C57BL/6J  
SRX033476 C57BL/6J  
SRX033478 C57BL/6J  
SRX033479 C57BL/6J  
SRX033472 DBA/2J  
SRX033473 DBA/2J  
SRX033474 DBA/2J  
SRX033475 DBA/2J  
SRX033491 DBA/2J  
SRX033484 DBA/2J  
SRX033492 DBA/2J  
SRX033485 DBA/2J  
SRX033493 DBA/2J  
SRX033486 DBA/2J  
SRX033494 DBA/2J 
Table 5.4 Bottomly dataset 
The Bottomly dataset contains 10 brain tissue samples from C57BL/6J mouse strain and 11 
brain tissue samples from DBA/2J strain. All samples are used in ERSSA. 
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Number of 
Replicatesa 
Union of all 
DE genesb 
Consensus DE 
genes [%]c 
n = 2 1099 1.27 
n = 3 1046 4.30 
n = 4 771 9.21 
n = 5 720 11.94 
n = 6 677 14.33 
n = 7 512 22.46 
n = 8 434 29.95 
n = 9 373 41.55 
Table 5.5 Effect of the number of replicates on the fidelity of DE gene identification: 
Bottomly dataset 
aA random selection of up to 30 unique subsamples were analyzed at each replicate level. 
bThe number of putative DE genes that were found in at least one of the subsample analyses. 
cThe fraction of those genes that were identified in every one of the subsample analyses.   
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Sample ID Condition Sample ID Condition 
NA06985 European NA18486 Nigerian 
NA06986 European NA18498 Nigerian 
NA06994 European NA18499 Nigerian 
NA07000 European NA18501 Nigerian 
NA07037 European NA18502 Nigerian 
NA07051 European NA18504 Nigerian 
NA07346 European NA18505 Nigerian 
NA07347 European NA18507 Nigerian 
NA07357 European NA18508 Nigerian 
NA10847 European NA18510 Nigerian 
NA10851 European NA18511 Nigerian 
NA11829 European NA18516 Nigerian 
NA11830 European NA18517 Nigerian 
NA11831 European NA18519 Nigerian 
NA11832 European NA18520 Nigerian 
NA11840 European NA18522 Nigerian 
NA11881 European NA18523 Nigerian 
NA11894 European NA18852 Nigerian 
NA11918 European NA18853 Nigerian 
NA11920 European NA18855 Nigerian 
NA11931 European NA18856 Nigerian 
NA11992 European NA18858 Nigerian 
NA11993 European NA18861 Nigerian 
NA11994 European NA18862 Nigerian 
NA11995 European NA18870 Nigerian 
Table 5.6 MP dataset 
25 replicates from each group were randomly selected from the original MP dataset for the 
purpose of ERSSA analysis.  
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Number of 
Replicatesa 
Union of all 
DE genesb 
Consensus DE 
genes [%]c 
n = 2 2085 0.00 
n = 3 2399 0.00 
n = 4 2936 0.07 
n = 5 3265 0.37 
n = 6 2892 0.59 
n = 7 3194 1.53 
n = 8 3122 2.15 
n = 9 3018 3.11 
n = 10 3056 3.73 
n = 11 2972 5.01 
n = 12 2819 5.89 
n = 13 2700 6.93 
n = 14 2477 9.69 
n = 15 2428 11.29 
n = 16 2269 13.75 
n = 17 2202 16.53 
n = 18 2073 18.86 
n = 19 1985 21.16 
n = 20 1835 24.58 
n = 21 1707 31.52 
n = 22 1608 36.88 
n = 23 1471 42.42 
n = 24 1364 52.93 
Table 5.7 Effect of the number of replicates on the fidelity of DE gene identification: 
MP dataset 
aA random selection of up to 50 unique subsamples were analyzed at each replicate level. 
bThe number of putative DE genes that were found in at least one of the subsample analyses. 
cThe fraction of those genes that were identified in every one of the subsample analyses. 
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Sample ID Condition 
SRR1655002 Control_siRNA  
SRR1655003 Control_siRNA 
SRR1655004 Control_siRNA 
SRR1655005 Control_siRNA 
SRR1655006 Control_siRNA 
SRR1655007 EHF_siRNA  
SRR1655008 EHF_siRNA 
SRR1655009 EHF_siRNA 
SRR1655010 EHF_siRNA 
SRR1655011 EHF_siRNA 
Table 5.8 Fossum dataset 
The Fossum dataset contains 5 replicates each of cell lines exposed to either control or EHF 
knockdown siRNA. 
 
 
 
Number of 
Replicatesa 
Union of all 
DE genesb 
Consensus DE 
genes [%]c 
n = 2 2312 0.35 
n = 3 1290 4.57 
n = 4 837 17.56 
Table 5.9 Effect of the number of replicates on the fidelity of DE gene identification: 
Fossum dataset 
aA random selection of up to 30 unique subsamples were analyzed at each replicate level. 
bThe number of putative DE genes that were found in at least one of the subsample analyses. 
cThe fraction of those genes that were identified in every one of the subsample analyses. 
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Chapter 6. Reinforcing Polylactide (PLA) with Tungsten 
Disulfide (WS2) nanotubes to enable thinner, radio-opaque 
bioresorbable vascular scaffolds 
6.1 Introduction 
The treatment of coronary heart disease (CHD), one of the leading causes of death in the 
world1,2, has seen significant breakthroughs due to improvements in percutaneous 
cardiovascular intervention. Drug-eluting metal stents (DES), the current standard of care for 
CHD, restore blood flow through the occluded artery by physically supporting the artery at 
the site of the lesion. Despite their success, DES are made from materials (e.g. Co-Cr alloys3) 
that are not biodegradable and consequently, lead to undesirable side effects. Patients 
implanted with metal stents (>1M in the US alone in 20084) suffer from angina, due to 
restricted arterial vasomotion, and are at risk of developing late stent thrombosis (LST), the 
most dreaded complication associated with stents5,6. A promising successor to DES is a 
bioresorbable vascular scaffold (BVS), which is made entirely out of a biodegradable 
polymer such as poly L-lactide (PLLA)7,8. Unlike DES, the first clinically-approved BVS 
(CE Mark in 20115 and FDA-approval in 20169) is a transient entity in the body; it supports 
the occluded artery for the requisite 3-6 months but is completely resorbed in 2-3 years10. 
Clinical reports on the five-year follow-up to the first-in-man trials for BVS indicated that 
they restore arterial vasomotion and eliminate the risk of LST11–13. However, subsequent 
clinical trials reported an increase in thrombosis for BVS compared to metal stents within 
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the first year14. Clinicians speculate that the greater thickness of BVSs (~150µm) relative to 
metal stents (~80µm) perturbs the flow of blood which contributes towards the risk of 
thrombosis12. Surgeons also find it challenging to implant a BVS under X-ray guidance as 
polymers are virtually transparent to X-rays. This difficulty in “seeing” the BVS during 
implantation can result in malapposed scaffolds at the site of the lesion, which in turn 
contributes towards thrombosis. Thus, physicians advocate for two main improvements in 
BVS to foster wider adoption and to serve a broader spectrum of patients: (1) reduce the 
thickness of BVS to treat smaller vessels and mitigate the risk of thrombosis, and (2) enhance 
the radio-opacity of BVS to improve visualization with X-rays.  
The key to a thinner ~80µm BVS is to confer radial strength comparable to the clinically-
approved 150µm BVS. PLLA can be made stronger via blending with other polymers15,16 or 
copolymerization17–19, but these methods do not provide any increase in radio-opacity and 
can lead to premature loss of radial strength due to accelerated degradation in the body20. 
Therefore, reinforcing PLLA with inorganic, radio-opaque nanoparticles seems to be a viable 
solution for tackling the dual challenge of a thinner, radio-opaque vascular scaffold. Widely 
used nanoparticles such as carbon nanotubes and graphene nanosheets can increase the 
strength of the polymer matrix21, but they disperse poorly without functionalization22, 
provide no increase in radio-opacity, and are toxic to mammalian cells23. Nanocomposites 
made with Group 3 (Mg, Zn, and Fe) and Group 4 (Ti) elements have been unsuccessful due 
to the lack of sufficient radio-opacity. Group 6 elements (W, Au, and Pt) are promising 
candidates as they provide radio-opacity comparable to an ~80µm-thick Co-Cr stent at a 
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relatively low volume fraction of ~6%. Of these three elements, we select Tungsten Disulfide 
(WS2) nanotubes (WSNTs) as they readily disperse in PLLA without any surface 
modification24 and show promising biocompatibility in vitro25–27. We select WSNTs over 
other WS2 nanoparticles (e.g spheres or fullerene-like) as their high-aspect ratio (70–200 nm 
diameter, 2–3 µm length) will favor preferential orientation along the hoop-direction of the 
BVS during processing, which can enhance radial strength.  
The clinically-approved BVS is made from a predominantly amorphous PLLA preform that 
is processed through a sequence of tube expansion, laser-cutting and crimping. Tube 
expansion subjects the PLLA preform to strains in excess of 400% on the order of seconds. 
This rapid deformation transforms the initially amorphous preform into a highly oriented, 
semicrystalline tube28. The expanded tube is subsequently laser-cut to create an “as-cut” 
scaffold with a lattice network of struts that permits crimping onto a balloon catheter. 
Crimping is performed near the glass transition temperature of PLLA and confers a unique 
morphology that facilitates deployment in the artery29 and provides lasting radial strength for 
months afterword30. Nanoparticles are known to alter morphology development during 
processing, particularly in semicrystalline polymers21,22, motivating the present study on the 
biocompatibility of WSNT-reinforced polylactide (PLA, <2% D-content) and the effects of 
WSNTs on the semicrystalline morphology of PLA under the influence of flow. Guided by 
prior literature showing that 0.1 wt% of WSNTs boost the compressive strength of 
polypropylenefumarate (PPF) by over 50%31, we examine up to 0.1 wt% of WSNTs in PLA. 
We assess the biocompatibility of bare WSNTs and PLA-WSNT films with appropriate 
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controls via microscopy and cytotoxicity assays in cells relevant to the human vasculature. 
In view of the importance of kinetically-controlled morphology in the clinically-approved 
BVS29,30, we study the development of PLA structure in real time under elongational and 
shear flow. In contrast to the scant literature on injection-molded PLA that only probes the 
final state of the material, we perform in situ measurements that reveal aspects of the PLA 
morphology that are only observed for short intervals during flow (e.g. inception of thread-
like precursors that template oriented crystals). The flow-induced crystallization experiments 
described in this report place an emphasis on the shear stress, which correlates with the 
degree of orientation of chain segments in the melt. We complement the in situ measurements 
with ex situ microscopy and X-ray scattering to provide deeper insight on the impact of 
WSNTs on the PLA morphology both during and post flow. 
 
6.2 Materials and Methods 
Preparation of nanoparticles 
Tungsten Disulfide (WS2) nanotubes (WSNTs; 70-200 nm diameter, 2-3 µm length) (Figure 
S1A) were purchased from NanoMaterials, Israel. Before use, the WSNTs were sonicated 
and centrifuged to eliminate agglomerates and small impurities (e.g. broken nanotubes) using 
the following procedure. First, 200 mg of WSNTs was dispersed in 200 mL of isopropyl 
alcohol; the resulting solution was then sonicated in a flask for 2 hours. Second, the sonicated 
solution was poured into falcon tubes (leaving behind the sediment at the bottom of the flask) 
and centrifuged at 1500 rpm for 15 minutes. Third, the supernatant was discarded and falcon 
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tubes containing the residue were immersed in a water bath at 50-60°C for a few days until 
the WSNTs were completely dry and ready to use. Zinc Oxide (ZnO) nanoparticles 
(catalogue #: 544906, Sigma-Aldrich) (Figure S1B) were used as a negative control in 
cytotoxicity experiments. For cell culture, the nanoparticles (WSNTs and ZnO) were 
sterilized by UV light overnight before they were solubilized in media using a combination 
of sonication and vortexing. Residual, non-solubilized aggregates were filtered out using a 
cell strainer with a 40 µm pore size. The nanoparticle-media mixture was then added to cell 
culture wells to reach the desired final treatment concentration. 
Preparation of nanocomposite films 
This study uses polylactide (PLA) with ~2% D-content32,33 and Mw ~ 125 kg/mol (values in 
Figure S2; gel-permeation chromatograms in Figure S3) purchased from NatureWorks, 
USA (Grade 4032D). To limit degradation of PLA at high temperatures (>150°C), PLA 
pellets are first dried under vacuum at 80°C for 1 day and subsequently at 40°C for an 
additional 4 days to reduce moisture. The vacuum-dried polymer is then dissolved in 
chloroform at 60°C for 2 hours. In parallel, a separate solution of WSNTs (0.05 or 0.1wt%) 
in chloroform is sonicated for ~30 mins to break up nanotube agglomerates. The solution of 
WSNTs is then added to the polymer solution and stirred for an additional 1 hour; the 
resulting solution is then cast into glass petri dishes and allowed to dry inside a fume-hood 
for ~2 days; the as-cast films are placed in an oven and dried for ~4 days under vacuum at 
80°C to remove residual solvent. The films are thereafter maintained at 40°C under vacuum.  
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SEM of nanoparticles 
Scanning electron micrographs of WSNTs and ZnO nanoparticles (Figure S1) were acquired 
at Caltech on a ZEISS 1550VP Field Emission SEM with an electron accelerating voltage of 
10kV. The SEM samples were prepared using the following protocol: (1) disperse 7.2 mg of 
nanoparticles (WSNTs or ZnO) in 12 mL of chloroform, (2) sonicate the dispersion for 20 
minutes to break-up agglomerates, and (3) drop-cast the sonicated solution (~0.5 mL) on a 
silicon wafer for imaging.  
Cell culture 
Pooled, Normal, Primary Umbilical Vein Endothelial Cells (HUVECs, ATCC PCS-100-
013) and Normal Human Primary Aortic Smooth Muscle Cells (HASMCs, ATCC PCS-100-
012) were obtained from the American Type Culture Collection (ATCC). HUVECs were 
grown in Vascular Cell Basal Medium with Endothelial Cell Growth Kit-BBE additive 
(ATCC). HASMCs were grown in Vascular Cell Basal Medium with Vascular Smooth 
Muscle Cell Growth Kit additive (ATCC). P5 to P7 HUVECs and P4 to P6 HASMCs were 
used in all cell culture experiments. All cell cultures were grown in a humidified incubator 
at 37˚C with 5% carbon dioxide to control media pH.  
Preparation of PLA, PLA-WSNT and PLA-ZnO disks for cell culture 
Disks were prepared by first cutting out circles (diameter: 22 mm) from solvent-cast PLA, 
PLA-WSNT (0.1 wt%), and PLA-ZnO films and then punching out their center (inner 
diameter: 6 mm) to facilitate transport of media (Figure S4A-B). The disks were then 
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sterilized through stringent washes in a 70% Ethanol, 30% water solution followed by 
thorough air drying. The dried disks were then inserted into 12-well cell culture plates at the 
start of the treatment (Figure S4C). At end of the treatment, the disks were carefully removed 
to facilitate assay reagent diffusion prior to the WST-1 assay and Live/Dead staining. 
WST-1 assay 
The WST-1 cell proliferation reagent (Roche) was first added to the cell culture media at the 
recommended working concentration; the reagent-media solution was subsequently 
incubated for four hours at 37°C. After incubation, 100 µL of the solution was transferred to 
each well of the 96-well plate for plate-reading using a Flexstation 3 microplate reader (440 
nm and 690 nm). The baseline absorption from the background and media was subtracted to 
isolate the contribution of the cells. All test wells were then normalized as a percentage of 
the mean control well value except for the disk overlay study, in which normalization was 
done as a percentage of the mean PLA well value. In the bare nanoparticle concentration 
series and time series experiments, statistical tests were performed between control and 
treated cells. In the disk overlay experiment, statistical tests were performed between cells 
exposed to PLA films and other conditions. A 10x Lysis Buffer (Thermo Scientific Pierce) 
was used as a lethal control (cells were treated for 15 mins prior to the WST-1 assay). For 
the time series experiments, each disk was incubated with 1 mL of the appropriate growth 
media for 24 hours in a humidified incubator maintained at 37°C. Cells were then exposed 
to this pre-conditioned media (growth media that was in contact with the disks) and their 
viability was assessed via WST-1 at three different time points (24, 48, and 72 hours).   
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Live/Dead staining and phase-contrast microscopy 
The LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) was used to simultaneously capture 
the status of both dead and live cells. At start of the assay, cells were washed once with 
Dulbecco's Phosphate-Buffered Saline (DPBS) before incubation for 30 minutes at 37˚C in 
the media-dye mixture. At end of incubation, cells were washed with DPBS and imaged on 
a Zeiss Axiovert 25CFL microscope. The FIJI software package was used to merge 
fluorescent signals into one image with red indicating dead cells and green indicating live 
cells. Phase contrast images were captured on the same microscopy system with bright-field 
illumination (see Figure S5 for phase contrast micrographs of the cells before and after the 
wash). A 10x Lysis Buffer (Thermo Scientific Pierce) was used as the lethal control and was 
added to wells for 15 minutes before Live/Dead staining. 
TEM of cells cultured with WSNT 
Cells were grown in 100 mm cell culture plates to near 50% confluency before treatment 
with 20 µg/mL of WSNTs . After 24 hours of treatment, the cells were washed with 
Cacodylate buffer and fixed with a 3% glutaraldehyde and 1% paraformaldehyde fixative 
solution. The cells were then gently scraped off and post-fixed with 2% Osmium Tetroxide, 
0.7% Potassium ferrocyanide in Cacodylate buffer. After post-fix, the cells were washed with 
additional Cacodylate buffer and distilled water before en bloc staining with 1% aqueous 
uranyl acetate. Finally, the cells were dehydrated with an acetone gradient series, infiltrated 
into an Epon-Araldite resin and transferred to embedding molds for polymerization. Semi-
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thick 400 nm sections of the samples were cut with a UC6 Ultramicrotome (Leica 
Microsystems) using a diamond knife (Diatome, Ltd.). The sections were placed on formvar-
coated, copper-rhodium 2 mm slot grids and stained with 3% uranyl acetate and lead citrate.  
The grids were placed in a dual-axis tomography holder (Model 2040, EA Fischione Inc.) 
and imaged with a Tecnai TF30ST transmission electron microscope (ThermoFisher 
Scientific) at 300 keV.  Images were recorded digitally with a US1000 CCD camera (Gatan, 
Inc.). Tomographic tilt-series data were acquired as described in the literature34. Briefly, the 
grids were tilted ±64° and images were acquired in 1° increments. The grid was then rotated 
90° and a similar series was taken about the orthogonal axis. Tomographic data and 
projection images were processed and analyzed using the IMOD software35,36 package on a 
MacPro Computer (Apple, Inc).  
Statistical analysis 
All biocompatibility statistical tests were performed in GraphPad Prism 7.00. The variation 
in cellular viability between different conditions was tested using two-way ANOVA for 
WST-1 assays (statistical significance threshold set at p-value < 0.05). In the nanoparticle 
concentration and time series studies, statistical tests were performed against untreated cells. 
In the disk overlay study, statistical tests were performed against cells exposed to PLA. 
Preparation of PLA and PLA-WSNT ingots 
Vacuum dried PLA pellets and PLA-WSNT films were compression-molded into an ~8 g 
cylindrical “ingot”, which is the starting material for the flow-induced crystallization 
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experiments described below. Heat and pressure are applied to the mold using a Carver hot-
press. The two platens of the hot-press are maintained at 200°C and the temperature of the 
mold is continuously recorded used a thermocouple. The mold is also connected to vacuum 
line (< 300 mTorr) to remove any moisture that can induce degradation of PLA near the melt. 
The mold is heated up to 180°C and held at that temperature for 10 mins under a pressure of 
~2 tonnes. The mold is then removed from the hot-press and rapidly quenched to ~60°C in 
dry ice. The ingot is subsequently extracted from the mold and stored under vacuum at 40°C.  
In situ flow induced crystallization (FIC) 
A custom-built apparatus37 was used to probe the impact of WSNTs on the microstructure of 
PLA during flow. PLA and PLA-WSNT ingots are first placed in the instrument’s reservoir, 
which is maintained at 200°C, above the melting temperature of PLA (Tm ~ 170°C). A 
narrow rectangular capillary termed the “shear cell” (6.35 cm x 6.35 mm x 500 µm) is located 
downstream of the reservoir; the shear cell is filled with material using a pressure-driven 
piston at the lowest possible wall shear stress to avoid pre-orientation of material. A pressure 
transducer located near the inlet of the shear cell enables calculation of the wall shear stress 
(σw; see equation S1). The shear cell is then maintained at 200°C for an additional 5 minutes 
to erase thermal history. The shear cell is cooled to the prescribed shear temperature (Ts: 125 
– 140°C) at ~8.5°C/min and a shear pulse (ts: 10–40 s; σw: 0.11–0.23 MPa) is applied using 
the pressurized piston. A pair of quartz windows at the outlet of the shear cell permit a path 
for plane polarized light (652 nm He-Ne laser) to interact with the material both during and 
post flow. A pair of detectors continuously record the transmitted intensity, which is used to 
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calculate the “retardance”, an optical property analogous to birefringence that provides a 
measure of oriented crystallization.  
Gel permeation chromatography (GPC) 
The molecular weight (Mw) of PLA and PLA-WSNT was measured using a Wyatt DAWN 
EOS Multi-Angle Light Scattering System (MALLS, λ = 690 nm) in conjunction with a 
Waters 410 differential refractometer (λ = 930 nm). The system uses degassed 
tetrahydrofuran (THF) as the mobile phase at a temperature and flow rate of 35°C and 0.9 
mL/min respectively. The samples are first dissolved in THF at a concentration of 5 mg/mL 
and the resulting solution is filtered through a 0.45 µm pore poly(tetrafluoroethylene) (PTFE) 
membrane. The filtered solution is injected into the system and separation is achieved 
(longest molecules elute first) using four Agilent PLgel columns (pore sizes: 103, 104, 105, 
and 106 Å) connected in series. Elution is complete in 50 minutes and data (light scattering 
and refractive index) are acquired at a resolution of 5 Hz. Data analysis is performed in the 
Wyatt Astra software (version 5.3.4) using the Zimm fitting formula with dn/dc = 0.042 ml/g 
for poly L-lactide. Cognizant that thermal degradation of PLA can alter our interpretation of 
the retardance data, we checked the Mw of the starting resin, the compression-molded ingots 
and the extruded material at the end of each flow-induced crystallization experiment. We 
found that our samples have good thermal stability during compression-molding and for the 
duration of the shear experiments (~4 hours) as little to no change in Mw was observed 
(Figure S2–S3). 
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Sectioning and Microscopy 
Sheared PLA and PLA-WSNT samples are first embedded in OCT (optimal cutting 
temperature) media to facilitate sectioning. The embedded samples are microtomed using 
Sakura Finentek’s Tissue Tek-Cryo3 into ~50 µm thick sections both normal to the flow-
direction (∇xv–∇v) and the vorticity-direction (v–∇v). The samples are sectioned at -35°C to 
minimize the impact of the stainless-steel knife (Sakura Accu-Edge 4685 blades) on the 
morphology of the samples. The microtomed sections are subsequently imaged at 4x through 
crossed-linear polarizers in a Zeiss Universal Microscope equipped with a Canon EOS DS30 
camera.  
X-ray scattering 
The morphology of PLA and PLA-WSNT samples subjected to shear flow was probed using 
X-rays at beamline 5-ID-D of the Advanced Photon Source (APS), Argonne National Labs. 
The incident X-ray beam with spot-size 250 µm x 250 µm was aligned parallel to the gradient 
(∇ v), flow (v) and vorticity-direction (∇ xv) to obtain a 3D-view of the morphology in each 
sample. Wide Angle X-ray Scattering (WAXS) patterns were acquired on a Rayonix CCD 
detector that was located 200.83 mm from the sample. Diffraction patterns were acquired 
with an exposure time of 0.5s using X-rays of wavelength 0.7293Å. Drift in the background 
scatter was monitored by periodically acquiring “air” scattering patterns (no sample in the 
path of the beam) at 0.5s exposure as well. The air frames were averaged to obtain a single 
background image that was subtracted from the sample images to isolate the scattering from 
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PLA/PLA-WSNT alone. The subtracted patterns were then normalized by the total number 
of counts to account for variations in thickness. 
 
6.3 Results 
In vitro biocompatibility assays were performed on bare WSNTs and PLA-WSNT 
nanocomposites with appropriate controls in two cell lines – Human Umbilical Vein 
Endothelial Cells (HUVECs) and Human Aortic Smooth Muscle Cells (HASMCs), which 
represent the major cell types that are likely to surround the deployed scaffold in the artery38. 
We performed a series of cell culture experiments to assess the biocompatibility of WSNTs 
and the PLA-WSNT nanocomposites.  To evaluate cell tolerance of bare WSNT, we used 
four methods: phase contrast microscopy39, Live/Dead staining40, WST-1 (water soluble 
tetrazolium with iodo, nitro and disulfo functional groups)27 assay, and transmission electron 
microscopy (TEM)26. The cytotoxicity of PLA-WSNT nanocomposite films in direct contact 
with HUVECs and HASMCs for 24 hours was assessed using phase contrast microscopy, 
Live/Dead staining and WST-1 assays. As an additional test, media that had been incubated 
with PLA-WSNT nanocomposites for 24 hrs was applied to cells and their metabolic activity 
was monitored at 24, 48, and 72 hrs.  Based on the encouraging results of these 
biocompatibility assays, we examined the effect of WSNT on morphology development of 
PLA during processing using short term shear experiments37,41. 
HUVEC and HASMC tolerate bare WSNT in vitro 
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Consistent with the prior literature on the biocompatibility of WSNTs with rat salivary 
cells26, human bronchial epithelial cells27, human hepatocytes27 and mouse macrophages27, 
phase contrast microscopy of HUVECs and HASMCs indicates that both cell lines retain 
their morphology when exposed to concentrations ranging from 5 to 100 µg/mL of WSNTs 
(see Figure 1A for a schematic of the experiment, 1B-C for microscopy images of 20 µg/mL 
and Figure S6A and S7A for other concentrations). Micrographs of cells subjected to 
Live/Dead staining confirm that cells which retain their expected morphology are indeed 
alive (Figure S8). In negative controls that received ZnO nanoparticle treatment, which is 
known to be cytotoxic42,43, both cell lines experience cell death at concentrations above 20 
µg/mL of ZnO nanoparticles, (Figure 1B-C and Figure S6B and S7B). Wells containing 20 
µg/mL of ZnO were dominated by detached and possibly apoptosed cells (black arrows, 
Figure 1B-C); it was difficult to find any cells with normal morphology in wells exposed to 
50 and 100 µg/mL of ZnO (Figure 1B-C bottom; and Figure S6B and S7B). 
WST-1 assays of the average metabolic activity performed after a 24-hour treatment with 
bare WSNTs show that WSNT treated cells, both HUVECs and HASMCs, retain at least 
70% of their metabolic activity relative to media controls (WS2, Figure 1D-E). As there is 
no evidence of cell death at 100 µg/mL of WSNTs (Figure S6A and S7A), it appears that 
WSNTs may be influencing the measured metabolic activity by reducing the metabolic 
and/or cell proliferation rates. In agreement with the micrographs (ZnO, Figure 1B-C, 
bottom; and Figure S6B and S7B), WST-1 measurements show a sharp drop in metabolic 
activity for ZnO at 20µg/mL, and negligible activity remains for cells exposed to 50 and 100 
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µg/mL ZnO (Figure 1D-E). The results were confirmed by replicate experiments at 20 
µg/mL for three time points (24, 48, and 72 hrs) that compared the vehicle control with 
WSNT and ZnO (Figure S9). 
HUVEC and HASMC tolerate direct contact with PLA-WSNT nanocomposites in vitro 
Phase contrast micrographs of cells in contact with PLA-WSNT (0.1 wt%) films for 24 hours 
show that both HUVECs and HASMCs have similar cell morphology and cell density as 
their respective media controls underneath the disk (Figure 2B-C, left). Surprisingly, all 
three polymeric samples tested—including the PLA-ZnO negative control—had cell density 
underneath and next to the nanocomposite similar to that of the control untreated cells 
(Figure S10). Since a cytotoxic material would induce cell death at the cell-material 
interface, constant cell density at the PLA disk interface suggests that the PLA matrix can 
sequester even a toxic nanoparticle under these testing conditions.  
Dead (red) and live (green) channel composite micrographs (right side of each pair of images 
in Fig 2B, C) indicate that all disk treatment conditions have comparable cell viability to the 
vehicle controls. Cell density appears to be consistent between conditions with only a few 
dead (red) cells detected. A separate set of samples placed in contact with a PLA or 
nanocomposite disk overlay was used for WST-1 assays of cell metabolic activity. In both 
HUVEC and HASMC samples, no detectable difference in metabolic activity was found 
between PLA compared to PLA-WSNT and PLA-ZnO (Figure 2D-E). A minor but 
statistically significant drop in metabolic activity was detected in HASMC between the 
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control and PLA. Additionally, these results were confirmed by experiments in which the 
medium was incubated with PLA nanocomposites for 24 hrs and then applied to cells in 
culture, which were analyzed at three incubation time points (24, 48 and 72 hrs; Fig S9). 
TEM of cells exposed to bare WSNT suggest endocytosis and association with cytosolic 
vesicles   
Transmission electron micrographs (TEM) of HUVECs and HASMCs treated with bare 
WSNTs show black features that are aggregates of WSNTs, intracellular gray regions where 
the protein or nucleic acid concentration is typical of cytoplasm or nuclear contents, 
intracellular pale gray to white regions containing vesicles, and pale gray outside the cells 
where there is embedding resin (Figure 3A-B). Of the 91 WSNT aggregates in HUVEC cells 
and 65 WSNT aggregates in HASMC cells identified in the TEM images, none were 
observed in the nucleus. The majority of intracellular WSNTs – ~84% (76/91) of the 
aggregates in HUVECs and ~85% (55/65) of the aggregates in HASMCs – are visibly 
associated with vesicles. In many of the TEM micrographs, the WSNT aggregates appear to 
be incompletely surrounded by vesicles (Figure 3A-IV). We attribute this observation to the 
inherent 3D pleomorphic structure of cellular compartments and the inability of TEM to 
accurately discern the borders of the vesicles in the 2D projection images. To confirm that 
WSNTs are indeed surrounded entirely by vesicles, tomographic reconstructions were 
prepared at selected nanoparticle locations to visualize the sample in 3D. Although 
tomography was limited to a smaller number of WSNT aggregates, the 3D images provided 
a confident delineation of the vesicle border relative to the nanoparticles within it. In these 
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reconstructions, the nanoparticle aggregates appear to be fully enclosed by the associated 
vesicles in both HUVECs and HASMCs (Movie S1 and S2).  
Probing the impact on WSNTs on the microstructure of PLLA during flow 
We probe changes in microstructure during and after flow with millisecond time resolution 
by measuring the optical retardance. The average retardance is measured using the variations 
of light intensity transmitted through crossed and parallel polarizers, with the polarizer and 
analyzer oriented at ±45° relative to the flow direction and with the laser pointed along the 
velocity gradient direction37. The average retardance is related to the integral of the 
birefringence over the thickness of the channel44,45. Here, there are three contributions to the 
birefringence: the melt flow birefringence, the birefringence due to formation of oriented 
PLA crystals, and the birefringence due to oriented nanotubes. 
First, consider the retardance during a 10s shear pulse of σw = 0.19 MPa as a function of 
shear temperature (Ts). The application of a flow field distorts the initially isotropic melt, 
which manifests as an increase in retardance (δ) for the duration of the shear pulse (inset of 
Figure 4A). For a fixed wall shear stress, decreasing Ts mildly increases the retardance 
during flow. In the absence of nanoparticles (Figure 4A, left), this increase is indicative of 
the increase in the melt normal stresses relative to the (fixed) shear stress.  For PLA-WSNT, 
the retardance during the shear pulse accords with the PLA melt retardance (Fig 4A, compare 
center to right insets), indicating that the contribution of the nanotubes is minimal. A new 
feature appears when the WSNT concentration is increased to 0.1wt%: near the end of the 
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shear pulse, the retardance rises steeply for Ts = 133, 130, and 127°C. Furthermore, the 
behavior after cessation of flow (t = 10s, Figure 4A, right) is incomplete and the surviving 
retardance after cessation of shear increases when Ts is lower than 135°C. This occurs 
despite the fact that the wall shear rate and the total shear strain decrease as Ts decreases 
(Figure S12, left). 
Next, consider the retardance after cessation of flow as a function of shear temperature (Ts) 
for matched growth conditions. After the melt relaxes (abrupt decrease in retardance upon 
cessation of shear), any subsequent increase in retardance is indicative of oriented 
crystallization templated by oriented precursors and/or oriented nanotubes. In every 
experiment, the retardance due to crystallization goes over orders (orders are marked by gray 
horizontal dashed lines, labelled in Figure 4C, left). Open circles mark the time each order 
of retardance is reached; the last full order observed is the last data point shown (limited by 
loss of transmitted intensity due to crystallization). In PLA alone, the increase in retardance 
due to oriented crystallization reaches the first order for Ts ≤ 137°C, indicating oriented 
precursors were created within 10s during flow (there are no nanotubes). Even though the 
behavior during the shear pulse is similar for PLA and PLA-WSNT (insets Figure 4A), the 
subsequent increase in retardance due to crystallization is significantly affected by WSNT: 
the increase in retardance after flow begins earlier and reaches higher values for the 
nanocomposites than for neat PLA, suggesting that WSNTs promote oriented crystallization 
in PLA (see t > 10s, Figure 4A). The effect of shear temperature shows that deeper 
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subcooling during the shear pulse results in stronger oriented growth (the rise in retardance 
begins earlier and the retardance reaches higher values). 
To examine the effect of shearing time (ts: 10–40s, Figure 4B) and shear stress (σw: 0.11–
0.23 MPa, Figure 4C), we chose a fixed shearing temperature (Ts = 130°C) that gives a 
significant retardance after cessation of flow and low enough viscosity to permit flow for 40s 
even at the highest wall shear stress (σw = 0.23 MPa). Increasing the shearing time (ts) 
increases the strength of oriented crystallization (Figure 4B).  This increase interacts with 
nanotubes: during sustained flow the shear pulse induces an “upturn” (labeled in Figure 4B, 
mid) in the retardance at t ≥ 30s, which increases significantly with the addition of WSNTs.  
Further, the upturn during shear correlates with significant features after cessation of flow: 
the retardance does not relax completely and the residual retardance is roughly proportional 
to the height of the upturn (see Figure 4B and Figure 5, left). In the literature, an upturn in 
the retardance is associated with a population of shish that survives melt relaxation and 
promotes growth of kebabs45–48, as evidenced by an earlier and strong increase in retardance 
after cessation of flow (Figure 4B). For PLA without nanotubes, increasing ts from 10s to 
40s shortens the time to reach the first order in retardance (δ = π) by 50s and increases the 
growth rate of retardance. With the addition of nanotubes, the effect of ts lessens: increasing 
ts from 10s to 40s reduces the time to reach first order only by ~20s for PLA-WSNT 0.05 
wt% and <10s for PLA-WSNT 0.1 wt%. Intriguingly, the transient retardance after flow 
becomes insensitive to ts at the highest WSNT concentration (0.1 wt%): the time required to 
observe the first four orders of retardance (δ = π, 2π, 3π and 4π) is nearly independent of ts 
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(Figure 4B, right). The effect of the wall shear stress (σw) reveals that WSNTs decrease the 
critical stress required for nucleation of oriented precursors; the stress required to induce an 
upturn decreases from σw ≥ 0.17 MPa for PLA to σw ≥ 0.13 MPa for PLA-WSNT 0.1wt% 
(Figure 4C). The interaction of shear stress with nanotubes in producing oriented precursors 
is also evident in the magnitude of the upturn. For example, at σw = 0.19MPa, the height of 
the upturn increases 5-fold with addition of 0.1wt% WSNT (Figure 5A, right)  
PLA and PLA-WSNT samples were extracted from the instrument and microtomed at -35°C 
both normal to the flow (sections in the vorticity–velocity gradient plane, denoted by ∇xv–
∇v) and normal to the vorticity (sections in the flow–velocity gradient plane, denoted by v–
∇v) for ex situ polarized light microscopy; therefore, pairs of images are shown for each 
composition and shearing time that are reminiscent of the classic skin–core morphology 
observed in injection molding of semicrystalline polymers49. The PLA sections are 
crystalline near the walls and predominantly amorphous towards the core (Figure 6A). The 
lack of significant crystallization in the core indicates the absence of quiescent nucleation 
events prior to removal of the shear cell from the heater block (at 1000s for all samples); the 
material in the shear cell then cools into glass within the next 300s. In contrast, the PLA-
WSNT sections have a completely crystalline, spherulitic core, indicating that WSNTs act 
as heterogenous nucleation sites even in the absence of flow (Figure 6B–C). Consistent with 
the in situ retardance data (Figure 4B), we observe an increase in the retardation of the fully 
solidified samples with increasing ts (see color scale
50 and corresponding retardation below 
Figure 6). Intriguingly, the increase in retardation with ts is more apparent in the plane 
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normal to the flow direction (∇xv–∇v, Figure 6A-C, left) than in the plane containing the 
flow direction (v–∇v, Figure 6A-C, right). For example, in PLA-WSNT 0.05 wt%, 
increasing ts results in a thicker birefringent skin that is readily evident in the ∇xv–∇v plane 
(orange-red Michel Levy color, Figure 6B, left), but there is little to no indication of an 
oriented skin in the v–∇v plane (Figure 6B, right). PLA-WSNT 0.1 wt% is the only 
exception to this trend; in addition to an oriented skin in the ∇xv–∇v plane (Figure 6C, left), 
a weak but distinct skin in the v–∇v plane is observed as well (for ts: 30–40s, Figure 6C, 
right). 
 
6.4 Discussion 
WSNT and PLA-WSNT nanocomposite biocompatibility 
WS2 nanoparticles possess beneficial physical and mechanical properties
51 and have recently 
been studied for various biomedical applications such as friction-reducing agents in nickel-
titanium alloys52 and for reinforcing orthopedic implants31. The first step in the use of these 
nanomaterials for any medical application is to assess their biocompatibility in relevant cells. 
In a study that explored the use of WSNTs to reinforce salivary gland scaffolds, the 
nanotubes were introduced to rat submandibular gland-derived A5 cells and found to have 
no effect on the rate of cell proliferation for concentrations up to 35.2 µg/mL26. Similarly, 
another study investigated WSNT biocompatibility in three different cell types (NL-20 
human bronchial epithelial cells, human liver-derived HepG2 cells and mouse Raw264 
macrophages) and found high cell survival rate with WSNT concentrations of up to 100 
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µg/mL27. In this study, we are interested in interrogating the potential cytotoxicity of WSNTs 
for use in a PLA nanocomposite scaffold that can be inserted into occluded arteries for 
structural support. We found that WSNTs are well tolerated in two relevant human primary 
cell lines, HUVECs and HAMSCs, for concentrations up to 100 µg/mL after 24 hours of 
exposure. Both cell lines show a modest, dose-dependent reduction of metabolic activity 
relative to controls: exposure to 20 µg/mL WSNT (for exposure up to 72 hrs, Figure S9) had 
no measurable effect, but exposure to 50 µg/mL and 100 µg/mL shows a measurable 
decrease of ~11-24% and up to ~32% respectively (Figure 1D-E). We did not observe an 
abnormal number of floating dead cells at the higher concentrations (100 µg/mL of WSNT), 
suggesting that WSNTs have a relatively mild impact on cellular metabolic and proliferation 
rates. Our choice of cytotoxic control (ZnO nanoparticles) was based on prior literature 
showing strong cytotoxicity of ZnO towards human astrocyte-like U87 cells43 and human 
cardiac microvascular endothelial cells42. In the present study on HUVECs and HASMCs, 
we establish a similar dosage-dependent cytotoxicity profile (24 hr, Figure 1D-E; up to 72 
hr, Figure S9). Transmission electron micrographs of cells treated with 20 µg/mL of WSNTs 
indicate that the nanotubes form aggregates that are endocytosed and enclosed within 
cytosolic vesicles (Figure 3); within the limitations of the image contrast and resolution, no 
discernable effect on the nucleus, mitochondria, or endoplasmic reticulum was observed.  
We also tested the biocompatibility of PLA-WSNT (0.1 wt%) nanocomposite films and 
found no indication of cytotoxicity with phase contrast microscopy, live/dead staining, and 
WST-1 metabolic assays. Comparison of the PLA control to PLA-WSNT in HUVECs and 
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HAMSCs after 24 hours of exposure showed: a) consistent cell density in the central open 
area and at the cell-film interface (Figure S10); b) consistent cell density under the film 
(Figure 2); c) indistinguishable, high viability of cells in the area that was underneath the 
film (Figure 2); and d) comparable metabolic levels as measured by WST-1 assays. Relative 
to cells that did not have a film placed on them, HASMCs (but not HUVECs) show a small, 
statistically significant decrease in metabolic activity, independent of WSNT content (Fig 
2E). Likely causes include reduced nutrient transport due to disk-overlay and/or disruption 
of cells due to insertion and removal of disks. Interestingly, the PLA-ZnO (0.1wt%) 
nanocomposite has favorable biocompatibility with little difference from the PLA control 
(Figure 2). This may be due to negligible hydrolysis of PLA during the treatment period (24 
hours), such that the ZnO nanoparticles remain trapped in the PLA matrix and consequently, 
have no detectable impact on cellular metabolic activity.  
In situ oriented crystallization in PLA-WSNT relative to PLA 
The literature on flow-induced crystallization is scarce for PLA, particularly for PLA-
nanocomposites. The majority of studies on the effects of shear on PLA morphology, 
particularly those that observe structure development during shear, impose shear flow using 
a parallel-plate geometry (Linkam CSS-450, shear rate: ?̇? = 1–100s-1)53–57. Prior studies of 
flow-induced crystallization of PLA include some that examine polymers similar to the 
present study (references 53-56 use PLA from same supplier, with similar <2% D-content 
and Mw).  Interestingly, prior works report relatively low densities of oriented structures 
(row-structures ~50µm apart)55–57, even for PLA containing 0.1wt% carbon nanotubes (row-
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structures ~10µm apart)56. In contrast, we observe densely packed oriented structures (<5µm 
apart, Figure 6) despite operating at a much lower shear rate (here ?̇? <1s-1) and shear duration 
(ts: <40s) compared to the studies described above
55–57 (?̇?: 5 to 30s-1; ts: 3 to 10 mins). Only 
at much higher shear rates (10, 25 and 100s-1)53,54 and shear durations (5 to 10 mins)53 are 
tightly packed oriented structures (shish-kebabs < 5 µm apart) reported.  Although the origin 
of this stark difference is unclear, a contributing factor might be a difference in molecular 
weight: the sample handling and experiment conditions in this study preserve the initial 
molecular weight (Figure S2–S3), in contrast to reports of a   >20% decrease in the PLA 
molecular weight53, or severe degradation54. Perhaps retaining high molecular weight species 
enhances formation of oriented precursors during flow. If the stress observed during prior 
experiments was known, it might be feasible to test this possibility; however, the stress was 
not measured in these previous studies53–57.  In addition to the rapid and highly oriented 
crystallization of PLA, we also observe a fascinating anisotropy in the oriented skin 
indicating that the structures are not cylindrulites (i.e., they are not isotropic in the plane 
orthogonal to the flow direction). The PLA-WSNT nanocomposites exaggerate the unusual 
behavior: nanotubes further enhance rapid, highly oriented crystallization and the peculiar 
anisotropy in the oriented skin increases (for increasing WSNT content, compare the bottom 
row in Figure 6, left column). The remainder of the Discussion is devoted to these intriguing 
features evident in our data: (1) why does an increase in WSNT concentration reduce the 
effect of shear time; (2) what is the molecular basis for the unusual morphology observed in 
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the PLA/PLA-WSNT micrographs; and (3) how does oriented crystallization vary through 
the thickness of a sample?  
PLA and PLA-WSNT differ in their response to an increase in the shear duration (ts). For 
PLA, an increase in ts increases the slope of the retardance traces after cessation of flow (PLA 
traces fan out, compare ts: 10–40s, Figure 4B, left, 50-200s). The increase in slope is 
consistent with the expected effect of increasing ts: the activation of point-like nuclei that 
form thread-like precursors continues for the duration of the shear pulse and the initial rate 
of increase of birefringence after cessation of flow is proportional to the total shish length 
per unit volume in the oriented skin45. The addition of WSNTs changes this behavior: the 
retardance profiles for PLA-WSNT at the end of the shear pulse are more or less unaffected 
by ts; the retardance traces are clustered together and have almost identical slopes (see Figure 
4B, mid–right). It appears that an increase in ts has little bearing on the concentration of 
thread-like precursors; this behavior is reminiscent of “saturation” of shish in isotactic 
polypropylene (iPP)46,48. This saturation effect in the retardance traces manifests in the ex 
situ micrographs as well: with increasing ts (Figure 6A, left), the degree of anisotropy in the 
layers near the wall clearly increases in PLA alone, but not for ts >20s in PLA-WSNT 0.05 
wt% (Figure 6B, left) nor for any ts in PLA-WSNT 0.1 wt% (Figure 6C, left). The effect of 
WSNT concentration (cf. PLA-WSNT 0.05 wt% and 0.1 wt% retardance post flow, Figure 
4B, mid–right) suggests that a concentration of 0.1 wt% has enough oriented nanotubes that 
any shear-induced oriented precursors have negligible effect: the curves are not only parallel, 
they are almost indistinguishable for all ts (Figure 4B, right). If WSNTs are dispersed 
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uniformly, a 0.1 wt% loading of oriented WSNTs translates to a spacing of ~3.5 µm (see SI 
for calculation) between adjacent nanotubes, which makes it likely that the nanotubes act as 
preexisting oriented structures in the PLA melt.  
The oriented skin in these samples has a feature we have not found in the shear-induced 
crystallization of any other semicrystalline polymer: a lack of rotational symmetry about the 
flow direction. To our knowledge, none of the copious literature on skin-core morphologies 
reports a deviation from rotational symmetry of the crystallites growing outward from the 
shish. Shear leads to shish that have the chain axis along the flow direction in isotactic 
polypropylene and polyethylene, among others. Lamellae nucleate on the shish and grow 
radially outward. Sections cut in the plane of the gradient and vorticity directions (such that 
the observer is looking down the flow direction, hence the chain axis in the shish) have an 
oriented skin that appears dark when viewed between crossed polars; this is usually 
interpreted to mean that the a- and b- axes are randomly oriented in the plane perpendicular 
to the c-axis46. This morphology is referred to as cylindrulitic. Sections cut in the plane of 
the flow and gradient directions (observer looking along the vorticity axis) have an oriented 
skin that appears bright when viewed between crossed polarizers, due to the pronounced 
difference in polarizability along the c-axis compared with the a- and b-axes of the crystal46.   
Electron microscopy on PLA confirms that formation of shish along the flow direction can 
be induced by shearing the subcooled melt, albeit for relatively long shearing times and high 
shear strain49,53. However, we were unable to find any mention of an unexpected asymmetry 
about the flow direction. In the present specimens, the pairs of images in the plane of the 
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gradient and vorticity (Figure 6A-C, left) and in the plane of the flow and gradient (see 
Figure6A-C, right) violate the expectation that the oriented skin on the left should show no 
retardance (here, a full wave retarder is used, and null retardation would appear first order 
red/purple). Instead, for each material and each shear time, that is the projection that appears 
bright—consistently brighter than its partner image in the plane of the velocity and gradient 
(on the right for each pair of images in Figure 6). We confirmed that the bright skin seen in 
(∇xv–∇v)-plane is due to preferentially-oriented crystallites and not densely packed 
spherulites by rotating the sample and observing that the skin appears bright when oriented 
-45° or 45° relative to the crossed polarizers and dark when it is parallel to them (Figure 
S19A-C, left). X-ray scattering data acquired along all three projections (v–∇xv, ∇xv–∇v, 
and v–∇v) confirm that the orientation distribution of crystallites is not symmetric about the 
flow direction (Figure 7). The observed WAXS patterns are a superposition of the scattering 
from a thin layer of oriented crystallites and a substantially thicker layer of spherulites. In the 
(v–∇xv)-plane, all three samples (PLA, PLA-WSNT 0.05%, and PLA-WSNT 0.1%) indicate 
a population of crystallites with their c-axes aligned along the v-direction (Figure 7A). 
However, when the same sections are probed in the (∇xv–∇v)–plane, we observe crystallites 
with their c-axes aligned along the ∇v-direction (Figure 7B), which may explain the presence 
of a bright skin viewed in this projection (Figure 6A-C, left image of each pair). In the (v–
∇v)-plane, there is little evidence of a preferred direction of orientation (Figure 7C), 
consistent with the absence of a distinct skin in the micrographs (Figure 6A-C, right image 
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of each pair). Thus, the X-ray data corroborate the micrographs and confirm the absence of 
cylindrical symmetry in the sheared samples.  
The observed in situ retardance profiles are depth-averaged measurements as the beam of 
plane polarized light passes through the entire 500 µm thickness (∇v-direction) of the sample. 
Therefore, we take advantage of the linear shear stress profile in the channel and apply a 
“depth-sectioning” approach44 to the series of experiments in which σw is varied with Ts and 
ts held fixed (Figure 4C).  The analysis isolates the transient retardance of the material at 
specific distances from the walls in a sample subjected to σw = 0.21 MPa. The depth-
sectioned traces for all three materials (PLA with 0, 0.05, and 0.1wt% WSNT) share some 
common features: the relaxation in retardance after cessation of flow is most pronounced in 
the layer farthest from the walls (~85 µm, Figure 8A); the retardance begins to increase 
within 5s after cessation of flow at every distance from the walls; the rate of retardance 
increase is greater the closer the material is to the walls (Figure 8A to D, i.e. the higher the 
local stress); and the time at which impingement of neighboring crystals (the inflection point 
in Figure 8) becomes evident is earlier the closer the material is to the wall.  All of these 
features are indicative of greater formation of flow-induced precursors at greater shear stress: 
oriented precursors prevent complete relaxation of retardance after cessation of shear, 
increase the number of oriented lamellae that subsequently nucleate, and decrease the 
distance oriented lamellae grow prior to impingement. At each distance from the wall, adding 
WSNTs causes the retardance to rise sooner and more steeply than it does for PLA alone. 
Quantitatively, oriented crystallization develops as rapidly in the PLA-WSNT 0.1wt% layer 
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farthest from the wall (~85µm, blue line in Figure 8A) as it does in the PLA layer closest to 
the wall (~20µm, black line in Figure 8D). This suggests that 0.1wt% WSNTs make up for 
a substantial stress deficit of ~0.05MPa over a distance of 60µm. The growth velocity is 
expected to be the same in all of these experiments (that of quiescent pure PLA at 135°C), 
so the differences in the initial rate of increase of the retardance reveal differences in the 
number of oriented lamellae that nucleate on shear-induced precursors, and differences in 
the time at which impingement occurs reveal the distance between precursors. If we consider 
the layer closest to the wall, the “roll-off” in the slope indicates that impingement occurs at 
~100s for PLA and ~70s for PLA-WSNT (~60s post flow for PLA and ~30s post flow for 
PLA-WSNT, see arrows in Figure 8D). Based on the time at which impingement becomes 
evident and the quiescent lamellar growth velocity of this grade of PLA (~1.8 µm/min at 
135°C55), we estimate that the separation between shish decreases from ~3.5µm apart in PLA 
to ~2µm apart in PLA-WSNT (both 0.05 and 0.5%). 
 
6.5 Conclusions 
There is an unmet need for a bioresorbable vascular scaffold (BVS) that has thickness 
comparable to metal stents (~80µm) for the treatment of lesions in smaller and tortuous 
arteries. The poor radio-opacity of polymers compared to metals is an added complication as 
surgeons find it challenging to visualize a BVS with X-rays. Towards the goal of a thinner, 
stronger, and radio-opaque BVS, we evaluate Tungsten Disulfide (WS2) nanotubes 
(WSNTs) as a candidate additive to polylactide (PLA) to reinforce PLA and confer radio-
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opacity comparable to clinical standards (e.g., platinum markers). Using cell lines (HUVEC 
and HASMC) that are relevant to vascular tissue, we assess the biocompatibility of bare 
WSNTs and PLA-WSNT nanocomposites (0.1 wt%) against appropriate controls. Cells 
treated with the bare WSNTs (up to 100 µg/mL) and PLA-WSNT films retain their 
morphology and metabolic activity. Transmission electron micrographs of cells exposed to 
20 µg/mL WSNTs indicate that the nanotubes are endocytosed and appear to be trapped in 
cytoplasmic vesicles.  
The promising in vitro biocompatibility of WSNTs motivated us to explore PLA-WSNT 
from a materials science perspective. The clinically-approved BVS derives its radial strength 
from an oriented microstructure that develops under elongational deformation. Therefore, 
we designed short term shear experiments that probe the impact of WSNTs on oriented 
crystallization of PLA. In situ rheo-optical measurements show that inclusion of 0.1wt% 
WSNTs reduced both the critical shear duration and the shear stress required for induction 
of oriented precursors during the short shear pulse. These template oriented crystallization, 
which can increase strength in semicrystalline polymers, relevant to the goal of enabling 
thinner vascular scaffolds. Ex situ polarized light microscopy and X-ray scattering led to a 
surprising discovery: in both PLA alone and PLA-WSNT, the shear-induced oriented 
semicrystalline morphology does not have cylindrical symmetry about the flow direction. 
The results presented in this report suggest that WSNTs may be viable reinforcing additives 
and X-ray contrast agents for biomedical implants. Proposed future biocompatibility studies 
include in vivo testing of the nanocomposite in appropriate animal models. Future in vitro 
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experiments may reveal the degradation kinetics and degradation products of WSNT. The 
flow-induced crystallization results provide an impetus to prepare PLA-WSNT preforms and 
to process them into ~80µm thick tubes to study laser cutting and crimping of PLA-WSNT. 
The connection between microstructure and strength for the PLA-WSNT BVS in the 
expanded, crimped, and deployed state might open a path toward a future generation of 
thinner, stronger, and radio-opaque scaffolds. 
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6.6 Figures and Tables 
 
Figure 6.1 Nanoparticle incubation followed by microscopy and metabolic assay 
(A) Schematic illustrating that cells grown in 6-well plates are treated with varying 
concentrations of WSNT or ZnO nanoparticles for 24 hours before (B-C) phase contrast 
microscopy and (D-E) WST-1 assays. Experiments were performed twice with six replicates 
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per condition. (B) HUVECs and (C) HASMCs incubated with 20 µg/mL WSNT retained 
normal cell morphology while those incubated with 20 µg/mL ZnO underwent cell death 
(black arrows). (D, E) Cells exposed to increasing concentrations of WSNT showed a 
moderate drop in metabolic activity. ZnO induced strong cytotoxicity at concentrations ≥ 
20µg/mL. Mean and standard error of mean plotted. All statistical tests were performed 
against control samples and stars indicate the magnitude of adjusted p-value              (* 
P≤0.05, ** P≤0.01, ***P≤0.001, **** P≤0.0001). 
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Figure 6.2 PLA disk incubation followed by microscopy and metabolic assay 
(A) Schematic of HUVECs and HASMCs treated with polymer disks for 24 hours in 12-well 
plates. (B-C, left) Phase contrast micrographs and (B-C, right) merged live (green) dead (red) 
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stained images of cells underneath the disk show that the treated cells retain their morphology 
and remain viable. (D-E) Cellular metabolic activity levels, inferred from the WST-1 assay, 
show no statistical difference in viability between cells treated with PLA disks and PLA 
nanocomposite (WSNT or ZnO) disks. Experiments were performed twice with four 
replicates per condition. Experiment-specific mean and standard deviation are plotted. All 
statistical tests were performed against the PLA condition; stars indicate the magnitude of 
adjusted p-value (* P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001). 
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Figure 6.3 TEM of cells with endocytosed WSNT 
TEM images of (A) HUVECs and (B) HASMCs exposed to 20 µg/mL WSNT for 24 hours. 
In A-B, (I–II) control HUVECs and HASMCs; (III & V) endocytosed WSNTs in HUVECs 
and HASMCs and (IV & VI) enlarged images of the endocytosed nanotubes in the regions 
bounded by a dashed box in (III & V).  
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Figure 6.4 In situ retardance profiles 
In situ retardance profiles during and after cessation of flow for (left) PLA, (mid) PLA-
WSNT (0.05 wt%) and (right) PLA-WSNT 0.1 wt% subjected to varying (A) shear 
temperature (Ts: 127 to 140°C), (B) shear duration (ts: 10 to 40s), and (C) wall shear stress 
(σw: 0.11 to 0.23 MPa) at matched thermal and flow conditions (Figure S11). In (A), the wall 
shear rate varies from ~0.15s-1 at 125°C to ~0.8s-1 at 140°C; in (B), the wall shear rate is ~ 
0.35s-1 for all cases; and in (C), the wall shear rate varies from ~0.19s-1 at 0.11MPa to ~ 
0.35s-1 at 0.23MPa. The wall shear rate is calculated from the extruded material (Figure 
S12A) and the Rabinowitsch correction (equations S2–S4) is applied to account for non-
Newtonian flow (Figure S12B). The onset of an “upturn” in the retardance during flow is 
indicated by a black arrow in (B, mid). Quantitative characteristics of the upturn for PLA and 
PLA-WSNT are presented in Figure 5. The dashed horizontal gray lines indicate the order 
of retardance (δ), which follows integer multiples of π (e.g. 1st order: δ = π; 2nd order: δ = 2π 
and so on). The retardance is calculated from normalized intensity traces presented in Figure 
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S13–S15. The extruded material from each condition was subject to gel permeation 
chromatography (GPC) measurements that indicated little to no change in molecular weight 
for the experiments in A-C (Figure S2-S3). 
 
 
 
Figure 6.5 Upturn height and residual retardance 
In situ retardance traces of PLA and PLA-WSNT were analyzed to compute (A) the “upturn 
height”, i.e., retardance at the upturn time (defined in Figure 4B inset) and (B) the residual 
retardance after cessation of flow as a function of (left) shear duration (see Figure 4B) and 
(right) wall shear stress (see Figure 4C).  We describe the calculation of the upturn height 
and residual retardance in the SI (Figure S16–17). 
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Figure 6.6 Polarized light micrograph 
Polarized light micrographs of ~50µm thick sections from samples sheared for ts from 10 to 
40s at Ts = 130°C and σw= 0.23MPa for (A) PLA, (B) PLA-WSNT (0.05 wt%) and (C) 
PLA-WSNT (0.1 wt%). For each composition, pairs of images are displayed: the first column 
(A-C, left) presents micrographs of sections cut normal to the flow direction (vorticity – 
velocity gradient plane, labelled as ∇xv–∇v) and the second column (A-C, right) presents 
micrographs of sections cut normal the vorticity direction (flow – velocity gradient plane, 
labelled as v–∇v). Images are acquired through linear crossed polarizers, analyzer (A) and 
polarizer (P) orientations are indicated in (B) 30s, right), with a full-wave retardation plate 
inserted (slow axis vertical, see Figure S18 for details). The Michel-Levy color chart at the 
bottom (adapted from Ref. [50]) relates colors to retardation in nm.  
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Figure 6.7 Wide Angle X-ray Scattering of PLA and PLA-WSNT 
Wide Angle X-ray Scattering (WAXS) data acquired on PLA, PLA-WSNT 0.05wt% and 
PLA-WSNT 0.1wt% samples sheared at Ts = 130°C, ts = 40s and σw = 0.21MPa. For each 
sample, the microstructure was probed along all three projections: (A) flow – vorticity (v–
∇xv), (B) vorticity – velocity gradient (∇xv–∇v) and (C) flow – velocity gradient (v–∇v). The 
WAXS data are presented as (A-C, left) 2D patterns and (A-C, right) azimuthally, I(q), and 
radially averaged, I(φ), intensity plots. Radial averaging for the I(φ) plots is performed near 
the (110)/(200) diffraction: 1.13 ≤ q ≤ 1.23 Å-1. The 1D plots for PLA, PLA-WSNT 0.05wt% 
and PLA-WSNT 0.1wt% (A-C, right) are presented in black, red and blue respectively. The 
WAXS patterns are presented using a custom colormap that varies from 0 [white] to 1.75e-5 
[red] counts. X-ray data acquired at different wall shear stresses (σw = 0.11 and 0.15 MPa) 
for each sample are presented in the SI (see Figure S20 – S22). 
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Figure 6.8 Local Retardance 
In situ retardance data acquired for PLA (black), PLA-WSNT 0.05wt% (red) and PLA-
WSNT 0.1wt% (blue) at varying wall shear stresses (Figure 4C) are “depth-sectioned” to 
isolate the local retardance at (A) 85, (B) 65, (C) 40, and (D) 20 µm from the wall for σw = 
0.21MPa. The arrows in (D) mark inflection points. See equations S9–S10 and Table S1 for 
the depth-sectioning calculations.   
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6.8 Supplementary Information 
 
Figure S1. Scanning electron micrographs (SEM) of (A) Tungsten Disulfide (WS2) 
nanotubes (WSNTs) and (B) Zinc Oxide (ZnO) nanoparticles.  
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Figure S2. Weight-averaged molecular weights (Mw), inferred from the GPC traces in Figure 
S3, are presented for (A) PLA, (B) PLA-WSNT 0.05wt% and (C) PLA-WSNT 0.1wt% that 
were subjected to matched flow conditions under varying (left) shear temperature (Ts), 
(middle) shear duration (ts) and (right) wall shear stress (σw). The Mw of the starting material 
for each experiment, labelled as “ingot”, is presented as a horizontal line in each plot. The 
upper and lower horizontal lines indicate the uncertainty in the Mw of the ingot.  
 
 
Figure S3 Selected gel-permeation chromatography (GPC) traces for extruded (left) PLA, 
(mid) PLA-WSNT (0.05wt%) and (right) PLA-WSNT (0.1 wt%) samples subjected to flow 
under varying (A) shear temperature (Ts), (B) shear duration (ts) and (C) wall shear stress 
(σw). The selected traces encompass the start and the end of the short-term shear experiments 
(~4 hours) and show no sign of degradation when compared with the starting material 
(labelled as “ingot” in each plot). Traces from both the light scattering detector (solid lines) 
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and the refractive index detector (dashed lines) are presented. The molecular weights and 
GPC traces in Figures S2–S3 correspond to the in situ retardance profiles in Figure 4.  
 
 
 
Figure S4. (A) Dimensions of the PLA/nanocomposite disks that are cut from solvent-cast 
films. (B) Photographs of PLA, PLA-WSNT 0.1 wt% and PLA-ZnO 0.1wt% disks. (C) 
Photograph of the disks in (B) submerged in 12-well plates containing media.   
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Figure S5. Phase contrast micrographs of (A) HUVECs and (B) HASMCs in (left) vehicle 
control wells, (mid) wells treated with 20µg/mL WSNT for 24 hours and (right) wells treated 
with 20µg/ml WSNTs that are subsequently washed after 24 hrs to remove non-endocytosed 
nanoparticles. 
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Figure S6. Phase contrast micrographs of HUVECs treated with increasing concentrations 
of (A) WSNTs and (B) ZnO nanoparticles for 24 hours.  
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Figure S7. Phase contrast micrographs of HASMCs treated with increasing concentrations 
of (A) WSNTs and (B) ZnO nanoparticles for 24 hours.  
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Figure S8. Live/Dead staining images of (A) HUVECs and (B) HASMCs after 24 hours of 
treatment (with and without bare nanoparticles). (A-B, left) Phase contrast micrographs and 
(A-B, right) merged dead (red) and live (green) staining images of the treated cells. A 
majority of the cells treated with ZnO underwent detachment and were subsequently 
removed during the assay wash steps. 
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Figure S9. Time course cell viability assay for HUVECs and HASMCs exposed to bare 
nanoparticles and disk-treated media with appropriate controls. (A) Schematic of HUVECs 
and HASMCs grown in 96-well plates before the media is replaced with one that either 
contains nanoparticles or has been conditioned with polymer disks for 24 hours. Separate 
samples were used at 24, 48 and 72 hours after treatment for the WST-1 assay. Experiments 
were performed three times with six replicates per condition. (B) Metabolic activity 
measurements generated by the WST-1 assay. All statistical tests were performed against 
vehicle control samples at each respective time point. Mean and standard error of mean 
plotted. The stars indicate the magnitude of adjusted p-value (* P≤0.05, ** P≤0.01, *** 
P≤0.001, **** P≤0.0001).  
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Figure S10. Phase contrast micrographs of (A) HUVECs and (B) HASMCs exposed to PLA, 
PLA-WSNT 0.1wt% and PLA-ZnO 0.1 wt% disks for 24 hours. The images indicate 
consistent cell density across the edge of the disk in each case.  
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PLA and PLA-WSNT are subjected to matched thermal histories during shear 
experiments  
We probe the influence of WSNTs on the flow-induced crystallization of PLA by 
systematically varying the crystallization temperature (nucleant effects increase with 
increasing temperature above the fastest-crystal growth temperature), shearing time (nuclei 
formed by PLA increase with increasing shear time, but the number of nanoparticles does 
not), and shear stress (which correlates with different degrees of polymer orientation in the 
melt).  We start by erasing thermal history by heating the sample to 200°C.  In every case, 
the sample is subjected to the same thermal profile during cooling (Figure S11, left, time zero 
set to the onset of cooling). When the temperature at the observation point ("Outlet") reaches 
the desired shearing temperature, short term shear is induced by rapidly imposing a high 
pressure at the inlet of the rectangular channel (Figure S11, right, time zero set to 0.02s prior 
to the onset of the pressure rise) and rapidly releasing the inlet pressure to stop shearing when 
the desired shear time (ts) is reached. Note that we vary the temperature during the shear 
pulse, but impose the same growth conditions by selecting the moment at which the shear 
pulse is triggered (Figure S11A, left, gray and black lines show the moment shear is triggered 
for Ts = 140°C and 125°C, respectively, since the moment cooling began; Fig S11A, right, 
shows seven 10s pressure pulses with respect to time from the onset of the shear pulse). For 
the remaining protocols, the shear pulse was triggered at the moment the temperature falls to 
130°C to examine the effects of either shear time (ts, Figure S11B) or wall shear stress (σw, 
proportional to the pressure drop from inlet to exit of the channel shown in Figure S11C) 
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Figure S11. Temperature (left) and pressure traces (right) for short-term shear experiments 
with varying (A) shear temperature (Ts), (B) shear duration (ts), and (C) wall shear stress 
(σw). The temperature of the flow cell is measured near the inlet, at the outlet and midway 
between the inlet and the outlet. The flow-cell is equipped with a pair of quartz windows at 
the outlet to permit acquisition of in situ retardance data. Therefore, the temperature at the 
outlet is used to trigger shear at a prescribed Ts. The inlet is deliberately kept ~20°C warmer 
than the outlet at the time of shear to prevent choking at the inlet. A pressure transducer 
records the pressure imposed at the inlet of the flow-cell and is also used to infer the wall 
shear stress experienced by the sample. In (A), Ts is varied from 140°C (gray lines) to 125°C 
(black lines) using the same shear duration (10s) and wall shear stress (0.19 MPa). In (B) and 
(C), Ts is held constant (130°C, black lines) but the shear duration (ts: 10–40s) and wall shear 
stress (σw: 0.11–0.23 MPa) are varied respectively. In (A-C, left), the temperature is plotted 
with respect to the onset of cooling. In (A-C, right), the pressure traces are plotted with 
respect to the onset of shear at a specific Ts. The thermal and deformation histories presented 
in (A-C) correspond to the in situ retardance data presented in Figure 4A-C and Figure S13–
15.   
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Calculation of the wall shear rate  
In the experiments described in this report, we impose flow at a fixed wall shear stress (σw), 
which is inferred from the pressure drop (∆P), and the width (w: 0.5mm), height (h: 6.35mm) 
and length (l: 63.5mm) of the channel (S1)1. By shearing at a prescribed wall shear stress, we 
allow the material to respond to the imposed flow at a shear rate that reflects its viscosity and 
Mw distribution.  
𝜎𝑤 =  
∆𝑃
𝑙
 (
ℎ
2 (1 + ℎ 𝑤⁄
)                                                              [𝑆1] 
𝑄 =  
𝑚𝑎𝑠𝑠 𝑒𝑥𝑡𝑟𝑢𝑑𝑒𝑑
𝑠ℎ𝑒𝑎𝑟 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 . 𝜌𝑃𝐿𝐴
                                                       [𝑆2] 
𝛾?̇? =  
6𝑄
𝑤. ℎ2
                                                                          [𝑆3] 
Using the volumetric flow rate (Q), which is calculated from the density of PLA (ρ : 1.25 
mg/mm3)2 and the mass of extruded material (S2), we compute an apparent shear rate that is 
applicable to Newtonian flow (S3). In order to account for the non-Newtonian behavior of 
polymer melts, we apply a correction (S4) based on the Weissenberg–Rabinowitsch–Mooney 
equation3. However, this correction requires measurement of the apparent shear rate as a 
function of the wall shear stress. Thus, Figure S12 reports the apparent wall shear rate 𝛾?̇? for 
experiments performed at constant σw (Figure 4A-B) and the true wall shear rate 𝛾?̇? for 
experiments performed with varying σw (Figure 4C).  
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𝛾?̇? =
𝛾?̇?
3
  [2 +  
𝑑(ln 𝛾?̇?)
𝑑 (ln 𝜎𝑤)
]                                                             [𝑆4] 
 
 
Figure S12. (A) The mass extruded from each short-term shear experiment is used to 
compute the corresponding (B) wall shear rate 𝛾?̇?for data acquired at varying (left) shear 
temperature (Ts), (mid) shear duration (ts) and (right) wall shear stress (σw). The apparent 
wall shear rate is presented in (B, left–mid); the true wall shear rate is only presented in (B, 
right) as the correction requires the variation in the mass extruded with respect to the wall 
shear stress.  
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Figure S13. Normalized intensity profiles for (left) PLA, (mid) PLA-WSNT 0.05 wt% and 
(right) PLA-WSNT 0.1 wt% at varying shear temperature (Ts: 125–140°C). The samples 
were extruded for a duration (ts) of 10s at a wall shear stress (σw) of 0.19 MPa.  
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Figure S14. Normalized intensity profiles for (left) PLA, (mid) PLA-WSNT 0.05 wt% and 
(right) PLA-WSNT 0.1 wt% at varying shear duration (ts: 10–40s). The samples were 
extruded at Ts = 130°C at a wall shear stress (σw) of 0.23 MPa.  
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Figure S15. Normalized intensity profiles for (left) PLA, (mid) PLA-WSNT 0.05 wt% and 
(right) PLA-WSNT 0.1 wt% at varying wall shear stress (σw: 0.11–0.23 MPa). The samples 
were extruded at Ts = 130°C for a duration (ts) of 40s.  
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Estimating the average spacing between WSNTs dispersed in the PLA matrix  
Let us consider a 1cm3 volume element of PLA that contains 0.1 wt% of homogenously 
dispersed WSNTs (diameter ~200nm, length ~ 2µm). Based on the density of PLA (1.25 
g/cm3) and WS2 (7.5 g/cm
3), this volume of element is expected to contain 1.3 µg of WS2 
that occupies a volume of ~1.73 x 107 µm3. As a result, 0.1 wt% of WSNTs occupy 0.0017 
volume % in the PLA matrix.  
Based on the volume of an individual nanotube (0.0628 µm3), 1 cm3 of PLA, which contains 
1.73 x 107 µm3 WS2, is expected to contain ~ 2.75 x 10
8 nanotubes. Therefore, the volume 
of polymer surrounding each individual nanotube is ~ 36µm3. Assuming uniform dispersion, 
the average spacing between WSNTs is the cube root of 36µm3 or ~ 3.3 µm.  
Calculating the birefringence associated with WSNTs 
To determine the birefringence associated with 0.1 wt% WSNTs relative to the PLA melt, 
we apply Weiner’s equations4 that were developed for an analogous case of microtubules 
dispersed in a medium. The birefringence (Δn, S5) is defined as the difference between the 
extraordinary (ne) and ordinary (no) refractive indices.  
∆𝑛 =  𝑛𝑒 −  𝑛𝑜                                                                      [𝑆5] 
We compute ne (S6)
4 and no (S7)
4 using refractive indices of WSNTs (n1 = 4)
5 and PLA (n2 
= 1.46)6, and the volume fraction of WSNTs (f = 1.7x10-5 for 0.1wt% WSNTs) in the PLA 
melt.   
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𝑛𝑒 =  𝑛2 √1 +  
(𝑛1
2 −  𝑛2
2)
𝑛2
2 . 𝑓                                                                     [𝑆6] 
𝑛𝑜 =  𝑛2 √
𝑛1
2 +  𝑛2
2 + 𝑓(𝑛1
2 −  𝑛2
2)
𝑛1
2 +  𝑛2
2 − 𝑓(𝑛1
2 −  𝑛2
2)
                                                            [𝑆7] 
From equations S5–S7, we infer that the birefringence associated with 0.1wt% of WSNTs is 
~ 6.17x10-5, which translates to a retardance (δ, S8) of ~0.3 for the optical train used in our 
instrument [sample thickness (d): 500µm and laser wavelength (λ): 632nm]. At 0.05wt% 
WSNTs (0.00085 vol%), the resulting retardance is ~0.15 (for f << 1, the birefringence is 
proportional to f).  
𝛿 =   
2 𝜋 ∆𝑛 𝑑
𝜆
                                                                              [𝑆8] 
 
Depth-sectioning the in situ PLA and PLA-WSNT retardance traces  
The depth-sectioning approach was developed by Fernandez-Ballester et al7 to isolate the 
retardance contributed by individual layers of material through the thickness of isotactic 
polypropylene subjected to a shear flow. We apply the same approach to our experiments 
with PLA and PLA-WSNT. We begin by acquiring in situ retardance data at the highest wall 
shear stress (σw,i), and then collect data at progressively lower wall shear stresses (σw,i+1).  
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𝛥𝛿(𝜎𝑤,𝑖, 𝜎𝑤,𝑖+1)𝑎𝑝𝑝 =  𝛿(𝜎𝑤,𝑖) −  
 𝜎𝑤,𝑖+1
 𝜎𝑤,𝑖
 𝛿(𝜎𝑤,𝑖+1)                               [𝑆9]  
 
𝛥𝛿(𝜎𝑤,𝑖, 𝜎𝑤,𝑖+1)𝑡𝑟𝑢𝑒 =  
𝜎𝑤,𝑖
(𝜎𝑤,𝑖 −  𝜎𝑤,𝑖+1)
 .
1
𝑑
2⁄
 . 𝛥𝛿(𝜎𝑤,𝑖, 𝜎𝑤,𝑖+1)𝑎𝑝𝑝                       [𝑆10] 
 
The depth-sectioning approach relies on the linear variation of shear stress from the walls 
(maximum) to the core (zero) of the sample (the thickness, d, is 500µm along the velocity 
gradient direction). It enables isolation of the residual or depth-sectioned retardance 
contributed by a slice of material that experiences a shear stress varying from (σw,i) to (σw,i+1) 
by subtraction of the retardance profiles acquired at the two different wall shear stresses. 
Prior to subtraction, the data acquired at the lower wall shear stress δ(σw,i+1) is rescaled by 
the ratio of the lower (σw,i+1) to the higher wall shear stress (σw,i+1) (S9). The resulting residual 
retardance is then normalized by the thickness of the layer, which is calculated based on the 
linear shear stress profile (see correction factor before the residual retardance term, Δδ, in 
S10).  
In Figure 7, depth-sectioned retardance profiles are presented for layers located ~20µm, 
40µm, 65µm and 85µm from the wall of the channel. Table S1 below lists the pair of 
retardance profiles from Figure 4C that were used to compute the depth-sectioned profiles in 
Figure 7.    
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Table S1: Pairs of retardance traces acquired at differing wall shear stresses that were used 
to compute the depth-sectioned traces 
Layer Position Residual Retardance 
~20µm Δδ (σ0.21MPa, σ0.17MPa) 
~40µm Δδ (σ0.19MPa, σ0.15MPa) 
~65µm Δδ (σ0.17MPa, σ0.13MPa) 
~85µm Δδ (σ0.15MPa, σ0.11MPa) 
  
Quantifying the upturn and residual retardance  
We present select retardance traces for PLA-WSNT (0.05 wt%) acquired at three different 
wall shear stresses (σw: 0.11, 0.17, and 0.23 MPa) to illustrate how we compute the height of 
the upturn (Figure S16) and the residual retardance (Figure S17). The same method is applied 
to PLA and PLA-WSNT (0.1 wt%) data.  
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Figure S16. Retardance traces acquired at a wall shear stress of (left) 0.11MPa, (mid) 
0.17MPa and (right) 0.23MPa are plotted for 10 ≤ t(s) ≤ 40s to illustrate the increase in the 
upturn as a function of increasing wall shear stress. To quantify the height of the upturn, we 
subtract a baseline (dashed black line) that corresponds to the plateau retardance (taken as 
the average of all values for 10 ≤ t(s) ≤ 15) from the retardance at the end of the shear pulse 
(t = 40s).  
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Figure S17. Retardance traces acquired at a wall shear stress of (left) 0.11MPa, (mid) 
0.17MPa and (right) 0.23MPa are plotted for 10 ≤ t(s) ≤ 50s to illustrate the correspondence 
between the height of the upturn (see Figure S16) and the residual retardance after cessation 
of flow. The black arrows (identified as the minima in retardance traces for 40 ≤ t(s) ≤ 50) 
quantify the increase in the residual retardance as a function of increasing wall shear stress.  
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Figure S18. PLA sections (σw = 0.23MPa, Ts = 130°C and ts = 40s; ∇xv–∇v plane) are rotated 
in the microscope in 45° intervals (left to right) to highlight anisotropy in the core and the 
skin. The same approach is applied to PLA-WSNT sections as well (see Figure S19). (A) 
Photographs of microtomed PLA sections (~50µm thick) in the microscope and (B-C) 
polarized light micrographs of a PLA section in all three orientations (-45°, 0° and 45°) (B) 
without a retardation plate and (C) with a full-wave retardation plate. The orientation of the 
analyzer and polarizer for all images in (B-C) is indicated in (B, left). The orientation of the 
slow axis of the full-wave retardation plate for the images in (C) is indicated in (C, left). The 
Michel-Levy color chart (adapted from Ref. [50] of main text) at the bottom connects the 
observed colors to the retardation in nm.   
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Polarized light microscopy indicates oriented crystallites normal to the flow direction  
 
Figure S19. Polarized light micrographs acquired at three different orientations of the 
~50µm thick sections relative to the polarizer and the analyzer (indicated in the top-right 
corner of each image) from samples sheared for ts = 40s at Ts = 130°C and σw = 0.23MPa 
for (A) PLA, (B) PLA-WSNT 0.05wt% and (C) PLA-WSNT 0.1wt%. Images were acquired 
through linear crossed polarizers with a full-wave retardation plate (see Figure S18 for 
details). Pairs of images show sections cut in the vorticity–velocity gradient plane (∇xv –∇v) 
on the left and flow–velocity gradient plane (v –∇v) on the right). The top row of images are 
the same ts = 40s images in Fig 6A–C; from top to bottom are successive 45° rotations of the 
sample. Note that the slow axis of the waveplate is vertical in the top image, CW 45° in the 
middle image and horizontal in the bottom image. The Michel-Levy color chart (adapted 
from Ref. [50] of main text) at the bottom connects the observed colors to the retardation in 
nm.  
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Wide Angle X-ray scattering reveals orientation of crystallites in PLA  
 
Figure S20. Wide angle X-ray scattering (WAXS) data were acquired on PLA sections 
subjected to varying wall shear stress (σw = 0.11, 0.15 and 0.21MPa at Ts = 130°C and ts = 
40s) along the (A) flow – vorticity plane (v – ∇xv), (B) vorticity – velocity gradient plane 
(∇xv – ∇v) and (C) flow – velocity gradient plane (v – ∇v). WAXS data are presented as (A-
C, left) 2D patterns and (A-C, right) azimuthally [I(q)] and radially averaged [I(φ)] plots. 
Radial averaging for the I(φ) plots is performed in the vicinity of the (110)/(200) diffraction: 
1.13 ≤ q ≤ 1.23 Å-1. The WAXS patterns are presented using a custom colormap with a scale 
that varies from 0 [white] to 1.75e-5 [red] counts. The crystallinity observed for PLA in the 
flow – gradient plane (part C) is higher than usual as the samples have been subjected to a 
thermal ramp (heat from 30°C to 180°C at 10°C/min and immediately cool back to 30°C at 
10°C/min) prior to data acquisition. Transient X-ray patterns acquired during the ramp 
indicate that the material gains crystallinity and preserves the orientation distribution of 
crystallites.  
  
410 
 
Wide Angle X-ray scattering reveals orientation of crystallites in PLA-WSNT 0.05wt% 
 
Figure S21. Wide angle X-ray scattering (WAXS) data were acquired on PLA-WSNT 
0.05wt% sections subjected to varying wall shear stress (σw = 0.11, 0.15 and 0.21MPa at Ts 
= 130°C and ts = 40s) along the (A) flow – vorticity plane (v – ∇xv), (B) vorticity – velocity 
gradient plane (∇xv – ∇v) and (C) flow – velocity gradient plane (v – ∇v). WAXS data are 
presented as (A-C, left) 2D patterns and (A-C, right) azimuthally [I(q)] and radially averaged 
[I(φ)] plots. Radial averaging for the I(φ) plots is performed in the vicinity of the (110)/(200) 
diffraction: 1.13 ≤ q ≤ 1.23 Å-1. The WAXS patterns are presented using a custom colormap 
with a scale that varies from 0 [white] to 1.75e-5 [red] counts. 
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Wide Angle X-ray scattering reveals orientation of crystallites in PLA-WSNT 0.1wt% 
 
Figure S22. Wide angle X-ray scattering (WAXS) data were acquired on PLA-WSNT 
0.1wt% sections subjected to varying wall shear stress (σw = 0.11, 0.15 and 0.21MPa at Ts = 
130°C and ts = 40s) along the (A) flow – vorticity plane (v – ∇xv), (B) vorticity – velocity 
gradient plane (∇xv – ∇v), and (C) flow – velocity gradient plane (v – ∇v). WAXS data are 
presented as (A-C, left) 2D patterns and (A-C, right) azimuthally [I(q)] and radially averaged 
[I(φ)] plots. Radial averaging for the I(φ) plots is performed in the vicinity of the (110)/(200) 
diffraction: 1.13 ≤ q ≤ 1.23 Å-1. The WAXS patterns are presented using a custom colormap 
with a scale that varies from 0 [white] to 1.75e-5 [red] counts.  
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Appendix A. Protocol and results from shotgun proteomics 
experiments 
A.1 Introduction 
BONCAT with pSILAC (introduced in Chapter 1.3) was used to probe the proteomic 
expression variation after peptide treatment in vascular endothelial cells. In one experiment, 
the cells were exposed to the integrin-binding RGD peptide (contains Arg-Gly-Asp integrin 
binding motif) and control RGE peptide (binds integrins at a much lower affinity1) to identify 
the proteomic changes after integrin modulation. In a second experiment, cells were treated 
with ALG-1001 therapeutic peptide and vehicle control in an effort to discover the proteomic 
regulation after drug exposure. In both studies, proteins synthesized during the peptide 
incubation period were enriched and analyzed using mass spectrometry to calculate the 
quantitative expression ratio between conditions. The following sections detail our 
experimental protocol as well as some observations from these two studies. This work was 
done in collaboration with Dr. Kai Yuet and Dr. Graham Hamblin, previous members of the 
Tirrell lab (Caltech).  
 
A.2 RGD experiment 
Reagents and methods 
Pooled passage 2 (P2) Human Umbilical Vein Endothelial Cells (HUVECs) from American 
Type Culture Collection (ATCC) were cultured to P5 in a humidified incubator with pH 
controlled by 5% CO2. The cells were grown in Vascular Cell Basal Medium (ATCC) with 
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Endothelial Cell Growth Kit-BBE (ATCC) and Antibiotic Antimycotic Solution (Sigma-
Aldrich) added according to the manufacturer’s instruction. The media was exchanged every 
two days. At P6, HUVECs were seeded at 5,000 cells per cm2 density into eight T75 cell 
culture flasks (Greiner Bio-One) and cultured for three days in Endothelial Growth Medium 
(EGM, Lonza) with EGM Endothelial Cell Growth Medium SingleQuots (Lonza) and 
Antibiotic Antimycotic Solution added according to the manufacturer’s instruction. 
At end of the three day culture, the media were switched to BONCAT with pSILAC media 
(referred to as proteomics media) containing azidohomoalanine (AHA) and labeled amino 
acids. The proteomics media was based on a custom EGM media (Lonza) without 
manufacturer-added L-Arginine, L-Lysine and L-Methionine. The media was supplemented 
with EGM Endothelial Cell Growth Medium SingleQuots and Antibiotic Antimycotic 
Solution comparable to the standard EGM media except Fetal Bovine Serum (FBS) was 
replaced with dialyzed FBS (Thermo Fisher Scientific). L-Methionine (Sigma-Aldrich) was 
added to a final concentration of 33µM while AHA (Iris Biotech GmbH) was added to a final 
concentration of 1mM to achieve a 1:30 ratio (previously reported to be optimal for 
BONCAT experiments2). The media was also supplemented with either medium-labeled or 
heavy-labeled L-Lysine (medium: D4 L-Lysine, heavy: 
13C6
15N2 L-Lysine) and L-Arginine 
(medium: 13C6 L-Arginine, heavy: 
13C6
15N4 L-Arginine) sourced from Cambridge Isotope 
Laboratories. Labeled L-Lysine was added to a final concentration of 1mM while labeled L-
Arginine was added to final concentration of 0.3mM. For four of the eight flasks, media were 
switched to the proteomics media with medium L-Lysine and L-Arginine while the other 
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four were switched to the proteomics media with heavy L-Lysine and L-Arginine. 
Concurrently, RGD peptide (sequence: GRGDTP, CPC Scientific) was added to two flasks 
with proteomics media containing medium-labeled amino acids and two flasks with 
proteomics media containing heavy-labeled amino acids. RGE (sequence: GRGESP, CPC 
Scientific) was added in similar manner to the remaining four flasks with both peptides added 
to a final concentration of 1mM.  
Cells were incubated in the proteomics media for 24 hours and then detached using Typsin-
EDTA solution (ATCC) and pelleted with a table top centrifuge (Beckman Coulter). We 
observed that at the end of the incubation, a fraction of the cells (estimate around 30%) 
exposed to the RGD peptide were detached from the flask and were not collected (detached 
cells likely undergo apoptosis with degraded proteome that may interfere with subsequent 
analysis). Cell lysis was performed with lysis buffer – PBS (Thermo Fisher) with 1% Sodium 
Dodecyl Sulfate (SDS, Sigma Aldrich), 100mM 2-chloroacetamide (Sigma Aldrich) and 1x 
protease inhibitor cocktail (Roche), at 90˚C for 10 minutes in the dark. Cellular debris was 
pelleted by centrifugation and the supernatant solution containing the total protein extract 
was collected for down-stream analysis. Total protein concentration was measured using 
Pierce BCA Protein Assay Kit (Thermo Fisher) followed by dilution of all samples to the 
same protein concentration using additional lysis buffer. 
Next, replicates of RGD were individually paired with RGE samples and mixed in 1:1 ratio. 
In particular, medium-labeled samples were mixed with heavy-labeled samples to enable 
quantification of protein expression ratio in down-stream mass spectrometry analysis. After 
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mixing, 1/5th volume of PBS containing 0.8% SDS and 600mM 2-chloroacetamide (referred 
to as PBS/SDS/2Chl solution) was added to each sample and allowed to incubate for 30 
minutes in the dark at 65˚C on a centrifuge tube shaker (Eppendorf). Meanwhile, 50uL per 
sample of DBCO agarose beads (Click Chemistry Tools) were washed three times with 
10mL of PBS/SDS/2Chl solution. After 30 minutes of incubation on the shaker, the samples 
were then transferred to individual 15mL centrifuge tubes containing the washed DBCO 
agarose beads. Sample volume of PBS containing 8M urea, 0.85M NaCl, and 1x protease 
inhibitor was used to rinse the emptied sample tubes to collect any remaining sample solution 
and was added to the 15mL centrifuge tubes.  
Samples were allowed to incubate with the beads for three hours covered in foil on a rotary 
mixer to facilitate click reaction enrichment of AHA-incorporated proteins. At end of the 
incubation step, 20µL of 100mM AHA was added for an additional 10 minute incubation on 
the rotary mixer. Afterwards, the samples were centrifuged and supernatant removed. Water 
was next added to wash the beads. Beads were then resuspended in 0.5mL of PBS/SDS/2Chl 
solution containing 1mM DTT (Sigma Aldrich) for 15 minute incubation at 70˚C, followed 
by 15 minutes cool down to room temperature. Supernatants were removed through 
centrifugation and beads incubated again with 0.5mL of PBS/SDS/2Chl solution containing 
40mM iodoacetamide (Sigma Aldrich) for 30 minutes in the dark on the tube shaker. 
The beads were next washed with 40mL of PBS/SDS/2Chl solution, 40mL of Tris (pH 8.0, 
Thermo Fisher) containing 8M urea (Sigma Aldrich) and 40mL of 20% acetonitrile in water 
(Sigma Aldrich). Washes were performed with 5mL of wash solution at a time and in the 
417 
 
order described above. After the washes, the beads were suspended in 200uL of 10% 
acetonitrile in 50mM ammonium bicarbonate (ammbic) and transferred to 1.7mL centrifuge 
tubes. Beads were then gently spun down and supernatant removed while keeping 100uL in 
each tube. On-bead digestion of the proteins was then performed by adding 10uL of 10% 
acetonitrile in 50mM ammbic containing 0.1µg of trypsin to each sample. The beads were 
allowed to incubate overnight on the shaker at 37˚C in the dark. 
Following overnight trypsin digestion, the samples were added to filter columns with 
additional 20% acetonitrile in water used to ensure transfer of all samples. The solutions 
containing digested proteins were then collected by centrifugation and dried on a vacuum 
concentrator. Dried peptide pellets were then resuspended in 100uL of 50mM ammbic with 
a combination of vortex and sonication for 15 minutes. Next, HiPPR Detergent Removal 
Spin Column (Thermo Fisher) was used to remove detergent contaminants in the sample by 
following the manufacturer’s instruction. Formic acid was then added to a final concentration 
of 0.2% to acidify the sample before sample concentration using C18 ZipTip (EMD 
Millipore) following the manufacturer’s instruction. The sample was allowed to dry in the 
vacuum concentrator and then resuspended in 10uL of 0.2% formic acid with a combination 
of vortex and sonication. Finally, 5uL of each sample were analyzed using an EASY II nano-
UPLC (Thermo Fisher) connected on-line to an Orbitrap Fusion Tribrid Mass Spectrometer 
(Thermo Fisher) with two hours of run time per sample. All raw files obtained were then 
analyzed together in one MaxQuant search against human proteome obtained from 
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UniProt3,4. MaxQuant was set up to detect AHA and SILAC amino acids as well as with “re-
quantification” and “match between runs” settings turned on.  
Results and discussion 
In this study, around 1200 to 1500 protein groups were identified in each sample. However, 
not all protein groups have a measurable heavy to medium-labeled protein ratio. Overall, 
1092 protein groups were found to have at least one measured protein ratio with 439 groups 
contain ratio in all four samples. The protein groups with at least one protein ratio were 
submitted to Limma for differential expression analysis5. For each protein group, the leading 
protein with the most peptide evidence was chosen for analysis. In the rare cases where two 
or more protein groups have the same leading protein, the one with the most peptide evidence 
was retained. Results of Limma showed around 20% (229/1092) of the protein groups were 
identified to be differentially expressed (DE) with roughly 2/3rd of them up-regulated in the 
RGD-treated samples (Figure A.1).   
Functional analysis of the DE proteins was performed using DAVID with the up- and down-
regulated proteins analyzed separately6. All discovered gene ontology (GO) biological 
processes were visualized using REVIGO, with similarity level set to medium and GO 
annotation size determined using the Uniport Homo Sapiens database4,7. GO biological 
processes with FDR<0.05 were considered to be statistically significant. With both the up- 
and down-regulated protein lists, “cell-cell adhesion” was the only biological process found 
to be strongly enriched (Figure A.2).  
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In context of the natural roles of RGD-containing proteins and their targeted integrins in cell 
adhesion and recognition8, modulation of proteins associated with “cell-cell adhesion” after 
integrin binding is not unexpected. During RGD exposure, binding of the peptide with cell 
surface integrins likely activated a diverse group of downstream pathways that regulated 
adhesion-related protein expression9. Previous microarray studies that probed RGD-induced 
transcriptome regulation found genes in immune response, hematological system 
development, cell migration, development, growth, and death are modulated10–12. In our 
proteomics study, we were unable to validate many of these previous findings, possibly due 
to the differences in throughput of the technologies: microarray is able to measure expression 
changes across tens of thousands of genes, while our proteomics approach quantified only 
around one thousand proteins. Nevertheless, modulation of “cell-cell adhesion” proteins is 
consistent with known mechanism of the RGD peptide. 
 
A.3 ALG-1001 experiment 
Reagents and methods 
The BONCAT with pSILAC experiment with RGD and RGE demonstrated that proteomics 
can be used to identify proteome perturbation during peptide treatment. Next, we applied the 
technique to identify proteomic changes during ALG-1001 exposure. Between the two 
studies, some additional improvements were made to the proteomics sample preparation 
protocol with the updated protocol shown below. 
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Pooled P2 Human Umbilical Vein Endothelial Cells (HUVECs) from American Type 
Culture Collection (ATCC) were cultured to P4 in a humidified incubator with pH controlled 
by 5% CO2. The cells were grown in Vascular Cell Basal Medium (ATCC) with Endothelial 
Cell Growth Kit-BBE (ATCC) and Antibiotic Antimycotic Solution (Sigma-Aldrich) added 
according to the manufacturer’s instruction. The media was exchanged every two days. At 
P5, HUVECs were seeded at 4,000 cells per cm2 density into twelve T75 cell culture flasks 
(Greiner Bio-One) and cultured for two days in Endothelial Growth Medium (EGM, Lonza) 
with EGM Endothelial Cell Growth Medium SingleQuots (Lonza) and Antibiotic 
Antimycotic Solution added according to the manufacturer’s instruction. 
At end of two day culture, the media were switched to BONCAT with pSILAC media 
(referred to as proteomics media) containing AHA and labeled amino acids. The proteomics 
media was based on a custom EGM media (Lonza) without manufacturer-added L-Arginine, 
L-Lysine and L-Methionine. The media was supplemented with EGM Endothelial Cell 
Growth Medium SingleQuots and Antibiotic Antimycotic Solution comparable to the 
standard EGM media except FBS was replaced with dialyzed FBS (Thermo Fisher 
Scientific). L-Methionine (Sigma-Aldrich) was added to a final concentration of 33µM while 
AHA (Iris Biotech GmbH) was added to a final concentration of 1mM to achieve a 1:30 ratio 
(previously reported to be optimal for BONCAT experiments2). The media was also 
supplemented with either medium-labeled or only heavy-labeled L-Lysine (medium: D4 L-
Lysine, heavy: 13C6
15N2 L-Lysine) and L-Arginine (medium: 
13C6 L-Arginine, heavy: 
13C6
15N4 L-Arginine) sourced from Cambridge Isotope Laboratories. Labeled L-Lysine was 
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added to a final concentration of 1mM while labeled L-Arginine was added to a final 
concentration of 0.3mM. For six of the twelve flasks, media were switched to the proteomics 
media with medium L-Lysine and L-Arginine while the other six were switched to the 
proteomics media with heavy L-Lysine and L-Arginine. Concurrently, concentrated ALG-
1001 peptide (CPC Scientific) dissolved in DI water was added to a final concentration of 
100uM in three flasks with proteomics media containing medium-labeled amino acids and 
three flasks with proteomics media containing heavy-labeled amino acids. An equal volume 
of sterilized DI water was added in similar manner to the remaining six flasks to serve as 
vehicle control.  
Cells were incubated in the proteomics media for 48 hours and then detached using Typsin-
EDTA solution (ATCC) and pelleted with a table top centrifuge (Beckman Coulter). Cell 
lysis was performed with lysis buffer – PBS (Thermo Fisher) with 1% Sodium Dodecyl 
Sulfate (Sigma Aldrich), 100mM 2-chloroacetamide (Sigma Aldrich) and 1x protease 
inhibitor cocktail (Roche), at 90˚C for 10 minutes in the dark. Cellular debris was pelleted 
by centrifugation and the supernatant solution containing the total protein extract was 
collected for down-stream analysis. Total protein concentration was measured using Pierce 
BCA Protein Assay Kit (Thermo Fisher) followed by dilution of all samples to the same 
protein concentration using additional lysis buffer. 
Next, replicates of ALG-1001 treated samples were paired with control samples and mixed 
in 1:1 ratio to form six samples. In particular, medium-labeled samples were mixed with 
heavy-labeled samples to enable quantification of protein expression ratio in down-stream 
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mass spectrometry analysis. After mixing, 1/5th volume of PBS containing 0.8% SDS and 
600mM 2-chloroacetamide (subsequently referred to as PBS/SDS/2Chl solution) was added 
to each sample and allowed to incubate for 30 minutes in the dark at 65˚C on a centrifuge 
tube shaker (Eppendorf). Meanwhile, 50uL per sample of DBCO agarose beads (Click 
Chemistry Tools) were washed with 10mL of PBS/SDS/2Chl solution, 10mL of Tris (pH 
8.0, Thermo Fisher) containing 8M urea (Sigma Aldrich), 10mL of 20% acetonitrile in water 
and 20mL of PBS/SDS/2Chl solution. After 30 minutes incubation on the shaker, the samples 
were then transferred to individual 15mL centrifuge tubes containing the washed DBCO 
agarose beads. Sample volume of PBS containing 8M urea, 0.85M NaCl and 1x protease 
inhibitor was used to rinse the emptied sample tubes to collect any remaining sample solution 
and are then added to the 15mL centrifuge tubes. Samples were incubated for three hours 
covered in foil on a rotary mixer to facilitate click reaction enrichment of AHA-incorporated 
proteins. Next, sample volume of PBS containing 8M urea, 0.85M NaCl and 1x protease 
inhibitor was added and the samples were allowed to incubate overnight in foil on the rotary 
mixer. The additional incubation step helps improve the amount of AHA-containing proteins 
recovered. 
At end of incubation, 30µL of 100mM AHA was added for additional 10 minute incubation 
on the rotary mixer. Afterwards, the samples were centrifuged and the supernatant removed. 
Water was next added to wash the beads and removed through centrifugation. Beads were 
then resuspended in 0.5mL of PBS/SDS/2Chl solution containing 1mM DTT (Sigma 
Aldrich) for 15 minute incubation at 70˚C, followed by 15 minutes cool down to room 
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temperature. Supernatants were removed through centrifugation and beads incubated again 
with 0.5mL of PBS/SDS/2Chl solution containing 40mM iodoacetamide (Sigma Aldrich) 
for 30 minutes in the dark on the tube shaker. 
The samples were next washed with 40mL of PBS/SDS/2Chl solution, 40mL of Tris (pH 
8.0, Thermo Fisher) containing 8M urea (Sigma Aldrich) and 40mL of 20% acetonitrile in 
water (Sigma Aldrich). Washes were performed with 5mL of wash solution at a time and in 
the order described above. After the washes, the beads were suspended in 200uL of 10% 
acetonitrile in 50mM ammonium bicarbonate (ammbic) and transferred to 1.7mL centrifuge 
tubes. Beads were then gently spin down and supernatant removed while keeping 150uL in 
each tube. On bead digestion of proteins was then performed by adding 10uL of 10% 
acetonitrile in 50mM ammbic containing 0.2µg of Lys-C protease to each sample. The beads 
were allowed to incubate for two hours on shaker at 37˚C in the dark. Next, 10uL of 10% 
acetonitrile in 50mM ammbic containing 0.2µg of trypsin was added to each sample and the 
samples allowed to incubate overnight on the shaker at 37˚C in the dark. 
After overnight trypsin digestion, the samples were added to filter columns and 20% 
acetonitrile in water was used to ensure transfer of all samples. The solution containing 
digested proteins was collected by centrifugation and dried on a vacuum concentrator. Dried 
peptide pellets were then resuspended in 100uL of 50mM ammbic with a combination of 
vortex and sonication for 15 minutes. Next, HiPPR Detergent Removal Spin Column 
(Thermo Fisher) was used to remove detergent contaminants in the sample by following the 
manufacturer’s instruction.  
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After detergent cleanup, vacuum centrifuge was used to reduce sample volume to around 
20uL. Formic acid was then added to a final concentration of 0.2% to acidify the sample 
before sample concentration using C18 ZipTip (EMD Millipore) following the 
manufacturer’s instruction. ZipTip was performed twice to improve recovery of samples. 
The samples were then dried in vacuum concentrator and then resuspended in 20uL of 0.2% 
formic acid with a combination of vortex and sonication. Finally, 1uL of each sample was 
analyzed using an EASY II nano-UPLC (Thermo Fisher) connected on-line to an Orbitrap 
Fusion Tribrid Mass Spectrometer (Thermo Fisher) with two hours of run time per sample. 
All raw files obtained were then analyzed together in one MaxQuant search against human 
proteome obtained from UniProt3,4. MaxQuant was set up to detect AHA and SILAC amino 
acids as well as with “re-quantification” and “match between runs” settings turned on.  
Among the six samples tested, detection doubled to around 2700 to 2800 protein groups per 
sample, due to several improvements in sample preparation. One major improvement 
potentially came from the extended (48 hours in this study vs. 24 hours in RGD vs. RGE 
study) proteomics media exposure that ensured there is a larger fraction of AHA-
incorporated proteome for enrichment. Next, bead-based click reaction was optimized to 
improve overall efficiency and was allowed to react overnight to enhance enrichment of 
newly synthesized proteins. After that, both Lys-C and trypsin proteases were used to 
enhance the digestion of proteins into expected peptide fragments. Lastly, the ZipTip 
desalting step was performed twice to increase the amount of peptide recovery. Overall, 
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implementation of these technical changes significantly improved protein group detection in 
mass spectrometry.  
Results and discussion 
Among the protein groups discovered, 2440 were found to have at least one measured protein 
ratio and 1141 groups that contained ratios in all six samples. The protein groups with at least 
one protein ratio were submitted to Limma for differential expression analysis5. For each 
protein group, the leading protein with the most peptide evidence associated was chosen for 
analysis. In the rare cases where two or more protein groups have the same leading protein, 
the one with the most peptide evidence was retained.  
Limma results showed that no detectable proteins was found to be differentially expressed 
with statistical significance (Figure A.3). After further analysis, we found that compared to 
the RGD vs. RGE study, a larger fraction of proteins have a close to zero fold change in this 
study (Figure A.4). Additionally, this pattern is consistent with two previous RNA-seq 
studies that found perturbation by RGD is significantly stronger than ALG-1001 (Kornfield 
group, Caltech, unpublished). On the other hand, the two proteomics studies presented here 
are not directly comparable, since many experimental parameters and sample preparation 
steps were changed. Experimentally, treatment time was doubled (48 hours in this study vs. 
24 hours in the RGD vs. RGE study), while the peptide concentration was reduced by 10 
folds. The lower concentration was used to reduce effects of non-specific binding, but this 
dosage may be too mild to elicit detectable proteomic changes. Thus, these findings do not 
demonstrate the proteome is not regulated after ALG-1001 treatment, but that the effect on 
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the proteome may be too small to be detected at the dosage tested. To improve discovery, 
higher dosages of ALG-1001 and more biological replicates should be employed. 
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A.4 Figures and tables 
 
Figure A.1 Volcano plot of Limma result containing proteins regulated between RGD 
and RGE treatments 
Limma-measured fold change and adjusted p-values were plotted with each dot representing 
a protein. Proteins colored red are considered DE by an adjusted p-value (FDR) cutoff of 
0.05 (blue dotted line).  
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Figure A.2 REVIGO plot of GO biological processes-enriched with DE genes between 
RGD and RGE treatments 
Up- (A) and down-regulated (B) DE proteins were submitted for GO enrichment with results 
visualized using REVIGO. P-value is REVIGO-derived GO enrichment P-value. Size is the 
number of human proteins associated with each GO term. Strongly enriched processes are 
labeled.  
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Figure A.3 Volcano plot of Limma results shows no protein regulated by ALG-1001 
with statistical significance 
Limma-measured fold change and adjusted p-values are plotted with each dot representing a 
protein. No DE proteins are detected with an adjusted p-value (FDR) cutoff of 0.05 (blue 
dotted line).  
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Figure A.4 Density plot of the fold changes measured among the two comparisons 
Fold changes calculated by Limma are plotted in form of density plot. Area under the curve 
sums to 1 for each of the comparisons. ALG vs. Ctrl is ALG-1001 vs. vehicle control 
comparison, which shows more proteins with near zero fold change.  
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